PCB-associated steatohepatitis and the role of nuclear receptors.

Heather Brooke Clair

University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd

Part of the Nutritional and Metabolic Diseases Commons

Recommended Citation


https://doi.org/10.18297/etd/2867

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.
PCB-ASSOCIATED STEATOHEPATITIS AND THE ROLE OF NUCLEAR RECEPTORS

By

Heather Brooke Clair
B.S. University of Georgia, 1999
M.S. University of Georgia, 2001
M.S. University of Louisville, 2015

A Dissertation
Submitted to the Faculty of the
School of Medicine of the University of Louisville
in Partial Fulfillment of the Requirements
for the Degree of

Doctor of Philosophy
In Biochemistry and Molecular Genetics

Department of Biochemistry and Molecular Genetics
University of Louisville
Louisville, KY

December, 2017
PCB-ASSOCIATED STEATOHEPATITIS AND THE ROLE OF NUCLEAR RECEPTORS

By

Heather Brooke Clair
B.S. University of Georgia, 1999
M.S. University of Georgia, 2001
M.S. University of Louisville, 2015

A Dissertation Approved on

October 20, 2017

by the following Dissertation Committee:

_________________________________
Matthew C. Cave, M.D.

_________________________________
Russell A. Prough, Ph.D.

_________________________________
Barbara J. Clark, Ph.D.

_________________________________
Aruni Bhatnagar, Ph.D., FAHA

_________________________________
Juliane I. Arteel (nee Beier), Ph.D.
DEDICATION

For my family: you were my purpose and strength.

For my friends: you were my support and my shelter.

For my teachers: you stood as my examples.

For Michael, who is all three.
ACKNOWLEDGEMENTS

I would like to thank the investigators and participants involved in the Anniston Community Health Survey for their tireless commitment to the health of those within their own community and beyond. I would also like to thank my department, committee members, and lab personnel for their help in the conception and execution of these projects, as well as the preparation of this publication.
ABSTRACT

PCB-ASSOCIATED STEATOHEPATITIS AND THE ROLE OF NUCLEAR RECEPTORS

Heather B. Clair

May 17, 2017

Metabolic diseases, including fatty liver disease, hyperglycemia, and obesity, result when body systems responsible for managing allostasis (dynamic homeostasis across systems) are pressured beyond their collective compensatory reserve. Nutritional excess contributes to this state, the capacity of which is limited by genetic variation, and failure of one system will gradually lead to pathological overload in the others. Agents which act directly on the communication machinery linking these connected systems can also change the point at which allostatic load becomes allostatic overload. Environmental exposure to polychlorinated biphenyls (PCBs), a class of persistent organic pollutant, is associated with a specific form of toxicant-associated steatohepatitis, fatty liver disease with inflammatory infiltration. PCBs are known to be ligands for the xenobiotic receptors, which, when activated, modulate the transcription of both xenobiotic and intermediary metabolic targets. We investigated the prevalence and characteristics of liver disease in a human population with high environmental PCB exposure, transcriptional changes in the liver in a mouse model of PCB/high-fat diet coexposure, and transcriptional changes attributable to xenobiotic receptors in a primary hepatocyte model.
TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>SECTION</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>X</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>X</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>X</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>X</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>1</td>
</tr>
<tr>
<td>CHAPTER ONE: PCBs are associated with toxicant-associated steatohepatitis, inflammation, and metabolic dysregulation in an exposed human population</td>
<td>24</td>
</tr>
<tr>
<td>MATERIALS AND METHODS</td>
<td>29</td>
</tr>
<tr>
<td>RESULTS</td>
<td>36</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>71</td>
</tr>
<tr>
<td>CHAPTER TWO: PCBs induce differential transcription in liver tissue from a mouse model of chronic PCB/dietary coexposure</td>
<td>79</td>
</tr>
<tr>
<td>MATERIALS AND METHODS</td>
<td>81</td>
</tr>
<tr>
<td>RESULTS</td>
<td>86</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>133</td>
</tr>
<tr>
<td>CHAPTER THREE: PCB exposure induces a differential transcriptome which partially overlaps with that of prototypical xenobiotic receptor ligands in a mouse primary hepatocyte model</td>
<td>138</td>
</tr>
<tr>
<td>MATERIALS AND METHODS</td>
<td>140</td>
</tr>
<tr>
<td>RESULTS</td>
<td>143</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>156</td>
</tr>
<tr>
<td>CONCLUSIONS</td>
<td>162</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>181</td>
</tr>
<tr>
<td>APPENDIX</td>
<td></td>
</tr>
<tr>
<td>Appendix Table 1. Fold change and summary information for 123 targets differentially transcribed with Aroclor 1260 exposure compared to prototypical ligand exposure</td>
<td>213</td>
</tr>
<tr>
<td>CURRICULUM VITA</td>
<td>237</td>
</tr>
</tbody>
</table>
# LIST OF TABLES

<table>
<thead>
<tr>
<th>TABLE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Composition of commercial Aroclor mixtures by PCB homolog group</td>
<td>5</td>
</tr>
<tr>
<td>2. Structural/functional groupings of PCB congeners measured in ACHS-II</td>
<td>11</td>
</tr>
<tr>
<td>3. 2003-2004 NHANES data – AOR for unexplained ALT elevation by exposure quartile</td>
<td>15</td>
</tr>
<tr>
<td>4. Criteria for the diagnosis of Metabolic Syndrome (MS/CVD and IR/T2DM)</td>
<td>21</td>
</tr>
<tr>
<td>5. PCB congeners associated with AOR for unexplained ALT elevations in NHANES 2003-2004</td>
<td>28</td>
</tr>
<tr>
<td>6. Demographics in ACHS by liver disease status – continuous variables</td>
<td>37</td>
</tr>
<tr>
<td>7. Demographics in ACHS by liver disease status – biometric categorical variables</td>
<td>38</td>
</tr>
<tr>
<td>8. Demographics in ACHS by liver disease status – lifestyle categorical variables</td>
<td>39</td>
</tr>
<tr>
<td>9. Demographics in ACHS-II by liver disease status – continuous variables</td>
<td>40</td>
</tr>
<tr>
<td>10. Demographics in ACHS-II by liver disease status – biometric categorical variables</td>
<td>41</td>
</tr>
<tr>
<td>11. Demographics in ACHS-II by liver disease status – health and lifestyle categorical variables</td>
<td>42</td>
</tr>
<tr>
<td>12. Demographic characteristics and liver disease status of ACHS microRNA subcohort</td>
<td>43</td>
</tr>
<tr>
<td>13. Univariate associations between demographic/exposure variables and the serum cytokeratin 18 M65 and M30 biomarkers used to categorize liver disease status</td>
<td>44</td>
</tr>
<tr>
<td>14. Unadjusted ACHS biomarker levels by liver disease status</td>
<td>46</td>
</tr>
<tr>
<td>15. Adjusted beta coefficients of associations of ( \sum \text{PCBs} ) (wet weight) and liver status with inflammatory biomarkers</td>
<td>48</td>
</tr>
<tr>
<td>16. Adjusted beta coefficients of associations of ( \sum \text{PCBs} ) (wet weight) and liver status with metabolic biomarkers</td>
<td>49</td>
</tr>
<tr>
<td>17. ACHS validation – miRNA data by CK18 liver disease group</td>
<td>51</td>
</tr>
<tr>
<td>18. Adjusted beta coefficients of CK18 and miRNA levels</td>
<td>52</td>
</tr>
<tr>
<td>19. ACHS-II validation – LFTs by CK18 liver disease group</td>
<td>53</td>
</tr>
</tbody>
</table>
20: Cutoff values for upper limit of normal for the clinical liver injury biomarker alanine aminotransferase (ALT) ........................................................................................................... 55

21: Effects of PCBs and BMI on liver disease status by multinomial logistic regression ....... 56

22: PCB groupings and CK18 liver disease status in ACHS and ACHS-II.............................. 57

23: Significant associations of ΣPCBs and miRNA species .................................................... 58

24: ACHS adjusted beta coefficients of significant associations of liver disease status and CK18 biomarkers by individual PCB congeners .................................................... 60

25: TEQ for dioxin-like PCBs and other dioxin-like species and CK18-indicated liver disease status in ACHS-II ................................................................................................ 62

26: Adjusted beta coefficients of significant associations of various TEQ summations and CK18 biomarkers in ACHS-II .................................................................................. 63

27: Unadjusted ACHS-II biomarker levels by sum of all PCBs (ΣPCBs) sum of 35 ortho-substituted congeners (ΣPCB-O) and all non-dioxin-like congeners (ΣNDL) ............ 65

28: Unadjusted ACHS-II biomarker levels by groups of ortho-substituted PCBs ................. 66

29: Unadjusted ACHS-II biomarker levels by groups of non-ortho-substituted and dioxin-like PCBs .................................................................................................................... 67

30: ACHS adjusted beta coefficients of associations of ΣPCBs (wet weight) with biomarkers ........................................................................................................................ 69

31: Adjusted beta coefficients of significant associations of PCB congeners with biomarkers of glucose metabolism ......................................................................................... 70

32: in vivo experiment dataset properties ............................................................................. 85

33: Enrichments for genes differentially transcribed in comparison CVvsC20 ................. 87

34: Enrichments for genes differentially transcribed in comparison CVvsC200 .................... 88

35: Enrichments for genes differentially transcribed in comparison HVvsH20 .................... 89

36: Enrichments for genes differentially transcribed in comparison HVvsH200 .............. 90

37: Enrichments for genes differentially transcribed in comparison CVvsHV ..................... 91

38: Enrichments for genes differentially transcribed in comparison C20vsH20 ............... 92

39: Enrichments for genes differentially transcribed in comparison C200vsH200 ............ 93

40: Common targets between moderate/high PCB exposure levels within the control diet groups .................................................................................................................... 97
41: Common targets between moderate/high PCB exposure levels within the high-fat diet groups
42: Common targets between all PCB exposure levels within diet comparisons
43: Enrichments for liver and metabolic disease endpoints in comparison CVvsC20
44: Enrichments for liver and metabolic disease endpoints in comparison CVvsC200
45: Enrichments for liver and metabolic disease endpoints in comparison HVvsH20
46: Enrichments for liver and metabolic disease endpoints in comparison HVvsH200
47: Targets associated with liver disease enrichments and change vs. vehicle control by comparison
48: Targets associated with metabolic disease enrichments (overnutrition/obesity) and their change vs. vehicle control in each comparison
49: Targets associated with metabolic disease enrichments (Type 2 Diabetes Mellitus) and their change vs. vehicle control in each comparison
50: Targets associated with metabolic disease enrichments (Metabolic Syndrome) and their change vs. vehicle control in each comparison
51: Targets associated with metabolic disease enrichments (insulin resistance) and their change vs. vehicle control in each comparison
52: Top ten transcription factor enrichments for condition CVvsC20
53: Top ten transcription factor enrichments for condition CVvsC200
54: Top ten transcription factor enrichments for condition HVvsH20
55: Top ten transcription factor enrichments for condition HVvsH200
56: Percent activation for engaged transcription factors identified in all conditions
57: Percent activation for engaged transcription factors identified in 1-3 conditions
58: Treatment summary
59: Targets differentially regulated with Aroclor 1260 exposure
60: Concordance in direction of differential transcription between PCB-DTGs and prototypical ligand DTGs
61: Fold induction of prototypical targets for AhR, PXR, and CAR with prototypical ligand exposure
62: Enriched pathways for PCB-DTG set
63: Transcription factors with targets in the PCB-dependent differentially-transcribed gene set ............................................................................................................................... 155

64: Differentially transcribed circadian-rhythm related targets from in vivo and in vitro experiments ........................................................................................................................................... 169
# LIST OF FIGURES

<table>
<thead>
<tr>
<th>FIGURE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Basic structure of a polychlorinated biphenyl</td>
<td>4</td>
</tr>
<tr>
<td>2. Structural characteristics of PCBs compared to TCDD and other dioxin-like chemicals</td>
<td>9</td>
</tr>
<tr>
<td>3. Equations for calculated parameters in human epidemiological studies</td>
<td>14</td>
</tr>
<tr>
<td>4. Distribution of ortho/non-ortho structures within homolog groups</td>
<td>17</td>
</tr>
<tr>
<td>5. Origin and detection of cytokeratin 18 in serum samples</td>
<td>26</td>
</tr>
<tr>
<td>6. ΣPCBs were inversely associated with metabolic biomarkers in ACHS</td>
<td>64</td>
</tr>
<tr>
<td>7. Distribution of ALT levels in ACHS by liver disease category</td>
<td>73</td>
</tr>
<tr>
<td>8. PCB exposure and high-fat diet induce phenotypic changes in C57/BL6 mice</td>
<td>82</td>
</tr>
<tr>
<td>9. Moderate and high PCB exposures produce overlapping DTG sets (vs. vehicle)</td>
<td>95</td>
</tr>
<tr>
<td>10. Comparison of PCB/diet interactions</td>
<td>99</td>
</tr>
<tr>
<td>11. IL-6-mediated acute-phase response in hepatocytes</td>
<td>107</td>
</tr>
<tr>
<td>12. IL-6/STAT-3 signaling pathways</td>
<td>108</td>
</tr>
<tr>
<td>13. Transcription factors regulated by PXR or PXR/RXR via protein-protein interactions</td>
<td>127</td>
</tr>
<tr>
<td>14. Nipk/Trib3 signaling pathways downstream of PPAR-alpha</td>
<td>129</td>
</tr>
<tr>
<td>15. Arnt/Bmal1 pathway related to circadian signaling</td>
<td>130</td>
</tr>
<tr>
<td>16. Claudin-1 and e-cadherin pathways related to EMT</td>
<td>132</td>
</tr>
<tr>
<td>17. Summary of transcriptional differences between groups</td>
<td>134</td>
</tr>
<tr>
<td>18. Histograms of differential transcriptomes produced by PCB/prototypical ligand exposure</td>
<td>144</td>
</tr>
<tr>
<td>19. Venn diagram showing the overlapping differential gene sets between PCB and prototypical ligand exposures</td>
<td>147</td>
</tr>
<tr>
<td>20. A portion of the PCB-DTG overlapped with DTGs for AhR, PXR, CAR and LXR prototypical ligands</td>
<td>148</td>
</tr>
</tbody>
</table>
21. Pathways related to EMT were enriched in genes in the PCB-DTG set ....................... 154

22. Exposure to PCB with or without HFD coexposure alters transcription of multiple components of IL-6 signaling .............................................................................................................. 165

23. Ephrin ligand A1 (Efna1) was differentially regulated in multiple comparisons .......... 172

24. Ephrin ligand A5 (Efna5) was differentially regulated in multiple comparisons ............ 173

25. Ephrin receptor B2 (EphB2) was differentially regulated in multiple comparisons .......... 174

26. *in vivo* comparison diagrams .......................................................................................... 179
BACKGROUND

Toxicant-associated steatohepatitis (TASH) is a term applied to a unique subset of nonalcoholic fatty liver disease (NAFLD) related to chemical exposures. Though the liver is known to be a primary target in many industrial chemical exposures, environmental chemical exposures represent a much more widespread and insidious threat to liver health. Persistent organic pollutants (POPs) are lipophilic, and while some compounds are metabolized, relatively unmetabolizable chemicals distribute to fat depots of exposed biota. Consumption of these POPs-bearing biota represents the major route of environmental toxicant exposure for humans and other apex consumers. Consequently, even though the same classes of chemicals may be involved in industrial and environmental exposures, an environmental toxicant exposome is acquired slowly throughout the life cycle and is enriched in less metabolizable chemicals, while an industrially-acquired exposome more likely involves higher levels of more readily metabolized chemicals acquired acutely by adults. This is an important consideration, because the same endpoints are used to evaluate toxicity in either case, but the differences in acquisition timeframe and composition may render the effects of chronic exposures subclinical and change toxicity mechanisms. These differences can affect the biomarkers used for screening assays, hindering diagnosis and treatment of TAFLD and TASH at earlier, more reversible stages and thereby masking the extent of liver injury.

The class of POPs collectively referred to as polychlorinated biphenyls (PCBs) typify the most challenging aspects of research in environmentally-acquired toxicant exposures. 1) Because of their chemical stability, PCBs continue to persist in the environment and in the tissues of humans decades after discontinuation of production. 2) PCBs are a class of chemicals invariably encountered as mixtures both in industrial and environmental exposures, and the
structures present within those mixtures are diverse enough that they are likely to have multiple and potentially overlapping or competing mechanisms of toxicity. 3) Although compositions of these mixtures have been exhaustively documented in production, the environment, and in the tissues of biota including humans, for historical and political reasons, both the mixtures themselves and their effects are still often summarized by a single component which assumes one mechanism: in this case the subset of congeners bearing structural similarity to dioxins and expected to act as arylhydrocarbon receptor (AhR) agonists. 4) The direct effects of chronic, low-level PCB exposures differ from the more thoroughly evaluated effects of high-level, industrial exposures – likely because different distributions of congeners drive different engagement of xenobiotic receptors. 5) The ultimate effects of chronic PCB exposure-related TASH have great potential to be modulated or exacerbated by long-term nutritional coexposures, and race/ethnicity and gender differences, and these differences are understudied. 6) PCBs, like other toxicants associated with TASH, appear to cause a form of liver disease which is mechanistically and diagnostically distinct from other forms of fatty liver disease, making its detection by typical laboratory screening techniques difficult. These points may explain some characteristics which frustrate the recognition of environmentally-acquired PCB impact on human health and hinder its resolution.

PCBs remain a focus of environmental and human health research, occupying (in various groupings) 3 out of the top 20 positions in the 2015 Substance Priority List published by the Agency for Toxic Substances Disease Registry (ATSDR). We hypothesized that, in humans, chronic environmental PCB exposure would be associated with increased liver injury biomarkers indicating TASH. We furthermore hypothesized that PCB exposure in mice and primary mouse hepatocytes would induce differential transcription of targets related to liver disease and that in primary mouse hepatocytes, that differential transcription would overlap with the response to prototypical ligands for specific xenobiotic receptors.
Manufacture and chemical characteristics of PCBs

Every human health effect of PCBs must be evaluated in light of one critical consideration: from the moment of manufacture to the moment of exposure, PCBs never exist as a single chemical, but as a fluctuating mixture of related chemicals each with unique biological and chemical properties. The basic structure of a PCB, shown in Figure 1, is that of a biphenyl ring with as few as 1 or as many as 10 chlorine substitutions in various positions about the molecule, leading to 209 potential congener configurations. PCBs were produced throughout the world via ferric chloride-catalyzed chlorination of biphenyl. Three cities in the U.S. were sites for commercial manufacture of PCBs: Anniston, AL from 1929-1930 (Swann Research, Inc.) and 1930-1971 (Monsanto, Inc.), Saguet, IL until 1977 (Monsanto, Inc.) and Houston, TX from 1972-1974 (Geneva Industries). PCBs were produced mainly for use as dielectric fluids in electrical equipment, but were also used as lubricants, plasticizers, sealants and carriers in many products. The desired material properties of chemical stability and low flammability offered by PCB mixtures are related to the component structures and correspond roughly to the degree of chlorination. PCBs produced by Monsanto, Inc. were marketed as mixtures called Aroclors, with a number corresponding to the nominal average percent chlorine (e.g. Aroclor 1260 is approximately 60% chlorine by weight).

This production and marketing methodology gives rise to one scheme for grouping PCBs: PCB homologs are defined as sets of congeners with a common number of chlorine substitutions. In addition to providing a way to estimate levels of total production, use and disposal of PCBs and to equate these amounts with contamination levels, grouping by homologs allows the appreciation of certain general characteristics and trends. More heavily substituted homologs have higher average melting and boiling points, higher vapor pressure and are more miscible in lipids (quantified as higher octanol-water partition coefficients). Aroclor mixtures including Aroclor 1260, 1254 and 1248 were composed mainly of higher-molecular weight homologs (tetrachlorobiphenyl and above). Within each homolog group, PCB congeners with different substitution patterns are referred to as isomers. The composition of commercial Aroclor mixtures by PCB homolog group is shown in Table 1.
Figure 1. Basic structure of a polychlorinated biphenyl.

The basic structure of a PCB is a biphenyl ring with 1-10 chlorine substitutions at carbons 2 (2') and 6 (6'). Substitutions in the ortho positions favor rotation of the rings relative to one another, with the functional consequence of reduced coplanarity with each additional ortho substitution. PCB congeners with less (tri, di, mono-ortho) or no ortho substitutions (non-ortho) assume an increasingly more coplanar structure.
### Table 1
Composition of commercial Aroclor mixtures by PCB homolog group

<table>
<thead>
<tr>
<th>PCB homolog group</th>
<th>Empirical Formula</th>
<th>% Chlorine (by weight) in various homolog groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>1016</td>
<td>C_{12}H_{10}Cl</td>
<td>1</td>
</tr>
<tr>
<td>1221</td>
<td>C_{12}H_{9}Cl</td>
<td>2</td>
</tr>
<tr>
<td>1232</td>
<td>C_{12}H_{8}Cl_{2}</td>
<td>3</td>
</tr>
<tr>
<td>1242</td>
<td>C_{12}H_{7}Cl_{3}</td>
<td>4</td>
</tr>
<tr>
<td>1248</td>
<td>C_{12}H_{6}Cl_{5}</td>
<td>5</td>
</tr>
<tr>
<td>1254</td>
<td>C_{12}H_{5}Cl_{5}</td>
<td>6</td>
</tr>
<tr>
<td>1260</td>
<td>C_{12}H_{4}Cl_{5}</td>
<td>7</td>
</tr>
<tr>
<td>1276</td>
<td>C_{12}H_{3}Cl_{5}</td>
<td>8</td>
</tr>
<tr>
<td>1292</td>
<td>C_{12}H_{2}Cl_{5}</td>
<td>9</td>
</tr>
<tr>
<td>1310</td>
<td>C_{12}H_{1}Cl_{5}</td>
<td>10</td>
</tr>
</tbody>
</table>

The distribution of homologs of several commercial Aroclor mixtures (Erickson et al., 2015), and selected human tissues including serum-NHANES (Patterson et al., 2009), and selected human tissues including serum-ACHS (AA = African American/Black, NHW = Non-Hispanic White) (Pavuk et al., 2014), adipose (McFarland et al., 1999), liver, muscle, kidney, and brain (Chu et al., 2003) by homolog is shown. The percent chlorine (by weight) is shown for each homolog group (column 3). The relative percent composition of several commercial Aroclor mixtures are shown in columns 4-10.
Unsurprisingly, the environmental persistence of individual congeners within the mixture is also related to structure. Weathering is a term applied to PCB mixtures undergoing profile changes due to physical or chemical processes such as water washing, photodegradation, volatilization, and evaporation. It can also refer to aerobic degradation due to microbial action. Weathering disproportionately affects lighter molecular weight congeners, particularly mono-, di-, and tri-substituted congeners, resulting in mixtures with proportionately more tetra- and penta-substituted congeners. Congeners bioaccumulating within the fatty tissue of exposed biota also tend to be those with more chlorine substitutions, and are dependent on two properties related to structure and influenced by degree of chlorination: resistance to non-metabolic clearance (increased lipophilicity) and structural inaccessibility to metabolic machinery (substitution pattern).

In summary, PCBs were manufactured to meet a demand for industrial fluids that were highly stable, thermoresistant, and miscible in lipids, the same characteristics underlying the persistence of PCBs in the environment. It is important to note, however, that PCB congeners are not equally affected by processes of physical and chemical degradation, leading to changes in the profile of PCB mixtures from manufacture to environmental substrates to eventual bioaccumulation in humans. This is particularly critical to the design of models which reflect the current PCB exposure conditions: uptake of weathered and pre-metabolized PCBs through ingestion of contaminated biota.

Bioactivity of PCBs in mixtures with widespread relevance to human health

Over 80 years have elapsed since the initial reports of human toxicity from PCB exposure, and in that time, substantial research efforts have been put toward understanding the chemical composition and health effects of manufactured PCB mixtures and occupational exposures. While this work has been critical to characterizing human disease resulting from industrial exposures, it has become somewhat obsolete for several reasons. First, except from a standpoint of longitudinal health and mortality assessment, research modeled on occupational PCB exposures is less relevant today because PCB production has been banned for 40 years,
therefore, new occupational exposures no longer occur in the process of PCB manufacture.

Second, the most common route of exposure in humans is low-level, environmental acquisition through ingestion of contaminated foodstuffs, and as congeners bioaccumulate at different rates, PCBs which make up the current exposome are more likely to be higher-substituted, highly-bioaccumulated and less metabolizable, generalizations which are reflected in assessments of serum PCB levels in exposed populations. Third, emerging data on the impact of nutritional coexposures suggests that the current obesity epidemic may significantly modulate the effects of PCBs on human health. Thus, different PCBs may be exerting their effects in a different internal environment currently than was explored in the original toxicity studies.

Early evaluation of the toxicity of PCBs focused on high-level exposures and acute toxicity which modeled the human health effects seen in occupational exposures, accidental contamination from PCB-containing electrical equipment, and poisoning incidents such as the Yusho and Yucheng events in which thousands of people in Japan and Taiwan (respectively) were exposed to PCBs, dioxins and dibenzofurans through ingestion of rice oil contaminated with a commercial PCB mixture. These incidents differ from the PCB exposure experienced by most U.S. citizens in both scale and composition. Health consequences such as chloracne (a noninflammatory skin condition characterized by cyst and closed comedone development with sebaceous gland atrophy), immunosuppression, reproductive and developmental effects, acute liver damage, and cancer were observed in some individuals within these cohorts. Importantly, elevated liver enzyme activity and other biomarkers of these effects were typically observed at very high exposures. This observation as well as a superficial resemblance of this pattern of human health effects to the constellation of pathologies induced by dioxins in laboratory animals led researchers to focus on a small subset of congeners within the exposure mixture with a specific structural characteristic: absence of chlorine substitutions in the four available ortho positions. This characteristic is related to but independent of the overall degree of chlorination in the molecule. Chlorine substitutions at these ortho positions affect the orientation of the rings relative to one another such that congeners with no substitutions in these
positions are relatively coplanar, while increasing numbers of chlorine substitutions in these positions increases the likelihood of a molecule with rings that are non-coplanar (perpendicular).

Coplanar PCBs share structural similarity to the molecule 2,3,7,8-tetrachlorodibenzo-\(p\)-dioxin (TCDD), which is an extensively studied, potent agonist for the AhR. Structural characteristics of PCBs compared to TCDD and other dioxin-like chemicals are shown in Figure 2. Coplanar PCBs, which can induce transactivation of targets under the control of a dioxin response element (DRE), are considered dioxin-like (DL) PCBs, while increasing ortho substitutions render a congener increasingly non-dioxin-like (NDL). The number of relatively potent (non-ortho) dioxin-like congeners is constrained by the requirement for unsubstituted ortho carbons (2, 2’, 4, and 4’) and becomes increasingly unlikely as the number of substitutions increases, such that only 1 non-ortho congener (PCB 169) exists among hexachlorobiphenyls and none exist among the higher molecular weight congeners.

Most research has focused on these dioxin-like congeners, which are present in only trace amounts within most commercial PCB mixtures and found at extraordinarily low levels in the tissues of exposed biota including humans. In rodent models, exposure to TCDD has been linked to many of the disease endpoints listed above, including immunotoxicity, reproductive effects, and cancer\textsuperscript{16}, although the connection between TCDD and other dioxins and these effects in humans is less clear\textsuperscript{17}. Even chloracne, which is the only consistently-reported human health marker of dioxin intoxication\textsuperscript{18}, is not a clear outcome of AhR induction and does not follow AhR induction by all ligands. Nevertheless, coplanar PCBs are also ligands for AhR, although they are much less effective than prototypical ligand TCDD at inducing transcription of Cyp1a1, the prototypical target of AhR, \textit{in vivo}\textsuperscript{16}.

NDL congeners are characterized by chlorine substitutions in the ortho positions, which induce non-coplanarity. These congeners tend to be more resistant to degradation and bioaccumulate to much higher levels. Historically, these congeners were dismissed as less toxic to humans and of a lower priority in remediation and human health research\textsuperscript{16}, however more recently, the recognition that these congeners are ligand activators of other xenobiotic receptors has led to a resurgence of interest. NDL congeners are direct ligands for the pregnane and
Figure 2. Structural characteristics of PCBs compared to TCDD and other dioxin-like chemicals.

(Adapted from Int. J. Mol. Sci. 2014, 15(8), 14044-14057.)
xenobiotic receptor (PXR) and the human constitutive androstane receptor isoforms 2 and 3 (hCAR2/3) but not human CAR isoform 1 (hCAR1), which is homologous to murine CAR (mCAR)\textsuperscript{19}. However, our laboratory recently reported that the both NDL and DL PCB congeners, as well as the mixture Aroclor 1260, inhibit activation of the human and murine epidermal growth factor receptor (EGFR), which provides an indirect mechanism for mCAR activation\textsuperscript{20, 21}.

Importantly, though AhR, CAR, and PXR are considered xenobiotic receptors and most research has focused on describing their role in the drug- or toxicant-dependent induction of xenobiotic metabolic machinery, they are also involved in transcriptional control of intermediary metabolism and inflammatory response. These functions may ultimately explain both the link between PCB exposure and metabolic disruption and some complexities of diet/PCB coexposures in metabolic disease. Our laboratory reported that, in mice, exposure to Aroclor 1260 alone was insufficient to induce a phenotype of steatohepatitis, and that a coexposure to high fat diet was required to observe the phenotypes of fatty liver and diabetes\textsuperscript{22, 23}.

Beyond the DL/NDL stratification, other groupings of PCB congeners reflect the ability of individual congeners to alter the function of receptors such as the ryanodine receptor\textsuperscript{24-26}, estrogen receptor\textsuperscript{27, 28}, and androgen receptor\textsuperscript{29, 30}, shown in Table 2.

In summary, humans encounter PCBs not as individual chemicals, but as complex mixtures of congeners, each of which has unique structural characteristics that influence stability and bioaccumulation patterns as well as the mechanisms of biological effect. The composition of PCB mixtures represented in historic occupational and accidental PCB intoxication events differs significantly from the mixture accumulated slowly through chronic environmental exposure, and this is likely to alter both the mechanism of effect and the phenotype. Therefore, experimental designs which involve single congeners and risk-assessment algorithms which assume only one mechanism are unlikely to realistically model the effect of environmental exposure.

\textit{Historic context for reliance on AhR induction estimates to define PCB toxicity}

As stated above, although PCBs are encountered as complex mixtures with complex effects, historically, the toxicity of PCBs was attributed entirely to AhR-mediated effects of dioxin-
# Table 2

Structural/functional groupings of PCB congeners measured in ACHS-II

## Structural groupings

<table>
<thead>
<tr>
<th>Structural groupings</th>
<th>Congeners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tri- and Tetra-ortho (ΣPCB-TO)</td>
<td>149, 151, 177, 178, 183, 187, 195, 196-203, 199, 206, 209</td>
</tr>
<tr>
<td>Mono-Ortho (ΣPCB-MO)</td>
<td>28, 66, 74, 105, 118, 156, 157, 167, 189</td>
</tr>
<tr>
<td>Non-Ortho (ΣPCB-NO)</td>
<td>81, 126, 169</td>
</tr>
</tbody>
</table>

## Functional groupings

<table>
<thead>
<tr>
<th>Functional groupings</th>
<th>Congeners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dioxin-Like (ΣDL)</td>
<td>81, 105, 118, 156, 157, 167, 189, 126, 169</td>
</tr>
<tr>
<td>Estrogen receptor (estrogenic)</td>
<td>18, 28, 30, 44, 49, 52, 99, 101, 103, 110, 128</td>
</tr>
<tr>
<td>Estrogen receptor (anti-estrogenic)</td>
<td>118, 138, 163, 170, 180, 187, 194, 199, 203</td>
</tr>
<tr>
<td>Androgen receptor (anti-androgenic)</td>
<td>28, 49, 66, 74, 105, 118</td>
</tr>
<tr>
<td>Ryanodine receptor</td>
<td>95, 136, 149, 176, 84, 96, 52, 151, 183, 187, 170, 101, 132, 180, 18</td>
</tr>
</tbody>
</table>

PCBs are grouped by structural and structural/functional characteristics to assess relationships between disease or biomarker parameters and the total serum levels of structures with common characteristics (structural) or mechanisms (structural/functional). For dioxin-like/non-dioxin-like congeners, the designation is based on the presence of ortho-substitutions (0 or 1 for dioxin-like, 2-4 for non-dioxin-like).
like congeners. Both political and practical considerations motivated this focus. From a practical standpoint, acute occupational exposures and high-level accidental poisoning with relatively undegraded PCB mixtures were readily observable, and therefore exposure to mixtures containing lower molecular weight and dioxin-like congeners was the primary PCB-related human health concern at the time. Aggressive exploration of environmental PCB contamination began in the 1970’s, following adoption of gas chromatography techniques which allowed identification of PCBs (as well as chlorinated pesticides) in the environment. In the same general time, political pressure revolving around the use of Agent Orange in the Vietnam War steered a great deal of research toward the health effects of dioxins and dioxin-like chemicals. The result of this was the adoption of the TCDD-equivalent factor (TEF) protocol to determine the TCDD equivalency (TEQ), a value normalizing any dioxin-like compound to TCDD based on its ability to induce AhR-mediated response in an in vivo or in vitro system. Classes included in this protocol include PCDDs, PCDFs and PCBs, the structures of which are shown in Figure 2. While this system allows for the quick estimation of AhR-mediated toxicity in complex mixtures and clinical or environmental samples by summing concentrations of individual compounds multiplied by their respective TEQs, there are problems inherent in the concept.

First, the protocol presupposes that “Most, if not all, toxic and biological effects of [PCDDs, PCDFs and PCBs] are mediated through the aryl hydrocarbon receptor.” This is certainly not true of mixtures such as PCBs in which all potential AhR ligands make up less than 1.5% of even unweathered commercial mixtures like 1260. Far from being inert, the remaining 98.5% of this mixture contains congeners which are known to induce other receptors, including both classical xenobiotic nuclear receptors and cell surface receptors. Second, classic assays based on induction or activity of xenobiotic metabolic targets of AhR presume that exposure-dependent changes in AhR-mediated induction in this subset of targets can be extrapolated to the entire complement of AhR targets. In fact, the transcriptional effects of AhR are selectively modified by the ligand, with more widely conserved effects across ligands on targets involved in xenobiotic metabolism or response to oxidative stress and more ligand-specific modulation of targets involved in lipid carbohydrate metabolism. Finally, the most powerful
application of the TEQ protocol is the ability to quickly summarize the AhR-mediated effects of various chemicals quantified by gas chromatography coupled to high-resolution mass spectrometry (GC/HRMS) by normalizing the contribution of each compound to TCDD using the TEF and then summing the resulting TEQs. This allows a total TEQ to be derived from multiple dioxin-like classes of chemical, including PCDDs, PCDFs and PCBs (Figure 3). Perhaps most pertinent to this particular study, although data from multiple human exposures to these compounds, including Yusho and Yucheng poisoning events and exposed individuals residing near the PCB manufacturing facility in Anniston, AL suggest that PCDDs and PCDFs contribute more to the overall TEQ. However, our laboratory’s evaluation of the 2003-2004 NHANES data showed that, among these classes, after adjustment for multiple comparisons, only PCBs were positively associated with liver injury (shown in Table 3).

In summary, a need to prioritize exposures for reasons of risk assessment and remediation led to methods, like the TEQ protocol, which weight the importance of one mechanism over others, and the selection of dioxins/AhR as the flagship toxicant was driven by both practical and political considerations. While this method may accurately represent the likelihood that PCBs will have effects mediated by AhR, neither AhR activation nor modulation of any other single mechanism can sufficiently describe the toxic/biological effects of complex environmental exposures. This is particularly true in the case of PCBs, where both the overall exposure level and the distribution of congeners comprising the mixture are known to differ considerably between acute/occupational and chronic/environmental exposures.

Environmental PCB exposures vs. industrial PCB exposures

High-level exposures to industrial PCB mixtures are known to cause liver injury as well as pathologies in other tissues in humans and other animals, as previously described. Although the effects of chronic, environmental PCB exposures on the liver are less well characterized, some conclusions can be drawn about the relationship between PCBs and liver injury based on the results of several studies: the NHANES study described above, a longitudinal examination of the
Equation 1. PCDD TEQ

\[ PCDD\ TEQ = \sum_{ni} (PCDD_i \times TEF_i)_n \]

Equation 2. PCDF TEQ

\[ PCDF\ TEQ = \sum_{ni} (PCDF_i \times TEF_i)_n \]

Equation 3. PCB TEQ

\[ PCB\ TEQ = \sum_{ni} (PCB_i \times TEF_i)_n \]

Equation 4. Total TEQ

\[ Total\ TEQ = \sum_{ni} (PCDD_i \times TEF_i)_n + \sum_{ni} (PCDF_i \times TEF_i)_n + \sum_{ni} (PCB_i \times TEF_i)_n \]

Equation 5: HOMA-IR

\[ HOMA - IR = \frac{(Glucose \times Insulin)}{22.5} \]

Equation 6: HOMA-β

\[ HOMA - \beta = \frac{(20 \times Insulin)}{(Glucose - 3.5)} \%

Equation 7: Total Lipids

\[ Total\ Lipids = (2.27 \times Total\ Cholesterol) + Triglycerides + 62.3\ mg/dl \]

Figure 3. Equations for calculated parameters in human epidemiological studies.

These equations are used to summarize and interpret differential biomarkers in human serum. Equations 1-4 are used to calculate the effects of various PCB congener groupings on the arylhydrocarbon receptor. Equations 5 & 6 are used the in homeostatic method of assessment (HOMA) model to discriminate between different etiologies in abnormal glycemic control. Equation 7 is used to estimate the total lipid content of serum from measured parameters of total cholesterol and triglycerides. “Total lipids” is then used as a variable to correct serum content of hydrophobic contaminants such as PCBs.
The relationships between biomarker‐indicated liver disease and PCBs in the 2003-2004 NHANES population are shown. Increased total PCB exposure was associated with an increased adjusted odds ratio (AOR) for unexplained ALT elevation, attributable to nonalcoholic fatty liver disease. From Cave et al, 2010*. Used with permission.
historically exposed Yusho population\textsuperscript{12}, PCB exposure in the Michigan fisheaters study\textsuperscript{38}, and data from exposed wildlife\textsuperscript{16, 39}.

At higher molecular weights, the distribution of congeners heavily disfavors non-ortho, strong AhR ligands. Bioaccumulation patterns favor higher molecular weight congeners, meaning that, for humans acquiring PCBs through the ingestion of contaminated biota, the initial exposure is to a higher average molecular weight, more ortho mixture (shown in Table 1), and the steady state distribution of congeners further reinforces this pattern, shown in Figure 4 and Table 1.

\textit{Sex, genotype and diet interactions in PCB-exposed humans and animal models}

From a standpoint of complexity, there is no more daunting area of human health research than metabolic disease. The metabolic machinery of humans is both versatile and robust. We can adapt to frequent physiological fluctuations in nutritional status, different food sources, and varying demands from multiple tissues to support daily function, development, and reproduction. In many cases, tissues can weather temporary metabolic disruption due to illness or intoxication and eventually regain homeostasis. This process is described by the concept of allostasis, or maintaining stability through change, an energy-dependent process involving concerted actions between multiple tissues\textsuperscript{40}. On the other hand, in the multistep and multisystem process that converts nutrients into metabolites and energy, a mutation leading to loss of function in one critical enzyme can eventually lead to failure in connected systems. Complex disease etiologies occur where additive pressures across connected systems eventually overwhelm compensatory processes. Eventually, component systems fail as additive pressures overwhelm their capacity to adapt, meaning that pressure from different causes can converge on shared pathological outcomes. Because of the multitude of processes in play, disease progression may be slow and pleiotropic, and the direct effects of causal agents may be obscured as the allostatic load is shunted to other systems.

In mammals, the liver is the primary biochemical interface between the environment and the organism, transducing signals and substrates in multiple directions to sense and respond to constantly-changing conditions. In terms of allostatic processes, this places the liver as both a
As molecular weight and number of chlorine substitutions increases, ortho substitutions become more likely. The four non-ortho substituted congeners which bioaccumulate to appreciable levels in humans are PCBs 77, 81, 126 and 169.
hub (because of its position in lipid and carbohydrate trafficking) and as a temporary terminus (because of its capacity for lipid and carbohydrate storage). The adaptive capacity of the liver is extraordinary, but not limitless. Lipid and carbohydrate uptake which chronically exceeds hepatic metabolic/export capacity can lead to steatosis. This has been demonstrated experimentally, using diets enriched in various fats or sugars to induce steatosis, (as well as obesity, dyslipidemia, hyperglycemia and hyperinsulinemia) in laboratory animals\textsuperscript{41-44}. The process is also indicated in humans by epidemiological studies which show a strong relationship between BMI or visceral obesity (proxy measurements for hypercaloric/high-fat/high-sugar diets) and metabolic dysregulation. In addition to the higher PCB exposures found in Anniston and other exposed human populations vs. the NHANES 2003-2004 population, the contributions of overweight/obesity to steatohepatitis and other metabolic disease cannot be ignored. These nutritional factors are additive stressors, increasing demand on tissues whose adaptive capacity is compromised by the effects of sensing or responding to xenobiotics. The boundaries of that capacity arise from genetic variation in the components of metabolic machinery and the combination of endobiotic and xenobiotic molecules interpreted as a need for functional change. Examples drawn from epidemiological studies include patatin-like phospholipase domain-containing-protein 3 (PNPLA3), which has been shown to segregate with racial/ethnic variations in NAFLD prevalence\textsuperscript{45} and the prevalent Q84R (missense) mutation in the human tribbles pseudokinase 3 gene (TRIB3) which is associated with insulin resistance/T2DM\textsuperscript{46, 47}, cardiovascular risk\textsuperscript{46}, and polycystic ovary syndrome in various human populations. Humans homozygous for dominant-negative PPAR\textgamma (adipose-prevalent isoform) have reduced body fat and greatly increased insulin resistance\textsuperscript{48}. Sex effects are also clear in epidemiological studies of PCB-associated disease. In exposed individuals from Anniston, AL, T2DM prevalence was increased only in females\textsuperscript{49}, a finding which echoed reports from a 24-year follow-up of the historic Yucheng poisoning incident, which found a 2-fold increase in the prevalence of diabetes among female but not male subjects\textsuperscript{50}. Males in the Yucheng cohort had a higher prevalence of mortality from liver cirrhosis and liver cancer\textsuperscript{51}. 
In summary, additive pressures from chemical exposures and nutrition can combine with sex- and genotype-specific variation in adaptive capacity to change the prevalence or the manifestation of metabolic disease. Because of its central position in both allostatic maintenance and metabolic and detoxification processes, the liver might be expected to show early and extensive effects from the multiple “hits” of xenobiotic and dietary exposures.

**PCBs and TASH**

The extraordinary range of molecular structures which can be recognized and successfully handled by one or more hepatic metabolic pathways is rivaled only by another unique quality: the liver can really take a beating. The liver can successfully regenerate after surgical removal more than 70% of its total mass\(^{52, 53}\), or the necrosis of 1/3 of the hepatic lobule following exposure to toxicants such as acetaminophen or carbon tetrachloride\(^{54}\).

Nonalcoholic fatty liver disease (NAFLD) is a widespread metabolic disease of the liver, affecting an estimated 25% of the population worldwide\(^{55}\). NAFLD is defined histologically by steatosis (pathological accumulation of lipids) within 5% or more of hepatocytes in the absence of excess alcohol consumption. First considering the liver as an isolated system, four general mechanisms can initiate lipid accumulation: increased lipid transport into the hepatocyte, increased de novo synthesis of lipids, decreased β-oxidation, or decreased lipid export\(^{56}\). As the hub of both intermediary metabolism and xenobiotic metabolism, the liver is essential to systemic homeostasis of both lipids and glucose as well as metabolism of endogenous and exogenous toxicants. It therefore possesses highly concerted machinery for sensing xenobiotics and systemic signaling molecules, and incorporating this context into programs that regulate nutrient/energy balance and nutrient outflow. From this perspective, it is not difficult to understand how a chemical could alter systemic lipid and glucose homeostasis through its direct effects on the liver; that is the concept underlying the use of metabolism-altering drugs with primary effects in the liver such as statins, fibrates, and metformin to affect systemic homeostasis of cholesterol, lipids, and glucose, respectively\(^{57-59}\). Toxicants which exert effects in the liver could be expected to have similar effects, depending on what combination of mechanisms they
perturb. In addition, both intrinsic and idiosyncratic reactions to drugs or toxicants can result in the development of steatosis\textsuperscript{60}, highlighting the complexity of exposure-genotype or exposure-genotype-nutrient interactions.

NAFLD is recognized as the liver manifestation of metabolic syndrome (MS), a constellation of metabolic alterations in multiple organ systems, including obesity, insulin resistance, dyslipidemia and hypertension, that appear to be connected (appear together more often than would be expected by chance). In 2004, the National Heart, Lung and Blood Institute (NHLBI) and the American Heart Association (AHA) released recommendations for diagnosis of MS with a primary outcome of cardiovascular disease. According to the Adult Treatment Panel-III (ATP-III), MS may be diagnosed by the presence of abnormalities in three or more of the following five criteria, shown in Table 4\textsuperscript{61}. With similar tools but a focus on insulin-resistant diabetes as the pathological endpoint of interest, the International Diabetes Federation released similar guidelines which require obesity as well as abnormality in two of the other criteria\textsuperscript{62}.

Regardless of the exact cutoffs required for diagnosis, the criteria cluster around several interrelated components: obesity, insulin resistance, dyslipidemia, and progressive cardiovascular disease. NAFLD is not currently part of the criteria for MS diagnosis, however, it is frequently found with other components of MS and the presence of NAFLD (by persistent elevations in liver enzymes ALT using the lower, gender-specific ranges defined by Prati \textit{et al.}, 2002\textsuperscript{63}) had a significantly higher positive predictive value for development of insulin resistance than ATP-III in nonobese, nondiabetic subjects\textsuperscript{64}. Multiple studies (reviewed in Anstee \textit{et al.}, 2013) indicate that the presence of NAFLD/NASH can predict the development of cardiovascular disease and T2DM after adjustment for obesity\textsuperscript{65}. The significance of these findings is straightforward: the liver is an early site of dysfunction in MS, and liver injury can predict both MS and its component diseases early in the natural history of this complex syndrome.

The liver, therefore, is a central hub in the progression of MS, however, because fatty liver disease may be a cause or effect of systemic metabolic dysfunction, there may be differences in specific direct and compensatory responses of hepatocytes depending on the initiating event(s). These differences in engaged pathways may also affect the mechanisms
## Table 4

### Criteria for the diagnosis of Metabolic Syndrome (MS/CVD and IR/T2DM)

<table>
<thead>
<tr>
<th>Component Disease</th>
<th>Test Parameter</th>
<th>NHLBI/AHA: ATP-III Criteria, CHF/CVD primary outcome (3 of the 5 required)</th>
<th>IDF: IR/T2DM primary outcome (Visceral obesity required + 2 of the 4 remaining)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Obesity</strong></td>
<td>Visceral obesity (waist circumference)</td>
<td>&gt; 102 cm in men or &gt; 88 cm in women</td>
<td>For Europid, Sub-Saharan African and Eastern Mediterranean and Middle Eastern: Men: ≥ 94 cm, Women: ≥ 80 cm. For South Asian, Chinese, Ethnic south and central American: Men: ≥ 90 cm, Women: ≥ 80 cm. For Japanese: Men ≥ 85 cm, Women ≥ 90 cm.</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td>Elevated blood pressure</td>
<td>&gt; 130/85 mm Hg</td>
<td>&gt; 130/85 mm Hg (or treatment history)</td>
</tr>
<tr>
<td><strong>Insulin Resistance</strong></td>
<td>Hyperglycemia (elevated fasting plasma glucose)</td>
<td>&gt; 6.1 mmol/L</td>
<td>≥ 5.6 mmol/l</td>
</tr>
<tr>
<td><strong>Atherogenic dyslipidemia</strong></td>
<td>Elevated (fasting) serum triglycerides</td>
<td>&gt; 1.7 mmol/L</td>
<td>≥ 1.7 mmol/l (or treatment history)</td>
</tr>
<tr>
<td></td>
<td>Low HDL cholesterol</td>
<td>&lt; 1.04 mmol/L</td>
<td>&lt; 1.03 mmol/l for men, &lt; 1.29 mmol/l for women</td>
</tr>
</tbody>
</table>

Criteria for the diagnosis of metabolic syndrome are shown. Because the endpoints of interest to the American Heart Association (column 3) and International Diabetes Foundation (column 4) differ, slightly different criteria are used to define metabolic syndrome.
which drive changes in circulating biomarkers, including mechanistic biomarkers of hepatocyte
death, transcription and release of microRNAs, and release of liver-specific functional enzymes
which can be used for liver injury screening. This is important, because while liver disease
occurs early in MS and can be causal, it is also generally asymptomatic, making non-invasive,
low-risk detection techniques imperative.

Imaging techniques are non-invasive and low-risk and may eventually (in combination
with serum biomarkers) provide sensitive and specific diagnosis and staging of fatty liver disease
to subclinical populations. At present, however, ultrasonography is both subjective and
qualitative, and X-ray computed tomography (CT), proton magnetic resonance spectroscopy (1H-
MRS), and magnetic resonance imaging (MRI) are all resource-intensive and still cannot reliably
distinguish simple steatosis from steatohepatitis. Elevated liver transaminases are widely used
clinically for diagnosis of liver injury, but they are far more effective for indicating liver injury from
endogenous causes (cholestatic, vascular, or autoimmune injury) acute, severe intoxication (i.e.
occupational exposures to chemicals or alcohol-induced liver injury) overdose-related or
idiosyncratic drug-induced liver injury (DILI), or infectious hepatitis (Hepatitis A, B, C). TASH
related to chronic organochlorine exposure may be particularly problematic, as previous research
suggests that transaminase levels may remain subclinical even with severe injury. For the
purposes of environmental health research, the use of transaminases as indicators of liver injury
presents an additional problem: transaminase activity is lost relatively quickly in stored blood or
serum, even under optimal storage conditions, reducing the ability of liver transaminase
panels to reflect injury in archived samples. Emerging serum biomarkers such as microRNA 122,
or the mechanistic biomarker cytokeratin 18 (CK18) may offer alternative methods to non-
invasively detect subacute or chronic liver injury and liver injury of different etiologies, including
TASH. CK18, because it is relatively storage-stable and can be detected in both whole and
caspase-cleaved forms, can discriminate hepatocyte death due to necrosis (the
predominant mechanism in TASH) from hepatocellular apoptosis (the predominant mechanism in
ASH, NASH, and viral hepatitis), is a particularly appealing biomarker.
In summary, NAFLD is recognized as a component of MS, and the functional role of the liver in both intermediary and xenobiotic metabolism suggests that progressive hepatic dysfunction could cause, contribute to, or derive from systemic metabolic dysfunction. TASH is a subcategory of NAFLD which is histologically indistinguishable from NASH and ASH but mechanistically and diagnostically unique. This difference presents an opportunity to distinguish TASH from other forms of fatty liver disease using mechanistic biomarkers, but also hinders diagnosis of liver injury due to chronic toxicant exposure because it is undetectable using typical clinical laboratory screening techniques. This is important to the field of environmental health science because exposures occurring incrementally through ingestion of contaminants are more likely to be low-level and chronic, resulting in slowly-progressive subclinical disease.
Anniston, Alabama was the location of a chemical manufacturing plant where an estimated 400,000 metric tons of PCBs were produced between 1929 and the 1971\textsuperscript{74}. At least 20.5 metric tons of PCBs were released into the atmosphere prior to plant closure in 1971, and nearly 19,000 metric tons of PCBs or PCB distillation residue were buried in unlined landfills near the plant site before and after production was halted\textsuperscript{74}. The environment near the manufacturing plant is highly contaminated; assessment of tree bark in the area revealed PCB concentrations of 171.93 µg/g lipid near the plant and landfills, which dropped dramatically to 35 ng/g lipid within 17 kilometers\textsuperscript{75}. In the late 1990s and early 2000s, several environmental assessments of contamination in Anniston were published, renewing concern over exposures in the residential population and the potential health effects. At that time, there existed over 6 decades of data indicating the status of PCBs as human toxicants\textsuperscript{6}, although the human health effects from environmental exposure were less well characterized than industrial exposures. Nevertheless, concerns from residents, university collaborators and environmental groups initiated the Anniston Community Health Survey (ACHS) in 2003, funded by the Agency for Toxic Substances Disease Registry (ATSDR)\textsuperscript{76, 77}. ACHS, and a follow-up study (ACHS-II, undertaken in 2014) are both large, cross-sectional research projects which provided an opportunity to evaluate accumulation of environmental pollutants (POPs, heavy metals, etc.) in a residential population, and to assess health effects related to these exposures as well as the effects of coexposures/comorbid conditions\textsuperscript{49, 76, 78-80}. Important findings from the ACHS include increased mean PCB levels compared to NHANES (2-3 fold), which are significantly different between non-Hispanic white and African-American/black participants\textsuperscript{78}. Importantly, laboratories working with serum samples and
data from the ACHS project have independently reported elevated prevalence of diseases related to metabolic syndrome including obesity (54%)\textsuperscript{81}, hypertension\textsuperscript{76}, diabetes\textsuperscript{49}, and dyslipidemia\textsuperscript{79}. Blood pressure elevations (both in hypertensive and normotensive ranges), dyslipidemia, and diabetes (particularly in women over 55 years of age) were significantly associated with the total body burden of PCBs\textsuperscript{49, 76, 79, 82}.

As previously stated, NAFLD is the liver manifestation of metabolic syndrome, therefore, we undertook an investigation of liver disease in the Anniston cohorts. We hypothesized that biomarker-indicated liver injury would be prevalent in the ACHS and ACHS-II populations, due to the high prevalence of other metabolic disease. Because of the BMI-independent relationship between liver injury and PCB load reported in our NHANES study\textsuperscript{37} and the specific hepatocyte death mechanism detected in other studies of TASH\textsuperscript{66, 69}, we further hypothesized that PCB-exposed individuals in Anniston would display a pattern of hepatocellular necrosis indicative of TASH. Because steatohepatitis has previously been associated with insulin resistance and systemic inflammation\textsuperscript{83, 84}, we anticipated that dysregulation in biomarkers of these conditions would be observed along with elevations in indicators of liver damage and death.

Our primary biomarker of hepatocyte injury was cytokeratin 18, an intermediate filament enriched in epithelioid cells, especially hepatocytes (Figure 5). Early in apoptosis, CK-18 is cleaved by caspases, producing a neoepitope, CK18-M30. Both total CK18-M65 and the caspase-cleaved component CK18-M30 are released from dying cells and can be detected in the serum, therefore, the relative levels of these two forms can provide insight as to whether hepatocytes are undergoing predominantly apoptotic or predominantly necrotic cell death. CK18-M30 is a well-characterized biomarker of hepatocellular apoptosis. Many groups have demonstrated the utility of CK18-M30 as a diagnostic tool for steatohepatitis due to infection, alcohol, and NASH. Our lab previously demonstrated that total CK18, but not caspase-cleaved CK18, was elevated in individuals with severe liver damage due to vinyl chloride inhalation. We recognized that the effect of PCBs on liver injury could be direct or indirect (by promoting systemic metabolic dysfunction through some other mechanism or target). We
Figure 5. Origin and detection of cytokeratin 18 in serum samples

(A) Cytokeratin 18 (CK18) is an intermediate filament enriched in hepatocytes and arranged in filaments from the nuclear surface to the plasma membrane. (B) In cells undergoing apoptosis, CK18 is cleaved by caspases and released from disintegrating apoptotic bodies. (C) In cells undergoing necrosis, disintegration of the plasma membrane releases whole CK18. (D) Both cleaved and uncleaved CK18 can be detected in the serum, using an antibody against an epitope on all CK18 proteins (M65 – red stars) or an antibody against a neoepitope exposed by cleavage (M30 – yellow stars). The predominance of each form indicates the primary mechanism of hepatocyte death. Serum from individuals with NASH related to metabolic disease have a primarily apoptotic CK18 profile, while serum from individuals exposed to vinyl chloride have a primarily necrotic CK18 profile.
hypothesized in the Anniston cohorts, a positive relationship would exist between serum concentrations of PCBs and serum levels of total CK18 due to their toxicant exposure. We hypothesized that a positive relationship between serum concentrations of PCBs and serum levels of caspase-cleaved CK18 would exist if PCBs influenced liver injury indirectly through effects on other organ systems, leading to NASH.

In addition, we evaluated the relationships between serum PCB levels and various other biomarkers of liver pathology and systemic inflammation, as well as biomarkers and calculated values reflecting metabolic function. The purpose of these evaluations was to determine the relationship (if any) between serum PCB concentration and components of the metabolic syndrome.

Lastly, because PCBs exist as a mixture, different congeners and/or groups of congeners acting on shared mechanism(s) could have differential effects, depending on the mechanisms. In the NHANES study, a significant association was found between liver injury and several individual congeners (Table 5). We hypothesized that serum levels individual congeners and congener groups would have differential associations with biomarkers of hepatocyte apoptosis and necrosis, fibrosis, insulin resistance, pancreatic function, and systemic inflammation.

To investigate our hypotheses, we determined the prevalence of TASH in both populations using the mechanistic hepatocyte death biomarker cytokeratin 18 (CK18) and other liver injury biomarkers, as well as serologic biomarkers of systemic inflammation and metabolic function (glucose and lipid metabolism).
Table 5

<table>
<thead>
<tr>
<th></th>
<th>Quartile</th>
<th>1&lt;sup&gt;st&lt;/sup&gt;</th>
<th>2&lt;sup&gt;nd&lt;/sup&gt;</th>
<th>3&lt;sup&gt;rd&lt;/sup&gt;</th>
<th>4&lt;sup&gt;th&lt;/sup&gt;</th>
<th>p-value</th>
<th>Ptrend</th>
<th>Ptrend-adj</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0.6 (0.2–1.5)</td>
<td>2.9 (1.6–5.4)</td>
<td>1.9 (0.9–4.0)</td>
<td>0.003</td>
<td>0.011</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dioxin-like PCB congeners</td>
<td>66 referent</td>
<td>2.2 (1.0–5.1)</td>
<td>3.0 (1.5–6.0)</td>
<td>6.0 (2.4–14.9)</td>
<td>&lt;0.001</td>
<td>0.004</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.2 (0.5–3.0)</td>
<td>2.8 (1.2–6.5)</td>
<td>3.4 (1.1–10.9)</td>
<td>0.015</td>
<td>0.031</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>118 referent</td>
<td>1.8 (0.7–4.8)</td>
<td>3.8 (1.3–11.1)</td>
<td>4.4 (1.4–13.7)</td>
<td>0.006</td>
<td>0.016</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.5 (0.6–3.5)</td>
<td>3.3 (1.5–7.2)</td>
<td>4.3 (2.0–9.4)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>156 referent</td>
<td>2.2 (1.0–4.5)</td>
<td>3.4 (1.3–8.7)</td>
<td>5.0 (1.5–17.2)</td>
<td>&lt;0.001</td>
<td>0.004</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>157 referent</td>
<td>4.1 (1.8–9.2)</td>
<td>2.1 (0.6–7.6)</td>
<td>7.1 (2.2–22.4)</td>
<td>0.006</td>
<td>0.016</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.9 (0.4–2.2)</td>
<td>2.2 (1.0–4.8)</td>
<td>2.7 (1.0–7.0)</td>
<td>5.0 (1.9–13.3)</td>
<td>0.032</td>
<td>0.011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>167 referent</td>
<td>3.5 (1.3–9.7)</td>
<td>5.0 (1.8–14.0)</td>
<td>2.4 (0.4–12.8)</td>
<td>0.032</td>
<td>0.061</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>118 referent</td>
<td>1.9 (0.8–4.1)</td>
<td>2.5 (1.0–6.0)</td>
<td>6.7 (2.1–21.5)</td>
<td>0.001</td>
<td>0.009</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>146 referent</td>
<td>2.2 (1.0–4.5)</td>
<td>2.7 (1.1–6.9)</td>
<td>6.8 (1.8–25.5)</td>
<td>0.004</td>
<td>0.019</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>151 referent</td>
<td>0.8 (0.3–2.1)</td>
<td>1.0 (0.4–2.3)</td>
<td>2.6 (1.2–5.8)</td>
<td>0.030</td>
<td>0.068</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>153 referent</td>
<td>1.5 (0.6–3.6)</td>
<td>2.3 (0.7–7.4)</td>
<td>7.2 (1.7–29.9)</td>
<td>0.006</td>
<td>0.023</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>170 referent</td>
<td>2.1 (1.0–4.3)</td>
<td>3.1 (1.1–8.7)</td>
<td>4.4 (1.3–14.4)</td>
<td>0.015</td>
<td>0.042</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>172 referent</td>
<td>2.1 (0.8–5.4)</td>
<td>2.7 (0.9–8.1)</td>
<td>3.4 (1.2–9.7)</td>
<td>0.007</td>
<td>0.023</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>177 referent</td>
<td>2.0 (1.0–3.9)</td>
<td>4.2 (1.7–10.4)</td>
<td>6.5 (2.8–15.3)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>178 referent</td>
<td>2.1 (0.8–3.9)</td>
<td>4.6 (1.4–15.3)</td>
<td>4.8 (1.3–17.4)</td>
<td>0.014</td>
<td>0.042</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>183 referent</td>
<td>4.0 (0.6–26.8)</td>
<td>3.1 (0.4–23.2)</td>
<td>7.8 (0.9–63.9)</td>
<td>0.017</td>
<td>0.042</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>187 referent</td>
<td>2.8 (1.6–5.0)</td>
<td>4.6 (1.6–13.3)</td>
<td>10.5 (3.2–34.6)</td>
<td>&lt;0.001</td>
<td>0.002</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>196/203 referent</td>
<td>3.6 (0.9–13.8)</td>
<td>4.1 (1.1–16.0)</td>
<td>8.2 (1.7–39.3)</td>
<td>14.7 (3.3–65.3)</td>
<td>&lt;0.001</td>
<td>0.002</td>
<td></td>
</tr>
</tbody>
</table>

In the 2003-2004 NHANES study, individual PCB congeners associated with a significantly increased odds ratio for unexplained ALT elevation. The adjusted p-trend adjusts for age, sex, race/ethnicity, insulin resistance (HOMA-IR), income (PIR), and obesity (BMI). Adapted from Cave, et al 2010. Used with permission.
CHAPTER ONE: MATERIALS AND METHODS

Study design and recruitment of the ACHS and ACHS-II Cohorts

ACHS

The ACHS cohort was assembled in 2003 and has been previously described\textsuperscript{49, 76}. The two-stage sampling procedure involved, first, the random selection of 3,320 households from a list of all residences within the Anniston city limits. Residences in West Anniston, nearer to the PCB manufacturing facility, were oversampled. ACHS staff visited each of the selected residences, contacting 1,823 of the targeted households. One adult (>18 years of age) from each of 1,110 households agreed to participate and completed an exhaustive questionnaire covering demographic, family history, health history, and specific exposure- and lifestyle-relevant questions. The selected individual also completed a clinic visit, in which biometric measurements (height, weight, blood pressure) were assessed and a fasting serum sample was submitted. The overall completion rate was 61% (of targeted households).

The 738 serum samples represented in our ACHS mechanistic liver damage assessment and cyto/adipokine evaluation are comprised of adults completing both the survey and a clinic visit, in which a fasting blood sample was successfully submitted for analysis.

ACHS MicroRNA subcohort

152 ACHS samples submitted to the laboratory of Dr. Brian Chorley (US EPA) were selected from a stratified subset of the original 738 in which the above parameters were assessed (stratifications based on CK18 determined TASH/no liver disease, sex and race).
ACHS-II

ACHS-II was designed to remedy limitations in the original ACHS study design and to provide longitudinal data on exposures and health outcomes in this population. ACHS-II is a subset of the original ACHS cohort, and was approached as an effort to recontact every surviving subject from ACHS. Individuals were recruited to the ACHS-II cohort by a multi-stage and multi-platform methodology described in detail by Birnbaum et al.80 Methods used by ACHS staff to initiate contact or determine ineligibility were: recruitment letters (to all original ACHS participants at baseline addresses) and a public meeting (advertised and covered by local media), further attempts via phone contact (to last known phone numbers of ACHS participants), Social Security Death Index searches. To determine the status and location of participants not reachable at their last listed number, study staff searched the Social Security Death Index, and a second recruitment mailing to all original and updated addresses. Through a combination of these approaches, 359 eligible participants were enrolled in ACHS-II, and of these, the blood volumes of 345 subjects were of adequate quantity for biomarker determination.

The University of Louisville Institutional Review Board approved the studies performed on archived, de-identified samples from these cohorts.

Collection of samples and analysis of polychlorinated organic pollutant concentrations

The de-identified serum samples examined in these studies were collected during the ACHS and ACHS-II studies and archived at -80°C. Identification and quantification of the levels of PCBs (35 ortho-substituted congeners in ACHS and 38 dioxin-like and non-dioxin-like congeners for ACHS-II) and other contaminants was determined by high-resolution gas chromatography/isotope dilution high-resolution mass spectrometry performed at the National Center for Environmental Health Laboratory of the Centers for Disease Control and Prevention (Atlanta, GA)49, 76, 78, 79.

Serum concentrations of contaminants were compared to biomarkers and calculated disease parameters both individually and based on several summation schemes based on
previously reported risk assessment protocols and mechanistic studies. For ACHS, 35 ortho-
substituted congeners were analyzed. In ACHS-II, 35 ortho-substituted congeners, 3 non-ortho,
and several other classes of chemical contaminants were analyzed, including the polychlorinated
dibenzo dioxin (PCDD) and polychlorinated dibenzofuran (PCDF) classes. Composition of these
groupings by individual congener are described in Table 2. Structural/functional groupings of PCB
congeners measured in ACHS-II.

**Measurement of steatohepatitis biomarkers**

CK18 is a structural protein enriched in hepatocytes which can be detected in both whole
and caspase-cleaved forms, allowing for the differentiation of hepatocellular apoptosis (caspase-
cleaved CK18 or M30) from necrosis (CK18 M65). Because the hepatocellular death mechanism
appears to vary by etiology of fatty liver disease, the pattern of CK18 elevation has been used
to differentiate TASH (predominantly necrotic, elevations in CK18 M65 alone) from other fatty liver
diseases (predominantly apoptotic, elevated CK18 M30 and M65). Moreover, unlike
transaminases, which the detectable property of enzyme activity is not retained during long-term
storage, CK18 levels are determined by immunoassay-based protein quantitation, detectable in
samples archived for several decades. This was an important consideration for biomarker
selection, as the original ACHS samples had been archived for 7-9 years prior to our analysis. In
both phases of the Anniston Community Health Survey, CK18 M65 and M30 (PEVIVA 10020 and
10010, Diapharma, Cincinnati, OH) were measured by separate enzyme-linked immunosorbent
assays each using a monoclonal antibody recognizing a different CK18 epitope.

Quantifiable variations in several serum microRNA are associated with liver injury and
other metabolic diseases. A subset of serum samples from the ACHS cohort representing subjects
randomly selected from groups stratified by sex, race and liver disease status (TASH vs. no liver
disease as determined by CK-18) were evaluated for serum levels of 60 liver-associated
microRNAs. These analyses were performed by firefly analysis through our collaborator Brian
Chorley of the EPA.
Liver function tests including alanine transaminase (ALT), asparagine transaminase (AST), alkaline phosphatase (ALP), bilirubin, and albumin are widely used non-invasive clinical screening tools for the assessment of liver injury (of diverse origins). Importantly, however, toxicant-associated steatohepatitis usually presents without transaminitis, in contrast to other forms of liver injury including NASH and ASH when commonly-used normal ranges are applied. A liver function panel including ALT, AST, ALP, total and direct bilirubin and albumin was carried out on ACHS-II samples at the University of Louisville Hospital Clinical Laboratory. Due to limited sample volumes and long storage times, clinical liver function tests were not performed on serum from ACHS.

**Evaluation of other serum biomarkers**

Fasting insulin, adipokines, and pro-inflammatory cytokines were also measured in archived samples from both phases of the Anniston Community Health Survey. Adipocytokines were measured using two separate multiplex bead arrays run on a Luminex IS100 system (EMD Millipore Corporation, Billerica, MA). The first array (HADK2MAG-61K) measured interleukin 6 (IL-6), interleukin 8 (IL-8), monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor α (TNFα), interleukin 1-β (IL-1β), insulin, and leptin. For the second array (HADK1MAG-61K), samples were diluted 1:400 in the provided assay buffer, and adiponectin, resistin, and total plasminogen activator inhibitor-1 (PAI-1) were measured. The homeostatic models of assessment (HOMA) were used to evaluate insulin resistance (HOMA-IR) and pancreatic beta cell function (HOMA-B).

In ACHS-II, hyaluronic acid, an additional fibrosis biomarker was measured by ELISA (#029-001, Corgenix, Inc., Broomfield, CO). Endotoxin was measured by limulus amoebocyte assay (#50-650U, Lonza Walkersville, Inc., Walkersville, MD) and total antioxidant activity was measured by chromogenic assay (#709001, Cayman Chemical Company, Ann Arbor, MI). Serum levels of a wide range of cytokines were provided by collaborators at ATSDR and SUNY, and were evaluated for associations with PCB exposures and TASH indicators.
Derivation of calculated values

Substituted values for contaminant levels beyond the detectable range

Levels of individual congeners reported by the ATSDR laboratory as “undetectable” were substituted with a value equal to the lower limit of detection for the specific congener divided by the square root of 2. When measured concentrations below the stated lower limit of detection were reported from the laboratory, those measurements (rather than substituted values) were used. This method was previously employed to analyze and report associations between serum PCB level and diabetes and hypertension in the ACHS cohort.

Substituted values for serum biomarker levels beyond the detectable range

Biomarkers assessed in our laboratory which were below the level of detection (IL-1β < 1.3 pg/ml; IL-6 < 0.96 pg/ml; insulin < 9.6 pg/ml; IL-8 < 0.64 pg/ml; MCP-1 < 1.3 pg/ml; TNFα < 0.64 pg/ml) were set to half the lower limit of detection. Leptin levels greater than the upper limit of quantification (leptin > 600 ng/ml, 1 record) were set to 600 ng/ml.

Total Lipids

Values for total lipids were calculated by a standard which has been used previously to report findings in the ACHS cohort. The formula for total lipids is listed in Figure 3, Equation 7.

Lipid-adjusted PCB

PCBs are highly lipophilic and move between physiological compartments along with lipids. Therefore, adjustment for the total lipid content of serum is used to normalize total PCB concentrations in serum, and PCBs are expressed PCB wet weight per gram lipid.

HOMA-IR and HOMA-B

The homeostatic model of assessment uses weighted fasting serum glucose and insulin measurements to assess adequacy of compensation mechanisms: insulin secretion in response to glucose load and glucose disposal in response to insulin secretion. Together, they are models
used to determine pancreatic dysfunction vs. insulin resistance as etiologies in hyperglycemia85, 88. The results are dimensionless and represent insulin resistance and percent pancreatic function. Formulae for calculating HOMA parameters are listed in Figure 3, Equations 5 and 6.

**PCB groupings and TEQ**

PCBs have been grouped in various ways by structure and function for purposes of risk assessment and association studies. We incorporated several of these techniques into our analyses. Because only 35 ortho PCBs were quantified in serum samples from the ACHS cohort, for purposes of evaluating significant associations with our measured parameters, we presented the data as lipid-adjusted serum levels of individual congeners and lipid-adjusted levels of the sum of all 35 congeners measured (ΣPCB-O). In ACHS-II, the panel of PCBs and other contaminants was expanded, increasing the number of dioxin-like compounds measured. In this group, we were therefore able to present associations between measured parameters and the lipid-adjusted serum levels of individual congeners and various summations listed in Table 2. Structural/functional groupings of PCB congeners measured in ACHS-II.

As discussed in the introduction, historic focus on toxicity mechanisms dependent on AhR led to the adoption of the toxic equivalency, which is a measure of potency with regards to AhR normalized to the effects of the AhR ligand TCDD. Toxic equivalency factors (TEFs) have been established for some dioxin-like chemicals37. Besides PCBs, other chemical contributors to the total dioxin equivalency (Total Dioxin TEQ) that were measured in ACHS2 included polychlorinated dibenzo-p-dioxins (PCDDs, n=7), polychlorinated dibenzofurans (PCDFs, n=10) and polybrominated diphenyl ethers (PBDEs, n=12). Using the 2005 World Health Organization TEFs, we established toxic equivalency (TEQ) values for each dioxin-like congener, as well as TEQ by class (PCBs, PCDDs, PCDFs) and Total Dioxin TEQ for each sample within the ACHS-II cohort to explore the relationship between AhR activation and biomarker/disease status. TEQs for each congener were derived by multiplying the concentration in each sample by the TEF, and summation of TEQ by class and for all dioxins was carried out by the formulae listed in Figure 3, Equations 1-3 and 4, respectively.
Statistical Analysis

Stratification into liver disease categories

For each cohort, subjects were stratified into three groups based solely on the combination of CK18 M65 and M30 levels: one group without evident liver disease (no liver disease, or NLD, M30<200 U/L and M65<300 U/L) and two groups with liver disease. The two liver disease groups differ by hepatocyte death mechanism: primarily necrotic hepatocyte death characteristic of TASH (M30<200 U/L and M65>300 U/L), and primarily apoptotic hepatocyte death encompassing other forms of liver disease (other liver disease, or OLD, M30>200 U/L). These cutoff values were based on prior studies [69, 89].

Associations between liver disease category and demographic groups or biomarkers

Counts and percentages for the main predictors were determined in the entire ACHS population and for each stratification based on liver disease category. Differences in means and frequencies by liver disease category were tested with a one-way ANOVA or chi-square test, respectively. The TASH and OLD liver disease categories were always compared against NLD. For each biomarker, regression lines were plotted within each category of liver disease status to generate a β coefficient describing the relationship between biomarker and status. Biomarkers were analyzed with multivariable generalized linear models to assess the relationship between serum PCB levels and each outcome including with or without confounders. Unless specified elsewhere, PCB levels were adjusted for log-transformed lipid levels.

Using SAS version 9.4 (SAS Institute, Cary, NC), and a statistical significance level of 0.05, Multinomial logistic regressions models were constructed to analyze the associations of PCB, BMI, and an interaction between PCB levels and BMI adjusted with and without additional confounders. Biomarkers, PCB levels, and total lipid levels were log-transformed. All models used wet-weight (ng/g serum) log-transformed individual PCB congeners with total lipids (also log-transformed) as a covariate. Unless noted elsewhere, all analyses were adjusted for age (years; continuous), body mass index (BMI, kg/m²; continuous), gender (male vs. female), race (African-American vs. non-Hispanic white), diabetes status (none, pre-diabetic, or diabetic), alcohol use and lipid levels.
CHAPTER ONE: RESULTS

Liver injury is prevalent and persistent in a human population highly exposed to environmentally-acquired PCBs

Summaries of population demographics for the three cohorts described are provided in Tables 6-12. In ACHS, the 738-subject cohort was comprised of a high percentage of African-Americans (46.8%), females (70.1%), subjects ≥50 years old (63.0%), non-drinkers (70.6%), and non-smokers (69.0%). Most subjects (80.3%) were either overweight (BMI≥25 kg/m²) or obese (BMI≥30 kg/m²). Subjects were categorized by liver disease status based on elevated CK18 levels consistent with either hepatocellular necrosis (TASH) – elevated CK18-M65 without CK18-M30 elevation, or apoptosis (OLD) with elevated CK18-M30. The prevalence of liver disease was 60.2% including 48.6% with TASH and 11.5% with Other. Higher CK18 M65 levels were found in non-Hispanic whites compared to African-Americans (p<0.001). A univariate sensitivity analysis excluding thirteen subjects with total wet-weight PCB levels beyond four standard deviations of the mean was performed (Table 13). This analysis showed that CK18 M65 was higher in non-Hispanic whites (p<0.001) and in males (p=0.03); while CK18 M30 was higher in non-Hispanic whites (p<0.001) and decreased with age (p=0.01).

In ACHS-II, the 345-subject cohort was comprised of a high percentage of African-Americans (48.7%), females (73.0%), and subjects ≥50 years old (86.1%). As in ACHS, most of the subjects were non-smokers (79.4%), however, more of the participants in ACHS-II consumed alcohol (60.0%), with 51.3% drinking within defined limits and 8.7% drinking more than defined limits. Most subjects (80.0%) were either overweight (25.5%) or obese (51.3%) by the criteria listed above. Prevalence of liver disease in this cohort was 62.0%: 46% with TASH and 16% with OLD. Participants with liver disease were more likely to be younger (p=0.03) and white (p=0.01).
### Table 6
Demographics in ACHS by Liver Disease Status – continuous variables

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>None (n = 294)</th>
<th>TASH (n = 359)</th>
<th>Other (n = 85)</th>
<th>P-value</th>
<th>Total (n = 738)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>54.1±15.7</td>
<td>56.0±16.3a</td>
<td>51.5±15.1</td>
<td>0.04</td>
<td>54.7±15.9</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.5±7.8</td>
<td>30.9±7.7</td>
<td>32.1±7.7</td>
<td>0.34</td>
<td>31.25±7.7</td>
</tr>
<tr>
<td>∑PCBs (ortho, whole weight)</td>
<td>6.4±9.1</td>
<td>7.2±14.4</td>
<td>5.4±10.3</td>
<td>0.40</td>
<td>6.7±12.1</td>
</tr>
<tr>
<td>Total lipids (mg/dL)</td>
<td>611.1±131.7</td>
<td>643.6±163.6b</td>
<td>656.9±192.4c</td>
<td>0.01</td>
<td>632.2±156.3</td>
</tr>
<tr>
<td>Cytokeratin 18 M65 (U/dL)</td>
<td>233.6±42.6</td>
<td>430.6±122.1a,b</td>
<td>792.5±584.9c</td>
<td>&lt;0.001</td>
<td>393.8±276.0</td>
</tr>
<tr>
<td>Cytokeratin 18 M30 (U/dL)</td>
<td>97.9±22.0</td>
<td>124.0±28.2a,b</td>
<td>407.6±324.6c</td>
<td>&lt;0.001</td>
<td>146.3±147.1</td>
</tr>
</tbody>
</table>

Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that cytokeratin 18 levels were used for categorization procedures.

P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories.

- a adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category.
- b adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category.
- c adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
- d Limits are <= 30 drinks for females and <=60 drinks for males.
### Table 7

Demographics in ACHS by Liver Disease Status – biometric categorical variables

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>None (n = 294)</th>
<th>TASH (n = 359)</th>
<th>Other (n = 85)</th>
<th>P-value</th>
<th>Total (n = 738)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>72 (24.5)</td>
<td>123&lt;sup&gt;b&lt;/sup&gt; (34.3)</td>
<td>26 (30.6)</td>
<td><strong>0.03</strong></td>
<td>221 (30.0)</td>
</tr>
<tr>
<td>Female</td>
<td>222 (75.5)</td>
<td>236 (65.7)</td>
<td>59 (69.4)</td>
<td></td>
<td>517 (70.1)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
<td><strong>&lt;0.001</strong></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>117 (39.8)</td>
<td>223&lt;sup&gt;b&lt;/sup&gt; (62.1)</td>
<td>53&lt;sup&gt;c&lt;/sup&gt; (62.4)</td>
<td></td>
<td>393 (53.3)</td>
</tr>
<tr>
<td>African/American</td>
<td>177 (60.2)</td>
<td>136 (37.9)</td>
<td>32 (37.7)</td>
<td></td>
<td>345 (46.8)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td><strong>0.13</strong></td>
<td></td>
</tr>
<tr>
<td>&lt; 30</td>
<td>24 (8.2)</td>
<td>31 (8.7)</td>
<td>8 (9.4)</td>
<td></td>
<td>63 (8.5)</td>
</tr>
<tr>
<td>30-40</td>
<td>41 (14.0)</td>
<td>25 (7.0)</td>
<td>12 (14.1)</td>
<td></td>
<td>78 (10.6)</td>
</tr>
<tr>
<td>40-50</td>
<td>45 (15.3)</td>
<td>69 (19.2)</td>
<td>18 (21.2)</td>
<td></td>
<td>132 (17.9)</td>
</tr>
<tr>
<td>50-60</td>
<td>66 (22.5)</td>
<td>75 (20.9)</td>
<td>20 (23.5)</td>
<td></td>
<td>161 (21.8)</td>
</tr>
<tr>
<td>60-70</td>
<td>63 (21.4)</td>
<td>75 (20.9)</td>
<td>15 (17.7)</td>
<td></td>
<td>153 (20.7)</td>
</tr>
<tr>
<td>≥70</td>
<td>55 (18.7)</td>
<td>84 (23.4)</td>
<td>12 (14.1)</td>
<td></td>
<td>151 (20.5)</td>
</tr>
<tr>
<td>BMI (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
<td><strong>0.40</strong></td>
<td></td>
</tr>
<tr>
<td>&lt; 18.5</td>
<td>3 (1.0)</td>
<td>2 (0.6)</td>
<td>0 (0.0)</td>
<td></td>
<td>5 (0.7)</td>
</tr>
<tr>
<td>18.5 - 24.9</td>
<td>61 (20.8)</td>
<td>67 (18.7)</td>
<td>14 (16.5)</td>
<td></td>
<td>142 (19.3)</td>
</tr>
<tr>
<td>25 - 29.9</td>
<td>62 (21.1)</td>
<td>109 (30.4)</td>
<td>20 (23.5)</td>
<td></td>
<td>191 (26.0)</td>
</tr>
<tr>
<td>30 - 34.9</td>
<td>77 (26.2)</td>
<td>90 (25.1)</td>
<td>22 (25.9)</td>
<td></td>
<td>189 (25.7)</td>
</tr>
<tr>
<td>35 -39.9</td>
<td>48 (16.3)</td>
<td>48 (13.4)</td>
<td>15 (17.7)</td>
<td></td>
<td>111 (15.1)</td>
</tr>
<tr>
<td>≥40</td>
<td>42 (14.3)</td>
<td>42 (11.7)</td>
<td>14 (16.5)</td>
<td></td>
<td>98 (13.3)</td>
</tr>
<tr>
<td>Missing</td>
<td>1 (0.3)</td>
<td>1 (0.3)</td>
<td>0 (0.0)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that cytokeratin 18 levels were used for categorization procedures. P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories.

- **a adj-p<=0.05** in pair-wise comparison of TASH vs. Other liver disease category.
- **b adj-p<=0.05** in pair-wise comparison of None vs. TASH liver disease category.
- **c adj-p<=0.05** in pair-wise comparison of None vs. Other liver disease category.
### Table 8
Demographics in ACHS by Liver Disease Status – lifestyle categorical variables

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>None (n = 294)</th>
<th>TASH (n = 359)</th>
<th>Other (n = 85)</th>
<th>P-value</th>
<th>Total (n = 738)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of drinks in last 30 days</strong></td>
<td></td>
<td></td>
<td></td>
<td>0.70</td>
<td></td>
</tr>
<tr>
<td>No drinks</td>
<td>205 (69.7)</td>
<td>254 (70.8)</td>
<td>62 (72.9)</td>
<td></td>
<td>521 (70.6)</td>
</tr>
<tr>
<td>Within defined limits&lt;sup&gt;d&lt;/sup&gt;</td>
<td>63 (21.4)</td>
<td>73 (20.3)</td>
<td>14 (16.5)</td>
<td></td>
<td>150 (20.3)</td>
</tr>
<tr>
<td>More than limit</td>
<td>16 (5.4)</td>
<td>23 (6.4)</td>
<td>8 (9.4)</td>
<td></td>
<td>47 (6.4)</td>
</tr>
<tr>
<td>Missing</td>
<td>10 (3.4)</td>
<td>9 (2.5)</td>
<td>1 (1.2)</td>
<td></td>
<td>20 (2.7)</td>
</tr>
<tr>
<td><strong>Current Smoker</strong></td>
<td></td>
<td></td>
<td></td>
<td>0.69</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>208 (70.8)</td>
<td>243 (67.7)</td>
<td>58 (68.2)</td>
<td></td>
<td>509 (69.0)</td>
</tr>
<tr>
<td>Yes</td>
<td>86 (29.3)</td>
<td>116 (32.3)</td>
<td>27 (31.8)</td>
<td></td>
<td>229 (31.0)</td>
</tr>
<tr>
<td><strong>West Anniston resident</strong></td>
<td></td>
<td></td>
<td></td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>43 (14.6)</td>
<td>62 (17.3)</td>
<td>12 (14.1)</td>
<td></td>
<td>117 (15.9)</td>
</tr>
<tr>
<td>Yes</td>
<td>251 (85.4)</td>
<td>297 (82.7)</td>
<td>73 (85.9)</td>
<td></td>
<td>621 (84.2)</td>
</tr>
</tbody>
</table>

Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that cytokeratin 18 levels were used for categorization procedures. P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories.

- <sup>a</sup> adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category.
- <sup>b</sup> adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category.
- <sup>c</sup> adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
- <sup>d</sup> Limits are <= 30 drinks for females and <=60 drinks for males.
## Table 9

Demographics in ACHS-II by Liver Disease Status – continuous variables

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>None (n = 131)</th>
<th>TASH (n = 158)</th>
<th>Other (n = 56)</th>
<th>P-value</th>
<th>Total (n = 345)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63.8±12.7</td>
<td>63.4±13.3</td>
<td>59.1±12.9</td>
<td>0.06</td>
<td>62.9±13.1</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>32.0±9.5</td>
<td>31.2±7.2</td>
<td>32.2±7.2</td>
<td>0.59</td>
<td>31.7±8.1</td>
</tr>
<tr>
<td>ΣPCBs (ortho and non-ortho, whole weight), ppb</td>
<td>6.0±6.4</td>
<td>5.4±7.2</td>
<td>5.6±9.8</td>
<td>0.20</td>
<td>5.7±7.4</td>
</tr>
<tr>
<td>Cytokeratin 18 M65 (U/dL)</td>
<td>231.8±46.0</td>
<td>436.7±142.9</td>
<td>624.8±368.1</td>
<td>&lt;.001</td>
<td>389.4±226.5</td>
</tr>
<tr>
<td>Cytokeratin 18 M30 (U/dL)</td>
<td>84.1±26.5</td>
<td>111.6±36.3</td>
<td>380.1±269.8</td>
<td>&lt;.001</td>
<td>144.7±153.1</td>
</tr>
<tr>
<td>Total lipids (mg/dL)</td>
<td>611.1±143.7</td>
<td>632.5±162.1</td>
<td>622.1±154.8</td>
<td>0.47</td>
<td>622.7±154.0</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.07</td>
</tr>
<tr>
<td>Male</td>
<td>26 (19.9)</td>
<td>49 (31.0)</td>
<td>18 (32.1)</td>
<td></td>
<td>93 (27.0)</td>
</tr>
<tr>
<td>Female</td>
<td>105 (80.2)</td>
<td>109 (69.0)</td>
<td>38 (67.9)</td>
<td></td>
<td>252 (73.0)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>50 (38.2)</td>
<td>90 (57.0)</td>
<td>28 (50.0)</td>
<td></td>
<td>168 (48.7)</td>
</tr>
<tr>
<td>African/American</td>
<td>81 (61.8)</td>
<td>68 (43.0)</td>
<td>28 (50.0)</td>
<td></td>
<td>177 (51.3)</td>
</tr>
</tbody>
</table>

Data are n(%) or mean±SD. Not all percents add to 100% due to rounding.

P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories.

Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease; ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis
Table 10

Demographics in ACHS-II by Liver Disease Status – biometric categorical variables

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Liver disease status</th>
<th>P-value</th>
<th>Total (n = 345)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None (n = 131)</td>
<td>TASH (n = 158)</td>
<td>Other (n = 56)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>26 (19.9)</td>
<td>49 (31.0)</td>
<td>18 (32.1)</td>
</tr>
<tr>
<td>Female</td>
<td>105 (80.2)</td>
<td>109 (69.0)</td>
<td>38 (67.9)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>50 (38.2)</td>
<td>90 (57.0)</td>
<td>28 (50.0)</td>
</tr>
<tr>
<td>African/American</td>
<td>81 (61.8)</td>
<td>68 (43.0)</td>
<td>28 (50.0)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 30</td>
<td>0</td>
<td>3 (1.9)</td>
<td>0</td>
</tr>
<tr>
<td>30-40</td>
<td>6 (4.6)</td>
<td>5 (3.2)</td>
<td>5 (8.9)</td>
</tr>
<tr>
<td>40-50</td>
<td>13 (9.9)</td>
<td>11 (7.0)</td>
<td>5 (8.9)</td>
</tr>
<tr>
<td>50-60</td>
<td>24 (18.3)</td>
<td>43 (27.2)</td>
<td>23 (41.1)</td>
</tr>
<tr>
<td>60-70</td>
<td>42 (32.0)</td>
<td>41 (26.0)</td>
<td>10 (17.9)</td>
</tr>
<tr>
<td>≥70</td>
<td>46 (35.1)</td>
<td>55 (34.8)</td>
<td>13 (23.2)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 18.5</td>
<td>1 (0.8)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>18.5 - 24.9</td>
<td>26 (20.0)</td>
<td>32 (20.8)</td>
<td>9 (16.1)</td>
</tr>
<tr>
<td>25 - 29.9</td>
<td>39 (30)</td>
<td>44 (28.6)</td>
<td>15 (26.8)</td>
</tr>
<tr>
<td>30 - 34.9</td>
<td>28 (21.5)</td>
<td>33 (21.4)</td>
<td>11 (19.6)</td>
</tr>
<tr>
<td>35 -39.9</td>
<td>16 (12.3)</td>
<td>28 (18.2)</td>
<td>9 (16.1)</td>
</tr>
<tr>
<td>≥40</td>
<td>20 (15.4)</td>
<td>17 (11.0)</td>
<td>12 (21.4)</td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are n(%) or mean±SD. Not all percents add to 100% due to rounding.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories.
Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease; ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis
Table 11

Demographics in ACHS-II by Liver Disease Status – health and lifestyle categorical variables

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Liver disease status</th>
<th>P-value</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None (n = 131)</td>
<td></td>
<td>(n = 345)</td>
</tr>
<tr>
<td></td>
<td>TASH (n = 158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other (n = 56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes Status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever Diabetic</td>
<td>44 (33.6)</td>
<td>69 (43.7)</td>
<td>24 (42.9)</td>
</tr>
<tr>
<td>Non-diabetic</td>
<td>87 (66.4)</td>
<td>89 (56.3)</td>
<td>32 (57.1)</td>
</tr>
<tr>
<td>Typical Number of Drinks in Past 12 Months</td>
<td></td>
<td>0.43</td>
<td></td>
</tr>
<tr>
<td>No drinks</td>
<td>56 (42.8)</td>
<td>57 (36.1)</td>
<td>25 (44.6)</td>
</tr>
<tr>
<td>Within defined limits&lt;sup&gt;d&lt;/sup&gt;</td>
<td>66 (50.4)</td>
<td>87 (55.1)</td>
<td>24 (42.9)</td>
</tr>
<tr>
<td>More than limit</td>
<td>9 (6.9)</td>
<td>14 (8.9)</td>
<td>7 (12.5)</td>
</tr>
<tr>
<td>Current Smoker</td>
<td></td>
<td>0.88</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>105 (80.8)</td>
<td>124 (78.5)</td>
<td>44 (78.6)</td>
</tr>
<tr>
<td>Yes</td>
<td>25 (19.2)</td>
<td>34 (21.5)</td>
<td>12 (21.4)</td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

Data are n(%) or mean±SD. Not all percents add to 100% due to rounding.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories.

<sup>d</sup> Limits are <= 1 drink/day for females and <=2 drinks/day for males.

Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease; ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis.
Table 12

Demographic characteristics and liver disease status of ACHS microRNA subcohort

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>None</th>
<th>TASH</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 76)</td>
<td>(n = 76)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>56.5±13.8</td>
<td>55.3±14.5</td>
<td>0.62</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30.2±6.0</td>
<td>32.6±8.1</td>
<td>0.045</td>
</tr>
<tr>
<td>∑PCBs (whole weight)</td>
<td>6.8±8.6</td>
<td>11.3±26.6</td>
<td>0.16</td>
</tr>
<tr>
<td>Total lipids (mg/dL)</td>
<td>605.8±139.0</td>
<td>658.6±173.5</td>
<td>0.04</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>38 (50.0)</td>
<td>38 (50.0)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>38 (50.0)</td>
<td>38 (50.0)</td>
<td></td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>31 (40.8)</td>
<td>44 (57.9)</td>
<td></td>
</tr>
<tr>
<td>Nonwhite</td>
<td>45 (59.2)</td>
<td>32 (42.1)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td>0.32</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>2 (2.6)</td>
<td>4 (5.3)</td>
<td></td>
</tr>
<tr>
<td>30-40</td>
<td>10 (13.2)</td>
<td>6 (7.9)</td>
<td></td>
</tr>
<tr>
<td>40-50</td>
<td>11 (14.5)</td>
<td>16 (20.1)</td>
<td></td>
</tr>
<tr>
<td>50-60</td>
<td>16 (20.1)</td>
<td>22 (29.0)</td>
<td></td>
</tr>
<tr>
<td>60-70</td>
<td>22 (29.0)</td>
<td>13 (17.1)</td>
<td></td>
</tr>
<tr>
<td>≥70</td>
<td>15 (19.7)</td>
<td>15 (19.7)</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td></td>
<td>0.31</td>
</tr>
<tr>
<td>18.5 - 24.9</td>
<td>17 (22.7)</td>
<td>9 (12.0)</td>
<td></td>
</tr>
<tr>
<td>25 - 29.9</td>
<td>18 (24.0)</td>
<td>20 (26.7)</td>
<td></td>
</tr>
<tr>
<td>30 - 34.9</td>
<td>24 (32.0)</td>
<td>21 (28.0)</td>
<td></td>
</tr>
<tr>
<td>35 - 39.9</td>
<td>9 (12.0)</td>
<td>13 (17.1)</td>
<td></td>
</tr>
<tr>
<td>≥40</td>
<td>7 (9.3)</td>
<td>12 (16.0)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Number of drinks in last 30 days</td>
<td></td>
<td></td>
<td>0.80</td>
</tr>
<tr>
<td>No drinks</td>
<td>53 (69.7)</td>
<td>53 (69.7)</td>
<td></td>
</tr>
<tr>
<td>Within defined limits**</td>
<td>16 (20.1)</td>
<td>13 (17.1)</td>
<td></td>
</tr>
<tr>
<td>More than limit</td>
<td>5 (6.6)</td>
<td>8 (10.5)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>2 (2.6)</td>
<td>2 (2.6)</td>
<td></td>
</tr>
<tr>
<td>Current Smoker</td>
<td></td>
<td></td>
<td>0.49</td>
</tr>
<tr>
<td>No</td>
<td>50 (65.8)</td>
<td>54 (71.1)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>26 (34.2)</td>
<td>22 (29.0)</td>
<td></td>
</tr>
<tr>
<td>West Anniston resident</td>
<td></td>
<td></td>
<td>0.29</td>
</tr>
<tr>
<td>No</td>
<td>6 (7.9)</td>
<td>10 (13.2)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>70 (92.1)</td>
<td>66 (86.8)</td>
<td></td>
</tr>
</tbody>
</table>

* Not all percents add to 100% due to rounding
** Limits are <= 30 drinks for females and <=60 drinks for males.
Table 13

Univariate associations between demographic/exposure variables and the serum cytokeratin 18 M65 and M30 biomarkers used to categorize liver disease status.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate SE</th>
<th>p-value</th>
<th>Estimate SE</th>
<th>p-value</th>
<th>Estimate SE</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All data</td>
<td>Sensitivity analysis</td>
<td>All data</td>
<td>Sensitivity analysis</td>
<td>All data</td>
<td>Sensitivity analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>-0.46 0.34</td>
<td>0.18</td>
<td>-0.43 0.17</td>
<td>0.01</td>
<td>-1.27 0.46</td>
<td>0.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>12.54 11.82</td>
<td>0.29</td>
<td>-7.44 5.91</td>
<td>0.21</td>
<td>-3.00 27.21</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td>-19.19 10.84</td>
<td>0.08</td>
<td>-21.82 5.39</td>
<td>&lt;0.001</td>
<td>-103.06 24.66</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>1.07 0.71</td>
<td>0.13</td>
<td>0.19 0.35</td>
<td>0.60</td>
<td>-0.06 0.97</td>
<td>0.36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current Smoker</td>
<td>16.32 11.7</td>
<td>0.16</td>
<td>-30.58 26.88</td>
<td>0.53</td>
<td>0.33 0.53</td>
<td>0.53</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB, wet weight</td>
<td>-0.33 0.45</td>
<td>0.46</td>
<td>-1.27 0.43</td>
<td>0.003</td>
<td>-0.46 1.03</td>
<td>0.60</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB, lipid-adjusted</td>
<td>-0.003 0.003</td>
<td>0.36</td>
<td>-0.007 0.003</td>
<td>0.006</td>
<td>-0.004 0.006</td>
<td>0.52</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Sensitivity analysis includes participants with total PCB wet weight values within four standard deviations of the mean. Thirteen participants of 738 were excluded.

Abbreviations: BMI, body mass index; PCB, polychlorinated biphenyls.
Results are presented as Estimates and Standard Error from a generalized linear model analysis.
Results are adjusted for total lipids.

Results are presented as Estimates and Standard Error from a generalized linear model analysis.

Results are adjusted for total lipids.

Results are presented as Estimates and Standard Error from a generalized linear model analysis.

Results are adjusted for total lipids.

Results are presented as Estimates and Standard Error from a generalized linear model analysis.

Results are adjusted for total lipids.

Results are presented as Estimates and Standard Error from a generalized linear model analysis.

Results are adjusted for total lipids.

Results are presented as Estimates and Standard Error from a generalized linear model analysis.

Results are adjusted for total lipids.

Results are presented as Estimates and Standard Error from a generalized linear model analysis.

Results are adjusted for total lipids.

Results are presented as Estimates and Standard Error from a generalized linear model analysis.

Results are adjusted for total lipids.
Significant demographic differences were seen across liver disease categories with respect to age, gender, and race/ethnicity. Males were more likely than females to have TASH (55.7% vs. 45.6%, p<0.05) in ACHS, with gender differences found to be nonsignificant in ACHS-II. In both studies, subjects with TASH were significantly more likely to be non-Hispanic white than subjects without liver disease (62.1% vs. 39.8% in ACHS and 57.0% vs. 38.2% in ACHS-II). The combined prevalence of liver disease was highest among males (67.4% in ACHS and 72.0% in ACHS-II) and non-Hispanic whites (70.2% in both cohorts). These results are consistent with the increased susceptibility to fatty liver disease in Caucasians (compared to African Americans) and males as reported previously in other epidemiological studies. TASH was associated with significantly increased age compared to Other in ACHS (56.0±16.3 vs. 51.5±15.1), but not in ACHS-II. No intragroup differences were seen in other demographic or exposure variables including total PCBs (wet weight) or West Anniston residence, body mass index, alcohol consumption, or smoking status.

Total lipids were significantly increased in both TASH and Other in ACHS (Table 6) while there were no significant intragroup differences for this parameter in ACHS-II (Table 9). Because both necrotic and apoptotic (M30) hepatocyte death contribute to total CK18 (M65), it is not surprising, based on the classification procedures, that CK18 M65 was significantly increased in both liver disease groups compared to None. However, the absolute M65 level was increased to a greater degree in Other compared to TASH, even though only M30 abnormality was used to discriminate between the two.

Liver injury in Anniston is associated with increased pro-inflammatory cytokines and metabolic abnormalities.

Steatohepatitis is associated with increased serum pro-inflammatory cytokines, which can result from and/or lead to liver injury and metabolic disease. As shown in Table 14, IL-1β, IL-6, IL-8, MCP-1, PAI-1, and TNFα were all numerically higher across liver disease categories (graphs), but only MCP-1 (p=0.01) and PAI-1 (p=0.001) reached statistical significance in the
Table 14

Unadjusted ACHS Biomarker levels by liver disease status.

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>None (n = 294)</th>
<th>TASH (n = 359)</th>
<th>Other (n = 85)</th>
<th>P-value</th>
<th>Total (n = 738)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adiponectin ng/ml</td>
<td>17.2±12.4</td>
<td>18.3±19.1</td>
<td>15.1±10.2</td>
<td>0.22</td>
<td>17.5±15.8</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>105.1±40.4</td>
<td>108.2±40.9</td>
<td>115.7±53.9</td>
<td>0.13</td>
<td>107.8±42.5</td>
</tr>
<tr>
<td>HOMA-B</td>
<td>164.2±223.7</td>
<td>183.5±334.3</td>
<td>219.6±306.7</td>
<td>0.29</td>
<td>180.0±291.9</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>3.9±5.4</td>
<td>5.1±8.4</td>
<td>6.4±8.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.01</td>
<td>4.8±7.4</td>
</tr>
<tr>
<td>IL-1β pg/ml</td>
<td>2.4±7.0</td>
<td>10.0±76.4</td>
<td>13.1±79.9</td>
<td>0.17</td>
<td>7.3±60.0</td>
</tr>
<tr>
<td>Not detectable</td>
<td>195</td>
<td>214</td>
<td>52</td>
<td>461</td>
<td></td>
</tr>
<tr>
<td>IL-6 pg/ml</td>
<td>8.5±42.0</td>
<td>16.4±84.9</td>
<td>13.2±40.6</td>
<td>0.32</td>
<td>12.9±66.4</td>
</tr>
<tr>
<td>Not detectable</td>
<td>35</td>
<td>23</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>IL-8 pg/ml</td>
<td>78.7±199.0</td>
<td>101.4±257.4</td>
<td>86.7±304.5</td>
<td>0.49</td>
<td>90.7±242.1</td>
</tr>
<tr>
<td>Not detectable</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Insulin pg/ml</td>
<td>492.8±567.2</td>
<td>642.3±1067.2</td>
<td>757.7±918.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.02</td>
<td>596.0±886.4</td>
</tr>
<tr>
<td>Not detectable</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>LDL, mg/dl</td>
<td>117.0±32.7</td>
<td>116.0±39.8</td>
<td>116.5±40.1</td>
<td>0.94</td>
<td>116.5±37.1</td>
</tr>
<tr>
<td>Leptin ng/ml</td>
<td>30.5±27.0</td>
<td>29.3±39.7</td>
<td>26.1±25.1</td>
<td>0.57</td>
<td>29.4±33.6</td>
</tr>
<tr>
<td>Not detectable</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>MCP-1 pg/ml</td>
<td>269.7±175.2</td>
<td>295.1±244.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>314.9±193.6</td>
<td>0.01</td>
<td>294.6±194.1</td>
</tr>
<tr>
<td>Not detectable</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>PAI-1 ng/ml</td>
<td>49.0±19.4</td>
<td>54.9±21.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>56.0±23.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.001</td>
<td>52.7±21.1</td>
</tr>
<tr>
<td>Resistin ng/ml</td>
<td>41.0±31.7</td>
<td>44.1±29.8</td>
<td>37.8±19.1</td>
<td>0.15</td>
<td>42.1±29.6</td>
</tr>
<tr>
<td>TNFα pg/ml</td>
<td>6.4±5.5</td>
<td>9.2±24.2</td>
<td>7.0±7.1</td>
<td>0.11</td>
<td>7.8±17.4</td>
</tr>
<tr>
<td>Not detectable</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>119.3±75.5</td>
<td>147.0±107.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>160.6±130.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.0002</td>
<td>137.5±100.3</td>
</tr>
</tbody>
</table>

P-value is one-way ANOVA, across all liver disease categories, unadjusted.

<sup>a</sup> adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
<sup>b</sup> adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category.
<sup>c</sup> adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category.
unadjusted model. MCP-1 was higher in TASH than None (295.1±244.4 pg/ml vs. 269.7±175.2 pg/ml, p=0.009). PAI-1 was increased in both TASH (54.9±21.4 ng/ml, p=.001) and Other (56.0±23.3 ng/ml, p=0.02) compared to None (49.0±19.4 ng/ml).

NAFLD is also commonly associated with insulin resistance and hypertriglyceridemia. The mean HOMA-IR for the overall cohort was elevated (4.8±7.4) beyond one proposed cutoff for insulin resistance (HOMA-IR >4.65 or HOMA-IR >3.60 and BMI >27.5 kg/m²). HOMA-IR varied significantly across liver disease groups (p=0.01), and it was increased in Other compared to None (6.4±8.3 vs. 3.9±5.4, p=.017). While HOMA-IR was numerically higher in TASH (5.1±8.4) than None, this trend did not reach statistical significance. Fasting insulin varied in a pattern like that observed for HOMA-IR (Table 14), and likely accounted for the observed difference in HOMA-IR as glucose levels were not different between groups. Triglycerides varied by liver disease category (p=0.007) and were higher in both TASH (147.0±107.5 mg/dl, p=.001) and Other (160.6±130.7 mg/dl, p=.002) vs. None (119.3±75.5 mg/dl). In summary, both TASH and Other were associated with increased PAI-1 and triglycerides. MCP-1 was also increased in TASH, while both HOMA-IR and insulin were increased in Other.

In ACHS, TASH was associated with increased levels of IL-1β (p=0.04), IL-6 (p=0.03), and PAI-1 (p=0.03) in our unadjusted model (Table 15). Beta coefficients for other pro-inflammatory cytokines including IL-8, MCP-1, resistin, and TNFα were positive in TASH but did not reach statistical significance. TASH was also associated with increased HOMA-IR (p=0.001) with increased pancreatic insulin production (HOMA-B, p=0.003) and increased insulin levels (p=0.01) (Table 16) Other was associated with increased IL-6 (p=0.01), HOMA-IR (p=0.02), insulin (p=0.04), and decreased leptin (p=0.01). Thus, the liver disease categories remained associated with increased pro-inflammatory cytokines and hepatic insulin resistance after adjustment for confounders, although the specific cytokines varied slightly between models. This increases the certainty that the categorization procedures correctly identified liver disease. TASH appeared more pro-inflammatory than Other due to the greater number of associated cytokines.
Table 15

Adjusted* beta coefficients of associations of ΣPCBs (wet weight) and liver status with inflammatory biomarkers

<table>
<thead>
<tr>
<th></th>
<th>PCB</th>
<th>TASH vs. None</th>
<th>Other vs. None</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1β</td>
<td>0.01</td>
<td>0.18</td>
<td>0.25</td>
</tr>
<tr>
<td></td>
<td>0.05</td>
<td>0.09</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td>0.90</td>
<td>0.04</td>
<td>0.07</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.05</td>
<td>0.27</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>0.05</td>
<td>0.09</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td>0.33</td>
<td>0.003</td>
<td>0.01</td>
</tr>
<tr>
<td>IL-8</td>
<td>0.08</td>
<td>0.15</td>
<td>-0.04</td>
</tr>
<tr>
<td></td>
<td>0.07</td>
<td>0.12</td>
<td>0.18</td>
</tr>
<tr>
<td></td>
<td>0.25</td>
<td>0.20</td>
<td>0.83</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.02</td>
<td>0.01</td>
<td>-0.07</td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>0.05</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td>0.53</td>
<td>0.91</td>
<td>0.36</td>
</tr>
<tr>
<td>PAI-1</td>
<td>-0.01</td>
<td>0.07</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>0.02</td>
<td>0.03</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>0.51</td>
<td>0.03</td>
<td>0.15</td>
</tr>
<tr>
<td>TNFα</td>
<td>0.04</td>
<td>0.07</td>
<td>-0.04</td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>0.06</td>
<td>0.09</td>
</tr>
<tr>
<td></td>
<td>0.26</td>
<td>0.20</td>
<td>0.65</td>
</tr>
</tbody>
</table>

*Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity, diabetes, and alcohol use.
Table 16

Adjusted\(^a\) beta coefficients of associations of ΣPCBs (wet weight) and liver status with metabolic biomarkers

<table>
<thead>
<tr>
<th>Cytokine/Adipokine</th>
<th>β</th>
<th>Standard Error</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adiponectin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB</td>
<td>0.01</td>
<td>0.03</td>
<td>0.69</td>
</tr>
<tr>
<td>TASH vs. None</td>
<td>-0.04</td>
<td>0.05</td>
<td>0.43</td>
</tr>
<tr>
<td>Other vs. None</td>
<td>-0.06</td>
<td>0.08</td>
<td>0.43</td>
</tr>
<tr>
<td>Glucose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB</td>
<td>&lt;0.001</td>
<td>0.01</td>
<td>1.00</td>
</tr>
<tr>
<td>TASH vs. None</td>
<td>0.00</td>
<td>0.02</td>
<td>0.90</td>
</tr>
<tr>
<td>Other vs. None</td>
<td>0.03</td>
<td>0.03</td>
<td>0.18</td>
</tr>
<tr>
<td>Insulin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB</td>
<td>-0.07</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>TASH vs. None</td>
<td>0.22</td>
<td>0.06</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Other vs. None</td>
<td>0.19</td>
<td>0.09</td>
<td>0.04</td>
</tr>
<tr>
<td>HOMA-B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB</td>
<td>-0.07</td>
<td>0.04</td>
<td>0.08</td>
</tr>
<tr>
<td>TASH vs. None</td>
<td>0.20</td>
<td>0.07</td>
<td>0.003</td>
</tr>
<tr>
<td>Other vs. None</td>
<td>0.13</td>
<td>0.10</td>
<td>0.22</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB</td>
<td>-0.08</td>
<td>0.04</td>
<td>0.03</td>
</tr>
<tr>
<td>TASH vs. None</td>
<td>0.21</td>
<td>0.06</td>
<td>0.001</td>
</tr>
<tr>
<td>Other vs. None</td>
<td>0.21</td>
<td>0.09</td>
<td>0.02</td>
</tr>
<tr>
<td>Leptin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB</td>
<td>-0.14</td>
<td>0.04</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TASH vs. None</td>
<td>-0.06</td>
<td>0.06</td>
<td>0.32</td>
</tr>
<tr>
<td>Other vs. None</td>
<td>-0.24</td>
<td>0.09</td>
<td>0.01</td>
</tr>
<tr>
<td>Resistin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCB</td>
<td>0.01</td>
<td>0.03</td>
<td>0.81</td>
</tr>
<tr>
<td>TASH vs. None</td>
<td>0.06</td>
<td>0.05</td>
<td>0.20</td>
</tr>
<tr>
<td>Other vs. None</td>
<td>-0.06</td>
<td>0.07</td>
<td>0.41</td>
</tr>
</tbody>
</table>

\(^a\)Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity, diabetes, and alcohol use.
Liver injury in Anniston was validated by microRNA analysis and clinical liver function tests

Analysis of serum microRNA was used to validate the findings of ACHS in a subset of the cohort, described as the ACHS miRNA cohort. Demographic findings for this population are shown in Table 12. This semi-balanced subgroup differs from the other two in several demographic characteristics. TASH participants tended to have higher BMI (kg/m²: 32.6 vs. 30.2, p = 0.045), total lipids (mg/dL: 659 vs. 606, p = 0.04) and insulin/HOMA-B/HOMA-IR (p = 0.01, 0.045, 0.01). They were more likely to be non-Hispanic white (58% vs. 41%, p = 0.03). Serum levels of 68 microRNAs related to liver and other metabolic disease were quantified by Firefly assay and compared between CK18-defined TASH and NLD groups in this subcohort.

Differential levels of several microRNAs related to liver injury were seen between two liver disease categories. The well-characterized biomarker of liver injury, microRNA 122 (miR-122-5p), was significantly increased in the TASH group vs. the no liver disease (NLD) group. Several other liver- and metabolic disease-associated microRNA were different between the two groups as well, including miR-22-3p, miR-320a, and miR-375 (significantly increased), and miR-223-3p was significantly decreased in TASH vs. NLD (Table 17).

Several microRNA showed significant positive and/or negative associations with the individual isoforms of CK18, including miR-122, which was associated with an increase in CK18-M30 and a smaller positive association with CK18-M65. Of the microRNA transcripts assayed, only miR-877-5p displayed a similar pattern. Other microRNA showed either positive (hsa_miR_22_3p, hsa_miR_320a, hsa_miR_375, or negative (hsa_miR_21_5p, hsa_miR_375, hsa_miR_92a_3p) association with CK18-M65 alone. Positive and negative associations (β-coefficients) for microRNA vs. CK-18 isoforms are shown in Table 18.

Liver injury in ACHS-II was validated using clinical liver function tests (LFT). Clinical liver function tests including ALT, AST, Alkaline phosphatase, and total bilirubin were significantly elevated in the liver disease categories vs. control (Table 19). It is interesting to note, however, that by standard cutoffs used by the NHANES laboratory, prevalence of ALT abnormality in ACHS2 for females and males (respectively) would be 7.6% and 3.9% in the NLD category, 42% and 56% in the OLD category, and 22% and 8.2% in the TASH category, respectively. By the cutoffs
### Table 17

ACHS validation - miRNA data by CK18 liver disease group

<table>
<thead>
<tr>
<th>Probe</th>
<th>Fold</th>
<th>Adj-P</th>
<th>FDR</th>
<th>Raw-P</th>
<th>NLD</th>
<th>TASH</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa_miR_122_5p</td>
<td>1.58</td>
<td>0.02</td>
<td>0.01</td>
<td>0.003</td>
<td>83.37</td>
<td>132.13</td>
</tr>
<tr>
<td>hsa_miR_223_3p</td>
<td>0.91</td>
<td>0.33</td>
<td>0.06</td>
<td>0.047</td>
<td>533.99</td>
<td>485.08</td>
</tr>
<tr>
<td>hsa_miR_22_3p</td>
<td>1.09</td>
<td>0.26</td>
<td>0.05</td>
<td>0.04</td>
<td>865.24</td>
<td>941.12</td>
</tr>
<tr>
<td>hsa_miR_320a</td>
<td>1.09</td>
<td>0.04</td>
<td>0.01</td>
<td>0.01</td>
<td>1320.94</td>
<td>1444.48</td>
</tr>
<tr>
<td>hsa_miR_375</td>
<td>1.18</td>
<td>0.12</td>
<td>0.03</td>
<td>0.02</td>
<td>6.94</td>
<td>8.19</td>
</tr>
<tr>
<td>hsa_miR_92a_3p</td>
<td>0.93</td>
<td>0.02</td>
<td>0.01</td>
<td>0.003</td>
<td>1457.91</td>
<td>1357.75</td>
</tr>
</tbody>
</table>

A subset of samples from ACHS Phase 1 were analyzed for levels of specific microRNA (miRNA) species associated with liver and/or metabolic disease. Individuals with CK18-indicated TASH (TASH) were compared to individuals with CK levels indicating no liver disease (NLD). Included in this table are those with a significant difference between groups (raw p-value < .05).
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa_miR_122_5p</td>
<td>1.00 0.33</td>
<td>0.003</td>
<td>0.20 0.09</td>
<td>0.02</td>
</tr>
<tr>
<td>hsa_miR_21_5p</td>
<td>0.01 0.13</td>
<td>0.94</td>
<td>-0.19 0.08</td>
<td>0.02</td>
</tr>
<tr>
<td>hsa_miR_22_3p</td>
<td>0.09 0.09</td>
<td>0.31</td>
<td>0.14 0.05</td>
<td>0.01</td>
</tr>
<tr>
<td>hsa_miR_29a_3p</td>
<td>-0.05 0.08</td>
<td>0.52</td>
<td>-0.10 0.05</td>
<td>0.06</td>
</tr>
<tr>
<td>hsa_miR_29c_3p</td>
<td>-0.10 0.10</td>
<td>0.36</td>
<td>-0.10 0.06</td>
<td>0.11</td>
</tr>
<tr>
<td>hsa_miR_320a</td>
<td>0.09 0.07</td>
<td>0.19</td>
<td>0.10 0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>hsa_miR_375</td>
<td>0.09 0.15</td>
<td>0.55</td>
<td>0.20 0.09</td>
<td>0.03</td>
</tr>
<tr>
<td>hsa_miR_503_5p</td>
<td>-0.04 0.10</td>
<td>0.70</td>
<td>-0.12 0.06</td>
<td>0.05</td>
</tr>
<tr>
<td>hsa_miR_877_5p</td>
<td>0.20 0.10</td>
<td>0.04</td>
<td>0.14 0.06</td>
<td>0.02</td>
</tr>
<tr>
<td>hsa_miR_92a_3p</td>
<td>-0.08 0.05</td>
<td>0.15</td>
<td>-0.09 0.03</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Several miRNA species showed significant positive or negative associations with either CK18 M30 level or CK18 M65 level.
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>None (n = 131)</th>
<th>TASH (n = 158)</th>
<th>Other (n = 56)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST</td>
<td>25.9±8.1</td>
<td>29.0±12.1</td>
<td>42.2±27.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ALT</td>
<td>22.8±8.6</td>
<td>29.6±9.8</td>
<td>38.3±19.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Alk Phos</td>
<td>85.5±22.7</td>
<td>91.1±38.9</td>
<td>104.7±58.0</td>
<td>0.01</td>
</tr>
<tr>
<td>Albumin</td>
<td>4.2±0.4</td>
<td>4.2±0.4</td>
<td>4.2±0.5</td>
<td>0.85</td>
</tr>
<tr>
<td>Total Bilirubin</td>
<td>0.36±0.16</td>
<td>0.42±0.24</td>
<td>0.46±0.24</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Liver injury was validated in ACHS 2 (Phase 2) using the clinical liver injury biomarkers aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (Alk Phos), albumin, and total bilirubin.
suggested in Prati et al., (Table 20) prevalence of ALT abnormality in ACHS2 for females and males (respectively) would be 61% and 15% in the NLD category, 76% and 94% in the other liver disease (OLD) category, and 82% and 33% in the TASH category. By either set of definitions, ALT performs better as a diagnostic tool for individuals with liver injury in which the predominant mechanism of cell death is apoptosis.

**Associations between ΣPCBs on Liver Disease as assessed by CK18, LFTs and miRNA 122**

Previous epidemiologic studies have demonstrated dose responses for PCBs in liver disease \(^{95-99}\), and animal studies have demonstrated interactions between PCBs and diet-induced obesity in steatohepatitis\(^{22, 23}\). Univariate analysis was performed in the ACHS-1 cohort to determine associations between ΣPCBs and the liver injury biomarkers used to derive the liver injury categories (Table 13). There were no significant associations between ΣPCB exposure variables (lipid-adjusted or wet weight) and either CK18 M65 or M30 in the population overall. A sensitivity analysis was performed, excluding thirteen participants of 738 with total PCB wet weight values within four standard deviations of the mean. In this sensitivity analysis alone, significant negative associations were found between both lipid-adjusted and wet-weight serum PCB content and CK18 M30, but not M65.

Multinomial logistic regression was performed using multivariate models adjusted with or without additional confounders to investigate possible relationships between ΣPCBs and BMI and liver disease status (Table 21). Liver disease status was not associated with either ΣPCB levels or BMI whether alone or in combination. In both cohorts, there was no association between ΣPCBs or ΣPCB-O on liver disease status as determined by CK-18 (Table 22). When taken together, these results demonstrate that these two summation techniques, ΣPCBs and ΣPCB-O, were not associated with CK-18-indicated liver disease status.

In the ACHS microRNA subcohort, after adjustment for age and race there was no association between ΣPCB-O and miRNA 122. Two other miRNA were significantly positively associated (hsa-let-7d-5p and hsa-miR-181d-5p) (Table 23). In ACHS-II, after adjustment, there was were no associations between ΣPCB-O and clinical LFTs (data not shown).
### Table 20

**Cutoff values for upper limit of normal for the clinical liver injury biomarker alanine aminotransferase (ALT)**

<table>
<thead>
<tr>
<th>Age Group</th>
<th>UofL upper limit of reference</th>
<th>Prati, 2002 upper limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men 18-21</td>
<td>ALT ≥ 37 IU/L</td>
<td>ALT ≥ 70 IU/L</td>
</tr>
<tr>
<td>Men &gt;21</td>
<td>ALT ≥ 48 IU/L</td>
<td>ALT ≥ 70 IU/L</td>
</tr>
<tr>
<td>Women 18-21</td>
<td>ALT ≥ 30 IU/L</td>
<td>ALT ≥ 70 IU/L</td>
</tr>
<tr>
<td>Women &gt;21</td>
<td>ALT ≥ 31 IU/L</td>
<td>ALT ≥ 70 IU/L</td>
</tr>
</tbody>
</table>

Several cutoff values for the upper limit of normal have been proposed to define liver disease based on serum alanine aminotransferase levels.
Table 21: Effects of PCBs and BMI on liver disease status by multinomial logistic regression.

<table>
<thead>
<tr>
<th></th>
<th>Univariate Analysis</th>
<th>Multivariate Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Estimate (SE)</td>
<td>Estimate (SE)</td>
</tr>
<tr>
<td>PCBc</td>
<td>0.095 (0.24)</td>
<td>-0.01 (0.41)</td>
</tr>
<tr>
<td>BMI</td>
<td>0.009 (0.01)</td>
<td>0.002 (0.02)</td>
</tr>
<tr>
<td>PCBc*BMI</td>
<td>0.004 (0.01)</td>
<td>0.002 (0.01)</td>
</tr>
<tr>
<td>Lipidc, ng/g</td>
<td>0.93 (0.36)</td>
<td>0.70 (0.57)</td>
</tr>
<tr>
<td>Age, years</td>
<td>-0.004 (0.01)</td>
<td>-0.02 (0.01)</td>
</tr>
<tr>
<td>Gender</td>
<td>-0.46 (0.19)</td>
<td>-0.32 (0.29)</td>
</tr>
<tr>
<td>Race</td>
<td>-1.05 (0.21)</td>
<td>-1.01 (0.32)</td>
</tr>
<tr>
<td>Alcohol Use</td>
<td>0.14 (0.20)</td>
<td>0.02 (0.30)</td>
</tr>
<tr>
<td>Pre-diabetic</td>
<td>0.24 (0.22)</td>
<td>0.52 (0.34)</td>
</tr>
<tr>
<td>Diabetic</td>
<td>0.42 (0.21)</td>
<td>0.64 (0.32)</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; PCB, Polychlorinated Biphenyl; SE, standard error.

Notes: Reference category is no liver disease.

a Adjusted for age, gender, race, diabetes status, alcohol use, and lipid levels (natural log-transformed).

b Adjusted for lipid levels (natural log-transformed).

c Natural log-transformed.
### Table 22

**PCB groupings and CK-18 liver disease status in ACHS and ACHS-II**

<table>
<thead>
<tr>
<th>Group</th>
<th>Total (n = 738)</th>
<th>None (n = 294)</th>
<th>TASH (n = 359)</th>
<th>Other (n = 85)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td></td>
</tr>
<tr>
<td>ACHS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.4 ± 1.6</td>
<td>5.6 ± 0.4</td>
<td>8.0 ± 0.9</td>
<td>6.7 ± 1.2</td>
<td>0.40</td>
</tr>
<tr>
<td></td>
<td>6.2 ± 1.4</td>
<td>4.9 ± 1.3</td>
<td>7.7 ± 1.7</td>
<td>6.0 ± 0.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.7 ± 3.8</td>
<td>11.4 ± 3.5</td>
<td>14.8 ± 4.1</td>
<td>12.4 ± 3.2</td>
<td></td>
</tr>
</tbody>
</table>

**Note:**
- Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that cytokeratin 18 levels were used for categorization procedures.
- P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories. c adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.

---

**Table 22**

<table>
<thead>
<tr>
<th>Group</th>
<th>Total (n = 345)</th>
<th>None (n = 131)</th>
<th>TASH (n = 158)</th>
<th>Other (n = 56)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td></td>
</tr>
<tr>
<td>ACHS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.4 ± 1.6</td>
<td>5.6 ± 0.4</td>
<td>8.0 ± 0.9</td>
<td>6.7 ± 1.2</td>
<td>0.40</td>
</tr>
<tr>
<td></td>
<td>6.2 ± 1.4</td>
<td>4.9 ± 1.3</td>
<td>7.7 ± 1.7</td>
<td>6.0 ± 0.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.7 ± 3.8</td>
<td>11.4 ± 3.5</td>
<td>14.8 ± 4.1</td>
<td>12.4 ± 3.2</td>
<td></td>
</tr>
</tbody>
</table>

**Note:**
- Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that cytokeratin 18 levels were used for categorization procedures.
- P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories. c adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
Table 23

Significant associations of $\Sigma$PCBs and miRNA species

<table>
<thead>
<tr>
<th>miRNA species</th>
<th>$\beta$</th>
<th>Standard Error</th>
<th>Raw-P</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa_let_7d_5p</td>
<td>0.07</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td>hsa_miR_181d_5p</td>
<td>0.08</td>
<td>0.03</td>
<td>0.003</td>
</tr>
</tbody>
</table>

After adjustment for lipids, age, race, and inter-plate variation, no significant relationship was found between the specific liver injury biomarker miRNA-122 and $\Sigma$PCBs. Two other miRNA species, miRNA-let-7d and miRNA-181d, were positively associated with $\Sigma$PCBs.
**Associations between individual PCB congeners and CK18-indicated liver disease in ACHS**

In the ACHS 1 cohort, TASH was positively associated with 10 PCB congeners (PCB 28, 44, 49, 52, 66 101, 110, 128, 149, 151). Three congeners associated with TASH were also associated with Other (PCB 44, 49, 52). To explore the relationship between PCB levels and cell death mechanism, we examined associations between levels of individual congeners and absolute levels of CK18 M65 and M30. Thirteen congeners were positively associated with CK18 M65, while four PCBs were positively associated with M30 (Table 24). In ACHS1, consistent with the concept that TASH is ‘toxicant-associated’, more PCB congeners were associated with TASH than Other (10 vs. 3). The relationships between serum PCB concentration and CK18 M65/M30 were different for individual congeners than for summed groups. Although 13 congeners were positively associated with CK18 M65, ΣPCBs was not associated with this hepatocellular necrosis biomarker. While four congeners were positively associated with M30, ΣPCBs was inversely associated with this hepatocyte apoptosis biomarker.

In the ACHS1 population, therefore, PCBs were associated with both liver disease status and mode of hepatocyte death. Future experimental studies are required to evaluate the possible mechanistic role of PCBs in liver cell death. While animal studies have reported interactions between PCB exposures and diet-induced obesity in steatohepatitis, no significant interaction was found between ΣPCBs and BMI on liver disease status in this study. However, this analysis may have been limited by the high prevalence of overweight/obesity and the elevated PCB levels in this population.

**Associations between TEQs for PCB congeners and other dioxin-like species on CK18-indicated liver injury in ACHS-II**

Within the ACHS-II population, we estimated effects of dioxin-like chemicals on liver disease by using the TEQ protocol. As mentioned previously, the effects of dioxin-like chemicals have historically been attributed to AhR-mediated mechanisms, and the TEQ, by estimating the cumulative, weighted load of AhR ligands, can be used as an exposure variable to explore the
<table>
<thead>
<tr>
<th>PCB Congener</th>
<th>Liver Diseasea vs. None</th>
<th>M30b</th>
<th>M65b</th>
<th>TASH vs. None</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>0.24</td>
<td>0.03</td>
<td>0.07</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>44</td>
<td>0.45</td>
<td>0.04</td>
<td>0.73</td>
<td>0.02</td>
</tr>
<tr>
<td>49</td>
<td>0.66</td>
<td>0.004</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>52</td>
<td>0.37</td>
<td>0.01</td>
<td>0.09</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>66</td>
<td>0.29</td>
<td>0.002</td>
<td>0.05</td>
<td>0.01</td>
</tr>
<tr>
<td>101</td>
<td>0.20</td>
<td>0.05</td>
<td>0.05</td>
<td>0.02</td>
</tr>
<tr>
<td>105</td>
<td>0.04</td>
<td>0.04</td>
<td>0.05</td>
<td>0.04</td>
</tr>
<tr>
<td>110</td>
<td>0.36</td>
<td>0.11</td>
<td>0.10</td>
<td>0.11</td>
</tr>
<tr>
<td>114</td>
<td>0.04</td>
<td>0.03</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>117</td>
<td>0.04</td>
<td>0.03</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>128</td>
<td>0.22</td>
<td>0.02</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>149</td>
<td>0.24</td>
<td>0.02</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>151</td>
<td>0.25</td>
<td>0.01</td>
<td>0.05</td>
<td>0.04</td>
</tr>
<tr>
<td>172</td>
<td>0.04</td>
<td>0.02</td>
<td>0.03</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Note that all congeners given in this table had at least a 96.7% detection rate. No significant differences were seen for PCB congeners 74, 88, 99, 118, 138, 156, 157, 167, 170, 177, 180, 183, 189, 194, 196, 199, 206, 209.

Multinomial model adjusted for age, sex, race, alcohol use, log lipids, diabetes.

Regression model adjusted for age, sex, race, alcohol use, log lipids, diabetes (pre- and any vs. none).

Abbreviations: M30: M30-adjusted beta coefficients; M65: M65-adjusted beta coefficients; TASH: TASH-adjusted beta coefficients; Other vs. None: Other disease status vs. None; Liver Disease: Liver disease status; PCB: Polychlorinated biphenyls; Table 24: Table 24 from the text.
The relationship between AhR induction and disease biomarkers. Associations between Total dioxin TEQ, TEQ by individual class (PCDD, PCDF, PCB), and TEQ for each dioxin-like chemical with a TEF available in the 2005 WHO evaluation were evaluated and are presented in Table 25. Adjusted beta coefficients of significant associations of various TEQ summations and cytokeratin 18 biomarkers are shown in Table 26. We did not find significant associations between log transformed mean of any TEQ sum and TASH status vs. None. Non-Ortho PCB TEQ and Total Dioxins TEQ were significantly lower in the Other liver disease category compared to None.

**Associations between PCBs and other serum biomarkers**

PCB exposure has previously been associated with diabetes. However, less is known regarding the potential impact of PCBs on adipocytokines. For ACHS, the effects of lipid-adjusted ΣPCB levels on unadjusted adipocytokines and biomarkers of glucose and lipid metabolism are given as beta coefficients in Table 16. The pro-inflammatory cytokines TNFα (p<0.001) and IL-6 (p=0.001), were positively associated with ΣPCBs in the unadjusted model. PCBs had no significant effects on IL-1β, IL-8, MCP-1, PAI-1, or resistin. HOMA-B (p<0.001) and insulin (p=0.03) levels were inversely associated with ΣPCB levels; while no effect was seen on HOMA-IR. Adiponectin was positively associated with PCBs (p=0.01) while no difference was seen in leptin. Regression curves presented in Figure 6 graphically depict the relationships between log-transformed insulin and leptin levels with log-transformed ΣPCBs in ACHS.

For the ACHS-2 unadjusted model, biomarkers which varied significantly with changes to serum concentrations of all PCBs measured (ΣPCB), 35 ortho-substituted congeners (ΣPCB-O), or the non-dioxin-like congeners (ΣNDL) are shown in Table 27. In the same population and model, the biomarkers which varied significantly with changes to serum concentrations of tri/tetra-ortho substituted congeners (ΣPCB-TO), di-ortho substituted congeners (ΣPCB-DO), or mono-ortho substituted congeners (ΣPCB-MO) are shown in Table 28, while those which varied significantly with changes to serum concentrations of non-ortho substituted congeners (ΣPCB-NO), or dioxin-like (ΣDL) are shown in Table 29. A summary of the congeners represented in each grouping is presented in Table 2.
Table 25: TEQ for dioxin-like PCBs and other dioxin-like species and CK-18-indicated liver disease status in ACHS-II

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>None (n = 131)</th>
<th>TASH (n = 158)</th>
<th>Other (n = 56)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean SD</td>
<td>4.4 0.44</td>
<td>3.6 2.1</td>
<td>4.5 0.34</td>
<td></td>
</tr>
<tr>
<td>TEQ, log-transformed</td>
<td>2.0 1.4</td>
<td>3.0 1.9</td>
<td>3.0 1.7</td>
<td></td>
</tr>
<tr>
<td>PCB 126 TEQ, log-transformed</td>
<td>9.0 3.3</td>
<td>9.7 3.3</td>
<td>9.7 3.3</td>
<td></td>
</tr>
<tr>
<td>PCB 169 TEQ, log-transformed</td>
<td>1.7 1.0</td>
<td>1.7 1.0</td>
<td>1.7 1.0</td>
<td></td>
</tr>
<tr>
<td>Non-ortho PCBs TEQ, log-transformed</td>
<td>16.2 4.0</td>
<td>17.8 4.0</td>
<td>17.8 4.0</td>
<td></td>
</tr>
<tr>
<td>PCDD TEQ, log-transformed</td>
<td>12.2 7.8</td>
<td>12.2 7.8</td>
<td>12.2 7.8</td>
<td></td>
</tr>
<tr>
<td>PCDF TEQ, log-transformed</td>
<td>3.0 1.7</td>
<td>3.0 1.7</td>
<td>3.0 1.7</td>
<td></td>
</tr>
<tr>
<td>PCDD, PCDF, oCPS, log-transformed</td>
<td>25.2 20.7</td>
<td>25.2 20.7</td>
<td>25.2 20.7</td>
<td></td>
</tr>
<tr>
<td>Total Dioxin TEQ, log-transformed</td>
<td>29.2 24.1</td>
<td>29.2 24.1</td>
<td>29.2 24.1</td>
<td></td>
</tr>
<tr>
<td>12378_PeCDD TEQ, log-transformed</td>
<td>5.9 3.6</td>
<td>5.9 3.6</td>
<td>5.9 3.6</td>
<td></td>
</tr>
<tr>
<td>123678_HxCDD TEQ, log-transformed</td>
<td>3.2 1.9</td>
<td>3.2 1.9</td>
<td>3.2 1.9</td>
<td></td>
</tr>
<tr>
<td>23478_PeCDF TEQ, log-transformed</td>
<td>2.0 1.4</td>
<td>2.0 1.4</td>
<td>2.0 1.4</td>
<td></td>
</tr>
</tbody>
</table>

Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that cytokeratin 18 levels were used for categorization procedures. P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories. c adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
Table 26

Adjusted beta coefficients of significant associations of various TEQ summations and CK-18 biomarkers in ACHS-II.

<table>
<thead>
<tr>
<th>Exposure and CK18 values are log-transformed</th>
<th>Total TEQ</th>
<th>1,2,3,7,8-PcDF TEQ</th>
<th>Other summations</th>
<th>PDD and PCDF</th>
<th>Other non-ortho PCB</th>
<th>PCDF, PCDD, AND NON-ortho PCB</th>
</tr>
</thead>
<tbody>
<tr>
<td>TASH vs. None</td>
<td>0.08</td>
<td>0.01</td>
<td>0.01</td>
<td>0.78</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>M50a M59</td>
<td>0.09</td>
<td>0.01</td>
<td>0.01</td>
<td>0.78</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>Liver Disease</td>
<td>0.09</td>
<td>0.01</td>
<td>0.01</td>
<td>0.78</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>1,2,3,7,8-HxPCDD</td>
<td>0.12</td>
<td>0.02</td>
<td>0.02</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>1,2,3,6,7,8-HxPCDD</td>
<td>0.15</td>
<td>0.03</td>
<td>0.03</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>1,2,3,7,8-PcDF</td>
<td>0.18</td>
<td>0.04</td>
<td>0.04</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>1,2,3,7,8-PcDF</td>
<td>0.20</td>
<td>0.05</td>
<td>0.05</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>1,2,3,7,8-PcDF</td>
<td>0.23</td>
<td>0.06</td>
<td>0.06</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.25</td>
<td>0.07</td>
<td>0.07</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.28</td>
<td>0.08</td>
<td>0.08</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.30</td>
<td>0.09</td>
<td>0.09</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.33</td>
<td>0.10</td>
<td>0.10</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.35</td>
<td>0.11</td>
<td>0.11</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.38</td>
<td>0.12</td>
<td>0.12</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.40</td>
<td>0.13</td>
<td>0.13</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.43</td>
<td>0.14</td>
<td>0.14</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.45</td>
<td>0.15</td>
<td>0.15</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.47</td>
<td>0.16</td>
<td>0.16</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.49</td>
<td>0.17</td>
<td>0.17</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.51</td>
<td>0.18</td>
<td>0.18</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.53</td>
<td>0.19</td>
<td>0.19</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.55</td>
<td>0.20</td>
<td>0.20</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.57</td>
<td>0.21</td>
<td>0.21</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>2,3,4,7,8-PcDF</td>
<td>0.59</td>
<td>0.22</td>
<td>0.22</td>
<td>0.92</td>
<td>0.03</td>
<td>0.02</td>
</tr>
</tbody>
</table>

 exposure and CK18 values are log-transformed

 • Multinomial model adjusted for age, sex, race, alcohol use, diabetes (and log-transformed total lipids for whole weight sum of PCBs).
 • Regression model adjusted for age, sex, race, alcohol use, diabetes (and log-transformed total lipids for whole weight sum of PCBs).

Exposure

TASH vs. None

Liver Diseasea M50a M59 M50a M59

Adjusted beta coefficients of significant associations of various TEQ summations and CK-18 biomarkers in ACHS-II.

Exposure

TASH vs. None

Liver Diseasea M50a M59 M50a M59

Adjusted beta coefficients of significant associations of various TEQ summations and CK-18 biomarkers in ACHS-II.

Exposure

TASH vs. None

Liver Diseasea M50a M59 M50a M59
Figure 6. ΣPCBs were inversely associated with metabolic biomarkers in ACHS. Regression lines showing the change in insulin (Panel A) and leptin (Panel B) with increasing serum PCB load are shown for each liver disease group.
Table 27

Unadjusted ACHS-II biomarker levels by sum of all PCBs (\( \Sigma \text{PCBs} \)) sum of 35 ortho-substituted congeners (\( \Sigma \text{PCB-O} \)), and all non-dioxin-like congeners (\( \Sigma \text{NDL} \))

<table>
<thead>
<tr>
<th></th>
<th>( \Sigma \text{PCBs} )</th>
<th>( \Sigma \text{PCB-O} )</th>
<th>( \Sigma \text{NDL} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biomarker</td>
<td>Adiponectin (ug/ml)</td>
<td>( \beta ) 0.07</td>
<td>SE 0.03</td>
</tr>
<tr>
<td></td>
<td>MCP-1</td>
<td>( \beta ) -0.07</td>
<td>SE 0.03</td>
</tr>
<tr>
<td></td>
<td>TNFa</td>
<td>( \beta ) 0.07</td>
<td>SE 0.04</td>
</tr>
<tr>
<td></td>
<td>ALT (SGPT)</td>
<td>( \beta ) -0.06</td>
<td>SE 0.02</td>
</tr>
<tr>
<td></td>
<td>ALK PHOS</td>
<td>( \beta ) 0.04</td>
<td>SE 0.01</td>
</tr>
<tr>
<td></td>
<td>Albumin</td>
<td>( \beta ) -0.01</td>
<td>SE 0.00</td>
</tr>
<tr>
<td></td>
<td>Insulin</td>
<td>( \beta ) -0.12</td>
<td>SE 0.04</td>
</tr>
<tr>
<td></td>
<td>HOMA-IR</td>
<td>( \beta ) -0.10</td>
<td>SE 0.04</td>
</tr>
<tr>
<td></td>
<td>HOMA-B</td>
<td>( \beta ) 0.03</td>
<td>SE 0.01</td>
</tr>
<tr>
<td></td>
<td>Hyaluronic Acid (ng/ml)</td>
<td>( \beta ) 0.36</td>
<td>SE 0.04</td>
</tr>
<tr>
<td></td>
<td>CK18 M30</td>
<td>( \beta ) -0.08</td>
<td>SE 0.03</td>
</tr>
<tr>
<td>Biomarker</td>
<td>Adiponectin (ug/ml)</td>
<td>( \beta ) 0.08</td>
<td>SE 0.03</td>
</tr>
<tr>
<td></td>
<td>MCP-1</td>
<td>( \beta ) -0.08</td>
<td>SE 0.03</td>
</tr>
<tr>
<td></td>
<td>ALT (SGPT)</td>
<td>( \beta ) -0.07</td>
<td>SE 0.02</td>
</tr>
<tr>
<td></td>
<td>ALK PHOS</td>
<td>( \beta ) 0.03</td>
<td>SE 0.01</td>
</tr>
<tr>
<td></td>
<td>Albumin</td>
<td>( \beta ) -0.01</td>
<td>SE 0.00</td>
</tr>
<tr>
<td></td>
<td>Insulin</td>
<td>( \beta ) -0.13</td>
<td>SE 0.04</td>
</tr>
<tr>
<td></td>
<td>HOMA-IR</td>
<td>( \beta ) -0.12</td>
<td>SE 0.04</td>
</tr>
<tr>
<td></td>
<td>HOMA-B</td>
<td>( \beta ) 0.03</td>
<td>SE 0.01</td>
</tr>
<tr>
<td></td>
<td>Hyaluronic Acid (ng/ml)</td>
<td>( \beta ) 0.37</td>
<td>SE 0.04</td>
</tr>
<tr>
<td></td>
<td>CK18 M30</td>
<td>( \beta ) -0.08</td>
<td>SE 0.03</td>
</tr>
<tr>
<td></td>
<td>CK18 M65</td>
<td>( \beta ) -0.04</td>
<td>SE 0.02</td>
</tr>
</tbody>
</table>

For the ACHS-II unadjusted model, biomarkers which varied significantly with changes to serum concentrations of all PCBs measured (\( \Sigma \text{PCB} \)), 35 ortho-substituted congeners (\( \Sigma \text{PCB-O} \)), or the non-dioxin-like congeners (\( \Sigma \text{NDL} \)) are shown.
Table 28

Unadjusted ACHS-II biomarker levels by groups of ortho-substituted PCBs

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>β</th>
<th>SE</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ΣPCB-TO</td>
<td>Adiponectin (ug/ml)</td>
<td>0.08</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>MCP-1</td>
<td>-0.08</td>
<td>0.03</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>ALT (SGPT)</td>
<td>-0.07</td>
<td>0.02</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>ALK PHOS</td>
<td>0.03</td>
<td>0.01</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>Albumin</td>
<td>-0.01</td>
<td>0.00</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Insulin pmol/L</td>
<td>-0.13</td>
<td>0.03</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>HOMA-IR</td>
<td>-0.13</td>
<td>0.04</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>HOMA-B</td>
<td>-0.13</td>
<td>0.05</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Hyaluronic Acid (ng/ml)</td>
<td>0.34</td>
<td>0.04</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>Insulin</td>
<td>-0.13</td>
<td>0.03</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>CK18 M30</td>
<td>-0.07</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>ΣPCB-DO</td>
<td>Adiponectin (ug/ml)</td>
<td>0.07</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>MCP-1</td>
<td>-0.09</td>
<td>0.03</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>ALT (SGPT)</td>
<td>-0.07</td>
<td>0.02</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>ALK PHOS</td>
<td>0.03</td>
<td>0.01</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>Albumin</td>
<td>-0.01</td>
<td>0.00</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>Insulin pmol/L</td>
<td>-0.13</td>
<td>0.04</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>HOMA-IR</td>
<td>-0.12</td>
<td>0.04</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>HOMA-B</td>
<td>-0.13</td>
<td>0.05</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Hyaluronic Acid (ng/ml)</td>
<td>0.37</td>
<td>0.04</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>Insulin</td>
<td>-0.13</td>
<td>0.04</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>CK18 M30</td>
<td>-0.09</td>
<td>0.03</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>CK18 M65</td>
<td>-0.05</td>
<td>0.02</td>
<td>0.03</td>
</tr>
<tr>
<td>ΣPCB-MO</td>
<td>Adiponectin (ug/ml)</td>
<td>0.08</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>MCP-1</td>
<td>-0.06</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>TNFa</td>
<td>0.08</td>
<td>0.04</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>ALT (SGPT)</td>
<td>-0.08</td>
<td>0.02</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>ALK PHOS</td>
<td>0.04</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Albumin</td>
<td>-0.02</td>
<td>0.00</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>Insulin pmol/L</td>
<td>-0.11</td>
<td>0.04</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>HOMA-B</td>
<td>-0.14</td>
<td>0.05</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Hyaluronic Acid (ng/ml)</td>
<td>0.33</td>
<td>0.04</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>Insulin</td>
<td>-0.11</td>
<td>0.04</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>Leptin</td>
<td>0.23</td>
<td>0.05</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>CK18 M30</td>
<td>-0.08</td>
<td>0.03</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>CK18 M65</td>
<td>-0.06</td>
<td>0.02</td>
<td>0.01</td>
</tr>
</tbody>
</table>

For the ACHS-II unadjusted model, biomarkers which varied significantly with changes to serum concentrations of tri/tetra-ortho substituted congeners (ΣPCB-TO), di-ortho substituted congeners (ΣPCB-DO), or mono-ortho substituted congeners (ΣPCB-MO) are shown.
<table>
<thead>
<tr>
<th>Biomarker</th>
<th>β</th>
<th>SE</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (SGOT)</td>
<td>-0.06</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>ALT (SGPT)</td>
<td>-0.08</td>
<td>0.02</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Albumin</td>
<td>-0.02</td>
<td>0.01</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Total Bilirubin</td>
<td>-0.07</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>Direct Bilirubin</td>
<td>-0.05</td>
<td>0.02</td>
<td>0.04</td>
</tr>
<tr>
<td>Hyaluronic Acid (ng/ml)</td>
<td>0.22</td>
<td>0.05</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.14</td>
<td>0.06</td>
<td>0.01</td>
</tr>
<tr>
<td>Leptin</td>
<td>0.27</td>
<td>0.06</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>CK18 M30</td>
<td>-0.08</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>CK18 M65</td>
<td>-0.06</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>TNFa</td>
<td>0.09</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>AST (SGOT)</td>
<td>-0.04</td>
<td>0.02</td>
<td>0.03</td>
</tr>
<tr>
<td>ALT (SGPT)</td>
<td>-0.08</td>
<td>0.02</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>ALK PHOS</td>
<td>0.04</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>Albumin</td>
<td>-0.01</td>
<td>0.00</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Insulin pmol/L</td>
<td>-0.10</td>
<td>0.03</td>
<td>0.00</td>
</tr>
<tr>
<td>HOMA-B</td>
<td>-0.14</td>
<td>0.04</td>
<td>0.00</td>
</tr>
<tr>
<td>Hyaluronic Acid (ng/ml)</td>
<td>0.31</td>
<td>0.04</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Insulin</td>
<td>-0.10</td>
<td>0.03</td>
<td>0.00</td>
</tr>
<tr>
<td>Leptin</td>
<td>0.18</td>
<td>0.05</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>CK18 M30</td>
<td>-0.07</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>CK18 M65</td>
<td>-0.05</td>
<td>0.02</td>
<td>0.01</td>
</tr>
</tbody>
</table>

For the ACHS-II unadjusted model, biomarkers which varied significantly with changes to serum concentrations of non-ortho substituted congeners (ΣPCB-NO), or dioxin-like (ΣDL) are shown.
In ACHS-II, significant positive relationships were observed between ΣPCBs and adiponectin, TNFα, alkaline phosphatase, and hyaluronic acid, while significant negative relationships were observed between ΣPCBs and MCP-1, ALT, Albumin, Insulin, HOMA-IR, and HOMA-B. Interestingly, while most of these relationships were conserved between ΣPCBs and other grouping structures, the positive relationship between summed PCBs and TNFα was observed only in the comparison with mono-ortho ($\beta=0.08\pm0.04$, $p=0.03$) and dioxin-like ($\beta=0.09\pm0.03$, $p=0.01$) PCBs, along with an additional positive relationship with IL-6 ($\beta=0.14\pm0.06$, $p=0.01$) observed in the dioxin-like group (Tables 27-29). This suggests a relationship between the inflammatory processes contributing to PCB-related TASH and the structural characteristics of congeners within the exposure mixture.

In the adjusted model, ΣPCBs remained associated with abnormal glucose metabolism. ΣPCBs were associated with decreased HOMA-IR ($p=0.03$) and insulin ($p=0.04$), with a trend towards decreased HOMA-B ($p=0.08$) (Table 30). ΣPCBs were also associated with decreased leptin ($p<0.001$). To investigate these associations further, we determined adjusted beta coefficients for individual PCB congeners and these biomarkers (Table 31). Significant inverse associations were seen between seven high molecular weight PCB congeners and both HOMA-IR and insulin. Twenty-six congeners (both low and high molecular weight) were inversely associated with leptin. Inverse associations were also found between HOMA-B and PCBs 180 and 194. ΣPCBs was no longer associated with increased pro-inflammatory cytokines in the adjusted model. Thus, PCBs appeared to modulate both liver cell death mechanism, intermediary metabolism, and adipokines. The liver-specific impact of PCBs on inflammation was less certain due to variability between the adjusted and unadjusted models.
Table 30

ACHS adjusted\(^{a}\) beta coefficients of associations of ΣPCBs (wet weight) with biomarkers

<table>
<thead>
<tr>
<th>Cytokine/Adipokine</th>
<th>β</th>
<th>SE</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose</td>
<td>&lt;0.001</td>
<td>0.01</td>
<td>1.00</td>
</tr>
<tr>
<td>Insulin</td>
<td>-0.07</td>
<td>0.04</td>
<td><strong>0.04</strong></td>
</tr>
<tr>
<td>HOMA-B</td>
<td>-0.07</td>
<td>0.04</td>
<td>0.08</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>-0.08</td>
<td>0.04</td>
<td><strong>0.03</strong></td>
</tr>
<tr>
<td>IL-1β</td>
<td>0.01</td>
<td>0.05</td>
<td>0.90</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.05</td>
<td>0.05</td>
<td>0.33</td>
</tr>
<tr>
<td>IL-8</td>
<td>0.08</td>
<td>0.07</td>
<td>0.25</td>
</tr>
<tr>
<td>Leptin</td>
<td>-0.14</td>
<td>0.04</td>
<td><strong>&lt;0.001</strong></td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.02</td>
<td>0.03</td>
<td>0.53</td>
</tr>
<tr>
<td>PAI-1</td>
<td>-0.01</td>
<td>0.02</td>
<td>0.51</td>
</tr>
<tr>
<td>Resistin</td>
<td>0.01</td>
<td>0.03</td>
<td>0.81</td>
</tr>
<tr>
<td>TNFα</td>
<td>0.04</td>
<td>0.03</td>
<td>0.26</td>
</tr>
</tbody>
</table>

\(^{a}\)Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity, diabetes, and alcohol use.
Table 31
Adjusted beta coefficients of significant associations of PCB congeners with biomarkers of glucose metabolism

<table>
<thead>
<tr>
<th>PCB Congener</th>
<th>HOMA-B PCB</th>
<th>HOMA-IR PCB</th>
<th>Insulin PCB</th>
<th>Leptin PCB</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>-0.08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>-0.16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>-0.10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>-0.06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>101</td>
<td></td>
<td>-0.07</td>
<td>-0.07</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td></td>
<td></td>
<td></td>
<td>-0.13</td>
</tr>
<tr>
<td>128</td>
<td></td>
<td></td>
<td></td>
<td>-0.09</td>
</tr>
<tr>
<td>138</td>
<td></td>
<td></td>
<td></td>
<td>-0.07</td>
</tr>
<tr>
<td>146</td>
<td></td>
<td></td>
<td></td>
<td>-0.07</td>
</tr>
<tr>
<td>151</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>153</td>
<td></td>
<td></td>
<td></td>
<td>-0.09</td>
</tr>
<tr>
<td>156</td>
<td></td>
<td></td>
<td></td>
<td>-0.13</td>
</tr>
<tr>
<td>157</td>
<td></td>
<td>-0.08</td>
<td>-0.08</td>
<td>-0.13</td>
</tr>
<tr>
<td>167</td>
<td></td>
<td></td>
<td></td>
<td>-0.06</td>
</tr>
<tr>
<td>170</td>
<td></td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.15</td>
</tr>
<tr>
<td>172</td>
<td></td>
<td></td>
<td></td>
<td>-0.06</td>
</tr>
<tr>
<td>177</td>
<td></td>
<td></td>
<td></td>
<td>-0.14</td>
</tr>
<tr>
<td>178</td>
<td></td>
<td></td>
<td></td>
<td>-0.12</td>
</tr>
<tr>
<td>180</td>
<td>-0.08</td>
<td>-0.08</td>
<td>-0.08</td>
<td>-0.16</td>
</tr>
<tr>
<td>183</td>
<td></td>
<td></td>
<td></td>
<td>-0.06</td>
</tr>
<tr>
<td>187</td>
<td></td>
<td></td>
<td></td>
<td>-0.10</td>
</tr>
<tr>
<td>189</td>
<td></td>
<td>-0.09</td>
<td></td>
<td>-0.16</td>
</tr>
<tr>
<td>194</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.08</td>
<td>-0.17</td>
</tr>
<tr>
<td>195</td>
<td></td>
<td></td>
<td></td>
<td>-0.13</td>
</tr>
<tr>
<td>196</td>
<td></td>
<td>-0.08</td>
<td>-0.08</td>
<td>-0.13</td>
</tr>
<tr>
<td>199</td>
<td></td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.15</td>
</tr>
<tr>
<td>206</td>
<td></td>
<td>-0.06</td>
<td></td>
<td>-0.13</td>
</tr>
<tr>
<td>209</td>
<td></td>
<td></td>
<td></td>
<td>-0.114</td>
</tr>
</tbody>
</table>

In ACHS-II, several individual congeners were associated with biomarkers or assessments of metabolic disease. Leptin was negatively associated with most congeners, while insulin and HOMA-IR were primarily negatively associated with higher molecular weight congeners.
CHAPTER ONE: DISCUSSION

To our knowledge, the 738 subjects in ACHS make this the largest environmental liver disease study ever undertaken using sensitive mechanistic biomarkers. The overall liver injury prevalence of over 60% is among the highest ever reported for a residential cohort, and is well above estimates of NAFLD prevalence in the US and worldwide. Importantly, this high prevalence was maintained across both phases, suggesting that the injury remains chronic and the biomarkers of that injury are persistent. Positive associations between TASH categorization and elevated pro-inflammatory cytokines, insulin resistance, and hypertriglyceridemia further support our conclusion that chronic steatohepatitis has occurred and is persistent in these subjects.

The individuals comprising the ACHS and ACHS-II cohorts are highly contaminated with PCBs due to the proximity to a former PCB-manufacturing facility and exposure to PCB-containing waste released into the environment. Most subjects within these cohorts were also overweight or obese, and the ACHS cohort was previously reported to have elevated prevalence of disease components of the metabolic syndrome, therefore, we expected to find increased prevalence of NASH, consistent with these reports, and we hypothesized that mechanism of hepatic injury would be consistent with TASH because of the toxicant exposure. Liver injury in 80% of ACHS and 73.8% of ACHS-II cases was associated with hepatocellular necrosis, a characteristic of TASH but not of NASH, or ASH, which are associated with increased hepatocellular apoptosis.

The liver is the principal target organ for organochlorine toxicants such as PCBs. Associations between PCBs and liver injury have been demonstrated in industrial exposures and in cases of accidental poisoning in humans, and chronic PCB exposure has been shown to cause steatohepatitis in laboratory animal models. Attempts to demonstrate a straightforward
relationship between environmental PCB exposure and liver injury in humans, however, has been frustrated, in part, by the lack of adequate biomarkers. In 2010, our laboratory published an evaluation of the 2003-2004 NHANES data, which showed an association between serum levels of PCBs and elevations of the clinical liver injury biomarker ALT. In this study, using upper limits defined in the 2003-2004 NHANES laboratory protocol\textsuperscript{104}, 10.6\% of subjects had ALT elevation not attributable to viral hepatitis, hemochromatosis, or alcohol abuse\textsuperscript{37}. Odds of inclusion in this group increased with increasing levels of serum PCBs, and inclusion was also associated with overweight/obesity and Hispanic/non-Hispanic White ethnicity, both of which are associated with increased NASH prevalence. The association between PCBs and liver injury in this population persisted even after adjustment for BMI, however, the use of ALT in the NHANES population does not allow discrimination between NASH and TASH as potential etiologies for liver injury\textsuperscript{37}.

The use of CK18 M30 and M65 in the ACHS cohorts allowed dissection of these etiologies based on cell death mechanism. Our validation studies using alternative (miRNA) or approved clinical (ALT) diagnostic methods indicate significantly elevated markers of liver injury in the CK18-designated liver injury groups vs. NLD indicate that CK18 can detect liver injury in a population such as the ACHS cohorts, where TASH is suspected. This capability is particularly important when one considers the findings of the ACHS-II clinical liver function tests, which indicate statistically significant but clinically irrelevant elevations in mean ALT within the TASH group. Mean values for both NLD and “TASH” groups are well below the clinical cutoffs used in the 2003-2004 NHANES study as well as in most clinical applications. Using the upper limits recommended in Prati et al., 2002\textsuperscript{63} (shown in Table 20), which redefined the cutoffs using a cohort at low risk for chronic HCV infection or NAFLD, a much larger proportion of the ACHS-II cohort has ALT values in the abnormal range (Figure 7), however, even by the Prati definitions, ALT abnormality was only detected in 33\% of males within the TASH group. This contrasts with females in the TASH group, 82\% of whom had ALT abnormalities with the lower cutoff. Liver injury due to chronic TASH or TASH superimposed on NASH may not be detected in a clinical
Figure 7. Distribution of ALT levels in ACHS by liver disease category.

Distribution of ALT levels for female (blue circles) and male (green squares) participants in the three CK18-defined liver disease categories, with lines indicating upper limits of normal based on the NHANES (black lines) or Prati definition (red lines). The upper limit of normal for females is the lower line in each color, while the upper limit of normal for males is the upper line in each color. Males tended to have higher ALT levels in all groups.
setting using common screening methods, and this could delay identification therapeutic intervention.

Neither ΣPCBs nor BMI was associated with liver disease in the ACHS cohorts, though ΣPCBs has been previously associated with liver disease in other epidemiologic studies\textsuperscript{37, 95-99}. Differences in methodologies and demographic/exposure variables might account for this discrepancy. However, exposures to 13 specific PCB congeners were associated with TASH and/or CK18 M65 elevation in the ACHS cohort. Of these, PCBs 66, 105, 149, 151, 172, 178, and 187 were previously associated with increased ALT in NHANES\textsuperscript{97}. The present study using mechanistic biomarkers greatly extends this prior work. Some of the thirteen identified PCB congeners (PCBs 28, 66, 105, and 128) have dioxin-like activity, while others have estrogenic (44, 49, 52, 101, 110) or phenobarbital-like (44, 49, 52, 101, 128, 149, 151, 187, 195) effects\textsuperscript{105}. Perhaps activation of the AhR, estrogen receptor, or the constitutive androstane receptor (CAR) may be involved in PCB-related TASH. While four congeners were associated with increased CK18 M30, an inverse association was observed between ΣPCBs and this apoptosis biomarker. Notably, activation of the PCB receptor CAR, was found to be anti-apoptotic in a mouse model of cholestatic liver disease\textsuperscript{106}. This supports our clinical observation that some phenobarbital-like PCBs, which activate CAR, were associated with TASH\textsuperscript{106}. Although not directly tested in this study, it is conceivable that PCBs could mediate a transition from NASH to TASH by decreasing apoptosis and promoting more pro-inflammatory necrotic hepatocyte death. While PCBs were a 'second hit' in the transition from diet-induced steatosis to more advanced liver disease in animal studies\textsuperscript{23, 107-109}, a significant interaction between PCBs and BMI on liver disease status was not observed in the present study. Perhaps the high rates of overweight/obesity and elevated PCB levels in the cohort limited the ability to detect interactions occurring at lower exposures and body weights.

In ACHS-II, the relationship between pro-inflammatory biomarkers and less ortho-substituted congener groupings again suggests receptor-mediated disease processes, although the loss of significant relationships in the model adjusted for diabetes may indicate that modulation of inflammatory response in TASH may be an extrahepatic effect.
In ACHS, liver disease affected males (67.2%) and non-Hispanic whites (70.2%) disproportionately. The sex difference is consistent with a recently published report documenting increased mortality from hepatic disease in men exposed to PCB through ingestion of contaminated rice oil\textsuperscript{110}. Moreover, men and Caucasians have increased susceptibility to NAFLD\textsuperscript{90}. Genetic polymorphisms may contribute to ethnic differences in NASH\textsuperscript{90, 111, 112}. For example, ethnic differences in the distribution of null alleles in the NASH susceptibility gene (patatin-like phospholipase domain containing protein 3 - PNPLA3), have been reported. We postulate that gene-environment interactions may also influence TASH; and that these interactions may have contributed to the ethnic differences observed in this study. In addition to PNPLA3, candidate genes include the pregnane X receptor (PXR), which is a PCB receptor\textsuperscript{19} with at least two polymorphisms previously associated with NAFLD severity\textsuperscript{113}. The observed gender differences could potentially be explained by estrogenic PCB congeners.

While steatohepatitis has long been associated abnormal adipocytokines\textsuperscript{83, 84} relatively less is known about the effects of PCBs on these biomarkers. In a cohort of 992 elderly Swedish subjects, \( \Sigma \text{PCBs} \) was significantly associated with vascular cell adhesion protein 1 but not IL-6, MCP-1, or TNF\( \alpha \)\textsuperscript{114}. However, Aroclor 1260 increased TNF\( \alpha \), IL-6, and PAI-1\textsuperscript{23, 108} in mice fed high fat diet. Adiponectin was inversely associated with PCB 28, 138, and 153 in a study of 98 Koreans\textsuperscript{115}; but \( \Sigma \text{PCBs} \) was not associated with adiponectin levels in the Great Lakes Sport Fish Caught Consumers Study (\( n=413 \))\textsuperscript{116}. Leptin receptor expression was decreased in PCB-exposed children\textsuperscript{117}; and PCB-exposures induced leptin resistance in the 3T3-L1 cell culture model while increasing both TNF\( \alpha \) and IL-6 production\textsuperscript{118}; In the present study, \( \Sigma \text{PCBs} \) was associated with increased TNF\( \alpha \) and IL-6, but only in the unadjusted model. While \( \Sigma \text{PCBs} \) was associated with increased adiponectin in the unadjusted model, it was associated with decreased leptin in the adjusted model. Importantly, in the adjusted model twenty-six PCB congeners were individually associated with decreased leptin. If PCBs decrease leptin expression while simultaneously inducing leptin resistance, this could be an important potential mechanism for PCB-related metabolic dysfunction.

A high prevalence of diabetes (27%) has previously been reported in the ACHS\textsuperscript{49}, and the impact of PCBs on diabetes has recently been reviewed\textsuperscript{100}. In the present study, \( \Sigma \text{PCBs} \) was
associated with decreased HOMA-B in the unadjusted model with a trend (p=0.08) towards decreased HOMA-B in the adjusted model. ΣPCBs and nine individual high molecular weight congeners were associated with decreased HOMA-IR in the adjusted model. ΣPCBs were inversely associated with insulin in both models. Adjustments were not made for diabetes medications, so it is difficult to draw firm conclusions from these data. Nonetheless, these data are by and large consistent with the findings from our recently published mouse model. In that experiment, C57Bl/6 male mice fed a 42% milk fat diet for 12 weeks with or without co-exposure to a high molecular weight PCB mixture (Aroclor 1260) at a dose designed to model ACHS. PCB treatment induced steatohepatitis, decreased HOMA-B and HOMA-IR but did not change glucose tolerance. Hepatic gluconeogenesis, glucose transporters, physical activity, food intake, and respiratory exchange rate appeared to be regulated, in part, by interactions between PCBs and the nuclear receptors Pxr and Car. These studies clearly demonstrate significant derangements in glucose metabolism occurring in the context of PCB-related liver disease. The mechanisms underpinning the complicated effects of PCBs on intermediary metabolism in steatohepatitis require further elucidation. However, based on the results of the present study, pancreatic β cell dysfunction, rather than insulin resistance (e.g., not Type II diabetes), may be involved in the diabetes associated with PCB exposures. Importantly, such dysfunction would appear to occur in the absence of anti-islet antibodies (e.g. not Type I diabetes), suggesting the potential for Type 3c or pancreatogenic diabetes among the mechanisms of PCB-associated liver disease.

CK18 is currently the most extensively validated serum biomarker for steatohepatitis as a stand-alone test correlating with histology, and the addition of transaminases to CK18 in order to create a prediction model did not improve the diagnostic value of CK18 alone in NASH. In a multi-center validation study, the sensitivity and specificity of CK18 M30 for biopsy-proven NASH (vs. steatosis alone) were as high as 77% and 92% respectively depending on the test threshold. While CK18 correlated with ALT, it offered improved diagnostic accuracy over ALT for histological NASH and TASH. While CK18 is less well validated in TASH than NASH, it showed superior performance to ALT in previously published studies.
This is the first analysis of liver disease in the ACHS, and the results have several limitations. The demographic and exposure characteristics of the ACHS cohort are not representative of the overall population, limiting the generalizability of the study results. Furthermore, the ACHS cohort likely had elevated exposures to unmeasured environmental chemicals, including additional dioxin-like PCBs, most notably PCB 126. In a pilot study of 65 ACHS participants, median concentrations of the dioxin-like congeners PCB 126 and 169 approached the 95th percentile reported for the same age group in the general U.S. population for subjects age 40-59. Importantly, dioxin-like PCBs were among the most potent environmental chemicals associated with the development of steatosis in rodent studies \(^\text{121}\), and several dioxin-like congeners were associated with TASH in ACHS. PCB exposures may also have been accompanied by exposures to dioxins, dibenzofurans, metals, and other organics related to PCB production or releases from the nearby Anniston Army Depot Superfund Site or local ferro-manganese smelting operations. Although the potentially confounding effects of alcohol were taken into consideration, viral hepatitis were not excluded. Although CK18 is validated clinically, this may be the first application of CK18 in an epidemiological study. The follow-up ACHS-II study addresses some of these limitations. Additional measurements in ACHS-II will include evaluation of the relationships between CK-18 and individual congeners. Future liver imaging and/or biopsies would help to confirm the study results.

In summary, the 60.2% prevalence of liver disease in the PCB-exposed ACHS population is among the highest ever reported for a residential cohort. Assessment of steatohepatitis in ACHS/ACHS-II population using the mechanistic liver injury biomarker CK18 revealed increased prevalence of hepatocellular necrosis, and clinical LFT analysis indicated the absence of transaminitis. This pattern is characteristic of TASH, a specific subcategory of NAFLD associated with chemical exposures. The observed hepatocellular necrosis was associated with elevations in the pro-inflammatory cytokine IL-6 and metabolic abnormalities, also consistent with TASH. Assessment of the relationship between liver injury biomarkers and PCB exposure in this population indicated a relationship between total PCB load and biomarkers of metabolic dysfunction and fibrosis, however, increasing total PCB load was not associated with increases in
the liver injury biomarker CK18. Interestingly, positive relationships with pro-inflammatory biomarkers IL-6 and TNFα were only seen with non-ortho and dioxin-like congener groupings. Exposures to ten individual PCB congeners were also associated with TASH. This suggests that congener structures within the mixture may contribute to TASH in different ways. Individuals in this cohort are exposed to PCBs at a level 2-3 times higher than the general U.S. population, and, importantly, acquire PCBs through environmental (rather than industrial) exposure.

We therefore conclude that environmental PCB exposure is associated with increased liver injury. Individuals with TASH had corresponding elevations in other serum liver injury biomarkers, including miR-122, as well as indications of increased fibrosis and systemic inflammation. In the context of clinical hepatology practice, our findings suggest that a greater focus on the contribution of environmental chemical diseases is warranted, and the lack of correlation between clinical liver biomarkers and CK-18 and miR-122 findings suggests that standard screening practices may be insufficient to diagnose liver injury in some chemical-exposed populations.
CHAPTER TWO: PCBS INDUCE DIFFERENTIAL TRANSCRIPTION IN LIVER TISSUE FROM A MOUSE MODEL OF CHRONIC PCB/DIETARY COEXPOSURE

The implied mechanistic differences between obesity-related NASH and TASH suggest that widespread exposure to persistent organic pollutants may contribute to liver injury. Importantly, both dioxin-like and non-dioxin-like congeners appear to drive this difference, making it clear that an understanding of the underlying mechanism is needed to make therapeutic decisions and to revise risk assessment in populations exposed to related chemicals. The apparent multi-system effects of PCB exposure observed in the Anniston studies appear to converge on liver injury, but as PCB exposure in Anniston occurred in a complex coexposure environment, in the context of this epidemiological study, it is not straightforward to disentangle PCB effects from diet or metabolic disruption originating in organ systems outside the liver. We hypothesized that direct PCB effects in the liver would induce transcriptional changes that could be mapped to pathways and processes related to NASH.

A mouse model of diet-induced obesity and PCB coexposure has been evaluated in our laboratory, as previously reported. Notable findings from this study included the fact that exposure to PCBs decreased fasting glucose in control mice, but had had no discernable effect on histological or serological liver damage without dietary coexposure (high-fat diet, HFD). With dietary coexposure, there was more histologically evident liver damage at a moderate exposure to PCBs (HFD-A20) than at high exposure (HFD-A200). High fat diet increased body weight and fat pad weight at all three PCB exposure levels, though it was significantly less at the high dose.

Therefore, HFD and PCB exposure contribute to the phenotype of liver damage and metabolic dysfunction in this mouse model. Moreover, because the Anniston populations were observed to have high prevalence of obesity, serologic indicators of liver injury and elevations in
IL-6 and tPAI1 at PCB exposures at least 10-fold lower than the 200 mg/kg dose, the HFD+20mg/kg conditions most accurately models the PCB/dietary coexposures in Anniston. We hypothesized, therefore, that HFD coexposures would modulate the PCB-dependent transcriptome (or vice versa), producing transcriptional changes related to the phenotype in this model and in ACHS. We performed RNAseq analysis on RNA isolated from liver tissue in these animals, and performed in silico analysis of the differential transcriptome. Specifically, we expected to find that the genes differentially transcribed between CD/vehicle and CD/PCB treatment would be enriched in gene ontology terms related to insulin resistance, and genes differentially transcribed between CD/PCB and HFD/PCB would be enriched in terms related to liver diseases, metabolic diseases, and inflammation.
CHAPTER TWO: MATERIALS AND METHODS

Design of the animal study

In this chronic (12-week) study, male C57Bl/6J mice (8 weeks old; The Jackson Laboratory, BarHarbor, ME, USA) were assigned to 6 study groups (n=10) as summarized in Figure 7. Beginning at week 0, each group received one of two diets: control diet (CD, 10.2% kCal from fat; TD.06416 Harlan Teklad) or a high fat diet (HFD, 42% kCal from milk fat; TD.88137 Harlan Teklad), and were allowed one week to acclimate. Beginning at Week 1, each group received one of 3 exposures administered in corn oil by oral gavage: corn oil vehicle, Aroclor 1260 (AccuStandard, CT, USA) (vs. corn oil alone) at 20 mg/kg or at 200 mg/kg. Importantly, the 20 mg/kg exposure was designed to mimic the highest human PCB exposures in the ACHS cohort, while the 200 mg/kg exposure was similar to that used in rodent carcinogenesis studies. The two doses of Aroclor 1260 were administered over a different time period in order to manage acute toxicity at the higher dose, with the 20 mg/kg dose administered once (Week 1) and the 200 mg/kg dose administered as four 50 mg/kg doses (Weeks 1, 3, 5, and 7).

Mice were housed in a temperature- and light-controlled room (12 h light; 12 h dark) with food and water ad libitum. The animals were euthanized (ketamine/xylazine, 100/20 mg/kg body weight, i.p.) at the end of Week 12. Liver tissue was harvested and immediately disrupted in RNA Stat-60 reagent (AMS Biotechnology Limited, Abingdon UK) and stored on ice.

Preparation of RNA samples and RNAseq analysis

RNA was extracted by the RNA Stat-60 protocol according to manufacturer directions. For RNAseq analysis, RNA samples were multiplexed using sequence barcoding, and sequenced single ended to 75 base pair reads using a NextSeq500 to an approximate read count of 40
Figure 8. PCB exposure and high-fat diet induce phenotypic changes in C57/BL6 mice.
Six conditions evaluated in our mouse study are shown above, along with major phenotypic changes.
million reads per sample. Base calling (assigning nucleobase identity to chromatogram peaks) for these files was accomplished using Illumina’s bcl2fastq software. All sequences produced were aligned to the mouse reference genome (GRCm38.83) using the alignment software TopHat, and transcript expression levels were calculated in FPKM (fragments per kilobase of transcript per million mapped reads) units using Cufflinks\textsuperscript{122}. The quantification was guided by transcriptome annotation for the mouse downloaded from NCBI. Records corresponding to both mitochondrial and ribosomal RNA were removed (annotated as transcript\_biotype rRNA or Mt\_tRNA) to improve the accuracy of the transcriptome quantification. Differential analyses (FPKM units averaged from 4 replicates of each test vs. DMSO-treated controls) were performed using CuffDiff.

\textit{qPCR validation of selected targets}

Targets for validation were prototypical targets of the transcription factors AhR, CAR, and PXR. From the isolated RNA samples, cDNA was generated using the QuantiTect Reverse Transcription kit (Qiagen #205313) according to manufacturer recommendations. Multiplexed qPCR (target and GAPDH) was carried out on BioRad CFX384 system using the following TaqMan Gene Expression Array probes: Cyp1a2 (Applied Biosystems Mm00487224\_m1/FAM), Cyp3a11 (Applied Biosystems Mm00731567\_m1/FAM), Cyp2b10 (Applied Biosystems Mm01972453\_s1/FAM) and GAPDH (Applied Biosystems, Mm99999915\_g1/VIC).

\textit{Pathway and enrichment analyses}

Initial analysis of the datasets were performed using the MetaCore\textsuperscript{TM} (Thompson Reuters) software suite. For each treatment, the fold changes and p-values for each differentially transcribed gene (indexed by Ensembl ID) were uploaded into MetaCore\textsuperscript{TM} and recognized genes were associated with one or more MetaCore\textsuperscript{TM}-curated network objects. Prefilters were applied to each dataset using a species (\textit{M. musculus}) and tissue (liver) prefilter. Most of the raw Ensembl IDs for targets identified as differentially transcribed in each experimental comparison
were successfully mapped to network objects represented within the MetaCore™ curated
database (Table 32). An additional species and tissue prefilter applied to each dataset resulted in
object sets that were approximately 70% of the original size. The number of objects which could
be incorporated into one or more enrichment categories are also shown in Table 32. The fewest
objects were represented within disease enrichments (2-5% of each set), with the most
represented in GO processes (approximately 90-95%). There were no major discrepancies
between groups in representation within specific MetaCore™ ontologies.
The experiments listed above were analyzed individually using the MetaCore™ Enrichment
Analysis Workflow tool. Vehicle vs. PCB exposure within diet groups are represented by Groups
1 and 2, while Group 3 compares CD to HFD at 0 (Vehicle), 20 mg/kg or 200 mg/kg.
The four PCB exposures vs. vehicle control experiments were analyzed using the Toxicity
Workflow (Liver Toxicity filter) and Biomarkers Analysis (Metabolic Disease filter) to explore
enrichments specific to liver toxicity and metabolic disease, respectively. Genomic data from
these experiments was matched to maps, networks and biomarker lists from the peer-reviewed
literature database manually curated by Thomson Reuters.

Because xenobiotic receptors such as PXR, CAR and AhR are transcription factors which
are expected to mediate the transcriptional response to PCBs, as well as other xenobiotic and
endobiotic molecules, we assessed the differential expression of MetaCore™-curated
transcriptional targets of these receptors and their heterodimer complexes (PXR/RXR-alpha,
CAR/RXR-alpha, and AhR/ARNT).

Using the Build Network tool within MetaCore™, we analyzed connectivity between
network objects in each dataset and specific transcription factors, with the ten transcription
factors which could be expected to modulate transcription of the largest number of targets within
each dataset ranked highest. Because the xenobiotic receptors and heterodimer complexes are
additionally expected to crosstalk with other transcription factors by protein-protein interactions,
we built shortest-path networks showing the relationships between xenobiotic receptors and their
binding partners which have defined relationships curated in MetaCore™.
Table 32

*in vivo* experiment dataset properties

<table>
<thead>
<tr>
<th>Comparison number *</th>
<th>Comparisons</th>
<th># significant DTGs</th>
<th>Metacore network objects (unfiltered)</th>
<th>Metacore network objects (prefiltered)</th>
<th>Included in Metacore groupings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maps</td>
</tr>
<tr>
<td>Group 1 (Dose within CD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>CVvsC20</td>
<td>132</td>
<td>128</td>
<td>94</td>
<td>56</td>
</tr>
<tr>
<td>2</td>
<td>CVvsC200</td>
<td>1139</td>
<td>1088</td>
<td>825</td>
<td>327</td>
</tr>
<tr>
<td>Group 2 (Dose within HFD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>HVvsH20</td>
<td>793</td>
<td>750</td>
<td>544</td>
<td>262</td>
</tr>
<tr>
<td>4</td>
<td>HVvsH200</td>
<td>410</td>
<td>388</td>
<td>280</td>
<td>142</td>
</tr>
<tr>
<td>Group 3 (Diet within dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>C20vsH20</td>
<td>1436</td>
<td>1365</td>
<td>996</td>
<td>456</td>
</tr>
<tr>
<td>6</td>
<td>C200vsH200</td>
<td>1446</td>
<td>1379</td>
<td>1007</td>
<td>487</td>
</tr>
<tr>
<td>7</td>
<td>CVvsHV</td>
<td>1877</td>
<td>1801</td>
<td>1376</td>
<td>620</td>
</tr>
</tbody>
</table>

*The number associated with each comparison (column 1) is used throughout this section in the pathway maps generated with MetaCore software.

The six comparisons listed in column 2 were used to generate datasets of significantly differentially transcribed genes (column 3). Changes to the overall sizes of the datasets were induced by import into the MetaCore pathway analysis software and reconciliation with the MetaCore curated database (column 4), and the application of prefilters excluding targets not associated with species (Mus musculus) or tissue (liver) (column 5). Numbers of objects associated each of 4 core grouping mechanisms curated by MetaCore – maps, diseases, gene ontology (GO) processes, and process networks – are shown for each dataset in columns 6-9.
CHAPTER TWO: RESULTS

**PCB exposure induced differential transcription with and without HFD coexposure**

Seven comparisons were made between the aggregated RNAseq data from each condition and its respective control using CuffDiff, as indicated in Table 32. Metacore™ enrichment analyses for the DTG sets resulting from each comparison are shown in Tables 33-39.

Chronic PCB exposure in the control-diet-fed animals explored the effects of systemic PCB exposure alone on liver tissue. In the CVvsC20 comparison, DTGs were enriched in diseases related to nutritional and metabolic disease, obesity and overnutrition, although these mice were fed regular synthetic diet (Table 33). Terms related to circadian rhythm were enriched among maps, networks and processes within this DTG set as well.

The 200 mg/kg PCB exposure was a concentration based on rodent toxicity studies. Compared to vehicle, DTGs in this exposure were unsurprisingly enriched in terms related to previously reported sequelae of high-level PCB exposures: neoplastic disease biomarkers, immune-system and inflammatory process maps and networks. Disruption of cell regulatory processes was also indicated at this exposure level. Interestingly, processes and networks related to epithelial-mesenchymal transition and cell identity which are involved in both development and tissue remodeling (Wnt, TGFβ signaling), were over-represented in this dataset and, to a lesser extent, in the lower PCB exposure (Table 34).

Our evaluation of chronic moderate and high PCB exposures in the high-fat diet fed animals explored the interaction between diet and exposure, to more faithfully reconstruct conditions in many human PCB exposures, including Anniston. In the HVvsH20 and HVvsH200 comparisons, we generated datasets with genes significantly differentially transcribed in
## Table 33

Enrichments for genes differentially transcribed in comparison CVvsC20

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colonic Diseases</td>
<td>1.271E-11</td>
<td>1.169E-08</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>2.304E-11</td>
<td>1.169E-08</td>
</tr>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>2.949E-11</td>
<td>1.169E-08</td>
</tr>
<tr>
<td>Nutritional and Metabolic Diseases</td>
<td>3.875E-11</td>
<td>1.169E-08</td>
</tr>
<tr>
<td>Cardiovascular Diseases</td>
<td>7.116E-11</td>
<td>1.506E-08</td>
</tr>
<tr>
<td>Chemically-Induced Disorders</td>
<td>7.488E-11</td>
<td>1.506E-08</td>
</tr>
<tr>
<td>Obesity</td>
<td>1.554E-10</td>
<td>2.280E-08</td>
</tr>
<tr>
<td>Overnutrition</td>
<td>1.554E-10</td>
<td>2.280E-08</td>
</tr>
<tr>
<td>Vascular Diseases</td>
<td>1.712E-10</td>
<td>2.280E-08</td>
</tr>
<tr>
<td>Physiological Phenomena</td>
<td>2.045E-10</td>
<td>2.280E-08</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Networks</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurophysiological process_Circadian rhythm</td>
<td>2.999E-04</td>
<td>3.029E-02</td>
</tr>
<tr>
<td>Development_Hedgehog signaling</td>
<td>3.478E-03</td>
<td>1.756E-01</td>
</tr>
<tr>
<td>Proliferation_Negative regulation of cell proliferation</td>
<td>1.424E-02</td>
<td>2.721E-01</td>
</tr>
<tr>
<td>Regulation of metabolism_Bile acid regulation of lipid metabolism and negative FXR-dependent regulation of bile acids concentration</td>
<td>1.795E-02</td>
<td>2.721E-01</td>
</tr>
<tr>
<td>Chemotaxis</td>
<td>2.210E-02</td>
<td>2.721E-01</td>
</tr>
<tr>
<td>Cell adhesion_Cell-matrix interactions</td>
<td>2.427E-02</td>
<td>2.721E-01</td>
</tr>
<tr>
<td>CytoskeletonIntermediate filaments</td>
<td>2.537E-02</td>
<td>2.721E-01</td>
</tr>
<tr>
<td>Reproduction_Progesterone signaling</td>
<td>2.560E-02</td>
<td>2.721E-01</td>
</tr>
<tr>
<td>Development_EMT_Regulation of epithelial-to-mesenchymal transition</td>
<td>3.091E-02</td>
<td>2.721E-01</td>
</tr>
<tr>
<td>Development_Neurogenesis_Axonal guidance</td>
<td>3.354E-02</td>
<td>2.721E-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurophysiological process_Circadian rhythm</td>
<td>1.656E-04</td>
<td>3.987E-02</td>
</tr>
<tr>
<td>Action of GSK3 beta in bipolar disorder</td>
<td>3.242E-04</td>
<td>3.987E-02</td>
</tr>
<tr>
<td>DNA damage_ATM/ATR regulation of G1/S checkpoint</td>
<td>8.741E-04</td>
<td>7.167E-02</td>
</tr>
<tr>
<td>Development_TGF-beta receptor signaling</td>
<td>3.202E-03</td>
<td>1.199E-01</td>
</tr>
<tr>
<td>Development_GM-CSF signaling</td>
<td>3.202E-03</td>
<td>1.199E-01</td>
</tr>
<tr>
<td>Development_WNT signaling pathway Part 2</td>
<td>3.780E-03</td>
<td>1.199E-01</td>
</tr>
<tr>
<td>Development_YAP/TAZ-mediated co-regulation of transcription</td>
<td>4.416E-03</td>
<td>1.199E-01</td>
</tr>
<tr>
<td>Nicotine metabolism in liver</td>
<td>4.416E-03</td>
<td>1.199E-01</td>
</tr>
<tr>
<td>Immune response_IL-5 signaling via JAK/STAT</td>
<td>4.642E-03</td>
<td>1.199E-01</td>
</tr>
<tr>
<td>Effect of H. pylori infection on gastric epithelial cell proliferation</td>
<td>4.875E-03</td>
<td>1.199E-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>cellular response to chemical stimulus</td>
<td>4.435E-17</td>
<td>1.807E-13</td>
</tr>
<tr>
<td>circadian rhythm</td>
<td>1.032E-15</td>
<td>2.103E-12</td>
</tr>
<tr>
<td>rhythmic process</td>
<td>1.591E-15</td>
<td>2.161E-12</td>
</tr>
<tr>
<td>cellular response to oxygen-containing compound</td>
<td>6.827E-13</td>
<td>6.955E-10</td>
</tr>
<tr>
<td>regulation of developmental process</td>
<td>6.009E-12</td>
<td>3.794E-09</td>
</tr>
<tr>
<td>regulation of cell differentiation</td>
<td>6.012E-12</td>
<td>3.794E-09</td>
</tr>
<tr>
<td>response to chemical</td>
<td>6.518E-12</td>
<td>3.794E-09</td>
</tr>
<tr>
<td>cellular response to organic substance</td>
<td>1.324E-11</td>
<td>6.743E-09</td>
</tr>
<tr>
<td>regulation of circadian rhythm</td>
<td>1.493E-11</td>
<td>6.759E-09</td>
</tr>
<tr>
<td>response to oxygen-containing compound</td>
<td>1.939E-11</td>
<td>7.900E-09</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
Table 34

Enrichments for genes differentially transcribed in comparison CVvsC200

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoplasms</td>
<td>1.106E-19</td>
<td>1.136E-16</td>
</tr>
<tr>
<td>Pathological Conditions, Signs and Symptoms</td>
<td>1.280E-19</td>
<td>1.136E-16</td>
</tr>
<tr>
<td>Gastrointestinal Neoplasms</td>
<td>4.616E-19</td>
<td>2.488E-16</td>
</tr>
<tr>
<td>Neoplasms by Site</td>
<td>6.790E-19</td>
<td>2.488E-16</td>
</tr>
<tr>
<td>Respiratory Tract Neoplasms</td>
<td>7.238E-19</td>
<td>2.488E-16</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>9.070E-19</td>
<td>2.488E-16</td>
</tr>
<tr>
<td>Gastrointestinal Diseases</td>
<td>9.810E-19</td>
<td>2.488E-16</td>
</tr>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>2.239E-18</td>
<td>4.968E-16</td>
</tr>
<tr>
<td>Lung Neoplasms</td>
<td>4.384E-18</td>
<td>8.646E-16</td>
</tr>
<tr>
<td>Chemically-Induced Disorders</td>
<td>5.316E-18</td>
<td>9.436E-16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Networks</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein folding_Response to unfolded proteins</td>
<td>1.973E-08</td>
<td>3.058E-06</td>
</tr>
<tr>
<td>Protein folding_Folding in normal condition</td>
<td>1.576E-05</td>
<td>1.222E-03</td>
</tr>
<tr>
<td>Reproduction_Feeding and Neurohormone signaling</td>
<td>7.931E-05</td>
<td>3.470E-03</td>
</tr>
<tr>
<td>Development_EMT_Regulation of EMT</td>
<td>8.954E-05</td>
<td>3.470E-03</td>
</tr>
<tr>
<td>Signal transduction_WNT signaling</td>
<td>1.304E-04</td>
<td>4.041E-03</td>
</tr>
<tr>
<td>Inflammation_Amphoterin signaling</td>
<td>1.777E-04</td>
<td>4.207E-03</td>
</tr>
<tr>
<td>Cell cycle_G1-S Growth factor regulation</td>
<td>1.900E-04</td>
<td>4.207E-03</td>
</tr>
<tr>
<td>Apoptosis_Endoplasmic reticulum stress pathway</td>
<td>3.415E-04</td>
<td>6.617E-03</td>
</tr>
<tr>
<td>Signal Transduction_TGF-beta, GDF and Activin signaling</td>
<td>4.710E-04</td>
<td>8.112E-03</td>
</tr>
<tr>
<td>Inflammation_IL-6 signaling</td>
<td>6.253E-04</td>
<td>9.693E-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune response_HMGB1/RAGE signaling pathway</td>
<td>1.601E-06</td>
<td>1.242E-03</td>
</tr>
<tr>
<td>Immune response_IL-33 signaling pathway</td>
<td>4.092E-06</td>
<td>1.564E-03</td>
</tr>
<tr>
<td>Development_GM-CSF signaling</td>
<td>6.840E-06</td>
<td>1.564E-03</td>
</tr>
<tr>
<td>Development_Gastrin in cell growth and proliferation</td>
<td>8.063E-06</td>
<td>1.564E-03</td>
</tr>
<tr>
<td>CFTR folding and maturation (normal and CF)</td>
<td>1.214E-05</td>
<td>1.884E-03</td>
</tr>
<tr>
<td>Immune response_IL-4 signaling pathway</td>
<td>2.083E-05</td>
<td>2.323E-03</td>
</tr>
<tr>
<td>Immune response_TLR2 and TLR4 signaling pathways</td>
<td>2.326E-05</td>
<td>2.323E-03</td>
</tr>
<tr>
<td>Development_Growth factors in regulation of oligodendrocyte precursor cell survival</td>
<td>3.183E-05</td>
<td>2.745E-03</td>
</tr>
<tr>
<td>Apoptosis and survival_p53-dependent apoptosis</td>
<td>4.710E-05</td>
<td>3.655E-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>negative regulation of biological process</td>
<td>6.174E-24</td>
<td>3.243E-20</td>
</tr>
<tr>
<td>regulation of response to stimulus</td>
<td>1.167E-23</td>
<td>3.243E-20</td>
</tr>
<tr>
<td>regulation of apoptotic process</td>
<td>1.725E-23</td>
<td>3.243E-20</td>
</tr>
<tr>
<td>regulation of programmed cell death</td>
<td>1.820E-23</td>
<td>3.243E-20</td>
</tr>
<tr>
<td>regulation of signal transduction</td>
<td>2.106E-23</td>
<td>3.243E-20</td>
</tr>
<tr>
<td>regulation of cell death</td>
<td>6.601E-23</td>
<td>8.472E-20</td>
</tr>
<tr>
<td>negative regulation of cellular process</td>
<td>8.781E-23</td>
<td>9.659E-20</td>
</tr>
<tr>
<td>response to organic substance</td>
<td>4.861E-22</td>
<td>4.679E-19</td>
</tr>
<tr>
<td>regulation of cell communication</td>
<td>1.172E-21</td>
<td>1.002E-18</td>
</tr>
<tr>
<td>regulation of signaling</td>
<td>3.931E-21</td>
<td>3.027E-18</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/vehicle and control diet/200 mg/kg PCB (CVvsC200). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
Table 35

Enrichments for genes differentially transcribed in comparison HVvsH20

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>1.034E-34</td>
<td>1.907E-31</td>
</tr>
<tr>
<td>Chemically-Induced Disorders</td>
<td>4.035E-34</td>
<td>3.721E-31</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>9.344E-33</td>
<td>5.744E-30</td>
</tr>
<tr>
<td>Pathologic Processes</td>
<td>4.832E-32</td>
<td>2.227E-29</td>
</tr>
<tr>
<td>Pathological Conditions, Signs and Symptoms</td>
<td>1.681E-31</td>
<td>6.122E-29</td>
</tr>
<tr>
<td>Ovarian Diseases</td>
<td>2.159E-31</td>
<td>6.122E-29</td>
</tr>
<tr>
<td>Adnexal Diseases</td>
<td>2.324E-31</td>
<td>6.122E-29</td>
</tr>
<tr>
<td>Gonadal Disorders</td>
<td>2.441E-30</td>
<td>5.627E-28</td>
</tr>
<tr>
<td>Ovarian Neoplasms</td>
<td>2.986E-30</td>
<td>6.117E-28</td>
</tr>
<tr>
<td>Phenomena and Processes</td>
<td>5.235E-30</td>
<td>9.653E-28</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Networks</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inflammation_IL-6 signaling</td>
<td>7.402E-09</td>
<td>1.147E-06</td>
</tr>
<tr>
<td>Blood coagulation</td>
<td>3.335E-08</td>
<td>2.584E-06</td>
</tr>
<tr>
<td>Development_Blood_vesselmorphogenesis</td>
<td>2.242E-06</td>
<td>1.158E-04</td>
</tr>
<tr>
<td>Development_EMT_Regulation of EMT</td>
<td>1.976E-05</td>
<td>7.655E-04</td>
</tr>
<tr>
<td>Cell adhesion_Attractive and repulsive receptors</td>
<td>1.921E-04</td>
<td>4.604E-03</td>
</tr>
<tr>
<td>Reproduction_FSH-beta signaling pathway</td>
<td>2.121E-04</td>
<td>4.604E-03</td>
</tr>
<tr>
<td>Cell cycle_G1-S Growth factor regulation</td>
<td>2.376E-04</td>
<td>4.604E-03</td>
</tr>
<tr>
<td>Signal transduction_ESR1-nuclear pathway</td>
<td>2.984E-04</td>
<td>5.138E-03</td>
</tr>
<tr>
<td>Inflammation_Kallikrein-kinin system</td>
<td>3.730E-04</td>
<td>5.781E-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune response_IL-6-induced acute-phase response in hepatocytes</td>
<td>5.092E-13</td>
<td>3.753E-10</td>
</tr>
<tr>
<td>Reproduction_Gonadotropin-releasing hormone(GnRH) signaling</td>
<td>9.800E-07</td>
<td>2.408E-04</td>
</tr>
<tr>
<td>Immune response_IL-6 signaling pathway via JAK/STAT</td>
<td>9.800E-07</td>
<td>2.408E-04</td>
</tr>
<tr>
<td>Blood coagulation_Blood coagulation</td>
<td>1.335E-06</td>
<td>2.460E-04</td>
</tr>
<tr>
<td>Immune response_IL-5 signaling via JAK/STAT</td>
<td>4.937E-06</td>
<td>7.277E-04</td>
</tr>
<tr>
<td>Mitogenic action of Estradiol/ESR1(nuclear) in breast cancer</td>
<td>1.176E-05</td>
<td>1.444E-03</td>
</tr>
<tr>
<td>Signal transduction_mTORC2 downstream signaling</td>
<td>2.503E-05</td>
<td>2.636E-03</td>
</tr>
<tr>
<td>Blood coagulation_Platelet microparticle generation</td>
<td>4.165E-05</td>
<td>3.567E-03</td>
</tr>
<tr>
<td>Immune response_MIF-induced cell adhesion, migration and angiogenesis</td>
<td>4.763E-05</td>
<td>3.567E-03</td>
</tr>
<tr>
<td>Development_Ligand-dependent activation of the ESR1/AP-1 pathway</td>
<td>4.840E-05</td>
<td>3.567E-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>response to organic substance</td>
<td>1.741E-44</td>
<td>1.269E-40</td>
</tr>
<tr>
<td>response to chemical</td>
<td>5.052E-38</td>
<td>1.841E-34</td>
</tr>
<tr>
<td>cellular response to chemical stimulus</td>
<td>9.611E-37</td>
<td>2.336E-33</td>
</tr>
<tr>
<td>response to oxygen-containing compound</td>
<td>6.073E-33</td>
<td>1.107E-29</td>
</tr>
<tr>
<td>response to stress</td>
<td>9.920E-28</td>
<td>1.446E-24</td>
</tr>
<tr>
<td>response to organic cyclic compound</td>
<td>1.411E-27</td>
<td>1.714E-24</td>
</tr>
<tr>
<td>response to hormone</td>
<td>3.131E-25</td>
<td>3.261E-22</td>
</tr>
<tr>
<td>positive regulation of multicellular organismal process</td>
<td>6.891E-25</td>
<td>6.279E-22</td>
</tr>
<tr>
<td>response to lipid</td>
<td>2.898E-24</td>
<td>2.348E-21</td>
</tr>
<tr>
<td>cellular response to organic substance</td>
<td>7.733E-24</td>
<td>5.637E-21</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between high-fat diet/vehicle and high-fat diet/20 mg/kg PCB (HVvsH20). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
### Table 36

Enrichments for genes differentially transcribed in comparison HVvsH200

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathologic Processes</td>
<td>1.902E-22</td>
<td>2.574E-19</td>
</tr>
<tr>
<td>Pathological Conditions, Signs and Symptoms</td>
<td>3.351E-20</td>
<td>2.267E-17</td>
</tr>
<tr>
<td>Neoplasms, Ductal, Lobular, and Medullary</td>
<td>9.171E-20</td>
<td>4.136E-17</td>
</tr>
<tr>
<td>Neoplasms, Glandular and Epithelial</td>
<td>6.602E-19</td>
<td>2.233E-16</td>
</tr>
<tr>
<td>Neoplasms, Neuroepithelial</td>
<td>3.418E-18</td>
<td>9.250E-16</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>1.007E-17</td>
<td>2.022E-15</td>
</tr>
<tr>
<td>Digestive System Neoplasms</td>
<td>1.046E-17</td>
<td>2.022E-15</td>
</tr>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>1.713E-17</td>
<td>2.639E-15</td>
</tr>
<tr>
<td>Carcinoma</td>
<td>1.986E-17</td>
<td>2.639E-15</td>
</tr>
<tr>
<td>Stomach Diseases</td>
<td>1.996E-17</td>
<td>2.639E-15</td>
</tr>
<tr>
<td><strong>Networks</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reproduction_FSH-beta signaling pathway</td>
<td>1.355E-04</td>
<td>1.350E-02</td>
</tr>
<tr>
<td>Development_Regulation of angiogenesis</td>
<td>2.381E-04</td>
<td>1.350E-02</td>
</tr>
<tr>
<td>Development_EMT_Regulation of epithelial-to-mesenchymal transition</td>
<td>2.736E-04</td>
<td>1.350E-02</td>
</tr>
<tr>
<td>Apoptosis_Anti-apoptosis mediated by external signals via NF-kB</td>
<td>5.384E-04</td>
<td>1.758E-02</td>
</tr>
<tr>
<td>Protein folding_Response to unfolded proteins</td>
<td>5.940E-04</td>
<td>1.758E-02</td>
</tr>
<tr>
<td>Protein folding_Folding in normal condition</td>
<td>8.931E-04</td>
<td>2.203E-02</td>
</tr>
<tr>
<td>Signal transduction_WNT signaling</td>
<td>1.266E-03</td>
<td>2.677E-02</td>
</tr>
<tr>
<td>Proliferation_Negative regulation of cell proliferation</td>
<td>1.731E-03</td>
<td>3.162E-02</td>
</tr>
<tr>
<td>Apoptosis_Apoptotic nucleus</td>
<td>1.923E-03</td>
<td>3.162E-02</td>
</tr>
<tr>
<td>Proliferation_Positive regulation cell proliferation</td>
<td>2.434E-03</td>
<td>3.602E-02</td>
</tr>
<tr>
<td><strong>Maps</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development_Regulation of EMT</td>
<td>7.035E-06</td>
<td>3.737E-03</td>
</tr>
<tr>
<td>Immune response_IL-6-induced acute-phase response/hepatocytes</td>
<td>1.913E-05</td>
<td>3.737E-03</td>
</tr>
<tr>
<td>Development_Lipoxin inhibitory action on PDGF, EGF and LTD4 signaling</td>
<td>1.913E-05</td>
<td>3.737E-03</td>
</tr>
<tr>
<td>CFTR folding and maturation (normal and CF)</td>
<td>3.154E-05</td>
<td>4.620E-03</td>
</tr>
<tr>
<td>Impaired Lipoxin A4 signaling in CF</td>
<td>6.244E-05</td>
<td>7.318E-03</td>
</tr>
<tr>
<td>Immune response_IL-5 signaling via JAK/STAT</td>
<td>2.709E-04</td>
<td>2.645E-02</td>
</tr>
<tr>
<td>Immune response_Oncostatin M signaling via JAK-Stat</td>
<td>3.581E-04</td>
<td>2.998E-02</td>
</tr>
<tr>
<td>Development_Regulation of lung epithelial progenitor cell differentiation</td>
<td>4.474E-04</td>
<td>3.277E-02</td>
</tr>
<tr>
<td>Regulation of Tissue factor signaling in cancer</td>
<td>5.602E-04</td>
<td>3.648E-02</td>
</tr>
<tr>
<td>Immune response_TNF-R2 signaling pathways</td>
<td>6.931E-04</td>
<td>3.750E-02</td>
</tr>
<tr>
<td><strong>Processes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>response to organic substance</td>
<td>6.419E-23</td>
<td>3.433E-19</td>
</tr>
<tr>
<td>cellular response to chemical stimulus</td>
<td>3.993E-21</td>
<td>1.068E-17</td>
</tr>
<tr>
<td>response to oxygen-containing compound</td>
<td>1.463E-19</td>
<td>2.608E-16</td>
</tr>
<tr>
<td>regulation of signal transduction</td>
<td>3.241E-19</td>
<td>4.333E-16</td>
</tr>
<tr>
<td>response to hormone</td>
<td>7.205E-19</td>
<td>7.707E-16</td>
</tr>
<tr>
<td>negative regulation of cellular process</td>
<td>2.385E-18</td>
<td>2.105E-15</td>
</tr>
<tr>
<td>negative regulation of biological process</td>
<td>3.113E-18</td>
<td>2.105E-15</td>
</tr>
<tr>
<td>regulation of response to stimulus</td>
<td>3.148E-18</td>
<td>2.105E-15</td>
</tr>
<tr>
<td>response to organic cyclic compound</td>
<td>3.973E-18</td>
<td>2.361E-15</td>
</tr>
<tr>
<td>regulation of cell communication</td>
<td>5.115E-18</td>
<td>2.735E-15</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between high-fat diet/vehicle and high-fat diet/200 mg/kg PCB (HVvH200). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
### Table 37
Enrichments for genes differentially transcribed in comparison CVvsHV

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathological Conditions, Signs and Symptoms</td>
<td>1.668E-40</td>
<td>3.561E-37</td>
</tr>
<tr>
<td>Pathologic Processes</td>
<td>1.095E-38</td>
<td>1.169E-35</td>
</tr>
<tr>
<td>Nutritional and Metabolic Diseases</td>
<td>2.753E-37</td>
<td>1.959E-34</td>
</tr>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>4.662E-36</td>
<td>2.489E-33</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>9.122E-36</td>
<td>3.895E-33</td>
</tr>
<tr>
<td>Chemically-Induced Disorders</td>
<td>1.856E-34</td>
<td>6.605E-32</td>
</tr>
<tr>
<td>Metabolic Diseases</td>
<td>6.604E-32</td>
<td>2.014E-29</td>
</tr>
<tr>
<td>Respiratory Tract Neoplasms</td>
<td>3.016E-29</td>
<td>7.174E-27</td>
</tr>
<tr>
<td>Physiological Phenomena</td>
<td>3.024E-29</td>
<td>7.174E-27</td>
</tr>
<tr>
<td>Phenomena and Processes</td>
<td>1.560E-28</td>
<td>3.330E-26</td>
</tr>
</tbody>
</table>

### Networks

<table>
<thead>
<tr>
<th>Networks</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development_Regulation of angiogenesis</td>
<td>2.143E-05</td>
<td>3.387E-03</td>
</tr>
<tr>
<td>Cell adhesion_Platelet-endothelium-leucocyte interactions</td>
<td>4.700E-05</td>
<td>3.713E-03</td>
</tr>
<tr>
<td>Cell adhesion_Cell-matrix interactions</td>
<td>8.355E-05</td>
<td>4.400E-03</td>
</tr>
<tr>
<td>Chemotaxis</td>
<td>1.403E-04</td>
<td>5.542E-03</td>
</tr>
<tr>
<td>Cell adhesion_Leucocyte chemotaxis</td>
<td>4.519E-04</td>
<td>1.220E-02</td>
</tr>
<tr>
<td>Cell adhesion_Integrin-mediated cell-matrix adhesion</td>
<td>5.221E-04</td>
<td>1.220E-02</td>
</tr>
<tr>
<td>Cell cycle_G2-M</td>
<td>5.407E-04</td>
<td>1.220E-02</td>
</tr>
<tr>
<td>Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT</td>
<td>6.200E-04</td>
<td>1.224E-02</td>
</tr>
<tr>
<td>Signal Transduction_TGF-beta, GDF and Activin signaling</td>
<td>9.318E-04</td>
<td>1.560E-02</td>
</tr>
<tr>
<td>Translation_Translation initiation</td>
<td>9.871E-04</td>
<td>1.560E-02</td>
</tr>
</tbody>
</table>

### Maps

<table>
<thead>
<tr>
<th>Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcription_Sirtuin6 regulation and functions</td>
<td>2.545E-09</td>
<td>2.146E-06</td>
</tr>
<tr>
<td>Immune response_IL-4-induced regulators of cell growth, survival, differentiation and metabolism</td>
<td>4.351E-07</td>
<td>1.834E-04</td>
</tr>
<tr>
<td>Cell cycle_Regulation of G1/S transition (part 1)</td>
<td>3.614E-06</td>
<td>1.015E-03</td>
</tr>
<tr>
<td>Cell cycle_ESR1 regulation of G1/S transition</td>
<td>7.096E-06</td>
<td>1.495E-03</td>
</tr>
<tr>
<td>Development_TFs in segregation of hepatocytic lineage</td>
<td>1.382E-05</td>
<td>2.115E-03</td>
</tr>
<tr>
<td>Protein folding and maturation_Angiotensin system maturation \ Human version</td>
<td>1.505E-05</td>
<td>2.115E-03</td>
</tr>
<tr>
<td>Cell adhesion_ECM remodeling</td>
<td>3.057E-05</td>
<td>3.018E-03</td>
</tr>
<tr>
<td>Cell cycle_Chromosome condensation in prometaphase</td>
<td>3.389E-05</td>
<td>3.018E-03</td>
</tr>
<tr>
<td>Role of ZNF202 in regulating gene expression in atherosclerosis</td>
<td>3.389E-05</td>
<td>3.018E-03</td>
</tr>
<tr>
<td>Cell adhesion_Integrin inside-out signaling in neutrophils</td>
<td>3.580E-05</td>
<td>3.018E-03</td>
</tr>
</tbody>
</table>

### Processes

<table>
<thead>
<tr>
<th>Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>response to organic substance</td>
<td>1.024E-38</td>
<td>9.358E-35</td>
</tr>
<tr>
<td>response to oxygen-containing compound</td>
<td>7.650E-31</td>
<td>3.335E-27</td>
</tr>
<tr>
<td>cellular response to chemical stimulus</td>
<td>1.095E-30</td>
<td>3.335E-27</td>
</tr>
<tr>
<td>single-organism metabolic process</td>
<td>8.462E-30</td>
<td>1.933E-26</td>
</tr>
<tr>
<td>response to endogenous stimulus</td>
<td>2.380E-28</td>
<td>4.349E-25</td>
</tr>
<tr>
<td>response to organic cyclic compound</td>
<td>7.309E-28</td>
<td>1.113E-24</td>
</tr>
<tr>
<td>response to stress</td>
<td>3.846E-27</td>
<td>5.021E-24</td>
</tr>
<tr>
<td>response to external stimulus</td>
<td>6.496E-27</td>
<td>7.419E-24</td>
</tr>
<tr>
<td>response to lipid</td>
<td>1.313E-26</td>
<td>1.333E-23</td>
</tr>
<tr>
<td>response to hormone</td>
<td>1.619E-26</td>
<td>1.391E-23</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/vehicle and high-fat diet/vehicle (CVvsHV). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
### Table 38

Enrichments for genes differentially transcribed in comparison C20vsH20

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>9.926E-38</td>
<td>2.026E-34</td>
</tr>
<tr>
<td>Chemically-Induced Disorders</td>
<td>4.539E-37</td>
<td>4.632E-34</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>8.728E-37</td>
<td>5.938E-34</td>
</tr>
<tr>
<td>Pathological Conditions, Signs and Symptoms</td>
<td>2.331E-36</td>
<td>1.189E-33</td>
</tr>
<tr>
<td>Pathologic Processes</td>
<td>3.434E-36</td>
<td>1.402E-33</td>
</tr>
<tr>
<td>Fibrosis</td>
<td>1.512E-34</td>
<td>5.142E-32</td>
</tr>
<tr>
<td>Phenomena and Processes</td>
<td>6.761E-34</td>
<td>1.971E-31</td>
</tr>
<tr>
<td>Physiological Phenomena</td>
<td>2.105E-33</td>
<td>5.371E-31</td>
</tr>
<tr>
<td>Body Weight</td>
<td>4.840E-32</td>
<td>1.098E-29</td>
</tr>
<tr>
<td>Nutritional and Metabolic Diseases</td>
<td>7.909E-32</td>
<td>1.614E-29</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Networks</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development, Regulation of angiogenesis</td>
<td>1.829E-09</td>
<td>2.889E-07</td>
</tr>
<tr>
<td>Development, Blood vessel morphogenesis</td>
<td>8.673E-06</td>
<td>6.851E-04</td>
</tr>
<tr>
<td>Development, EMT, Regulation of epithelial-to-mesenchymal transition</td>
<td>1.716E-05</td>
<td>9.036E-04</td>
</tr>
<tr>
<td>Inflammation, IL-6 signaling</td>
<td>1.992E-04</td>
<td>6.405E-03</td>
</tr>
<tr>
<td>Signal Transduction, BMP and GDF signaling</td>
<td>2.027E-04</td>
<td>6.405E-03</td>
</tr>
<tr>
<td>Inflammation, Amphoterin signaling</td>
<td>5.171E-04</td>
<td>1.191E-02</td>
</tr>
<tr>
<td>Regulation of metabolism, Bile acid regulation of lipid metabolism and negative FXR-dependent regulation of bile acids concentration</td>
<td>5.276E-04</td>
<td>1.191E-02</td>
</tr>
<tr>
<td>Apoptosis, Endoplasmic reticulum stress pathway</td>
<td>1.562E-03</td>
<td>3.086E-02</td>
</tr>
<tr>
<td>Cell adhesion, Attractive and repulsive receptors</td>
<td>1.912E-03</td>
<td>3.357E-02</td>
</tr>
<tr>
<td>Blood coagulation</td>
<td>2.654E-03</td>
<td>3.839E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcription, Sirtuin6 regulation and functions</td>
<td>8.710E-09</td>
<td>7.003E-06</td>
</tr>
<tr>
<td>Immune response, IL-6-induced acute-phase response/hepatocytes</td>
<td>8.699E-08</td>
<td>3.497E-05</td>
</tr>
<tr>
<td>Development, β-adrenergic receptors/brown adipocyte differentiation</td>
<td>1.118E-06</td>
<td>2.997E-04</td>
</tr>
<tr>
<td>Development, TGF-beta-dependent induction of EMT via MAPK</td>
<td>2.196E-06</td>
<td>4.414E-04</td>
</tr>
<tr>
<td>Role of ZNF202 in regulating gene expression in atherosclerosis</td>
<td>4.150E-06</td>
<td>6.673E-04</td>
</tr>
<tr>
<td>Protein folding/maturation, Angiotensin system maturation \ Human</td>
<td>5.728E-06</td>
<td>7.675E-04</td>
</tr>
<tr>
<td>Protein folding/maturation, Angiotensin system maturation \ Rodent</td>
<td>1.793E-05</td>
<td>2.060E-03</td>
</tr>
<tr>
<td>Signal transduction, mTORC1 downstream signaling</td>
<td>3.867E-05</td>
<td>3.526E-03</td>
</tr>
<tr>
<td>Immune response, IL-6 signaling pathway via JAK/STAT</td>
<td>4.800E-05</td>
<td>3.526E-03</td>
</tr>
<tr>
<td>Apoptosis and survival, Role of PKR in stress-induced apoptosis</td>
<td>4.824E-05</td>
<td>3.526E-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>response to oxygen-containing compound</td>
<td>1.007E-43</td>
<td>8.605E-40</td>
</tr>
<tr>
<td>response to organic substance</td>
<td>5.608E-42</td>
<td>2.397E-38</td>
</tr>
<tr>
<td>cellular response to chemical stimulus</td>
<td>1.522E-37</td>
<td>4.337E-34</td>
</tr>
<tr>
<td>response to organic cyclic compound</td>
<td>4.105E-34</td>
<td>8.772E-31</td>
</tr>
<tr>
<td>response to organonitrogen compound</td>
<td>2.307E-31</td>
<td>3.944E-28</td>
</tr>
<tr>
<td>response to chemical</td>
<td>2.647E-30</td>
<td>3.770E-27</td>
</tr>
<tr>
<td>response to external stimulus</td>
<td>3.106E-30</td>
<td>3.792E-27</td>
</tr>
<tr>
<td>response to nitrogen compound</td>
<td>4.595E-30</td>
<td>4.909E-27</td>
</tr>
<tr>
<td>single-organism metabolic process</td>
<td>1.205E-29</td>
<td>1.144E-26</td>
</tr>
<tr>
<td>response to lipid</td>
<td>2.262E-29</td>
<td>1.933E-26</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/20 mg/kg PCB and high-fat diet/20 mg/kg PCB (C20vsH20). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
Enrichments for genes differentially transcribed in comparison C200vsH200

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathologic Processes</td>
<td>2.843E-45</td>
<td>5.814E-42</td>
</tr>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>4.265E-40</td>
<td>4.139E-37</td>
</tr>
<tr>
<td>Pathological Conditions, Signs and Symptoms</td>
<td>6.071E-40</td>
<td>4.139E-37</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>4.134E-39</td>
<td>1.816E-36</td>
</tr>
<tr>
<td>Chemically-Induced Disorders</td>
<td>4.439E-39</td>
<td>1.816E-36</td>
</tr>
<tr>
<td>Nutritional and Metabolic Diseases</td>
<td>1.527E-31</td>
<td>5.204E-29</td>
</tr>
<tr>
<td>Metabolic Diseases</td>
<td>8.142E-31</td>
<td>2.379E-28</td>
</tr>
<tr>
<td>Vascular Diseases</td>
<td>2.710E-29</td>
<td>6.928E-27</td>
</tr>
<tr>
<td>Endocrine System Diseases</td>
<td>2.060E-28</td>
<td>4.681E-26</td>
</tr>
<tr>
<td>Cardiovascular Diseases</td>
<td>7.414E-28</td>
<td>1.516E-25</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Networks</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development_Regulation of angiogenesis</td>
<td>5.068E-06</td>
<td>4.739E-04</td>
</tr>
<tr>
<td>Chemotaxis</td>
<td>6.115E-06</td>
<td>4.739E-04</td>
</tr>
<tr>
<td>Immune response_Phagocytosis</td>
<td>1.356E-05</td>
<td>7.005E-04</td>
</tr>
<tr>
<td>Inflammation_IL-6 signaling</td>
<td>6.717E-05</td>
<td>2.603E-03</td>
</tr>
<tr>
<td>Cell adhesion_Attractive and repulsive receptors</td>
<td>1.385E-04</td>
<td>3.664E-03</td>
</tr>
<tr>
<td>Development_Blood_vessel morphogenesis</td>
<td>1.418E-04</td>
<td>3.664E-03</td>
</tr>
<tr>
<td>Cell adhesion_Leucocyte chemotaxis</td>
<td>2.759E-04</td>
<td>6.108E-03</td>
</tr>
<tr>
<td>Signal Transduction_Cholecystokinin signaling</td>
<td>1.198E-03</td>
<td>2.320E-02</td>
</tr>
<tr>
<td>Cell cycle_G1-S Interleukin regulation</td>
<td>1.407E-03</td>
<td>2.423E-02</td>
</tr>
<tr>
<td>Immune response_Phagosome in antigen presentation</td>
<td>1.960E-03</td>
<td>3.037E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune response_IL-4-induced regulators of cell growth, survival, differentiation and metabolism</td>
<td>3.816E-07</td>
<td>3.114E-04</td>
</tr>
<tr>
<td>Immune response_IL-6-induced acute-phase response/hepatocytes</td>
<td>9.473E-07</td>
<td>3.865E-04</td>
</tr>
<tr>
<td>Immune response_IL-2 activation and signaling pathway</td>
<td>3.245E-06</td>
<td>6.912E-04</td>
</tr>
<tr>
<td>Development_Role of IL-8 in angiogenesis</td>
<td>3.388E-06</td>
<td>6.912E-04</td>
</tr>
<tr>
<td>Neurophysiological_Receptor-mediated axon growth repulsion</td>
<td>1.057E-05</td>
<td>1.539E-03</td>
</tr>
<tr>
<td>Immune response_Antigen presentation by MHC class II</td>
<td>1.161E-05</td>
<td>1.539E-03</td>
</tr>
<tr>
<td>Transcription_Role of AP-1 in regulation of cellular metabolism</td>
<td>1.320E-05</td>
<td>1.539E-03</td>
</tr>
<tr>
<td>Putative pathways for BPA-stimulated fat cell differentiation</td>
<td>1.999E-05</td>
<td>2.039E-03</td>
</tr>
<tr>
<td>Cell cycle_ESR1 regulation of G1/S transition</td>
<td>3.414E-05</td>
<td>3.095E-03</td>
</tr>
<tr>
<td>Signal transduction мTORC1 downstream signaling</td>
<td>4.447E-05</td>
<td>3.629E-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>response to organic substance</td>
<td>1.995E-37</td>
<td>1.674E-33</td>
</tr>
<tr>
<td>single-organism metabolic process</td>
<td>1.987E-32</td>
<td>8.334E-29</td>
</tr>
<tr>
<td>small molecule metabolic process</td>
<td>2.501E-31</td>
<td>6.994E-28</td>
</tr>
<tr>
<td>response to stress</td>
<td>1.066E-29</td>
<td>1.913E-26</td>
</tr>
<tr>
<td>lipid metabolic process</td>
<td>1.140E-29</td>
<td>1.913E-26</td>
</tr>
<tr>
<td>response to oxygen-containing compound</td>
<td>5.001E-29</td>
<td>6.993E-26</td>
</tr>
<tr>
<td>cellular response to chemical stimulus</td>
<td>8.298E-29</td>
<td>9.946E-26</td>
</tr>
<tr>
<td>response to organic cyclic compound</td>
<td>2.895E-27</td>
<td>3.036E-24</td>
</tr>
<tr>
<td>response to chemical</td>
<td>8.844E-27</td>
<td>8.245E-24</td>
</tr>
<tr>
<td>response to hormone</td>
<td>1.217E-26</td>
<td>1.021E-23</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/200 mg/kg PCB and high-fat diet/200 mg/kg PCB (C200vsH200). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
HFD/PCB coexposure vs. HFD alone. In the HVvsH20 comparison, enriched diseases were associated with gonadal and ovarian disease, including ovarian neoplasms. Enriched networks and maps including both inflammatory and EMT-related categories (Table 35). The HVvsH200 comparison was notable for enrichments in inflammatory, immune-system and EMT-related networks and maps, and neoplastic diseases (Table 36). Interestingly, both of the HFD+PCB groups were highly enriched in multiple processes related to xenobiotic responses (Tables 35-36), while the CD+PCB groups were enriched in categories related to regulation of physiological processes (Tables 33-34).

Transcriptional effects of HFD exposure were modulated by coexposure to PCBs

Comparisons between CD and HFD at each level of PCB exposure (CVvsHV, C20vsH20, C200vsH200 comparisons) explored the transcriptional effects of HFD exposure without or with two levels of PCB coexposure (Tables 37-39). Unsurprisingly, nutritional and metabolic disease biomarkers were over-represented in all three comparisons. Enriched processes for comparisons at all levels were associated with changes in cellular response to endobiotic and xenobiotic organic cyclic compounds, with responses to endogenous compounds (e.g., hormone, lipid, etc.) featuring prominently in the CVvsHV comparison (Table 37), and responses to organonitrogens and external stimulus encroaching in the moderate exposure (Table 38). In a comparison between CD and HFD in the highest PCB exposure group, enrichments in process maps related to pro-inflammatory and anti-inflammatory cytokine signaling were over-represented (Table 39).

The sets of genes differentially transcribed by moderate and high PCB exposures within each diet partially overlapped

Figure 9 shows the relative size of the targets differentially transcribed in a comparison between vehicle and moderate (gold) or vehicle and high (red) PCB exposure in animals on control diet (Panel A) or HFD (Panel B). The overlapping areas indicate targets which are shared between moderate and high PCB exposure levels within a single diet condition. On control diet, a
Figure 9. Moderate and high PCB exposures produce overlapping DTG sets (vs. vehicle)

In an evaluation of PCB transcriptional effect, comparison between PCB exposure and control (vehicle) produced sets of significantly differentially transcribed genes (DTGs), which are shown for control diet (CD, Panel A) and high fat diet (HFD, Panel B). The number of targets which were differentially affected at both 20 mg/kg Aroclor 1260 and 200 mg/kg Aroclor 1260 are shown in the intersecting regions. Targets which were differentially regulated at only moderate (gold) or high (red) dose are shown in the non-intersecting regions. For CD, high PCB exposure resulted in a larger DTG set than moderate PCB exposure. For HFD, moderate PCB exposure resulted in a larger DTG set than high PCB exposure.
A larger number of targets were significantly differentially transcribed in response to chronic high PCB exposure (CVvsC200 comparison) than chronic moderate PCB exposure (CVvsC20 comparison). In the HFD groups, this pattern was reversed, with a smaller number of genes (both absolute and relative) differentially transcribed with the high PCB exposure (HVvsH200 comparison) and a larger number in the moderate PCB exposure (HVvsH20 comparison).

Enrichment analysis of DTGs common between moderate and high PCB exposure within the CD group are shown in Table 40. Targets perturbed in both exposures were over-represented in circadian rhythm-related categories within networks and processes, while processes involving response to endogenous and exogenous molecules comprised the remainder of the most ten enriched processes. Interestingly, hedgehog signaling and WNT signaling, both involved in development and remodeling, were differentially regulated in both moderate and high PCB exposures within this diet group. In the HFD-fed groups, enrichment analysis of DTGs common between both moderate and high PCB exposures were enriched in several networks and maps involved in development and EMT, particularly WNT signaling (Table 41). Hormone signaling pathways including FSH, progesterone and gonadotropin were also identified as commonly engaged networks.

HFD coexposure at different PCB doses resulted in DTG sets with large areas of overlap

When high fat diet was compared to control diet within each PCB exposure level (CDvsHFD, C20vsH20, C200vsH200), three large sets of differentially transcribed genes were identified, with substantial overlap (Figure 10). In the vehicle-treated comparison (black) the entire DTG set can be described as diet-dependent, and the overlapping areas between this and other sets can be described as targets which are differentially transcribed with HFD exposure in the presence or absence of Aroclor 1260 coexposure. The top enrichments for the DTGs produced are shown in Tables 42-46. The moderate (gold) and high (red) PCB coexposure-dependent DTGs are represented by the sections of those sets that do not overlap with the vehicle-treated comparison.
Table 40

Common targets between moderate/high PCB exposure levels within the control diet groups

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-house Adverse Events</td>
<td>3.271E-07</td>
<td>1.434E-12</td>
</tr>
<tr>
<td>Colonic Diseases</td>
<td>3.480E-07</td>
<td>9.982E-08</td>
</tr>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>3.774E-07</td>
<td>2.375E-12</td>
</tr>
<tr>
<td>Endocrine System Diseases</td>
<td>9.532E-07</td>
<td>2.795E-05</td>
</tr>
<tr>
<td>Chemically-Induced Disorders</td>
<td>1.422E-06</td>
<td>2.626E-12</td>
</tr>
<tr>
<td>Cardiovascular Diseases</td>
<td>1.731E-06</td>
<td>1.550E-08</td>
</tr>
<tr>
<td>Neoplasms, Bone Tissue</td>
<td>3.722E-06</td>
<td>2.101E-05</td>
</tr>
<tr>
<td>Vascular Diseases</td>
<td>4.292E-06</td>
<td>1.097E-08</td>
</tr>
<tr>
<td>Diabetes Mellitus, Type 2</td>
<td>4.349E-06</td>
<td>4.745E-04</td>
</tr>
<tr>
<td>Eye Diseases</td>
<td>6.021E-06</td>
<td>5.913E-04</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Networks</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reproduction, Progesterone signaling</td>
<td>2.405E-03</td>
<td>1.465E-01</td>
</tr>
<tr>
<td>Regulation of metabolism, Bile acid regulation of lipid metabolism</td>
<td>3.806E-03</td>
<td>1.465E-01</td>
</tr>
<tr>
<td>and negative FXR-dependent regulation of bile acids concentration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signal transduction, WNT signaling</td>
<td>7.644E-03</td>
<td>2.304E-02</td>
</tr>
<tr>
<td>Immune response, IL-5 signalling</td>
<td>1.238E-02</td>
<td>1.980E-01</td>
</tr>
<tr>
<td>Reproduction, Feeding and Neurohormone signaling</td>
<td>1.374E-02</td>
<td>1.489E-02</td>
</tr>
<tr>
<td>Development, Hedgehog signaling</td>
<td>2.575E-02</td>
<td>3.305E-01</td>
</tr>
<tr>
<td>Development, Ossification and bone remodeling</td>
<td>3.250E-02</td>
<td>3.387E-01</td>
</tr>
<tr>
<td>Cell adhesion, Glycoconjugates</td>
<td>3.519E-02</td>
<td>3.387E-01</td>
</tr>
<tr>
<td>Muscle contraction</td>
<td>4.152E-02</td>
<td>7.278E-02</td>
</tr>
<tr>
<td>Neurophysiological process, Circadian rhythm</td>
<td>4.519E-02</td>
<td>7.038E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development, WNT signaling pathway, Part 2</td>
<td>6.710E-04</td>
<td>4.347E-02</td>
</tr>
<tr>
<td>Nicotine metabolism in liver</td>
<td>7.887E-04</td>
<td>4.347E-02</td>
</tr>
<tr>
<td>Immune response, IL-5 signaling via JAK/STAT</td>
<td>8.307E-04</td>
<td>4.347E-02</td>
</tr>
<tr>
<td>Action of GSK3 beta in bipolar disorder</td>
<td>2.524E-03</td>
<td>8.628E-02</td>
</tr>
<tr>
<td>Immune response, IL-27 signaling pathway</td>
<td>2.748E-03</td>
<td>8.628E-02</td>
</tr>
<tr>
<td>Regulation of lipid metabolism, FXR-dependent negative-feedback</td>
<td>4.564E-03</td>
<td>1.090E-01</td>
</tr>
<tr>
<td>regulation of bile acids concentration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA damage, ATM/ATR regulation of G1/S checkpoint</td>
<td>4.856E-03</td>
<td>9.421E-02</td>
</tr>
<tr>
<td>Development, EPO-induced Jak-STAT pathway</td>
<td>6.121E-03</td>
<td>1.201E-01</td>
</tr>
<tr>
<td>Regulation of metabolism, Bile acids FXR regulation/glucose and lipid</td>
<td>7.886E-03</td>
<td>1.376E-01</td>
</tr>
<tr>
<td>metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulation of GSK3 beta in bipolar disorder</td>
<td>9.852E-03</td>
<td>8.940E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>cellular response to chemical stimulus</td>
<td>1.811E-12</td>
<td>6.576E-12</td>
</tr>
<tr>
<td>cellular response to organic substance</td>
<td>1.056E-09</td>
<td>1.657E-09</td>
</tr>
<tr>
<td>response to stimulus</td>
<td>5.204E-09</td>
<td>1.921E-06</td>
</tr>
<tr>
<td>cellular response to oxygen-containing compound</td>
<td>5.723E-09</td>
<td>4.689E-06</td>
</tr>
<tr>
<td>circadian rhythm</td>
<td>1.362E-08</td>
<td>1.522E-06</td>
</tr>
<tr>
<td>response to chemical</td>
<td>2.079E-08</td>
<td>8.674E-07</td>
</tr>
<tr>
<td>response to organic substance</td>
<td>5.529E-08</td>
<td>2.305E-14</td>
</tr>
<tr>
<td>rhythmic process</td>
<td>9.143E-08</td>
<td>4.206E-07</td>
</tr>
<tr>
<td>response to organic cyclic compound</td>
<td>1.641E-07</td>
<td>2.153E-10</td>
</tr>
<tr>
<td>cellular response to organic cyclic compound</td>
<td>2.955E-07</td>
<td>8.475E-05</td>
</tr>
</tbody>
</table>
### Table 41

Common targets between moderate/high PCB exposure levels within the high-fat diet groups

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoxia</td>
<td>1.987E-16</td>
<td>2.285E-13</td>
</tr>
<tr>
<td>Neoplasms, Ductal, Lobular, and Medullary</td>
<td>4.844E-16</td>
<td>2.785E-13</td>
</tr>
<tr>
<td>Physiological Phenomena</td>
<td>1.831E-15</td>
<td>7.121E-15</td>
</tr>
<tr>
<td>Ovarian Neoplasms</td>
<td>1.840E-15</td>
<td>2.478E-15</td>
</tr>
<tr>
<td>Ovarian Diseases</td>
<td>2.609E-15</td>
<td>3.432E-16</td>
</tr>
<tr>
<td>Adnexal Diseases</td>
<td>2.675E-15</td>
<td>3.432E-16</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>2.932E-15</td>
<td>2.308E-17</td>
</tr>
<tr>
<td>Vascular Diseases</td>
<td>3.321E-15</td>
<td>5.733E-15</td>
</tr>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>4.143E-15</td>
<td>7.903E-19</td>
</tr>
<tr>
<td>Signs and Symptoms, Respiratory</td>
<td>4.344E-15</td>
<td>4.996E-13</td>
</tr>
<tr>
<td>Networks</td>
<td>p-value</td>
<td>FDR</td>
</tr>
<tr>
<td>Reproduction_FSH-beta signaling pathway</td>
<td>2.903E-05</td>
<td>3.056E-03</td>
</tr>
<tr>
<td>Reproduction_Progesterone signaling</td>
<td>5.023E-05</td>
<td>3.056E-03</td>
</tr>
<tr>
<td>Proliferation_Positive regulation cell proliferation</td>
<td>6.596E-05</td>
<td>3.056E-03</td>
</tr>
<tr>
<td>Inflammation_IL-6 signaling</td>
<td>1.805E-04</td>
<td>9.444E-04</td>
</tr>
<tr>
<td>Signal transduction_ESR1-membrane pathway</td>
<td>2.894E-04</td>
<td>6.880E-03</td>
</tr>
<tr>
<td>Development_Regulation of angiogenesis</td>
<td>3.587E-04</td>
<td>6.880E-03</td>
</tr>
<tr>
<td>Signal transduction_WNT signaling</td>
<td>3.775E-04</td>
<td>6.880E-03</td>
</tr>
<tr>
<td>Development_EMT_Regulation of EMT</td>
<td>3.960E-04</td>
<td>6.880E-03</td>
</tr>
<tr>
<td>Cell cycle_G1-S Growth factor regulation</td>
<td>7.198E-04</td>
<td>1.112E-02</td>
</tr>
<tr>
<td>Reproduction_Gonadotropin regulation</td>
<td>8.224E-04</td>
<td>1.143E-02</td>
</tr>
<tr>
<td>Maps</td>
<td>p-value</td>
<td>FDR</td>
</tr>
<tr>
<td>IL-6-induced acute-phase response/hepatocytes</td>
<td>7.330E-06</td>
<td>3.084E-05</td>
</tr>
<tr>
<td>Lipoxin inhibitory action-PDGF/EGF/LTD4 signaling</td>
<td>7.330E-06</td>
<td>1.646E-03</td>
</tr>
<tr>
<td>Impaired Lipoxin A4 signaling in CF</td>
<td>2.013E-05</td>
<td>3.013E-03</td>
</tr>
<tr>
<td>Development_WNT signaling pathway, Part 2</td>
<td>5.040E-05</td>
<td>5.658E-03</td>
</tr>
<tr>
<td>Effect of H. pylori infection on gastric epithelial cell proliferation</td>
<td>7.811E-05</td>
<td>7.015E-03</td>
</tr>
<tr>
<td>Development_Gastrin in cell growth and proliferation</td>
<td>1.077E-04</td>
<td>7.580E-03</td>
</tr>
<tr>
<td>Development_Regulation of EMT</td>
<td>1.254E-04</td>
<td>7.580E-03</td>
</tr>
<tr>
<td>Ovarian cancer (main signaling cascades)</td>
<td>1.351E-04</td>
<td>7.580E-03</td>
</tr>
<tr>
<td>Development_Beta-adrenergic receptors transactivation of EGFR</td>
<td>1.753E-04</td>
<td>8.333E-03</td>
</tr>
<tr>
<td>Development_Ligand-dependent activation/ESR1/AP-1 pathway</td>
<td>1.856E-04</td>
<td>8.333E-03</td>
</tr>
<tr>
<td>Processes</td>
<td>p-value</td>
<td>FDR</td>
</tr>
<tr>
<td>response to organic substance</td>
<td>2.006E-20</td>
<td>5.752E-23</td>
</tr>
<tr>
<td>cellular response to chemical stimulus</td>
<td>2.280E-20</td>
<td>4.951E-17</td>
</tr>
<tr>
<td>regulation of signal transduction</td>
<td>4.488E-19</td>
<td>6.498E-16</td>
</tr>
<tr>
<td>regulation of cell communication</td>
<td>1.713E-18</td>
<td>1.860E-15</td>
</tr>
<tr>
<td>regulation of signaling</td>
<td>3.782E-18</td>
<td>3.286E-15</td>
</tr>
<tr>
<td>regulation of response to stimulus</td>
<td>1.437E-17</td>
<td>1.041E-14</td>
</tr>
<tr>
<td>response to chemical</td>
<td>2.895E-17</td>
<td>8.033E-20</td>
</tr>
<tr>
<td>response to oxygen-containing compound</td>
<td>3.049E-17</td>
<td>1.468E-15</td>
</tr>
<tr>
<td>positive regulation of cell communication</td>
<td>2.363E-16</td>
<td>1.140E-13</td>
</tr>
<tr>
<td>positive regulation of signaling</td>
<td>2.696E-16</td>
<td>1.171E-13</td>
</tr>
</tbody>
</table>

Top ten enrichments for each grouping, ranked from most to least significant by p-value.
Figure 10. Comparison of PCB/Diet interactions.

For each PCB exposure, control and high fat diet were compared to generate a differentially regulated target set. These differentially regulated target sets are compared in the figure above.
Enrichment analysis of common targets for all PCB exposure levels within diet comparisons (Table 42) showed nutritional, metabolic, and endocrine-related diseases among the highly-enriched disease biomarkers, and IL-6 signaling among the engaged maps and processes. Processes related to lipid and steroid metabolism, endobiotic and xenobiotic response were also commonly engaged in these comparisons.

**Differentially regulated targets within vehicle vs. PCB comparisons were enriched in liver and metabolic disease biomarkers**

Because the animal model phenotype suggested liver and metabolic disease processes at work, we further explored liver toxicity analysis and biomarker analysis for nutritional and metabolic disease within these datasets. In an evaluation of liver toxicity endpoints in the control diet groups, there were no significantly enriched pathways for the moderate exposure group (Table 43), however, the high exposure was significantly (FDR < 0.05) enriched in pathways related to ischemia and hypoxia (Table 44). In the high fat diet groups, significantly enriched categories within the liver toxicity analysis were cholestasis and steatosis pathways for moderate exposure (Table 45) and steatosis, fibrosis, and liver hypertrophy in the high exposure group (Table 46). Targets affected within the steatosis category are shown in Table 47, and included LIPE, ELOVL6, FADS3, GPAM, and several cytochrome P450s including members of the Cyp4A and Cyp2C subfamilies.

One liver injury pathway map which was highly enriched in DTGs from several of the conditions was IL-6-mediated acute-phase response in hepatocytes (Figure 11). Several immediate effectors of acute phase response down-stream of IL-6 signaling were up-regulated, particularly in the HVvsH20 condition, including serum amyloid proteins (A1, A2, and A3 isoforms), serum amyloid P-component, and fibrinogen components (alpha, beta, and gamma), shown in Figure 12. Engagement of this pathway of local hepatic inflammatory response is consistent with histological findings in this animal model, as well as serological findings of increased IL-6 and liver injury in both the animal model, and in the PCB-exposed population of Anniston, AL.
Table 42
Common targets between all PCB exposure levels within diet comparisons

<table>
<thead>
<tr>
<th>Diseases</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathological Conditions, Signs and Symptoms</td>
<td>6.116E-27</td>
<td>8.706E-24</td>
</tr>
<tr>
<td>Pathologic Processes</td>
<td>1.071E-26</td>
<td>8.706E-24</td>
</tr>
<tr>
<td>Drug-Related Side Effects and Adverse Reactions</td>
<td>2.676E-24</td>
<td>1.450E-21</td>
</tr>
<tr>
<td>In-house Adverse Events</td>
<td>1.478E-23</td>
<td>4.980E-21</td>
</tr>
<tr>
<td>Chemically-Induced Disorders</td>
<td>1.531E-23</td>
<td>4.980E-21</td>
</tr>
<tr>
<td>Nutritional and Metabolic Diseases</td>
<td>2.480E-23</td>
<td>6.722E-21</td>
</tr>
<tr>
<td>Metabolic Diseases</td>
<td>1.164E-22</td>
<td>2.704E-20</td>
</tr>
<tr>
<td>Phenomena and Processes</td>
<td>5.832E-22</td>
<td>1.185E-19</td>
</tr>
<tr>
<td>Physiological Phenomena</td>
<td>1.705E-21</td>
<td>3.081E-19</td>
</tr>
<tr>
<td>Endocrine System Diseases</td>
<td>4.360E-21</td>
<td>7.089E-19</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Networks</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development_Regulation of angiogenesis</td>
<td>3.424E-07</td>
<td>5.000E-05</td>
</tr>
<tr>
<td>Inflammation_IL-6 signaling</td>
<td>5.307E-06</td>
<td>3.874E-04</td>
</tr>
<tr>
<td>Development_Blood_vessel morphogenesis</td>
<td>3.416E-05</td>
<td>1.662E-03</td>
</tr>
<tr>
<td>Translation_Translation initiation</td>
<td>2.444E-04</td>
<td>8.920E-03</td>
</tr>
<tr>
<td>Translation_Elongation-Termination</td>
<td>1.509E-03</td>
<td>4.405E-02</td>
</tr>
<tr>
<td>Signal Transduction_Cholecystokinin signaling</td>
<td>4.062E-03</td>
<td>8.473E-02</td>
</tr>
<tr>
<td>Cell cycle_Meiosis</td>
<td>4.062E-03</td>
<td>8.473E-02</td>
</tr>
<tr>
<td>Reproduction_Feeding and Neurohormone signaling</td>
<td>4.882E-03</td>
<td>8.910E-02</td>
</tr>
<tr>
<td>Cell cycle_G0-G1</td>
<td>7.245E-03</td>
<td>1.109E-01</td>
</tr>
<tr>
<td>Blood coagulation</td>
<td>7.594E-03</td>
<td>1.109E-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholesterol Biosynthesis</td>
<td>7.453E-06</td>
<td>4.636E-03</td>
</tr>
<tr>
<td>Cell cycle_Role of Nek in cell cycle regulation</td>
<td>3.880E-05</td>
<td>1.207E-02</td>
</tr>
<tr>
<td>IL-6-induced acute-phase response/hepatocytes</td>
<td>7.792E-05</td>
<td>1.616E-02</td>
</tr>
<tr>
<td>Effect of H. pylori infection on gastric epithelial cell proliferation</td>
<td>1.643E-04</td>
<td>2.555E-02</td>
</tr>
<tr>
<td>Transcription_Sirtuin6 regulation and functions</td>
<td>3.062E-04</td>
<td>3.809E-02</td>
</tr>
<tr>
<td>Role of ZNF202 in regulation of expression of genes involved in atherosclerosis</td>
<td>7.644E-04</td>
<td>7.149E-02</td>
</tr>
<tr>
<td>Development_Beta adrenergic receptors in brown adipocyte differentiation</td>
<td>8.592E-04</td>
<td>7.149E-02</td>
</tr>
<tr>
<td>Expression targets of Tissue factor signaling in cancer</td>
<td>9.195E-04</td>
<td>7.149E-02</td>
</tr>
<tr>
<td>Signal transduction_mTORC1 downstream signaling</td>
<td>1.456E-03</td>
<td>9.691E-02</td>
</tr>
<tr>
<td>Regulation of Tissue factor signaling in cancer</td>
<td>1.719E-03</td>
<td>9.691E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>lipid metabolic process</td>
<td>1.500E-25</td>
<td>9.695E-22</td>
</tr>
<tr>
<td>response to organic cyclic compound</td>
<td>7.688E-24</td>
<td>2.484E-20</td>
</tr>
<tr>
<td>response to oxygen-containing compound</td>
<td>1.649E-23</td>
<td>3.553E-20</td>
</tr>
<tr>
<td>single-organism metabolic process</td>
<td>4.262E-23</td>
<td>6.635E-20</td>
</tr>
<tr>
<td>small molecule metabolic process</td>
<td>5.133E-23</td>
<td>6.635E-20</td>
</tr>
<tr>
<td>response to organic substance</td>
<td>8.934E-21</td>
<td>9.623E-18</td>
</tr>
<tr>
<td>response to external stimulus</td>
<td>2.110E-20</td>
<td>1.948E-17</td>
</tr>
<tr>
<td>response to drug</td>
<td>4.389E-20</td>
<td>3.546E-17</td>
</tr>
<tr>
<td>steroid metabolic process</td>
<td>5.788E-20</td>
<td>3.908E-17</td>
</tr>
<tr>
<td>single-organism process</td>
<td>6.046E-20</td>
<td>3.908E-17</td>
</tr>
</tbody>
</table>

Top ten enrichments for each grouping, ranked from most to least significant by p-value
Table 43

Enrichments for liver and metabolic disease endpoints in comparison CVvsC20

<table>
<thead>
<tr>
<th>Liver Toxicity Endpoint Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steatosis, development_liver</td>
<td>4.866E-02</td>
<td>5.422E-01</td>
</tr>
<tr>
<td>Fibrosis, development_liver</td>
<td>7.746E-02</td>
<td>5.422E-01</td>
</tr>
<tr>
<td>Hypertrophic organ growth_liver</td>
<td>1.679E-01</td>
<td>7.837E-01</td>
</tr>
<tr>
<td>Cell cycle, processes involved in G0-phase</td>
<td>3.450E-01</td>
<td>7.870E-01</td>
</tr>
<tr>
<td>Cell cycle, processes involved in G1-phase</td>
<td>4.245E-01</td>
<td>7.870E-01</td>
</tr>
<tr>
<td>Cholestasis, development_liver</td>
<td>4.409E-01</td>
<td>7.870E-01</td>
</tr>
<tr>
<td>Cell cycle, processes involved in G2-phase</td>
<td>4.702E-01</td>
<td>7.870E-01</td>
</tr>
<tr>
<td>Peroxisomal proliferation, induction_liver</td>
<td>5.235E-01</td>
<td>7.870E-01</td>
</tr>
<tr>
<td>Cell cycle, processes involved in S-phase</td>
<td>5.474E-01</td>
<td>7.870E-01</td>
</tr>
<tr>
<td>Apoptosis via Mitochondrial membrane dysfunction</td>
<td>6.746E-01</td>
<td>7.870E-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liver-Specific Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurophysiological process_Circadian rhythm</td>
<td>1.030E-04</td>
<td>9.994E-03</td>
</tr>
<tr>
<td>DNA damage ATM/ATR regulation of G1/S checkpoint</td>
<td>6.179E-04</td>
<td>2.997E-02</td>
</tr>
<tr>
<td>Development TGF-beta receptor signaling</td>
<td>2.286E-03</td>
<td>6.552E-02</td>
</tr>
<tr>
<td>Development WNT signaling pathway_Part 2</td>
<td>2.702E-03</td>
<td>6.552E-02</td>
</tr>
<tr>
<td>Signal transduction_mTORC2 downstream signaling</td>
<td>5.471E-03</td>
<td>1.061E-01</td>
</tr>
<tr>
<td>Development Signaling of β-adrenergic receptors via Beta-arrestins</td>
<td>7.044E-03</td>
<td>1.125E-01</td>
</tr>
<tr>
<td>DNA damage ATM/ATR regulation of G2/M checkpoint</td>
<td>8.240E-03</td>
<td>1.125E-01</td>
</tr>
<tr>
<td>Development SSTR1 in regulation of cell proliferation and migration</td>
<td>1.019E-02</td>
<td>1.125E-01</td>
</tr>
<tr>
<td>DNA damage Brca1 as a transcription regulator</td>
<td>1.088E-02</td>
<td>1.125E-01</td>
</tr>
<tr>
<td>Regulation of lipid metabolism_FXR-dependent negative-feedback regulation of bile acids concentration</td>
<td>1.159E-02</td>
<td>1.125E-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nutritional and Metabolic Disease Biomarkers</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypokalemia</td>
<td>6.052E-08</td>
<td>3.752E-06</td>
</tr>
<tr>
<td>Overnutrition</td>
<td>9.254E-04</td>
<td>1.707E-02</td>
</tr>
<tr>
<td>Obesity</td>
<td>9.254E-04</td>
<td>1.707E-02</td>
</tr>
<tr>
<td>Water-Electrolyte Imbalance</td>
<td>1.105E-03</td>
<td>1.707E-02</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>1.377E-03</td>
<td>1.707E-02</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>1.839E-03</td>
<td>1.901E-02</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>2.258E-03</td>
<td>2.000E-02</td>
</tr>
<tr>
<td>Hyperlipidemias</td>
<td>2.774E-03</td>
<td>2.150E-02</td>
</tr>
<tr>
<td>Nutrition Disorders</td>
<td>3.774E-03</td>
<td>2.600E-02</td>
</tr>
<tr>
<td>Insulin Resistance</td>
<td>7.968E-03</td>
<td>4.448E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nutritional and Metabolic Disease Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development Signaling of β-adrenergic receptors via Beta-arrestins</td>
<td>2.670E-03</td>
<td>9.095E-02</td>
</tr>
<tr>
<td>Regulation of lipid metabolism_FXR-dependent negative-feedback regulation of bile acids concentration</td>
<td>4.437E-03</td>
<td>9.095E-02</td>
</tr>
<tr>
<td>Bile acids regulation of glucose and lipid metabolism via FXR</td>
<td>7.673E-03</td>
<td>9.830E-02</td>
</tr>
<tr>
<td>Transcription Androgen Receptor nuclear signaling</td>
<td>9.590E-03</td>
<td>9.830E-02</td>
</tr>
<tr>
<td>Development IGF-1 receptor signaling</td>
<td>1.214E-02</td>
<td>9.958E-02</td>
</tr>
<tr>
<td>Unsaturated fatty acid biosynthesis</td>
<td>1.699E-02</td>
<td>1.161E-01</td>
</tr>
<tr>
<td>Transcription Transcription regulation of aminoacid metabolism</td>
<td>7.854E-02</td>
<td>2.751E-01</td>
</tr>
<tr>
<td>Triacylglycerol metabolism_p.2</td>
<td>8.456E-02</td>
<td>2.751E-01</td>
</tr>
<tr>
<td>Role of Diethylhexyl Phthalate and Tributyltin in fat cell differentiation</td>
<td>9.055E-02</td>
<td>2.751E-01</td>
</tr>
<tr>
<td>Vitamin B6 metabolism</td>
<td>9.353E-02</td>
<td>2.751E-01</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
<table>
<thead>
<tr>
<th>Liver Toxicity Endpoint Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemia-induced cellular changes liver</td>
<td>1.588E-03</td>
<td>2.179E-02</td>
</tr>
<tr>
<td>Hypoxia, development</td>
<td>2.421E-03</td>
<td>2.179E-02</td>
</tr>
<tr>
<td>Apoptosis via Mitochondrial membrane dysfunction</td>
<td>5.073E-02</td>
<td>2.521E-01</td>
</tr>
<tr>
<td>Fibrosis, development liver</td>
<td>7.399E-02</td>
<td>2.521E-01</td>
</tr>
<tr>
<td>Steatosis, development liver</td>
<td>8.062E-02</td>
<td>2.521E-01</td>
</tr>
<tr>
<td>Hypertrophic organ growth liver</td>
<td>8.403E-02</td>
<td>2.521E-01</td>
</tr>
<tr>
<td>Fibrosis, development liver</td>
<td>1.391E-01</td>
<td>3.576E-01</td>
</tr>
<tr>
<td>Apoptosis via Mitochondrial membrane dysfunction</td>
<td>5.073E-02</td>
<td>2.521E-01</td>
</tr>
<tr>
<td>Steatosis, development liver</td>
<td>8.062E-02</td>
<td>2.521E-01</td>
</tr>
<tr>
<td>Hypertrophic organ growth liver</td>
<td>8.403E-02</td>
<td>2.521E-01</td>
</tr>
<tr>
<td>Cell cycle, processes involved in G1-phase</td>
<td>3.839E-01</td>
<td>7.678E-01</td>
</tr>
<tr>
<td>Cell cycle, processes involved in G2-phase</td>
<td>5.009E-01</td>
<td>8.667E-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liver-Specific Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune response TLR2 and TLR4 signaling pathways</td>
<td>1.658E-05</td>
<td>5.109E-03</td>
</tr>
<tr>
<td>Apoptosis and survival p53-dependent apoptosis</td>
<td>3.762E-05</td>
<td>5.109E-03</td>
</tr>
<tr>
<td>G-protein signaling Proinsulin C-peptide signaling</td>
<td>5.040E-05</td>
<td>5.109E-03</td>
</tr>
<tr>
<td>Signal transduction mTORC2 upstream signaling</td>
<td>5.539E-05</td>
<td>5.109E-03</td>
</tr>
<tr>
<td>Immune response IL-1 signaling pathway</td>
<td>9.226E-05</td>
<td>5.608E-03</td>
</tr>
<tr>
<td>Immune response TLR5, TLR7, TLR8,TLR9 signaling pathways</td>
<td>1.064E-04</td>
<td>5.608E-03</td>
</tr>
<tr>
<td>Immune response IL-18 signaling</td>
<td>1.600E-04</td>
<td>7.170E-03</td>
</tr>
<tr>
<td>Histamine H1 receptor signaling/immune response</td>
<td>1.749E-04</td>
<td>7.170E-03</td>
</tr>
<tr>
<td>Development ERBB-family signaling</td>
<td>2.779E-04</td>
<td>9.580E-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nutritional and Metabolic Disease Biomarkers</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>3.371E-07</td>
<td>2.174E-05</td>
</tr>
<tr>
<td>Overnutrition</td>
<td>3.371E-07</td>
<td>2.174E-05</td>
</tr>
<tr>
<td>Nutrition Disorders</td>
<td>3.925E-06</td>
<td>1.688E-04</td>
</tr>
<tr>
<td>Vascular Calcification</td>
<td>9.711E-05</td>
<td>3.132E-03</td>
</tr>
<tr>
<td>Frontotemporal Dementia</td>
<td>5.455E-04</td>
<td>1.173E-02</td>
</tr>
<tr>
<td>Frontotemporal Lobar Degeneration</td>
<td>5.455E-04</td>
<td>1.173E-02</td>
</tr>
<tr>
<td>Hyperinsulin</td>
<td>9.153E-04</td>
<td>1.687E-02</td>
</tr>
<tr>
<td>Diabetes Mellitus, Type 1</td>
<td>1.805E-03</td>
<td>2.911E-02</td>
</tr>
<tr>
<td>Insulin Resistance</td>
<td>4.129E-03</td>
<td>5.918E-02</td>
</tr>
<tr>
<td>Calciosis</td>
<td>5.304E-03</td>
<td>6.842E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nutritional and Metabolic Disease Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-protein signaling Proinsulin C-peptide signaling</td>
<td>1.347E-06</td>
<td>2.102E-04</td>
</tr>
<tr>
<td>Development Activation of ERK by Alpha-1 adrenergic receptors</td>
<td>4.336E-06</td>
<td>2.431E-04</td>
</tr>
<tr>
<td>Immune response IL-18 signaling</td>
<td>4.675E-06</td>
<td>2.431E-04</td>
</tr>
<tr>
<td>Development IGF-1 receptor signaling</td>
<td>1.332E-05</td>
<td>5.196E-04</td>
</tr>
<tr>
<td>Putative pathways for BPA-stimulated fat cell differentiation</td>
<td>5.286E-05</td>
<td>1.649E-03</td>
</tr>
<tr>
<td>Apoptosis and survival Ceramides signaling pathway</td>
<td>1.942E-04</td>
<td>5.049E-03</td>
</tr>
<tr>
<td>Development β adrenergic receptors in brown adipocyte differentiation</td>
<td>1.109E-03</td>
<td>2.471E-02</td>
</tr>
<tr>
<td>Transcription Transcription regulation of aminoacid metabolism</td>
<td>1.875E-03</td>
<td>3.656E-02</td>
</tr>
<tr>
<td>Transcription Sirtuin6 regulation and functions</td>
<td>2.481E-03</td>
<td>4.221E-02</td>
</tr>
<tr>
<td>Membrane-bound ESR1: interaction with growth factors signaling</td>
<td>2.706E-03</td>
<td>4.221E-02</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
### Table 45

<table>
<thead>
<tr>
<th>Liver Toxicity Endpoint Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholestasis, development_liver</td>
<td>6.523E-04</td>
<td>9.480E-03</td>
</tr>
<tr>
<td>Steatosis, development_liver</td>
<td>1.053E-03</td>
<td>9.480E-03</td>
</tr>
<tr>
<td>Fibrosis, development_liver</td>
<td>1.364E-02</td>
<td>6.576E-02</td>
</tr>
<tr>
<td>Progression of oxidative stress</td>
<td>1.461E-02</td>
<td>6.576E-02</td>
</tr>
<tr>
<td>Inflammation, development</td>
<td>2.248E-02</td>
<td>8.092E-02</td>
</tr>
<tr>
<td>Hypertrophic organ growth_liver</td>
<td>1.108E-01</td>
<td>3.323E-01</td>
</tr>
<tr>
<td>Hypoxia, development</td>
<td>4.259E-01</td>
<td>1.000E+00</td>
</tr>
<tr>
<td>Apoptosis via Mitochondrial membrane dysfunction</td>
<td>5.346E-01</td>
<td>1.000E+00</td>
</tr>
<tr>
<td>Ischemia-induced cellular changes_liver</td>
<td>8.177E-01</td>
<td>1.000E+00</td>
</tr>
<tr>
<td>Apoptosis via Death Domain receptors cascades</td>
<td>8.298E-01</td>
<td>1.000E+00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liver-Specific Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6-induced acute-phase response/hepatocytes</td>
<td>4.661E-13</td>
<td>1.571E-10</td>
</tr>
<tr>
<td>Immune response_IL-6 signaling pathway via JAK/STAT</td>
<td>9.310E-07</td>
<td>1.569E-04</td>
</tr>
<tr>
<td>Signal transduction_mTORC2 downstream signaling</td>
<td>2.422E-05</td>
<td>2.721E-03</td>
</tr>
<tr>
<td>MIF-induced cell adhesion, migration and angiogenesis</td>
<td>4.658E-05</td>
<td>3.231E-03</td>
</tr>
<tr>
<td>Development_Ligand-dependent activation-ESR1/AP-1 pathway</td>
<td>4.793E-05</td>
<td>3.231E-03</td>
</tr>
<tr>
<td>Development_Beta-adrenergic receptors transactivation of EGFR</td>
<td>8.020E-05</td>
<td>4.505E-03</td>
</tr>
<tr>
<td>Transcription_Role of AP-1 in regulation of cellular metabolism</td>
<td>9.590E-05</td>
<td>4.617E-03</td>
</tr>
<tr>
<td>Glutathione metabolism</td>
<td>1.810E-04</td>
<td>7.624E-03</td>
</tr>
<tr>
<td>Development_VEGF signaling and activation</td>
<td>2.163E-04</td>
<td>8.100E-03</td>
</tr>
<tr>
<td>Immune response_IL-1 signaling pathway</td>
<td>2.509E-04</td>
<td>8.457E-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nutritional and Metabolic Disease Biomarkers</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrition Disorders</td>
<td>9.404E-08</td>
<td>7.284E-06</td>
</tr>
<tr>
<td>Obesity</td>
<td>1.539E-07</td>
<td>7.284E-06</td>
</tr>
<tr>
<td>Overnutrition</td>
<td>1.539E-07</td>
<td>7.284E-06</td>
</tr>
<tr>
<td>Diabetes Mellitus, Type 2</td>
<td>1.879E-06</td>
<td>6.669E-05</td>
</tr>
<tr>
<td>Dyslipidemias</td>
<td>6.992E-06</td>
<td>1.986E-04</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>2.684E-05</td>
<td>6.352E-04</td>
</tr>
<tr>
<td>Hyperinsulinism</td>
<td>2.901E-04</td>
<td>5.885E-03</td>
</tr>
<tr>
<td>Lipid Metabolism Disorders</td>
<td>4.613E-04</td>
<td>8.188E-03</td>
</tr>
<tr>
<td>Colorectal Neoplasms, Hereditary Nonpolyposis</td>
<td>6.567E-04</td>
<td>1.036E-02</td>
</tr>
<tr>
<td>Hyperlipidemias</td>
<td>1.077E-03</td>
<td>1.472E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nutritional and Metabolic Disease Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ligand-dependent activation of the ESR1/AP-1 pathway</td>
<td>1.295E-05</td>
<td>7.881E-04</td>
</tr>
<tr>
<td>β adrenergic receptors/brown adipocyte differentiation</td>
<td>1.397E-05</td>
<td>7.881E-04</td>
</tr>
<tr>
<td>Transcription_Role of AP-1 in regulation of cellular metabolism</td>
<td>1.681E-05</td>
<td>7.881E-04</td>
</tr>
<tr>
<td>Glutathione metabolism</td>
<td>2.174E-05</td>
<td>7.881E-04</td>
</tr>
<tr>
<td>Putative pathways for stimulation of fat cell differentiation by Bisphenol A</td>
<td>6.243E-05</td>
<td>1.811E-03</td>
</tr>
<tr>
<td>Immune response_IL-18 signaling</td>
<td>3.416E-04</td>
<td>8.259E-03</td>
</tr>
<tr>
<td>Transcription_Sirtuin6 regulation and functions</td>
<td>5.104E-04</td>
<td>1.057E-02</td>
</tr>
<tr>
<td>Development_α-1 adrenergic receptors signaling via Cyclic AMP</td>
<td>7.107E-04</td>
<td>1.288E-02</td>
</tr>
<tr>
<td>Insulin, IGF-1 and TNF-alpha in brown adipocyte differentiation</td>
<td>9.726E-04</td>
<td>1.567E-02</td>
</tr>
<tr>
<td>Regulation of metabolism_Bile acids regulation of glucose and lipid metabolism via FXR</td>
<td>2.027E-03</td>
<td>2.939E-02</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
<table>
<thead>
<tr>
<th>Liver Toxicity Endpoint Processes</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertrophic organ growth liver</td>
<td>1.768E-03</td>
<td>2.109E-02</td>
</tr>
<tr>
<td>Fibrosis, development liver</td>
<td>2.343E-03</td>
<td>2.109E-02</td>
</tr>
<tr>
<td>Steatosis, development liver</td>
<td>5.006E-03</td>
<td>3.004E-02</td>
</tr>
<tr>
<td>Cell cycle progression of Mitosis</td>
<td>8.310E-02</td>
<td>3.725E-01</td>
</tr>
<tr>
<td>Apoptosis via Mitochondrial membrane dysfunction</td>
<td>1.035E-01</td>
<td>3.725E-01</td>
</tr>
<tr>
<td>Cholestasis, development liver</td>
<td>1.580E-01</td>
<td>4.741E-01</td>
</tr>
<tr>
<td>Hypoxia, development</td>
<td>3.810E-01</td>
<td>9.793E-01</td>
</tr>
<tr>
<td>Inflammation, development</td>
<td>4.762E-01</td>
<td>9.971E-01</td>
</tr>
<tr>
<td>Cell cycle, processes involved in S-phase</td>
<td>5.009E-01</td>
<td>9.971E-01</td>
</tr>
<tr>
<td>Cell cycle, processes involved in G1-phase</td>
<td>6.586E-01</td>
<td>9.971E-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liver-Specific Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development Regulation of EMT</td>
<td>3.347E-06</td>
<td>8.870E-04</td>
</tr>
<tr>
<td>Immune response IL-6-induced acute-phase response in hepatocytes</td>
<td>1.092E-05</td>
<td>1.447E-03</td>
</tr>
<tr>
<td>Immune response Oncostatin M signaling via JAK-Stat</td>
<td>2.479E-04</td>
<td>2.190E-02</td>
</tr>
<tr>
<td>Signal transduction mTORC2 downstream signaling</td>
<td>4.219E-04</td>
<td>2.795E-02</td>
</tr>
<tr>
<td>Development IGF-1 receptor signaling</td>
<td>8.743E-04</td>
<td>4.215E-02</td>
</tr>
<tr>
<td>Development Ligand-dependent activation - ESR1/AP-1 pathway</td>
<td>1.180E-03</td>
<td>4.469E-02</td>
</tr>
<tr>
<td>Cell cycle ESR1 regulation of G1/S transition</td>
<td>1.376E-03</td>
<td>4.557E-02</td>
</tr>
<tr>
<td>Development Beta-adrenergic receptors transactivation of EGFR</td>
<td>1.895E-03</td>
<td>5.580E-02</td>
</tr>
<tr>
<td>Transcription Sirtuin6 regulation and functions</td>
<td>2.236E-03</td>
<td>5.926E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nutritional and Metabolic Disease Biomarkers</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>8.546E-05</td>
<td>2.606E-03</td>
</tr>
<tr>
<td>Overnutrition</td>
<td>8.546E-05</td>
<td>2.606E-03</td>
</tr>
<tr>
<td>Vascular Calcification</td>
<td>1.017E-04</td>
<td>2.606E-03</td>
</tr>
<tr>
<td>Nutrition Disorders</td>
<td>1.032E-04</td>
<td>2.606E-03</td>
</tr>
<tr>
<td>Frontotemporal Dementia</td>
<td>1.580E-04</td>
<td>2.659E-03</td>
</tr>
<tr>
<td>Frontotemporal Lobar Degeneration</td>
<td>1.580E-04</td>
<td>2.659E-03</td>
</tr>
<tr>
<td>Zellweger Syndrome</td>
<td>1.506E-03</td>
<td>2.165E-02</td>
</tr>
<tr>
<td>Peroxisome biogenesis disorders</td>
<td>1.715E-03</td>
<td>2.165E-02</td>
</tr>
<tr>
<td>Diabetes Mellitus, Type 2</td>
<td>2.031E-03</td>
<td>2.279E-02</td>
</tr>
<tr>
<td>Calcinosis</td>
<td>2.557E-03</td>
<td>2.582E-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nutritional and Metabolic Disease Maps</th>
<th>p-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development IGF-1 receptor signaling</td>
<td>2.504E-04</td>
<td>2.165E-02</td>
</tr>
<tr>
<td>Development Ligand-dependent activation - ESR1/AP-1 pathway</td>
<td>5.388E-04</td>
<td>2.165E-02</td>
</tr>
<tr>
<td>Transcription Sirtuin6 regulation and functions</td>
<td>6.629E-04</td>
<td>2.165E-02</td>
</tr>
<tr>
<td>Retinol metabolism</td>
<td>1.066E-03</td>
<td>2.612E-02</td>
</tr>
<tr>
<td>Unsaturated fatty acid biosynthesis</td>
<td>4.752E-03</td>
<td>9.314E-02</td>
</tr>
<tr>
<td>Galactose metabolism</td>
<td>6.265E-03</td>
<td>1.023E-01</td>
</tr>
<tr>
<td>Regulation of metabolism Bile acids regulation of glucose and lipid metabolism via FXR</td>
<td>1.028E-02</td>
<td>1.439E-01</td>
</tr>
<tr>
<td>Transcription Androgen Receptor nuclear signaling</td>
<td>1.407E-02</td>
<td>1.724E-01</td>
</tr>
<tr>
<td>Signal transduction PTMs in BAFF-induced signaling</td>
<td>1.857E-02</td>
<td>2.022E-01</td>
</tr>
<tr>
<td>Amitraz-induced inhibition of Insulin secretion</td>
<td>2.424E-02</td>
<td>2.127E-01</td>
</tr>
</tbody>
</table>

Enrichment is based on the significantly differentially transcribed genes (p<.05) in a comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20). Top ten enrichments for each grouping, ranked from most to least significant by p-value.
<table>
<thead>
<tr>
<th>Input IDs</th>
<th>Gene Symbol</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver toxicity: Steatosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000035561</td>
<td>Aldh1b1</td>
<td></td>
<td>-0.68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025003</td>
<td>Cyp2c39</td>
<td></td>
<td>-2.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000066072</td>
<td>Cyp4a10</td>
<td></td>
<td>-0.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000032349</td>
<td>Elovl5</td>
<td></td>
<td>-0.53</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000010663</td>
<td>Fads1</td>
<td></td>
<td>-0.64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025153</td>
<td>Fasn</td>
<td></td>
<td>-1.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000078650</td>
<td>G6pc</td>
<td></td>
<td>1.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027984</td>
<td>Hadh</td>
<td></td>
<td>-0.47</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000042632</td>
<td>Pla2g6</td>
<td>0.98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000023913</td>
<td>Pla2g7</td>
<td>0.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000440</td>
<td>Pparg</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver toxicity: fibrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000532</td>
<td>Acvr1b</td>
<td>0.97</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000041324</td>
<td>Inhba</td>
<td>1.24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000039304</td>
<td>Tnfsf10</td>
<td>1.10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000029661</td>
<td>Col1a2</td>
<td>-0.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000021820</td>
<td>Camk2g</td>
<td>0.80</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000029675</td>
<td>En</td>
<td>-0.87</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000026072</td>
<td>Il1r1</td>
<td>0.58</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000017057</td>
<td>Il13ra1</td>
<td>0.71</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000030748</td>
<td>Il4ra</td>
<td>0.57</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027947</td>
<td>Il6ra</td>
<td>-0.67</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000029304</td>
<td>Spp1</td>
<td>0.48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024620</td>
<td>Pdgfrb</td>
<td>-0.53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028599</td>
<td>Tnfrsf1b</td>
<td>0.58</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000021250</td>
<td>Fos</td>
<td>1.27</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Liver toxicity analysis for each comparison indicated gene sets associated with liver toxicity endpoints including steatosis and fibrosis. Differentially regulated gene targets are indicated. For each target, the fold change vs. control is shown.
Figure 11. IL-6-mediated acute-phase response in hepatocytes.

PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of IL-6-mediated acute-phase response in hepatocytes. In particular, components of the AP-1 complex (c-Jun, c-Fos) were differentially regulated in the CVvsC200 comparison (2), the HVvsH20 comparison (3), and the HVvsH200 comparison (4), along with changes in transcription of HNF1-alpha targets IBP1, G6PT and Fibrinogen alpha. The HVvsH20 condition was associated with differential transcription of the most targets associated with this pathway, in particular, targets of STAT3 transcriptional activation. An increase in local inflammation associated with this condition is consistent with our histological findings. Image generated using MetaCore™ from Thomson Reuters.
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of IL-6-signaling pathways. In particular, components of the AP-1 complex (c-Jun, c-Fos) were differentially regulated in the CVvsC200 comparison (2), the HVvsH20 comparison (3), and the HVvsH200 comparison (4). Image generated using MetaCore™ from Thomson Reuters.
Both the lack of transcription-level changes in biomarkers of liver disease in the CVvsC20 comparison and the relative abundance of changes in the HVvsH20 comparison vs. either of the higher PCB exposure groups is in keeping with the histological severity of liver disease in these groups. Few common targets were seen in this enrichment, which may suggest pleiotropic effects on hepatocyte toxicity, as well as complex interactions between nutrition/PCB coexposures on disease mechanisms.

Among nutritional and metabolic disease enrichments, the pattern presented by the individual comparisons was far more cohesive, with over-nutrition/obesity in the top enrichments for every comparison. Fold changes of differentially transcribed genes associated with over-nutrition/obesity for each vehicle vs. PCB comparison are listed in Table 48. Other metabolic diseases that were of interest to us and highly enriched in one or more datasets were type 2 diabetes mellitus (Table 49), metabolic syndrome (Table 50), and insulin resistance (Table 51). In each of these disease categories, the condition with the most changes vs. vehicle control was the HVvsH20 condition. These changes included down-regulation of fatty acid synthetase and beta 2-adrenergic receptor, polymorphisms of which have been associated with metabolic disease. Down-regulation of GLUT4 reduces insulin-sensitive glucose uptake in non-hepatocyte liver cells and other insulin-sensitive tissues. Metabolic disease enrichments for the CVvsC20 and CVvsC200 group indicated changes to PPAR-alpha and LXR-mediated glucose and lipid homeostasis, including alterations in expressions of the Tribbles-3 pseudokinase, which contributes to insulin resistance and down-regulation of Cyp7a1, which could lead to cholesterol accumulation.

*MetaCore* network analysis of dose-within-diet comparisons did not appear to indicate enrichment in transcriptional targets of the xenobiotic transcription factors AhR, PXR, or CAR.

Because xenobiotic receptors AhR, PXR, and CAR are classically associated with transcriptional response to PCBs and other chemicals, we used *MetaCore* to evaluate over-representation of curated transcriptional targets of these receptors. The direct transcriptional targets of these receptors as defined by the *MetaCore* database did not comprise a large
Table 48
Targets associated with metabolic disease enrichments (overnutrition/obesity) and their change vs. vehicle control in each comparison

<table>
<thead>
<tr>
<th>Input IDs</th>
<th>Gene Symbol</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic Disease Biomarkers: Obesity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000020917</td>
<td>Acly</td>
<td></td>
<td>-0.72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000031278</td>
<td>Acsl4</td>
<td>-0.47</td>
<td>1.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000035783</td>
<td>Acta2</td>
<td>-0.96</td>
<td>-0.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000026883</td>
<td>Dab2ip</td>
<td>0.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000042429</td>
<td>Adora1</td>
<td>0.81</td>
<td>-0.64</td>
<td>-0.66</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000022994</td>
<td>Adcy6</td>
<td>-0.69</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000005580</td>
<td>Adcy9</td>
<td>-0.92</td>
<td>-0.73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000046532</td>
<td>Ar</td>
<td>-0.86</td>
<td>-1.11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000027792</td>
<td>Bche</td>
<td>-0.67</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000055116</td>
<td>Arntl</td>
<td>2.19</td>
<td>1.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000045730</td>
<td>Adrb2</td>
<td>-1.04</td>
<td>-1.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000082361</td>
<td>Btc</td>
<td>1.10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000002944</td>
<td>Cd36</td>
<td>-0.75</td>
<td>0.74</td>
<td>-0.89</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000039804</td>
<td>Ncoa5</td>
<td>-0.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000029238</td>
<td>Clock</td>
<td>0.77</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000000326</td>
<td>Comt</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000056054</td>
<td>S100a8</td>
<td>1.44</td>
<td>1.49</td>
<td>1.62</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000056071</td>
<td>S100a9</td>
<td>1.39</td>
<td>1.69</td>
<td>1.58</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000019768</td>
<td>Esr1</td>
<td>0.57</td>
<td>0.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000025153</td>
<td>Fasn</td>
<td></td>
<td>-1.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000044167</td>
<td>Foxo1</td>
<td>-0.53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000048756</td>
<td>Foxo3</td>
<td>-0.79</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000019779</td>
<td>Frk</td>
<td>0.58</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000028001</td>
<td>Fga</td>
<td>1.06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000033831</td>
<td>Fgb</td>
<td>1.02</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000033860</td>
<td>Fgg</td>
<td>0.96</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000018566</td>
<td>Slc2a4</td>
<td>-1.78</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000031451</td>
<td>Gas6</td>
<td>-0.47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000091971</td>
<td>Hspa1a</td>
<td>-3.96</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000041798</td>
<td>Gck</td>
<td>-0.98</td>
<td>-1.01</td>
<td>-0.63</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000020429</td>
<td>Igfbp1</td>
<td>-0.46</td>
<td>1.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000020427</td>
<td>Igfbp3</td>
<td>0.44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000046070</td>
<td>Igfals</td>
<td>-0.70</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000027947</td>
<td>Il6ra</td>
<td></td>
<td>-0.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000038894</td>
<td>Irs2</td>
<td>0.57</td>
<td>0.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000025780</td>
<td>Itih5</td>
<td>0.60</td>
<td>1.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000055148</td>
<td>Klf2</td>
<td>-1.38</td>
<td>-0.74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000032796</td>
<td>Lama1</td>
<td>-0.63</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000053846</td>
<td>Lipg</td>
<td>-1.08</td>
<td>-0.78</td>
<td>-1.66</td>
<td>-0.94</td>
</tr>
<tr>
<td>ENSMUSG0000000020593</td>
<td>Lpin1</td>
<td>-0.76</td>
<td>-1.96</td>
<td>-0.70</td>
<td></td>
</tr>
</tbody>
</table>
Table 48 (continued)

Targets associated with metabolic disease enrichments (overnutrition/obesity) and their change vs. vehicle control in each comparison

<table>
<thead>
<tr>
<th>Input IDs</th>
<th>Gene Symbol</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000028553</td>
<td>Angptl3</td>
<td></td>
<td>-0.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000061132</td>
<td>Blnk</td>
<td>-1.59</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027556</td>
<td>Car1</td>
<td></td>
<td>-0.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000008845</td>
<td>Cd163</td>
<td>0.84</td>
<td>1.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028551</td>
<td>Cdkn2c</td>
<td></td>
<td>0.93</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020038</td>
<td>Cry1</td>
<td></td>
<td></td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000068742</td>
<td>Cry2</td>
<td></td>
<td></td>
<td>0.48</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000015312</td>
<td>Gadd45b</td>
<td>2.17</td>
<td>1.23</td>
<td>1.05</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000038039</td>
<td>Gcc2</td>
<td></td>
<td>0.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000026864</td>
<td>Hspa5</td>
<td></td>
<td>-1.17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000074896</td>
<td>Ifit3</td>
<td>1.13</td>
<td></td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000052684</td>
<td>Jun</td>
<td>1.15</td>
<td>0.62</td>
<td>0.80</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000049723</td>
<td>Mmp12</td>
<td></td>
<td></td>
<td>-0.97</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000003849</td>
<td>Nqo1</td>
<td>0.47</td>
<td>-1.28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020889</td>
<td>Nr1d1</td>
<td>1.04</td>
<td></td>
<td>-1.52</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020893</td>
<td>Per1</td>
<td></td>
<td>-0.97</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025509</td>
<td>Pnpla2</td>
<td>0.85</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000045038</td>
<td>Prkce</td>
<td></td>
<td>-0.53</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020641</td>
<td>Rsad2</td>
<td>0.89</td>
<td>0.72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000057465</td>
<td>Saa2</td>
<td>-1.37</td>
<td>2.06</td>
<td>2.62</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041567</td>
<td>Serpina12</td>
<td>-1.04</td>
<td>0.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000032902</td>
<td>Sla16a1</td>
<td>0.59</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020027</td>
<td>Socs2</td>
<td>1.10</td>
<td>0.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000023905</td>
<td>Tnfrsf12a</td>
<td>0.81</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000034485</td>
<td>Uaca</td>
<td>0.69</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000008348</td>
<td>Ubc</td>
<td>-0.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024924</td>
<td>Vldlr</td>
<td></td>
<td>-2.54</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Metabolic disease analysis for each comparison indicated gene sets associated with endpoints including obesity/overnutrition. Differentially regulated gene targets are indicated. For each comparison, fold change vs. control is shown.
Table 48 (continued)
Targets associated with metabolic disease enrichments (overnutrition/obesity) and their change vs. vehicle control in each comparison

<table>
<thead>
<tr>
<th>Input IDs</th>
<th>Gene Symbol</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000024052</td>
<td>Lpin2</td>
<td>-0.73</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000015568</td>
<td>Lpl</td>
<td>0.72</td>
<td>0.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027253</td>
<td>Lrp4</td>
<td>-0.73</td>
<td>-0.53</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000040584</td>
<td>Abcb1a</td>
<td></td>
<td>-2.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024589</td>
<td>Nedd4l</td>
<td>1.14</td>
<td>0.60</td>
<td>0.86</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000026822</td>
<td>Lcn2</td>
<td>1.18</td>
<td></td>
<td></td>
<td>1.47</td>
</tr>
<tr>
<td>ENSMUSG00000032715</td>
<td>Trib3</td>
<td>1.21</td>
<td>0.91</td>
<td>-0.59</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024413</td>
<td>Npc1</td>
<td>0.68</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000030659</td>
<td>Nucb2</td>
<td></td>
<td></td>
<td>0.82</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000029304</td>
<td>Spp1</td>
<td></td>
<td></td>
<td>0.48</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000038508</td>
<td>Gdf15</td>
<td></td>
<td>1.52</td>
<td>1.22</td>
<td>1.08</td>
</tr>
<tr>
<td>ENSMUSG000000055866</td>
<td>Per2</td>
<td>-1.39</td>
<td>-0.74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000033871</td>
<td>Ppargc1b</td>
<td>0.86</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000002289</td>
<td>Angptl4</td>
<td>-0.56</td>
<td>-0.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000032462</td>
<td>Pik3cb</td>
<td>0.89</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041417</td>
<td>Pik3r1</td>
<td>-0.47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000440</td>
<td>Pparg</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027540</td>
<td>Pttn1</td>
<td></td>
<td></td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000021876</td>
<td>Rnase4</td>
<td></td>
<td></td>
<td>0.66</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000022883</td>
<td>Robo1</td>
<td>-0.80</td>
<td>-1.82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028150</td>
<td>Rorc</td>
<td>-0.74</td>
<td>0.88</td>
<td>0.53</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000074115</td>
<td>Saa1</td>
<td>-1.44</td>
<td>2.34</td>
<td>2.41</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000075701</td>
<td>Selenos</td>
<td></td>
<td></td>
<td>-0.47</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000060807</td>
<td>Serpina6</td>
<td>-0.97</td>
<td>-1.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000553113</td>
<td>Scos3</td>
<td></td>
<td></td>
<td>1.08</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025006</td>
<td>Sorbs1</td>
<td>0.64</td>
<td>-0.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000012428</td>
<td>Steap4</td>
<td>-0.62</td>
<td>1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025743</td>
<td>Sdc3</td>
<td>0.49</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000029174</td>
<td>Tbc1d1</td>
<td>0.57</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028599</td>
<td>Tnfrsf1b</td>
<td></td>
<td></td>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000035799</td>
<td>Twist1</td>
<td>1.70</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000055254</td>
<td>Ntrk2</td>
<td>-1.28</td>
<td>-2.03</td>
<td>0.72</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027962</td>
<td>Vcam1</td>
<td>0.63</td>
<td>-0.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020484</td>
<td>Xbp1</td>
<td></td>
<td></td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028978</td>
<td>Nos3</td>
<td>-0.87</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041653</td>
<td>Pnpla3</td>
<td></td>
<td>-1.78</td>
<td>-1.17</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000034853</td>
<td>Acot11</td>
<td></td>
<td></td>
<td>1.52</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000004730</td>
<td>Adgre1</td>
<td></td>
<td></td>
<td>0.80</td>
<td></td>
</tr>
</tbody>
</table>
Table 49
Targets associated with metabolic disease enrichments (Type 2 Diabetes Mellitus) and their change vs. vehicle control in each comparison

<table>
<thead>
<tr>
<th>Input IDs</th>
<th>Gene Symbol</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000035783</td>
<td>Acta2</td>
<td>-0.96</td>
<td>-0.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000026883</td>
<td>Dab2ip</td>
<td>0.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000035561</td>
<td>Aldh1b1</td>
<td></td>
<td>-0.68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000026289</td>
<td>Atg16l1</td>
<td>-0.57</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000024391</td>
<td>Apom</td>
<td>0.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000019947</td>
<td>Arid5b</td>
<td>0.51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000046532</td>
<td>Ar</td>
<td>-0.86</td>
<td>-1.11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000032066</td>
<td>Bco2</td>
<td>-0.45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000027972</td>
<td>Bche</td>
<td>-0.67</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000055116</td>
<td>Amtl</td>
<td>2.19</td>
<td>1.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000033863</td>
<td>Klf9</td>
<td>0.91</td>
<td>0.80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000045730</td>
<td>Adrb2</td>
<td>-1.04</td>
<td>-1.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000082361</td>
<td>Btc</td>
<td>1.10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000027381</td>
<td>Bcl2l11</td>
<td></td>
<td>0.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000022637</td>
<td>Cblb</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000035042</td>
<td>Ccl5</td>
<td>-0.97</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000002944</td>
<td>Cd36</td>
<td>-0.75</td>
<td>0.74</td>
<td>-0.89</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000039804</td>
<td>Ncoa5</td>
<td>-0.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000326</td>
<td>Comt</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000068742</td>
<td>Cry2</td>
<td>0.48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000019997</td>
<td>Ctgf</td>
<td></td>
<td>-0.85</td>
<td>-0.63</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000025003</td>
<td>Cyp2c39</td>
<td>-2.02</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000003053</td>
<td>Cyp2c29</td>
<td>2.75</td>
<td>1.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000056054</td>
<td>S100a8</td>
<td>1.44</td>
<td>1.49</td>
<td>1.62</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000056071</td>
<td>S100a9</td>
<td>1.39</td>
<td>1.69</td>
<td>1.58</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000028914</td>
<td>Casp9</td>
<td>0.64</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000072082</td>
<td>Ccnf</td>
<td>0.46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000027533</td>
<td>Fabp5</td>
<td>0.80</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000054191</td>
<td>Klf1</td>
<td>-0.73</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000041112</td>
<td>Elmo1</td>
<td></td>
<td>0.87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000042787</td>
<td>Exog</td>
<td>-0.92</td>
<td>-0.88</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000019768</td>
<td>Esr1</td>
<td>0.57</td>
<td>0.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000010683</td>
<td>Fads1</td>
<td></td>
<td>-0.64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000039529</td>
<td>Atp8b1</td>
<td>0.42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000044167</td>
<td>Foxo1</td>
<td>-0.53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000048756</td>
<td>Foxo3</td>
<td>-0.79</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000049721</td>
<td>Gal3st1</td>
<td>1.51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000029992</td>
<td>Gfpt1</td>
<td>-0.75</td>
<td>-0.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000028645</td>
<td>Slc2a1</td>
<td>0.93</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000018566</td>
<td>Slc2a4</td>
<td>-1.78</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024978</td>
<td>Gpam</td>
<td>-1.08</td>
<td>-0.93</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000040562</td>
<td>Gstm2</td>
<td>-1.48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000031451</td>
<td>Gas6</td>
<td>-0.47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027984</td>
<td>Hadh</td>
<td>-0.47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000036594</td>
<td>H2-Aa</td>
<td>-0.42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000037025</td>
<td>Foxa2</td>
<td></td>
<td>-0.63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Input IDs</td>
<td>Gene Symbol</td>
<td>CVvsC20</td>
<td>CVvsC200</td>
<td>HVvsH20</td>
<td>HVvsH200</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>---------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>ENSMUSG00000043013</td>
<td>Onecut1</td>
<td>0.96</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000091971</td>
<td>Hspa1a</td>
<td>-3.95949</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041798</td>
<td>Gck</td>
<td>-0.98</td>
<td>-1.01</td>
<td>-0.63</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000032115</td>
<td>Hycu1</td>
<td>-1.35</td>
<td>0.52</td>
<td>-0.75</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000026185</td>
<td>Igfbp5</td>
<td>-1.14</td>
<td>-1.39</td>
<td>-0.97</td>
<td>-0.54</td>
</tr>
<tr>
<td>ENSMUSG00000026072</td>
<td>Il1r1</td>
<td>0.58</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027947</td>
<td>Il6ra</td>
<td>-0.67</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000038894</td>
<td>Irs2</td>
<td>0.57</td>
<td>0.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020653</td>
<td>Klf11</td>
<td>1.13</td>
<td>0.73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000052040</td>
<td>Klf13</td>
<td>-0.72</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000055148</td>
<td>Klf2</td>
<td>-1.38</td>
<td>-0.74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000032796</td>
<td>Lama1</td>
<td>-0.63</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020593</td>
<td>Lpin1</td>
<td>-0.76</td>
<td>-1.96</td>
<td>-0.70</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024052</td>
<td>Lpin2</td>
<td>-0.73</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000015568</td>
<td>Lpl</td>
<td>0.73</td>
<td>0.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000035202</td>
<td>Lars2</td>
<td>-1.38</td>
<td>-1.58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000026688</td>
<td>Mgst3</td>
<td>-1.19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000049723</td>
<td>Mmp12</td>
<td>-0.97</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000021025</td>
<td>Nfkb1</td>
<td>-0.51</td>
<td>-0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000032715</td>
<td>Trib3</td>
<td>1.21</td>
<td>0.91</td>
<td>-0.59</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024413</td>
<td>Npc1</td>
<td>0.68</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000030659</td>
<td>Nucb2</td>
<td>0.82</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000023034</td>
<td>Nr4a1</td>
<td>-0.63</td>
<td>0.94</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000096054</td>
<td>Syne1</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041827</td>
<td>Oasl1</td>
<td>1.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000168</td>
<td>Dlat</td>
<td>0.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000029304</td>
<td>Spp1</td>
<td>0.48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028211</td>
<td>Trp53inp1</td>
<td>1.08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000044254</td>
<td>Pcsk9</td>
<td>-0.99</td>
<td>-1.20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028525</td>
<td>Pde4b</td>
<td>0.73</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000038508</td>
<td>Gdf15</td>
<td>1.52</td>
<td>1.22</td>
<td>1.08</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000019577</td>
<td>Pdk4</td>
<td>1.04</td>
<td>1.37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025509</td>
<td>Pnpla2</td>
<td>0.85</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020893</td>
<td>Per1</td>
<td>-0.97</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000033871</td>
<td>Ppargc1b</td>
<td>0.86</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000032462</td>
<td>Pik3cb</td>
<td>0.89</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041417</td>
<td>Pik3r1</td>
<td>-0.47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000045038</td>
<td>Prkce</td>
<td>-0.53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000004440</td>
<td>Pparg</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027540</td>
<td>Ppil1</td>
<td>0.61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028150</td>
<td>Rorc</td>
<td>-0.74</td>
<td>0.88</td>
<td>0.53</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000015843</td>
<td>Rxrq</td>
<td>0.83</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000043895</td>
<td>S1pr2</td>
<td>1.20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000074115</td>
<td>Saa1</td>
<td>-1.44</td>
<td>2.34</td>
<td>2.41</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041567</td>
<td>Serpina12</td>
<td>-1.04</td>
<td>0.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000019970</td>
<td>Sgk1</td>
<td>0.77</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000038351</td>
<td>Sgsm2</td>
<td>0.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Input IDs</td>
<td>Gene Symbol</td>
<td>CVvsC20</td>
<td>CVvsC200</td>
<td>HVvsH20</td>
<td>HVvsH200</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>---------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>ENSMUSG0000000020027</td>
<td>Socs2</td>
<td>1.10</td>
<td></td>
<td></td>
<td>0.71</td>
</tr>
<tr>
<td>ENSMUSG0000000053113</td>
<td>Socs3</td>
<td>1.08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000025006</td>
<td>Sorbs1</td>
<td>0.64</td>
<td>-0.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000037465</td>
<td>Klf10</td>
<td>0.86</td>
<td>-0.54</td>
<td>-1.29</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000028599</td>
<td>Tnfrsf1b</td>
<td></td>
<td></td>
<td></td>
<td>0.58</td>
</tr>
<tr>
<td>ENSMUSG0000000022797</td>
<td>Tfrc</td>
<td></td>
<td>-0.80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000028128</td>
<td>F3</td>
<td>1.32</td>
<td>0.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000020123</td>
<td>Avpr1a</td>
<td>0.98</td>
<td>-1.29</td>
<td>0.72</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000027962</td>
<td>Vcam1</td>
<td>0.63</td>
<td>-0.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000024924</td>
<td>Vldr</td>
<td></td>
<td>-2.54</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000028978</td>
<td>Nos3</td>
<td>-0.87</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000041653</td>
<td>Pnpla3</td>
<td></td>
<td>-1.78</td>
<td>-1.17</td>
<td></td>
</tr>
</tbody>
</table>

Metabolic disease analysis for each comparison indicated gene sets associated with endpoints including diabetes mellitus. Differentially regulated gene targets are indicated. For each comparison, fold change vs. control is shown.
### Table 50

**Targets associated with metabolic disease enrichments (metabolic syndrome) and their change vs. vehicle control in each comparison**

<table>
<thead>
<tr>
<th>Input IDs</th>
<th>Gene Symbol</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000031278</td>
<td>Acsl4</td>
<td>-0.47</td>
<td>1.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000024391</td>
<td>Apom</td>
<td></td>
<td>0.76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000055116</td>
<td>Arntl</td>
<td>2.2</td>
<td>1.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000045730</td>
<td>Adrb2</td>
<td>-1.04</td>
<td>-1.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000002944</td>
<td>Cd36</td>
<td>-0.75</td>
<td>0.74</td>
<td>-0.89</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000029238</td>
<td>Clock</td>
<td></td>
<td>0.77</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000068742</td>
<td>Cry2</td>
<td></td>
<td>0.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000072082</td>
<td>Ccnf</td>
<td></td>
<td>0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000019768</td>
<td>Esr1</td>
<td></td>
<td>0.57</td>
<td>0.69</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000010663</td>
<td>Fads1</td>
<td></td>
<td></td>
<td>-0.64</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000028001</td>
<td>Fga</td>
<td></td>
<td>1.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000033831</td>
<td>Fgb</td>
<td></td>
<td>1.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000033860</td>
<td>Fgg</td>
<td></td>
<td>0.96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000020429</td>
<td>Igfbp1</td>
<td>-0.46</td>
<td>1.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000002421</td>
<td>Igfbp3</td>
<td></td>
<td>0.44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000026185</td>
<td>Igfbp5</td>
<td>-1.14</td>
<td>-1.39</td>
<td>-0.97</td>
<td>-0.54</td>
</tr>
<tr>
<td>ENSMUSG000000027947</td>
<td>Il6ra</td>
<td></td>
<td></td>
<td>-0.674195</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000020593</td>
<td>Lpin1</td>
<td>-0.76</td>
<td>-1.96</td>
<td>-0.70</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000015568</td>
<td>Lpl</td>
<td>0.72</td>
<td>0.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000059436</td>
<td>Max</td>
<td>-0.55</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000032715</td>
<td>Trib3</td>
<td>1.21</td>
<td>0.91</td>
<td>-0.59</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000027820</td>
<td>Mme</td>
<td>0.73</td>
<td>-0.81</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000019577</td>
<td>Pdk4</td>
<td>1.04</td>
<td></td>
<td>1.37</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000055866</td>
<td>Per2</td>
<td>-1.39</td>
<td>-0.74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000042632</td>
<td>Pla2g6</td>
<td></td>
<td>0.98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000023913</td>
<td>Pla2g7</td>
<td></td>
<td>0.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000000440</td>
<td>Ppar</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000027540</td>
<td>Ptpn1</td>
<td></td>
<td>0.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000027368</td>
<td>Dusp2</td>
<td>-1.27</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000020580</td>
<td>Rock2</td>
<td></td>
<td>-0.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000074115</td>
<td>Saa1</td>
<td>-1.44</td>
<td>2.34</td>
<td>2.41</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000041567</td>
<td>Serpina12</td>
<td>-1.04</td>
<td>0.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000012428</td>
<td>Steap4</td>
<td>-0.62</td>
<td>1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000028978</td>
<td>Nos3</td>
<td>-0.87</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000041653</td>
<td>Pnpla3</td>
<td></td>
<td>-1.78</td>
<td>-1.17</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000027962</td>
<td>Vcam1</td>
<td>0.63</td>
<td>-0.85</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 50 (continued)

<table>
<thead>
<tr>
<th>Input IDs</th>
<th>Gene Symbol</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000048376</td>
<td>F2r</td>
<td></td>
<td></td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000030748</td>
<td>Il4ra</td>
<td></td>
<td>0.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000021871</td>
<td>Pnp</td>
<td></td>
<td></td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000033220</td>
<td>Rac2</td>
<td></td>
<td>0.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000057465</td>
<td>Saa2</td>
<td></td>
<td>-1.37</td>
<td>2.06</td>
<td>2.62</td>
</tr>
<tr>
<td>ENSMUSG000000028599</td>
<td>Tnfrsf1b</td>
<td></td>
<td></td>
<td></td>
<td>0.58</td>
</tr>
</tbody>
</table>

Metabolic disease analysis for each comparison indicated gene sets associated with endpoints including metabolic syndrome. Differentially regulated gene targets are indicated. For each comparison, fold change vs. control is shown.
Table 51
Targets associated with metabolic disease enrichments (insulin resistance) and their change vs. vehicle control in each comparison

<table>
<thead>
<tr>
<th>Input IDs</th>
<th>Gene Symbol</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic Disease Biomarkers: Insulin resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000031278</td>
<td>Acsl4</td>
<td>-0.47</td>
<td>1.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000035783</td>
<td>Acta2</td>
<td>-0.96</td>
<td>-0.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024391</td>
<td>Apom</td>
<td></td>
<td>0.76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027792</td>
<td>Bche</td>
<td></td>
<td>-0.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000055116</td>
<td>Arntl</td>
<td></td>
<td>1.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000045730</td>
<td>Adrb2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000036098</td>
<td>Myrf</td>
<td></td>
<td></td>
<td>0.51</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000035042</td>
<td>Ccl5</td>
<td></td>
<td></td>
<td>-0.97</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000002944</td>
<td>Cd36</td>
<td>-0.75</td>
<td>0.74</td>
<td>-0.89</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000029238</td>
<td>Clock</td>
<td></td>
<td>0.77</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000068742</td>
<td>Cry2</td>
<td></td>
<td>0.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000072082</td>
<td>Ccnf</td>
<td></td>
<td>0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041220</td>
<td>Elov1</td>
<td></td>
<td>-0.89</td>
<td>-0.53</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000019768</td>
<td>Esr1</td>
<td></td>
<td>0.57</td>
<td>0.69</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000010663</td>
<td>Fads1</td>
<td></td>
<td></td>
<td>-0.64</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024664</td>
<td>Fads3</td>
<td>-0.91</td>
<td>-0.56</td>
<td>-0.91</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000044167</td>
<td>Foxo1</td>
<td></td>
<td>-0.53</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000048756</td>
<td>Foxo3</td>
<td></td>
<td>-0.79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028001</td>
<td>Fga</td>
<td></td>
<td>1.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000033831</td>
<td>Fgb</td>
<td></td>
<td>1.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000033860</td>
<td>Fgg</td>
<td></td>
<td>0.96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000049721</td>
<td>Gal3st1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000029992</td>
<td>Gfpt1</td>
<td>-0.75</td>
<td>-0.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000018566</td>
<td>Slc2a4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000021670</td>
<td>Hmgcr</td>
<td></td>
<td>-0.73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000043013</td>
<td>Onecut1</td>
<td></td>
<td>0.96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041798</td>
<td>Gck</td>
<td>-0.98</td>
<td>-0.63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020429</td>
<td>Igfbp1</td>
<td></td>
<td>-0.46</td>
<td>1.08</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020427</td>
<td>Igfbp3</td>
<td></td>
<td>0.44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000026185</td>
<td>Igfbp5</td>
<td></td>
<td>-0.97</td>
<td>-0.54</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027947</td>
<td>Il6ra</td>
<td></td>
<td>-0.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000038894</td>
<td>Irs2</td>
<td></td>
<td>0.57</td>
<td>0.83</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020593</td>
<td>Lpin1</td>
<td>-0.76</td>
<td>-0.70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000024052</td>
<td>Lpin2</td>
<td></td>
<td>-0.73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000015568</td>
<td>Lpl</td>
<td>0.72</td>
<td>0.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000054612</td>
<td>Mgmt</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000059436</td>
<td>Max</td>
<td></td>
<td>-0.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000054764</td>
<td>Mtnr1a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000021025</td>
<td>Nfkbia</td>
<td>-0.51</td>
<td>-0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Input IDs</td>
<td>Gene Symbol</td>
<td>CVvsC20</td>
<td>CVvsC200</td>
<td>HVvsH20</td>
<td>HVvsH200</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td>---------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>ENSMUSG00000032715</td>
<td>Trib3</td>
<td>1.21</td>
<td>0.91</td>
<td>-0.59</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000327820</td>
<td>Mme</td>
<td>0.73</td>
<td>-0.81</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000019577</td>
<td>Pdk4</td>
<td>1.04</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025509</td>
<td>Pnpla2</td>
<td>0.85</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000055866</td>
<td>Per2</td>
<td>-0.74</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000032462</td>
<td>Pik3cb</td>
<td>0.89</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000041417</td>
<td>Pik3r1</td>
<td>-0.47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000042632</td>
<td>Pla2g6</td>
<td>0.98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000023913</td>
<td>Pla2g7</td>
<td>0.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000440</td>
<td>Pparg</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000027540</td>
<td>Ptpn1</td>
<td>0.61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027368</td>
<td>Dusp2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020580</td>
<td>Rock2</td>
<td>-0.42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000074115</td>
<td>Saa1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000075701</td>
<td>Selenos</td>
<td>-0.47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041567</td>
<td>Serpina12</td>
<td>0.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000060807</td>
<td>Serpina6</td>
<td>-0.97</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000053113</td>
<td>Soc3</td>
<td>1.08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000012428</td>
<td>Steap4</td>
<td>-0.62</td>
<td>1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028599</td>
<td>Tnfrsf1b</td>
<td></td>
<td>0.58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000027962</td>
<td>Vcam1</td>
<td>0.63</td>
<td>-0.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000044786</td>
<td>Zfp36</td>
<td>-0.53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000028978</td>
<td>Nos3</td>
<td>-0.87</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000041653</td>
<td>Pnpla3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000008845</td>
<td>Cd163</td>
<td>0.84</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000048376</td>
<td>F2r</td>
<td>0.44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000044674</td>
<td>Fzd1</td>
<td>0.53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000030748</td>
<td>Il4ra</td>
<td>0.57</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000021871</td>
<td>Pnp</td>
<td>0.61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000033871</td>
<td>Ppargc1b</td>
<td>0.86</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000033220</td>
<td>Rac2</td>
<td>0.56</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000015843</td>
<td>Rxrg</td>
<td>0.83</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG0000000057465</td>
<td>Saa2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Metabolic disease analysis for each comparison indicated gene sets associated with endpoints including insulin resistance. Differentially regulated gene targets are indicated. For each comparison, fold change vs. control is shown.
proportion of the DTG sets. Comparison of these results to outputs of the same network frame showing DTG sets in vitro primary hepatocyte exposure to prototypical ligands for these receptors, however, indicates that the sets of direct transcriptional targets as curated by MetaCore™ are probably not comprehensive (data not shown). Other software tools may be needed to further explore these relationships.

Analysis of dose-within-diet comparisons indicated enrichment in disease-associated transcription factors

Transcription factor analysis for the CVvsC20, CVvsC200, HVvsH20 and HVvsH200 are shown in Tables 52-55. These analyses are based on gene ontology, therefore the transcription factors ranked highest in the list of engaged transcription factors were those with the most literature-based relationships among the DTGs in each dataset. Many of these connections are based on chromatin immunoprecipitation studies or computational binding site prediction, and are of unspecified effect, however, when only the defined relationships (activation or inhibition via transcriptional regulation) were considered, we were able to develop a percent activation for each listed transcription factor under each condition: the number differentially regulated in a direction consistent with TF activation/total differentially regulated. These are listed in Tables 56 and 57. Overall, transcription factors tended to increase in percent activation with increasing PCB concentration and decrease with HFD exposure. Interestingly, transcription factors which were targets of PXR regulation by binding showed evidence of increased activation at the 20 mg/kg exposure, compared to the 200 mg/kg exposure, shown in Figure 13. PXR targets of regulation by protein-protein interaction.

Specific targets within pathways engaged in these experiments are related to metabolic syndrome components, including fatty liver disease and diabetes, as well as liver damage and regeneration pathways.

Several of the targets differentially regulated under one or more of the experimental conditions have been characterized as potential contributors to metabolic diseases, including
Table 52: Top ten transcription factor enrichments for condition CVvsC20

<table>
<thead>
<tr>
<th>Transcription Factor</th>
<th>Network GO Processes</th>
<th>Nodes</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CREB1</td>
<td>rhythmic process (46.2%; 2.27E-13), circadian rhythm (36.1%; 6.65E-17), rhythmic process (51.9%; 1.73E-15)</td>
<td>37</td>
<td>3.10E-121</td>
</tr>
<tr>
<td>c-Myc</td>
<td>circadian rhythm (35.5%; 2.16E-14), rhythmic process (38.7%; 3.44E-12), circadian regulation of gene expression (19.4%; 1.75E-09)</td>
<td>31</td>
<td>1.55E-102</td>
</tr>
<tr>
<td>p53</td>
<td>negative regulation of cellular process (84.4%; 7.36E-11), circadian rhythm (37.5%; 6.22E-16), rhythmic process (40.6%; 2.99E-11)</td>
<td>31</td>
<td>4.96E-101</td>
</tr>
<tr>
<td>C/EBPalpha</td>
<td>cellular response to chemical stimulus (71.0%; 2.98E-11), circadian rhythm (35.5%; 2.16E-14), rhythmic process (45.2%; 3.80E-15)</td>
<td>27</td>
<td>1.10E-97</td>
</tr>
<tr>
<td>HIF1A</td>
<td>cellular response to oxygen-containing compound (77.0%; 3.89E-10), circadian rhythm (37.9%; 8.99E-15), rhythmic process (41.4%; 1.32E-12)</td>
<td>29</td>
<td>2.40E-94</td>
</tr>
<tr>
<td>RelA (p65 NF-κB subunit)</td>
<td>cellular response to oxygen-containing compound (70.0%; 1.28E-10), circadian rhythm (36.7%; 1.40E-14), rhythmic process (40.0%; 2.16E-12)</td>
<td>29</td>
<td>2.40E-94</td>
</tr>
<tr>
<td>c-Jun</td>
<td>circadian rhythm (42.9%; 8.72E-17), rhythmic process (46.4%; 2.37E-14), cellular response to chemical stimulus (75.0%; 1.49E-11), response to oxygen-containing compound (60.7%; 6.51E-10)</td>
<td>27</td>
<td>1.10E-87</td>
</tr>
<tr>
<td>C/EBPβ</td>
<td>cellular response to oxygen-containing compound (76.0%; 6.79E-11), circadian rhythm (40.7%; 3.46E-15), rhythmic process (48.1%; 1.29E-14)</td>
<td>26</td>
<td>2.31E-84</td>
</tr>
<tr>
<td>ESR1</td>
<td>circadian rhythm (38.5%; 1.29E-13), rhythmic process (46.2%; 2.64E-13), circadian regulation of gene expression (23.1%; 5.58E-10), negative regulation of gene expression (57.7%; 5.89E-10)</td>
<td>26</td>
<td>2.31E-84</td>
</tr>
<tr>
<td>Other significantly enriched transcription factors included Androgen receptor, C/EBPα, PPAR-γ, HNF4-α, SMAD3, Oct-3/4, TCF7L2, AP-2, SP1, CREB1, NRSF, and SMAD4.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other significantly enriched transcription factors included Androgen receptor, C/EBPα, PPAR-γ, HNF4-α, SMAD3, Oct-3/4, TCF7L2, AP-2, SP1, CREB1, NRSF, and SMAD4.
<table>
<thead>
<tr>
<th>Nodes</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>101</td>
<td>1.93e-17</td>
</tr>
<tr>
<td>103</td>
<td>3.26e-14</td>
</tr>
<tr>
<td>179</td>
<td>2.07e-18</td>
</tr>
<tr>
<td>143</td>
<td>2.01e-26</td>
</tr>
<tr>
<td>133</td>
<td>1.90e-28</td>
</tr>
<tr>
<td>113</td>
<td>2.90e-28</td>
</tr>
<tr>
<td>110</td>
<td>1.37e-19</td>
</tr>
<tr>
<td>113</td>
<td>2.99e-23</td>
</tr>
<tr>
<td>133</td>
<td>1.99e-23</td>
</tr>
<tr>
<td>110</td>
<td>1.02e-21</td>
</tr>
<tr>
<td>101</td>
<td>1.99e-21</td>
</tr>
<tr>
<td>110</td>
<td>1.14e-17</td>
</tr>
<tr>
<td>113</td>
<td>1.37e-19</td>
</tr>
<tr>
<td>133</td>
<td>1.99e-23</td>
</tr>
<tr>
<td>933</td>
<td>1.57e-16</td>
</tr>
<tr>
<td>133</td>
<td>1.66e-23</td>
</tr>
<tr>
<td>110</td>
<td>1.02e-21</td>
</tr>
<tr>
<td>113</td>
<td>1.37e-19</td>
</tr>
</tbody>
</table>

Other significantly enriched transcription factors included STAT3, YY1, GCR, NANOG, E2F1, C/EBPbeta, PPARgamma, SRF, GATA3, HNF4gamma.

**Table 53**

<table>
<thead>
<tr>
<th>Top ten transcription factor enrichments for condition CV vs C200</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Network GO Processes</strong></td>
</tr>
<tr>
<td>Nodes p-Value</td>
</tr>
<tr>
<td>101</td>
</tr>
<tr>
<td>103</td>
</tr>
<tr>
<td>179</td>
</tr>
<tr>
<td>143</td>
</tr>
<tr>
<td>133</td>
</tr>
<tr>
<td>113</td>
</tr>
<tr>
<td>110</td>
</tr>
<tr>
<td>113</td>
</tr>
<tr>
<td>133</td>
</tr>
<tr>
<td>933</td>
</tr>
<tr>
<td>133</td>
</tr>
<tr>
<td>110</td>
</tr>
<tr>
<td>113</td>
</tr>
<tr>
<td>133</td>
</tr>
<tr>
<td>110</td>
</tr>
<tr>
<td>133</td>
</tr>
</tbody>
</table>

**Network GO Processes**

**Nodes p-Value**

| 101   | 1.93e-17 |
| 103   | 3.26e-14 |
| 179   | 2.07e-18 |
| 143   | 2.01e-26 |
| 133   | 1.90e-28 |
| 113   | 2.90e-28 |
| 110   | 1.37e-19 |
| 113   | 1.99e-23 |
| 133   | 1.99e-23 |
| 933   | 1.57e-16 |
| 133   | 1.66e-23 |
| 110   | 1.02e-21 |
| 113   | 1.37e-19 |
| 133   | 1.99e-23 |
| 110   | 1.02e-21 |
| 133   | 1.99e-23 |

**Network GO Processes**

**Nodes p-Value**

| 101   | 1.93e-17 |
| 103   | 3.26e-14 |
| 179   | 2.07e-18 |
| 143   | 2.01e-26 |
| 133   | 1.90e-28 |
| 113   | 2.90e-28 |
| 110   | 1.37e-19 |
| 113   | 1.99e-23 |
| 133   | 1.99e-23 |
| 933   | 1.57e-16 |
| 133   | 1.66e-23 |
| 110   | 1.02e-21 |
| 113   | 1.37e-19 |
| 133   | 1.99e-23 |
| 110   | 1.02e-21 |
| 133   | 1.99e-23 |

**Network GO Processes**

**Nodes p-Value**
### Top Ten Transcription Factor Enrichments for Condition HVvsH20

<table>
<thead>
<tr>
<th>Network GO processes</th>
<th>Nodes 199</th>
<th>p-Value 1.150E-299</th>
</tr>
</thead>
<tbody>
<tr>
<td>CREB1 response to organic substance (47.0%; 3.429e-19), response to oxygen-containing compound (35.4%; 1.098e-18), response to organonitrogen compound (26.3%; 4.006e-17), response to extracellular stimulus (19.7%; 7.007e-17), response to nitrogen compound (26.8%; 2.991e-16)</td>
<td>199</td>
<td>1.150E-299</td>
</tr>
<tr>
<td>c-Myc regulation of apoptotic process (45.3%; 1.557e-28), regulation of cell death (46.8%; 2.561e-28), regulation of programmed cell death (45.3%; 2.621e-28), negative regulation of cell death (36.0%; 6.566e-25), negative regulation of apoptotic process (33.1%; 3.790e-23)</td>
<td>141</td>
<td>5.530E-290</td>
</tr>
<tr>
<td>SP1 response to organic substance (66.7%; 1.091e-33), cellular response to chemical stimulus (61.5%; 9.303e-32), regulation of cell death (49.6%; 3.956e-31), response to oxygen-containing compound (51.9%; 1.154e-30), regulation of apoptotic process (46.7%; 1.956e-29)</td>
<td>135</td>
<td>1.890E-284</td>
</tr>
<tr>
<td>Androgen receptor regulation of cell death (43.7%; 2.988e-21), regulation of apoptotic process (42.0%; 3.922e-21), regulation of programmed cell death (42.0%; 5.874e-21), response to organic substance (57.1%; 2.958e-20), response to chemical (66.4%; 4.642e-19)</td>
<td>120</td>
<td>3.290E-264</td>
</tr>
<tr>
<td>p53 regulation of cell death (50.0%; 8.565e-28), regulation of apoptotic process (46.6%; 7.797e-26), regulation of programmed cell death (46.6%; 1.231e-25), positive regulation of biological process (77.1%; 5.883e-25), positive regulation of macromolecule metabolic process (57.6%; 1.154e-23)</td>
<td>117</td>
<td>1.410E-249</td>
</tr>
<tr>
<td>ESR1 response to organic substance (66.4%; 4.157e-28), cellular response to chemical stimulus (61.9%; 2.760e-27), response to oxygen-containing compound (51.3%; 2.433e-25), response to chemical (73.5%; 1.489e-24), regulation of cell death (47.8%; 2.494e-24)</td>
<td>114</td>
<td>5.010E-242</td>
</tr>
<tr>
<td>c-Jun response to organic substance (68.6%; 2.067e-28), response to oxygen-containing compound (54.3%; 1.411e-26), regulation of cell death (51.4%; 2.464e-26), regulation of apoptotic process (49.5%; 4.376e-26), regulation of programmed cell death (49.5%; 6.780e-26)</td>
<td>106</td>
<td>5.370E-237</td>
</tr>
<tr>
<td>HIF1A regulation of cell death (54.9%; 3.336e-29), regulation of apoptotic process (52.0%; 6.901e-28), regulation of programmed cell death (52.0%; 1.084e-27), response to organic substance (67.6%; 9.912e-27), cellular response to chemical stimulus (63.7%; 1.773e-26)</td>
<td>101</td>
<td>1.150E-299</td>
</tr>
<tr>
<td>RelA (p65 NF-kB subunit) regulation of cell death (55.1%; 2.578e-28), regulation of apoptotic process (53.1%; 5.735e-28), regulation of programmed cell death (53.1%; 8.944e-28), response to oxygen-containing compound (56.1%; 1.138e-26), response to organic substance (68.4%; 2.053e-26)</td>
<td>98</td>
<td>5.530E-290</td>
</tr>
<tr>
<td>GCR cellular response to chemical stimulus (68.8%; 8.421e-30), response to organic substance (71.9%; 2.788e-29), response to organic cyclic compound (51.0%; 6.592e-29), response to oxygen-containing compound (57.3%; 2.736e-27), regulation of cell death (27.9%; 9.909e-27)</td>
<td>96</td>
<td>1.890E-284</td>
</tr>
<tr>
<td>Other significantly enriched transcription factors included Oct-3/4, C/EBPbeta, STAT3, HNF4-alpha, C/EBPalpha, PPAR-gamma, NANOG, SP3, TCF7L2 (TCF4), c-fos, AHR, EZF1, HIF1A, FOXL2, YY1, KLFA, FOXOA1, GATA-3, NFB, ERG1, VDR, CREB1, GCR, OR, 70-kD TLF1s (TCP4), c-fos, AHR, EZF1, HIF1Α, FOXL2, YY1, KLFA, FOXOA1, GATA-3, NFB, ERG1, VDR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 54**

Network GO Processes

<table>
<thead>
<tr>
<th>Nodes</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>199</td>
<td>1.150E-299</td>
</tr>
<tr>
<td>141</td>
<td>5.530E-290</td>
</tr>
<tr>
<td>135</td>
<td>1.890E-284</td>
</tr>
<tr>
<td>120</td>
<td>3.290E-264</td>
</tr>
<tr>
<td>117</td>
<td>1.410E-249</td>
</tr>
<tr>
<td>114</td>
<td>5.010E-242</td>
</tr>
<tr>
<td>106</td>
<td>5.370E-237</td>
</tr>
<tr>
<td>101</td>
<td>1.150E-299</td>
</tr>
<tr>
<td>98</td>
<td>5.530E-290</td>
</tr>
<tr>
<td>96</td>
<td>1.890E-284</td>
</tr>
<tr>
<td>123</td>
<td>1.130E-272</td>
</tr>
</tbody>
</table>

**Nodes**
Table 55
Top ten transcription factor enrichments for condition HV vs H200

<table>
<thead>
<tr>
<th>Network GO processes</th>
<th>Nodes</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CREB1 negative regulation of cellular process (66.4%; 7.735e-20), negative regulation of biological process (66.4%; 1.009e-17), regulation of cell death (39.7%; 6.005e-17), response to hormone (31.9%; 3.075e-16)</td>
<td>116</td>
<td>0.000E+00</td>
</tr>
<tr>
<td>c-Myc positive regulation of macromolecule metabolic process (60.5%; 9.952e-20), positive regulation of metabolic process (60.5%; 2.515e-18), response to organic substance (61.6%; 4.053e-18), regulation of cell death (46.5%; 7.414e-18), regulation of apoptotic process (44.2%; 2.690e-17)</td>
<td>87</td>
<td>4.730E-245</td>
</tr>
<tr>
<td>SP1 response to endogenous stimulus (52.4%; 8.326e-21), negative regulation of cellular process (73.8%; 6.342e-20), response to organic substance (64.3%; 1.169e-19), negative regulation of biological process (75.0%; 5.559e-19), response to hormone (40.5%; 9.947e-19)</td>
<td>83</td>
<td>1.280E-231</td>
</tr>
<tr>
<td>p53 regulation of cell death (50.6%; 5.417e-20), response to organic substance (64.2%; 6.069e-19), response to endogenous stimulus (50.6%; 9.129e-19), positive regulation of macromolecule metabolic process (60.5%; 1.103e-18), regulation of apoptotic process (46.9%; 2.117e-18)</td>
<td>80</td>
<td>5.070E-223</td>
</tr>
<tr>
<td>ESR1 (nuclear) response to organic substance (68.0%; 2.838e-20), response to endogenous stimulus (53.3%; 2.041e-19), negative regulation of cell death (42.7%; 4.796e-19), cellular response to chemical stimulus (61.3%; 3.687e-18), regulation of cell death (49.3%; 1.071e-17)</td>
<td>77</td>
<td>2.480E-216</td>
</tr>
<tr>
<td>RelA (p65 NF-κB subunit) response to organic substance (69.2%; 5.822e-22), cellular response to chemical stimulus (64.1%; 7.683e-21), positive regulation of metabolic process (65.4%; 3.572e-20), response to chemical (76.9%; 7.676e-20), regulation of cell death (51.3%; 8.300e-20)</td>
<td>77</td>
<td>1.930E-214</td>
</tr>
<tr>
<td>C/EBPβ response to organic substance (70.1%; 2.198e-22), cellular response to chemical stimulus (63.6%; 2.997e-20), regulation of cell death (51.9%; 4.482e-20), response to chemical (76.6%; 2.190e-19), response to oxygen-containing compound (53.2%; 4.302e-19)</td>
<td>76</td>
<td>1.390E-211</td>
</tr>
<tr>
<td>HIF1α response to organic substance (70.1%; 2.192e-22), cellular response to chemical stimulus (66.2%; 3.372e-21), response to organic stimulus (67.1%; 7.032e-20), response to endogenous stimulus (61.2%; 6.032e-19), response to oxygen-containing compound (56.3%; 2.526e-18)</td>
<td>75</td>
<td>9.920E-209</td>
</tr>
<tr>
<td>GCR response to organic substance (76.0%; 1.606e-26), cellular response to chemical stimulus (70.7%; 4.137e-25), response to endogenous stimulus (58.7%; 1.692e-23), response to hormone (48.0%; 7.672e-23), response to oxygen-containing compound (58.7%; 1.099e-22)</td>
<td>74</td>
<td>7.060E-206</td>
</tr>
<tr>
<td>STAT3 response to organic substance (68.1%; 1.405e-20), positive regulation of metabolic process (68.1%; 1.574e-20), response to organic substance (69.4%; 1.574e-20), regulation of cell death (54.2%; 1.805e-20), regulation of apoptotic process (51.4%; 1.144e-19)</td>
<td>71</td>
<td>2.490E-197</td>
</tr>
<tr>
<td>Other significantly enriched transcription factors included Androgen receptor, c-Jun, C/EBPα, Oct-3/4, HNF4α, STAT1, FOXO3A, SOX2, c-Fos, NANOG, PPAR-α (nuclear), PPAR-γ (nuclear), p53, mTOR, IRF1, IRF4, AHR, EGR1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 56

Percent activation for engaged transcription factors identified in all conditions

<table>
<thead>
<tr>
<th>Factor</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH20</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>% CWA</td>
<td>Total</td>
<td>% CWA</td>
</tr>
<tr>
<td>CREB1</td>
<td>31</td>
<td>16%</td>
<td>48</td>
<td>52%</td>
</tr>
<tr>
<td>c-Myc</td>
<td>25</td>
<td>32%</td>
<td>72</td>
<td>32%</td>
</tr>
<tr>
<td>p53</td>
<td>19</td>
<td>37%</td>
<td>68</td>
<td>60%</td>
</tr>
<tr>
<td>SP1</td>
<td>23</td>
<td>30%</td>
<td>69</td>
<td>59%</td>
</tr>
<tr>
<td>HIF1A</td>
<td>21</td>
<td>38%</td>
<td>54</td>
<td>63%</td>
</tr>
<tr>
<td>RelA (p65 NF-kB subunit)</td>
<td>16</td>
<td>25%</td>
<td>53</td>
<td>64%</td>
</tr>
<tr>
<td>c-Jun</td>
<td>14</td>
<td>50%</td>
<td>37</td>
<td>73%</td>
</tr>
<tr>
<td>C/EBPbeta</td>
<td>14</td>
<td>64%</td>
<td>34</td>
<td>56%</td>
</tr>
<tr>
<td>ESR1 (nuclear)</td>
<td>18</td>
<td>33%</td>
<td>52</td>
<td>54%</td>
</tr>
<tr>
<td>GCR</td>
<td>16</td>
<td>56%</td>
<td>47</td>
<td>43%</td>
</tr>
<tr>
<td>Androgen receptor</td>
<td>13</td>
<td>15%</td>
<td>37</td>
<td>54%</td>
</tr>
<tr>
<td>C/EBPalpha</td>
<td>13</td>
<td>46%</td>
<td>25</td>
<td>60%</td>
</tr>
<tr>
<td>PPAR-gamma</td>
<td>9</td>
<td>78%</td>
<td>30</td>
<td>57%</td>
</tr>
<tr>
<td>HNF4-alpha</td>
<td>14</td>
<td>50%</td>
<td>29</td>
<td>62%</td>
</tr>
<tr>
<td>Oct-3/4</td>
<td>12</td>
<td>42%</td>
<td>54</td>
<td>50%</td>
</tr>
<tr>
<td>YY1</td>
<td>7</td>
<td>29%</td>
<td>19</td>
<td>42%</td>
</tr>
<tr>
<td>FKHR</td>
<td>7</td>
<td>43%</td>
<td>24</td>
<td>63%</td>
</tr>
<tr>
<td>STAT3</td>
<td>10</td>
<td>50%</td>
<td>44</td>
<td>45%</td>
</tr>
</tbody>
</table>

Relative activation of the most enriched transcription factors (second column for each comparison) was determined by comparing the proportion of differentially transcribed targets in which the direction of transcription was concordant with activation of the transcription factor, based on the MetaCore curated TF→target relationship and normalized to the total number of targets for that TF differentially transcribed in our experiment (first column for each comparison). This table shows % engagement for TFs which were enriched in all group 1-2 comparisons.
Table 57

Percent activation for engaged transcription factors identified in 1-3 conditions

<table>
<thead>
<tr>
<th>Factor</th>
<th>CVvsC20</th>
<th>CVvsC200</th>
<th>HVvsH200</th>
<th>HVvsH200</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>% CWA</td>
<td>Total</td>
<td>% CWA</td>
</tr>
<tr>
<td>SP3</td>
<td>6</td>
<td>33%</td>
<td>25</td>
<td>52%</td>
</tr>
<tr>
<td>TCF7L2 (TCF4)</td>
<td>7</td>
<td>43%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>c-Fos</td>
<td>9</td>
<td>33%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>SMAD3</td>
<td>8</td>
<td>38%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>PPAR-alpha</td>
<td>8</td>
<td>50%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>IRF8</td>
<td>8</td>
<td>13%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>SMAD2</td>
<td>5</td>
<td>20%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>NRF2</td>
<td>6</td>
<td>83%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>AP-2A</td>
<td>8</td>
<td>25%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>SRF</td>
<td>5</td>
<td>40%</td>
<td>26</td>
<td>42%</td>
</tr>
<tr>
<td>NRSF</td>
<td>4</td>
<td>25%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>SMAD4</td>
<td>5</td>
<td>100%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>NANOG</td>
<td>0</td>
<td>-</td>
<td>27</td>
<td>48%</td>
</tr>
<tr>
<td>E2F1</td>
<td>0</td>
<td>-</td>
<td>21</td>
<td>81%</td>
</tr>
<tr>
<td>GATA-3</td>
<td>0</td>
<td>-</td>
<td>9</td>
<td>33%</td>
</tr>
<tr>
<td>SOX2</td>
<td>0</td>
<td>-</td>
<td>18</td>
<td>39%</td>
</tr>
<tr>
<td>NF-kB</td>
<td>0</td>
<td>-</td>
<td>27</td>
<td>70%</td>
</tr>
<tr>
<td>KLF4</td>
<td>0</td>
<td>-</td>
<td>20</td>
<td>55%</td>
</tr>
<tr>
<td>p53</td>
<td>0</td>
<td>-</td>
<td>25</td>
<td>52%</td>
</tr>
<tr>
<td>NF-kB1 (p50)</td>
<td>0</td>
<td>-</td>
<td>13</td>
<td>62%</td>
</tr>
<tr>
<td>HSF1</td>
<td>0</td>
<td>-</td>
<td>27</td>
<td>26%</td>
</tr>
<tr>
<td>PU.1</td>
<td>0</td>
<td>-</td>
<td>26</td>
<td>65%</td>
</tr>
<tr>
<td>AHR</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>HNF3-beta</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>FOXO3A</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>EGR1</td>
<td>10</td>
<td>50%</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>VDR</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>STAT1</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>STAT6</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>SREBP1 (nuclear)</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>IRF4</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
</tbody>
</table>

Relative activation of the most enriched transcription factors (second column for each comparison) was determined by comparing the proportion of differentially transcribed targets in which the direction of transcription was concordant with activation of the transcription factor, based on the MetaCore curated TF→target relationship and normalized to the total number of targets for that TF differentially transcribed in our experiment (first column for each comparison). This table shows % engagement for TFs which were enriched in 1, 2, or 3 of the group 1-2 comparisons.
Figure 13. Transcription factors regulated by PXR or PXR/RXR via protein-protein interactions. Targets of inhibition shown in the blue boxes and targets of activation shown in the red box. The pie charts represent the proportion of targets differentially transcribed in a direction concordant with activation (red) or inhibition (blue) or discordant with the apparent status of activation (concordant with PXR activity) in the blue boxes. The apparent status of activation of CREB-1, HNF-3β, AR, HNF-4α, and FKHR (FOXO1) is more indicative of inhibition in the moderate-exposure conditions compared with the high-exposure conditions.
Trib3/NIPK, Arntl, and claudin-1. Associated pathway maps are shown in Figures 14-16, respectively.

The Tribbles 3 pseudokinase (NIPK or TRIB3) interrupts insulin signaling by binding and preventing phosphorylation of AKT, thereby promoting gluconeogenic down-stream targets such as PEPCK and diminishing the activity of GSK3B and associated glycogen synthesis\textsuperscript{127, 128} (Figure 14). TRIB3 can also dephosphorylate several MAP kinases and AMPK. TRIB3 is activated by PPARα and by endoplasmic reticulum stress (PERK-\textit{elf2alpha-ATF4-CHOP} arm of the unfolded protein response),\textsuperscript{129} thereby providing a mechanism by which ER stress can modulate the transduction energy and growth factor signaling to intermediary metabolic and developmental transcriptional outputs. The human TRIB3 polymorphism Q84R, which enhances its inhibition of AKT, has been linked to increased prevalence of insulin resistance and associated cardiovascular risk\textsuperscript{130}. TRIB3 is up-regulated in obesity and metabolic syndrome.

The arylhydrocarbon receptor nuclear translocator-like (Arntl) forms a heterodimer with CLOCK, an active complex driving transcription of circadian output genes such as the Period (Per1, 2, etc.) and Cryptochrome (Cry1, 2, etc.) genes (Figure 15). Another target up-regulated in all four comparisons was nuclear factor interleukin-3 (Nfil-3, or E4BP4), which encodes a protein that represses expression of the Period genes\textsuperscript{131, 132}. Processes related to circadian rhythm and control of rhythmic processes were enriched with moderate PCB exposure in our model. Again, disruption of normal circadian rhythm may be both cause and effect in metabolic disease\textsuperscript{133, 134}. The oscillatory patterns of circadian clock output genes (BMAL/CLOCK target genes) are disrupted in response to nutritional challenges\textsuperscript{135, 136}. Disrupted sleep patterns due to sleep apnea\textsuperscript{137} or shift work\textsuperscript{138} are also associated with metabolic disease progression. Another target of circadian rhythm circuitry is Kruppel-like factor 9 (KLF9), a transcription factor which expressed in epithelial cells and regulates daytime-specific expression of differentiation-related targets (Ell3) as well as targets related to glucocorticoid signaling (Fkbp5)\textsuperscript{139}.

Other targets associated with cell differentiation/identity, epithelial-to-mesenchymal transition and regenerative processes were differentially regulated, particularly within the moderate exposure models. These included up-regulated cell adhesion proteins such as claudin-
Figure 14. Nipk/Trib3 signaling pathway downstream of PPAR-alpha.

PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of signaling pathways downstream of PPAR-alpha. In particular, the tribbles pseudokinase (Nipk/Trib3) differentially regulated in all comparisons: CVvsC20 (1), CVvsC200 (2), HVvsH20 (3), HVvsH200 (4), C20vsH20 (5), C200vsH200 (6), and CVvsHV (7). Notably, transcription was upregulated in both control diet comparisons and in CVvsHV and downregulated in other comparisons. Image generated using MetaCore™ from Thomson Reuters.
Figure 15. Arntl/Bmal1 pathway related to circadian signaling.

PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of signaling pathways related to circadian signaling. In particular, the arylhydrocarbon receptor nuclear translocator-like (Arntl/Bmal1) was differentially regulated in comparison CVvsC20 (1), CVvsC200 (2), and C20vsH20 (5). Clock output targets such as Per1/2, and Cry1/2 were differentially regulated in comparisons HVvsH20 (3), HVvsH200 (4), and CVvsHV (7), as well as comparison 5. Image generated using MetaCore™ from Thomson Reuters.
1, endothelin-1, and vimentin, changes in which signal epithelial-to-mesenchymal or mesenchymal-to-epithelial transitions in hepatocytes (Figure 16). Other differentially regulated targets in this category, including Frizzled, bone morphogenic protein 2 (BMP-2, a TGFβ-family member), Kruppel-like factors 10/11 (KLF-10, KLF-11: TGFβ-inducible growth regulators) and ID-1/2 (inhibitor of DNA binding) are components of multiple development and differentiation pathways such as WNT (Frizzled), Hedgehog (BMP2), TGFβ (BMP2, TIEG), and Hippo (ID-1/2). Alterations in cell identity that accompany EMT are classically associated with neoplastic liver disease, however there is evidence to link alterations in Hedgehog, TGFβ, WNT, and Hippo signaling to the progression of steatohepatitis and fibrosis.
Figure 16. Claudin-1 and e-cadherin pathways related to EMT.

PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of signaling pathways related to epithelial to mesenchymal transition. The cell adhesion molecules claudin-1 and e-cadherin were differentially regulated in all or most conditions CVvsC20 (1), CVvsC200 (2), a HVvsH20 (3), HVvsH200 (4), C20vsH20 (5), C200vsH200 (6) and CVvsHV (7). Image generated using MetaCore™ from Thomson Reuters.
CHAPTER TWO: DISCUSSION

PCB exposure induced transcriptional changes in mouse liver, and higher PCB exposure substantially increased the number of genes differentially transcribed compared to lower PCB exposure in the absence of dietary coexposure, the pathway characteristics of which are summarized in Figure 17. The addition of HFD as a coexposure greatly affected the number of differentially transcribed genes produced by PCB exposure: increasing the number and changing the distribution of engaged pathways. HFD itself produces many transcriptional changes in mouse liver, as have previously been described. PCB exposure modulates this effect, resulting in sets of differentially transcribed genes which overlap substantially. In the CVvsC20 comparison, nutritional and metabolic disease biomarkers were over-represented, and along with cardiovascular and vascular disease categories (also metabolic syndrome components), occupied five of the top ten most enriched categories in this group. It is interesting that these indicators were enriched in regular defined diet-fed animals exposed to PCBs, and that the difference between vehicle and moderate PCB exposure was lost in HFD coexposure. This suggests that PCB and HFD exposure may converge on pathways regulating nutritional homeostasis, and that PCBs may contribute to metabolic dysregulation even in the absence of HFD.

With or without HFD coexposure, exposure to PCBs at 200 mg/kg increases enrichment in biomarkers of neoplastic disease. This is consistent with findings in previously reported rodent toxicity studies. Cancer outcomes have been a historic focus of PCB research, mainly due to the presence of dioxins and dioxin-like PCBs and dibenzofurans within the exposure mixture. Dioxins are potent carcinogens in mice, and have been classified as human carcinogens. Other than a recently reported increased prevalence of liver cancer among male Yusho (but not Yucheng)
Figure 17. Summary of transcriptional differences between groups.
victims, however, the evidence linking PCB to cancer in humans has been underwhelming. Interestingly, other than ovarian neoplasms in the HVvsH20 comparison, neoplastic disease categories were not in the top 10 disease enrichments by biomarker for either of the moderate exposure groups.

Our 20 mg/kg PCB exposure was based on the highest serum PCB level reported in the Anniston population, which itself has a mean several times higher than that of the US average. The moderate PCB dose, therefore, is more representative of environmentally-relevant human exposures, and we find that the distribution of diseases in these enrichments reflects this. Our analysis of the differential transcriptomes produced by liver tissue in these experiments in some ways recapitulated the proteomic and metabolic phenotype assessments. Within the HVvsH20 comparison, however, the most highly enriched disease category was IL-6 signaling (Table 45 and Figures 11-12). This is consistent with the findings of Wahlang et al., which indicated that the increased liver injury observed in the HVvsH20 model was not due to increased steatosis, but due to increased inflammation. Increases in serum IL6 and tPAI1 protein were observed in the HFD/moderate exposure. In our transcriptomic analysis of liver tissue, pathways involving hepatocyte acute-phase response triggered by IL6 were observed in the moderate exposure (comparison HVvsH20).

We also saw enrichment in pathways and processes associated with control of circadian rhythm and rhythmic processes with moderate PCB exposure. Interestingly, in a 2015 report using metabolic cages to carry out metabolic phenotyping on PCB-exposed mice, our laboratory showed increased movement during the light (typical sleep) cycle in transgenic mice chronically exposed to 20mg/kg Aroclor 1260. These differences were observed only in mice with ablated constitutive androstane receptor (CAR) or pregnane and xenobiotic receptor (PXR), with a nonsignificant increase in wild-type mice. HFD feeding alone has been reported to alter the oscillatory patterns of circadian rhythm output genes in wild-type mice (Nampt, Acss2/ACSA-downreg in all CDvsHFD comparisons, Cyp2a5), but not the core clock genes, which are more resistant to reprogramming by nutritional challenge. We also found differences in the
transcription of clock output genes with HFD and HFD/PCB coexposure, but with moderate PCB exposure alone, we saw differences in transcription of the core clock genes as well, suggesting that PCB exposure and nutritional coexposures may impact these systems by different and potentially interacting mechanisms.

Although neoplastic disease biomarkers may not be captured by enrichment analysis in more realistic models of human environmental exposure, processes such as cell adhesion, cell-cell communication, and pathways dictating cell identity changes through the processes of development and remodeling are over-represented in these models. The liver has extraordinary regenerative potential requiring plasticity in development and differentiation pathways even in adult hepatic tissue. Multiple pathways involved in development as well as repair were engaged in these models, including TGF-beta signaling, Wnt/β-Catenin signaling, Hedgehog signaling, and Hippo signaling. Because these pathways are involved in development and regeneration, they also share common processes related to cell identity, orientation, and cell-cell recognition. Although pathway analysis shows engagement of these pathways in our animal model of environmental liver disease, it is unclear whether this engagement indicates regenerative response to ongoing PCB/HFD-dependent liver damage or modulation of basal or HFD-driven liver regeneration through xenobiotic receptor mediated PCB effect.

Responses to endogenous and exogenous organic compounds were over-represented among engaged processes both in the presence and absence of HFD coexposure. Responses to xenobiotics are thought to be mediated by xenobiotic receptors, of which AhR, PXR, and CAR are the prototypical example. In addition, xenobiotic receptors may also be activated by endogenous molecules, and crosstalk at multiple levels with receptors transducing hormone and metabolite sensing to control of intermediary metabolic processes. Among the direct transcriptional targets of these receptors with defined relationships curated by MetaCore™, few were differentially regulated, however, MetaCore™ software does not offer a comprehensive database of interactions for these receptors, and even some prototypical transcriptional effects of receptor-target interactions, such as Mus musculus PXR transcriptional activation of Cyp3a11, are not among the curated dataset. Canonical prototypical targets of PXR, including Cyp3a11,
were up-regulated in the CVvsC20 condition. Alternative pathway analysis tools may offer more insight into the direct transcriptional effects of xenobiotic receptors in this model. It is interesting to note, however, that transcription factors which directly interact with and are inhibited by PXR showed a pattern consistent with increased engagement in the moderate exposure compared to the high exposures. Since these protein-protein interactions are ligand-dependent, it suggests that PXR (and potentially other xenobiotic receptors) may indeed be engaged, and that the mechanism of their effect in PCB-associated liver injury requires further study.

In summary, our RNAseq and subsequent pathway analysis of liver tissue from an animal model of PCB/HFD coexposure revealed several transcriptional changes which may be related to the observed phenotypic differences between groups. In particular, the enrichments in nutritional disease terms observed in the control diet animals exposed to PCBs may explain some of the differences in glucose handling which were previously reported for this experiment. Enrichments in IL-6 signaling with the moderate PCB/HFD coexposure may explain the increased histological evidence of liver injury observed only in this condition, while differential transcription affecting pathways involved in development and regeneration, as well as cell adhesion and cell-cell recognition may provide some insight into differences in regenerative/fibrotic processes observed in the animal model.
CHAPTER THREE

PCB EXPOSURE INDUCES A DIFFERENTIAL TRANSCRIPTOME WHICH PARTIALLY OVERLAPS WITH THAT OF PROTOTYPICAL XENOBIOTIC RECEPTOR LIGANDS IN A MOUSE PRIMARY HEPATOCYTE MODEL

Xenobiotic receptors are transcription factors which allow an organism to respond to chemical changes in the environment with appropriate metabolic adaptations. Although these changes are often circumscribed in the literature as encounters with environmental toxicants, it is important to recognize that xenobiotic receptors often respond to endobiotic signals as well, and are intimately involved in intermediary metabolism and inter-tissue communication along with the metabolism of xenobiotics. Even the arylhydrocarbon receptor (AhR), a classic focus of xenobiotic and toxicant research, affects hormonal signaling pathways and the metabolic products of gut commensals. It is not surprising, therefore, that AhR and other xenobiotic receptors such as the pregnane and xenobiotic receptor (PXR) and the constitutive androstane receptor (CAR), have been implicated in metabolic derangements associated with toxicant exposures. Such derangements may manifest clinically and experimentally as components of metabolic syndrome, including steatohepatitis.

Nuclear receptors including PXR, CAR, farnesoid X receptor (FXR) and the liver X receptor (LXR) are known to cross-talk at multiple levels, from common ligands, binding partners, and cofactors to conserved response elements characterized by a DR4 or other shared motifs. This last intersection is most intriguing because while PXR and CAR are known to be sensors and effectors in xenobiotic metabolism, induction of the sterol-sensor LXR and the bile acid receptor FXR directly induce lipogenic gene targets, a phenomenon which is known to be modulated by CAR, PXR, and AhR. LXR induction, particularly as an off-target effect of
pharmacotherapy, has been shown to lead to nonalcoholic fatty liver disease (NAFLD)\textsuperscript{154}.

Considering the interplay of these factors, it is not surprising that PXR, CAR, and LXR have been implicated along with the AhR in toxicant-associated steatohepatitis.

A further degree of complexity arises when we consider the effects of toxicant mixtures such as PCBs, which can be expected to affect several of these sensors simultaneously. PCBs are always encountered and bioaccumulated as mixtures of congeners, and persist at detectable levels in the serum of every adult in the United States\textsuperscript{37}. The distribution of congeners found in the adipose tissue and serum of humans contains species which are known to modulate the activity of AhR, PXR, CAR\textsuperscript{19, 34, 35, 155} and other receptors, and may, through crosstalking pathways, affect the transcriptional function of LXR. Because each of these receptors modulates gene targets related to steatohepatitis, an understanding of the contribution of each of these transcription factors to the overall PCB-modified transcriptome would assist with both risk assessment and the rational development of therapies.

Other groups have elucidated the subsets of the transcriptome modulated by AhR, PXR, and CAR individually in response to prototypical ligands. Findings have been intriguing for several reasons. Both in vivo and in vitro experiments suggest that for both AhR and PXR, differential transcription of target genes appears to be ligand-specific\textsuperscript{156}. Additionally, for primary hepatocytes, variations in cell isolation and culture techniques including culture time and plating substrate may drastically affect the expression levels of prototypical targets of AhR, CAR and PXR. In light of this, we sought to consolidate our assessment into a single primary murine hepatocyte model, examining the relationships between prototypical ligand responses and response to PCBs using RNAseq. We further sought to evaluate the PCB-dependent transcriptional output of this model for components of metabolic pathways related to steatosis and for gene ontology (GO) term enrichments within hepatic and metabolic disease categories.
CHAPTER THREE: MATERIALS AND METHODS

Animals and primary cell isolation procedure

Male C57BL6 mice 8-10 weeks of age were purchased from Jackson Labs and allowed to acclimate for 1 week on a defined control diet (Harlan Teklad Cat TD.06416). Mice were deeply anesthetized with ketamine/xylazine, and the liver was flushed by retrograde perfusion first with a washing solution for 6 minutes, then with a buffered collagenase solution for 10 minutes. After perfusion, the liver was isolated and the gallbladder removed in a dish of ice-cold FBS-supplemented Waymouth’s media. The liver was finely minced and the resulting suspension filtered through a 70 µm cell strainer. Cells were immediately centrifuged, washed twice with ice cold HBSS, and selected by density gradient centrifugation. The cell pellet was then resuspended in cold, supplemented Waymouth’s media, and viability and cell count were determined. Cells were plated on collagen-coated 12-well plates and allowed to adhere.

Adherent cells were exposed for 6 hours to 4 µl/well vehicle (DMSO) or test substance solubilized in DMSO: Aroclor 1260 at 5 µg/ml or a prototypical ligand for mPXR – summarized in Table 58 (10 µM pregnane carboxynitrile, PCN), mCAR (10 µM, TCPOBOP), LXR (1 µM GW3965 hydrochloride, GW) or AhR (50 µM benzathracene, BA). After exposure, media was removed and RNA was isolated by the RNASat60 manufacturer’s protocol.

RNAseq and gene transcription analysis

RNA samples were multiplexed using sequence barcoding, and sequenced single ended to 75 base pair reads using a NextSeq500 to an approximate read count of 40 million reads per
Table 58

Treatment summary

<table>
<thead>
<tr>
<th>Exposure</th>
<th>Anticipated Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO Control</td>
<td>Control</td>
</tr>
<tr>
<td>Benzanthracene (BA), 50 µM</td>
<td>AhR</td>
</tr>
<tr>
<td>Pregnane Carboxynitrile (PCN), 10µM</td>
<td>mPXR</td>
</tr>
<tr>
<td>GW3965 1µM</td>
<td>LXR</td>
</tr>
<tr>
<td>TCPOBOP µM</td>
<td>mCAR</td>
</tr>
<tr>
<td>Aroclor 1260 (PCB) 5µg/ml</td>
<td>--</td>
</tr>
</tbody>
</table>

Isolated primary mouse hepatocytes were exposed to Aroclor 1260 (a representative PCB mixture) or prototypical ligand for the above anticipated targets for 6h.
sample. The bcl files produced were basecalled using Illumina’s bcl2fastq software. All sequences produced were aligned to the mouse reference genome (GRCm38.83) using the alignment software TopHat, and transcript expression levels were calculated in FPKM units using Cufflinks\textsuperscript{122}. The quantification was guided by transcriptome annotation for the mouse downloaded from NCBI. Records corresponding to both mitochondrial and ribosomal RNA were removed (annotated as transcript\_biotype rRNA or Mt\_tRNA) to improve the accuracy of the transcriptome quantification. Differential analyses (FPKM units averaged from 4 replicates of each test vs. DMSO-treated controls) were performed using CuffDiff.

*Pathway and GO enrichment term analysis*

For each treatment, the fold changes and p-values for each differentially transcribed gene (indexed by Ensembl ID) were uploaded into MetaCore\textsuperscript{TM} (Thompson Reuters) and recognized genes were associated with one or more MetaCore\textsuperscript{TM}-curated network objects. Experiments were analyzed using the MetaCore\textsuperscript{TM} Enrichment Analysis Workflow tool, using a species (*M. musculus*) and tissue (liver) prefilter. With prefilters, the number of tags/genes was reduced to 87 targets (from 119).

*qPCR validation of selected targets:*

Targets for validation were selected based on RNAseq-induced up-regulation and relevance to implicated transcription factors, pathways and disease processes. cDNA was generated using the QuantiTect Reverse Transcription kit (Qiagen #205313) according to manufacturer recommendations. Multiplexed qPCR (target and GAPDH) was carried out on BioRad CFX384 system using the following TaqMan Gene Expression Array probes: Cyp1a2 (Applied Biosystems Mm00487224\_m1/FAM), Cyp3a11 (Applied Biosystems Mm00731567\_m1/FAM), Cyp2b10 (Applied Biosystems Mm01972453\_s1/FAM) and GAPDH (Applied Biosystems, Mm99999915\_g1/VIC).
Aroclor 1260 exposure at 5 μg/mL for 6h induced differential transcription in primary mouse hepatocytes

Under these conditions, 123 targets were significantly differentially transcribed with Aroclor 1260 treatment vs. DMSO control (Figure 18 and Table 59). Among these, 68 were down-regulated (FC > 0.5), with 13 genes showing greater than 1-fold reduction in transcription. Aroclor 1260 exposure resulted in up-regulation (FC < 0.5) of 55 genes, with 3 genes up-regulated more than 1-fold.

In this model, the Aroclor 1260-dependent DTG sets partially overlapped with DTG sets produced by exposure to ligands for AhR, PXR, CAR, and LXR

Of the 123 targets within the PCB-DTG set, 41 (33%) were not shared with the DTG sets produced by the prototypical ligands investigated, as shown in Figure 19. Most (67.5%) of the genes within the PCB-DTG set overlapped with DTG sets produced by prototypical ligands for murine AhR, PXR, CAR, and/or LXR, as shown in Figure 20. The largest areas of overlap as a proportion of the total PCB-DTG set occurred with the PXR agonist PCN (65 targets in common with PCB exposure) and the AhR agonist BA (64 targets in common with PCB exposure). These two prototypical ligands produced by far the largest differential transcriptomes: 672 and 720 total DTGs, respectively, and the proportion of these transcriptomes which were also modulated by PCBs was relatively small (9.7% and 8.9%, respectively). The smallest area of overlap occurred between PCB and GW3960, a specific inducer of LXR, with only 14 targets differentially transcribed under both conditions. Although the direct murine CAR agonist TCPOBOP produced
Figure 18. Histograms of differential transcriptomes produced by PCB/prototypical ligand exposure.

The differential transcriptome produced by Aroclor 1260 exposure in this model included both up-regulated and downregulated targets, with fold changes ranging from -3.73 to +1.3 (Panel A). Differential transcriptome FC ranges for prototypical ligands are shown in Panels B-E.
<table>
<thead>
<tr>
<th>Ensembl ID</th>
<th>Name</th>
<th>FC</th>
<th>Ensembl ID</th>
<th>Name</th>
<th>FC</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000026442</td>
<td>Nfasc</td>
<td>-3.73</td>
<td>ENSMUSG00000035171</td>
<td>Plin5</td>
<td>-0.61</td>
</tr>
<tr>
<td>ENSMUSG00000002489</td>
<td>Tiam1</td>
<td>-2.51</td>
<td>ENSMUSG00000011305</td>
<td>Gm19589</td>
<td>-0.59</td>
</tr>
<tr>
<td>ENSMUSG00000076434</td>
<td>Wfdc3</td>
<td>-2.45</td>
<td>ENSMUSG000000100798</td>
<td>Gm19619</td>
<td>-0.59</td>
</tr>
<tr>
<td>ENSMUSG00000034780</td>
<td>B3gal1</td>
<td>-1.81</td>
<td>ENSMUSG00000036941</td>
<td>Elac1</td>
<td>-0.56</td>
</tr>
<tr>
<td>ENSMUSG00000032315</td>
<td>Cyp1a1</td>
<td>-1.78</td>
<td>ENSMUSG00000045502</td>
<td>Hcar2</td>
<td>-0.53</td>
</tr>
<tr>
<td>ENSMUSG00000084923</td>
<td>Gm15611</td>
<td>-1.57</td>
<td>ENSMUSG00000028088</td>
<td>Fmo5</td>
<td>-0.53</td>
</tr>
<tr>
<td>ENSMUSG00000069919</td>
<td>Hba-a1</td>
<td>-1.47</td>
<td>ENSMUSG00000035202</td>
<td>Lars2</td>
<td>-0.52</td>
</tr>
<tr>
<td>ENSMUSG00000038156</td>
<td>Spon1</td>
<td>-1.43</td>
<td>ENSMUSG00000032310</td>
<td>Cyp1a2</td>
<td>-0.52</td>
</tr>
<tr>
<td>ENSMUSG00000032315</td>
<td>Cyp1a1</td>
<td>-1.43</td>
<td>ENSMUSG00000036941</td>
<td>Elac1</td>
<td>-0.56</td>
</tr>
<tr>
<td>ENSMUSG00000032315</td>
<td>Cyp1a1</td>
<td>-1.43</td>
<td>ENSMUSG00000036941</td>
<td>Elac1</td>
<td>-0.56</td>
</tr>
<tr>
<td>ENSMUSG00000032315</td>
<td>Cyp1a1</td>
<td>-1.43</td>
<td>ENSMUSG00000036941</td>
<td>Elac1</td>
<td>-0.56</td>
</tr>
<tr>
<td>ENSMUSG00000032315</td>
<td>Cyp1a1</td>
<td>-1.43</td>
<td>ENSMUSG00000036941</td>
<td>Elac1</td>
<td>-0.56</td>
</tr>
<tr>
<td>ENSMUSG00000032315</td>
<td>Cyp1a1</td>
<td>-1.43</td>
<td>ENSMUSG00000036941</td>
<td>Elac1</td>
<td>-0.56</td>
</tr>
</tbody>
</table>
Table 59 (Continued)

<table>
<thead>
<tr>
<th>Ensembl ID</th>
<th>Name</th>
<th>FC</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000078952</td>
<td>Lincenc1</td>
<td>0.65</td>
</tr>
<tr>
<td>ENSMUSG00000044134</td>
<td>Fam109a</td>
<td>0.65</td>
</tr>
<tr>
<td>ENSMUSG0000024912</td>
<td>Fosl1</td>
<td>0.66</td>
</tr>
<tr>
<td>ENSMUSG0000068299</td>
<td>1700019G17Rik</td>
<td>0.67</td>
</tr>
<tr>
<td>ENSMUSG0000078650</td>
<td>G6pc</td>
<td>0.68</td>
</tr>
<tr>
<td>ENSMUSG0000051439</td>
<td>Cd14</td>
<td>0.70</td>
</tr>
<tr>
<td>ENSMUSG0000022218</td>
<td>Tgm1</td>
<td>0.71</td>
</tr>
<tr>
<td>ENSMUSG0000017002</td>
<td>Slpi</td>
<td>0.71</td>
</tr>
<tr>
<td>ENSMUSG0000018774</td>
<td>Cd68</td>
<td>0.75</td>
</tr>
<tr>
<td>ENSMUSG0000020607</td>
<td>Fam84a</td>
<td>0.76</td>
</tr>
<tr>
<td>ENSMUSG0000041836</td>
<td>Ptpre</td>
<td>0.77</td>
</tr>
<tr>
<td>ENSMUSG0000026728</td>
<td>Vim</td>
<td>0.77</td>
</tr>
<tr>
<td>ENSMUSG0000063531</td>
<td>Sema3e</td>
<td>0.77</td>
</tr>
<tr>
<td>ENSMUSG0000056515</td>
<td>Rab31</td>
<td>0.84</td>
</tr>
<tr>
<td>ENSMUSG0000097073</td>
<td>9430037G07Rik</td>
<td>0.85</td>
</tr>
<tr>
<td>ENSMUSG0000097879</td>
<td>Gm26869</td>
<td>0.85</td>
</tr>
<tr>
<td>ENSMUSG0000046733</td>
<td>Gprc5a</td>
<td>0.89</td>
</tr>
<tr>
<td>ENSMUSG0000032643</td>
<td>Fhl3</td>
<td>0.91</td>
</tr>
<tr>
<td>ENSMUSG0000075707</td>
<td>Dio3</td>
<td>0.92</td>
</tr>
<tr>
<td>ENSMUSG0000029304</td>
<td>Spp1</td>
<td>0.93</td>
</tr>
<tr>
<td>ENSMUSG0000024803</td>
<td>Ankrd1</td>
<td>1.09</td>
</tr>
<tr>
<td>ENSMUSG0000037239</td>
<td>Spred3</td>
<td>1.31</td>
</tr>
<tr>
<td>ENSMUSG0000029188</td>
<td>Sic34a2</td>
<td>1.34</td>
</tr>
</tbody>
</table>

Gene targets differentially regulated with Aroclor 1260 exposure are shown. FC = fold change compared to DMSO control.
Figure 19. Venn diagram showing the overlapping differentially transcribed gene sets between PCB and prototypical ligand exposures.

Aroclor 1260 (PCB) exposure resulted in differential transcription of 41 (33.3%) targets not attributable to ligand-activated transcription by any of the other four transcription factors investigated. This uniquely regulated section of the PCB-dependent transcriptome included unique of CREB1, SP1, and c-Myc. Several of the differentially transcribed targets, including SOX-4, Ptpre (Receptor-type Protein Tyrosine Phosphatase epsilon) and Sik-1 (salt-inducible kinase 1) are implicated in regulation of hepatic intermediary metabolism.
Figure 20. A portion of the PCB-DTG overlapped with DTGs for AhR, PXR, CAR, and LXR prototypical ligands. The differential transcriptome produced by Aroclor 1260 (PCB) exposure in this model overlapped with the differential transcriptome produced by each of the 4 prototypical ligands studied. The largest differentially-transcribed gene (DTG) sets were produced by A. pregnane carboxynitrile (PCN), a pregnane and xenobiotic receptor agonist and B. Benzanthracene (BA), an arylhydrocarbon receptor agonist. These two prototypical ligands also produced the largest areas of overlap with PCB exposure (65 and 64 common DTGs, respectively). Two other prototypical ligands produced smaller total DTG sets. C. GW3965, a LXR agonist, produced a total differential transcriptome of 78 genes, 14 of which were also affected by PCB exposure. D. TCPOBOP, a direct constitutive androstane receptor (CAR) agonist, caused differential transcription of the smallest number of total genes (56), 20 of which were shared with PCB exposure. PCB exposure regulated a larger proportion of the total CAR differential transcriptome, however, than any other prototypical ligand studied (36%, vs 8% of BA-DTGs, 9% of PCN-DTGs, and 18% of LXR-DTGs).
the smallest differential transcriptome (56 targets), 20 targets within this set were also targets of
differential regulation by Aroclor 1260 exposure.

The direction of change in these common DTGs varied between treatment with Aroclor
and prototypical ligands, but agreed with the direction of PXR and AhR differential transcription in
most cases, as expected (Table 60), with more shared targets down-regulated than up-regulated.
Of the 65 targets shared between PCB and PCN, 87.7% agreed in direction. Exceptions included
the gene target Usp18, which was moderately up-regulated in the PXR prototypical ligand
condition and down-regulated with both Aroclor 1260 treatment and CAR prototypical ligand
treatment. Of the 64 targets shared between PCB and BA, 85.9% agreed in direction. The six
genes up-regulated with BA and down-regulated with Aroclor 1260 were all differentially regulated
by at least one other transcription factor, and in fact, two of the three DTGs common to all 5
conditions were represented in this group (Cyp1a1 and Lars2). DTGs shared between
GW3965/PCB and TCPOBOP/PCB included both up-regulated and down-regulated targets. In
both cases, the up-regulated target sets were entirely concordant (6/6 for GW3965 and 10/10 for
TCPOBOP, concurrently up-regulated/shared). 87.5% of genes were concordantly down-
regulated between GW3965 and PCB, while only half of the shared targets of TCPOBOP down-
regulated with PCB exposure agreed in direction. Although a tremendous amount of overlap
existed between the conditions investigated, we were surprised to find that 41 DTGs (33.3%)
were unique to Aroclor exposure and are not shared with other prototypical ligand treatment
(Figure 19 and Appendix Table 1), with 21 up-regulated and 20 down-regulated.

As expected, exposure to each of the prototypical ligands resulted in up-regulation of the
 corresponding prototypical target (Table 61). With Aroclor 1260 exposure, however, no
significantly different transcription occurred (vs. DMSO control) in any prototypical target other
than Cyp1a2, which was significantly down-regulated. This finding validates previous reports that
while PCB exposure leads to induction of CAR, PXR, AhR and LXR prototypical targets in vivo\textsuperscript{23},
these effects are not recapitulated in vitro.
Table 60

Concordance in direction of differential transcription between PCB-DTGs and Protot

<table>
<thead>
<tr>
<th>Ligand</th>
<th>Total up</th>
<th>Total down</th>
<th>Total concordance (%)</th>
</tr>
</thead>
</table>
| PCB-DTG | 20 | 14 | 65%
| GW39965 | 9 | 1 | 90.9%
| PCN | 6 | 7 | 72.0%
| BA | 3 | 2 | 60.0%

Concordance in direction of differential transcription between PCB-DTGs and prototypical ligands. Of the targets shared between PCB exposure and each prototypical ligand, most showed concordance in direction of regulation. Numerically, the largest gap in concordance existed between the 25 shared targets of Aroclor 1260 and PCN which were upregulated by Aroclor 1260 exposure, 18 of these were also upregulated by PCN and 7 were downregulated by PCN, resulting in an overall concordance of 72%. As a percentage, the largest gap in concordance existed between the 10 shared targets of Aroclor 1260 and TCPOBOP and downregulated by Aroclor 1260 exposure, 8 of these were also upregulated by PCN and 7 were downregulated by PCN which were upregulated by Aroclor 1260 exposure. Only half these targets (5) were also upregulated by TCPOBOP.
<table>
<thead>
<tr>
<th>Target</th>
<th>BA</th>
<th>PCN</th>
<th>TCPOBOP</th>
<th>Aroclor 1260</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyp1a2</td>
<td>1.25</td>
<td>-1.10</td>
<td>0.89</td>
<td>-0.52</td>
</tr>
<tr>
<td>Cyp3a11</td>
<td>0.41</td>
<td>0.970</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyp2b10</td>
<td></td>
<td></td>
<td>2.54</td>
<td></td>
</tr>
</tbody>
</table>

Fold induction of prototypical targets for AhR, PXR, and CAR with prototypical ligand exposure is shown.

As expected, exposure to each prototypical ligand induced upregulation of the corresponding prototypical targets (shown in bold). Exposure to Aroclor 1260 did not result in significant change in any prototypical target except for Cyp1a2 (AhR target), which was downregulated.
Aroclor1260 differentially transcribed genes are significantly enriched in pathway maps involved in cell identity and development, and in GO terms related to liver, endocrine, and metabolic disease

Initial output of in silico analysis using the MetaCore™ Enrichment analysis workflow identified 9 pathway maps significantly (FDR < .05) over-represented in the Aroclor1260 differentially transcribed gene set, shown in Table 62. Within these pathways, network objects related to differentiation or epithelial to mesenchymal transition (EMT) were enriched, particularly E-cadherin, vimentin, and claudin-1, which appeared separately or together in half of the top 10 enriched pathways. Pathways related to EMT were enriched for the PCB-DTG members. Figure 21 illustrates elements of this pathway.

Components of the PCB-DTG set were enriched in GO terms related to liver (31/4260 curated network objects, p = 6.0 E-05, FDR = 4.7 E-04), pancreatic (27/3463 curated network objects, p = 6.8e-5, FDR = 5.2 e-4) and metabolic (29/3584 curated network objects, p = 1.6 e-5, FDR = 2.0 e-4) disease biomarkers. Within these sets, E-cadherin, vimentin and claudin-1 figured prominently, as did HB-EGF, AMACR, and osteopontin.

Aroclor1260 DTGs contain known or putative targets of transcription factors with known involvement in fatty liver disease and metabolic dysfunction. Transcription factor analysis of Aroclor 1260 indicated that large subsets of the PCB-DTGs set were predicted to be influenced by specific transcription factors including CREB-1, SP-1 and cMyc. Nuclear receptors such as HNF4-α and PPAR-γ, with known roles in steatosis and steatohepatitis, were also found to modulate the transcription of targets within this set. Significantly overconnected transcription factors are listed in Table 63. Notably, several of these transcription factors are direct or downstream targets of EGFR activation.
<table>
<thead>
<tr>
<th>Pathway Description</th>
<th>p-value</th>
<th>FDR</th>
<th>Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development: WNT signaling pathway</td>
<td>4.315E-03</td>
<td>3.64E-02</td>
<td>E-cadherin, Vimentin, Claudin-1</td>
</tr>
<tr>
<td>Role of cell adhesion in vaso-occlusion in Sickle cell disease</td>
<td>1.37E-03</td>
<td>3.45E-02</td>
<td>CD63, Thrombospondin, Claudin-1</td>
</tr>
<tr>
<td>Development: TGF-beta-dependent induction of EMT via SMAD5</td>
<td>7.52E-03</td>
<td>2.35E-02</td>
<td>E-cadherin, Vimentin, Claudin-1</td>
</tr>
<tr>
<td>Development: TGF-beta-dependent induction of EMT via RhoA, PK and ILK</td>
<td>1.67E-03</td>
<td>2.34E-02</td>
<td>E-cadherin, Vimentin, Claudin-1</td>
</tr>
<tr>
<td>Development: TGF-beta-dependent induction of EMT via MAPK</td>
<td>1.74E-03</td>
<td>2.35E-02</td>
<td>E-cadherin, Vimentin, Claudin-1</td>
</tr>
<tr>
<td>Neurophysiological process: Receptor-mediated axon growth regulation</td>
<td>3.91E-03</td>
<td>2.34E-02</td>
<td>CD63, Histon H2, Histon H3, Histon H1</td>
</tr>
<tr>
<td>Bone disease</td>
<td>2.46E-03</td>
<td>2.34E-02</td>
<td>Histone H2, Histone H3, Histon H1</td>
</tr>
<tr>
<td>Vimentin, Claudin-1, Cingulin</td>
<td>3.29E-03</td>
<td>2.34E-02</td>
<td>Histone H2, CD63, Histone H1</td>
</tr>
<tr>
<td>Development: WNT signaling pathway, Part 2</td>
<td>1.52E-03</td>
<td>2.34E-02</td>
<td>E-cadherin, Vimentin, Claudin-1, Fra-1</td>
</tr>
</tbody>
</table>

**Table 62:** Enriched pathways for PCB-DTG set.
Figure 21. Pathways related to EMT were enriched in genes in the PCB-DTG set. The cell adhesion molecules claudin-1 and E-cadherin, as well as vimentin were important components of this pathway as well as others related to cell differentiation and tissue regeneration pathways. Image generated using MetaCore™ from Thomson Reuters.
### Table 63

Transcription factors with targets in the PCB-dependent differentially-transcribed gene set

<table>
<thead>
<tr>
<th>Network</th>
<th>Seed nodes</th>
<th>p-Value</th>
<th>zScore</th>
</tr>
</thead>
<tbody>
<tr>
<td>CREB1</td>
<td>33</td>
<td>3.050E-105</td>
<td>212.83</td>
</tr>
<tr>
<td>SP1</td>
<td>23</td>
<td>8.940E-73</td>
<td>176.55</td>
</tr>
<tr>
<td>c-Myc</td>
<td>21</td>
<td>2.420E-66</td>
<td>168.36</td>
</tr>
<tr>
<td>p53</td>
<td>20</td>
<td>3.910E-63</td>
<td>164.12</td>
</tr>
<tr>
<td>C/EBPbeta</td>
<td>19</td>
<td>6.230E-60</td>
<td>159.76</td>
</tr>
<tr>
<td>Androgen receptor</td>
<td>17</td>
<td>1.530E-53</td>
<td>150.68</td>
</tr>
<tr>
<td>c-Jun</td>
<td>15</td>
<td>3.570E-47</td>
<td>141.01</td>
</tr>
<tr>
<td>ESR1 (nuclear)</td>
<td>14</td>
<td>5.360E-44</td>
<td>135.93</td>
</tr>
<tr>
<td>PPAR-gamma</td>
<td>14</td>
<td>5.360E-44</td>
<td>135.93</td>
</tr>
<tr>
<td>HNF4-alpha</td>
<td>14</td>
<td>5.360E-44</td>
<td>135.93</td>
</tr>
<tr>
<td>NANOG</td>
<td>13</td>
<td>7.920E-41</td>
<td>130.65</td>
</tr>
<tr>
<td>C/EBPalpha</td>
<td>13</td>
<td>7.920E-41</td>
<td>130.65</td>
</tr>
<tr>
<td>STAT3</td>
<td>12</td>
<td>1.150E-37</td>
<td>125.15</td>
</tr>
<tr>
<td>HIF1A</td>
<td>12</td>
<td>1.150E-37</td>
<td>125.15</td>
</tr>
<tr>
<td>GATA-3</td>
<td>12</td>
<td>1.150E-37</td>
<td>125.15</td>
</tr>
<tr>
<td>ATF-4</td>
<td>12</td>
<td>1.150E-37</td>
<td>125.15</td>
</tr>
<tr>
<td>c-Fos</td>
<td>11</td>
<td>1.660E-34</td>
<td>119.4</td>
</tr>
<tr>
<td>RelA (p65 NF-kB subunit)</td>
<td>11</td>
<td>1.660E-34</td>
<td>119.4</td>
</tr>
<tr>
<td>Bcl-6</td>
<td>10</td>
<td>2.340E-31</td>
<td>113.37</td>
</tr>
<tr>
<td>SMAD3</td>
<td>10</td>
<td>2.340E-31</td>
<td>113.37</td>
</tr>
<tr>
<td>VDR</td>
<td>10</td>
<td>2.340E-31</td>
<td>113.37</td>
</tr>
<tr>
<td>IRF1</td>
<td>10</td>
<td>2.340E-31</td>
<td>113.37</td>
</tr>
<tr>
<td>SMAD2</td>
<td>10</td>
<td>2.340E-31</td>
<td>113.37</td>
</tr>
<tr>
<td>Oct-3/4</td>
<td>10</td>
<td>2.340E-31</td>
<td>113.37</td>
</tr>
<tr>
<td>JunD</td>
<td>9</td>
<td>3.250E-28</td>
<td>107.02</td>
</tr>
<tr>
<td>GCR</td>
<td>9</td>
<td>3.250E-28</td>
<td>107.02</td>
</tr>
<tr>
<td>FKHR</td>
<td>9</td>
<td>3.250E-28</td>
<td>107.02</td>
</tr>
<tr>
<td>PPAR-alpha</td>
<td>8</td>
<td>4.430E-25</td>
<td>100.27</td>
</tr>
<tr>
<td>TCF7L2 (TCF4)</td>
<td>8</td>
<td>4.430E-25</td>
<td>100.27</td>
</tr>
<tr>
<td>p63</td>
<td>8</td>
<td>4.430E-25</td>
<td>100.27</td>
</tr>
</tbody>
</table>

Transcription regulation pathway analysis was performed on the PCB-DTG dataset without prefilters.
CHAPTER THREE: DISCUSSION

Classically, the transcriptional effects of PCB exposure have been attributed entirely to ligand-dependent activation of AhR, PXR and CAR. We expected that the subset of genes differentially transcribed with Aroclor1260 exposure in this acute primary hepatocyte model would overlap almost entirely with the transcriptional output of prototypical ligands for these three receptors. We were therefore surprised to discover that fully 1/3 of DTGs were unique to Aroclor1260 in this system, possibly due to the transcriptional effects of another xenobiotic receptor or by an indirect mechanism. Our laboratory has recently reported that EGFR is also a target of inhibition by both Aroclor1260 and individual PCB congeners. PCBs therefore would be expected to function as an indirect CAR activator in both mice and humans by the same mechanism as phenobarbital\textsuperscript{21}. 

The canonical cytochrome P450 targets of CAR and PXR activation cyp2b10 and cyp3a11 did not appear among the RNA-seq derived PCB-DTG gene set, while cyp1a1 and cyp1a2 (prototypical targets of AhR induction) were both down-regulated in the PCB-DTG set. Interestingly, cyp1a1 and cyp1a2 were also down-regulated by PCN treatment in this model. Regulation of cyp1a1 was particularly complex: up-regulated by inducers of CAR and LXR as well as AhR and down-regulated by PXR induction. We conclude that differential regulation of the proportion of PCB-DTGs overlapping with targets of the evaluated receptors is complex and may be influenced by the combined effects of these and other xenobiotic receptors.

The targets most strongly up-regulated with Aroclor 1260 exposure, slc34a2 (+1.34-fold vs. control) and spred3 (+1.31-fold vs. control) were uniquely up-regulated by PCBs in this model. Although slc34a2 was also a target differentially regulated by PCN exposure, it was down-regulated in that condition and unchanged with exposure to other prototypical ligands. The targets
most strongly down-regulated with Aroclor 1260 exposure, nfasc (-3.73-fold vs. control) Tiam1(-0.51-fold vs. control) and wfdc3 (-2.45-fold vs. control) were also strongly down-regulated by PCN treatment (-4.20, -2.73, and -2.13-fold vs. control, respectively). PXR is involved in differential regulation of transcription related to PCB exposure, however, it seems more involved in inhibition of these targets than induction.

Several of the genes differentially transcribed with PCB exposure in this model are differentially transcribed in the incidence or progression of liver disease or liver disease biomarkers. Osteopontin (Spp), which was up-regulated with PCB (+0.93-fold vs. control) is up-regulated in NASH fibrosis has been shown to oppose EMT in liver progenitor cells\textsuperscript{157}. Four And A Half LIM Domains 3 (FHL3), which was up-regulated with PCB (+0.91-fold vs. control) affects transcription of tPAI1, a fibrosis biomarker up-regulated in PCB-exposed humans. RAB31, a member RAS Oncogene Family, which was up-regulated with PCB (+0.84-fold vs. control), is associated with invasive/metastatic characteristics and worse prognosis in HCC\textsuperscript{158}. Semaphorin 3E (Sema3e), which was up-regulated in PCB exposure (+0.77 vs. control) is expressed by damaged hepatocytes and secreted, inducing contraction of sinusoidal epithelial cells and activation of stellate cells. Chronic exposure to Semaphorin 3E in a mouse model of CCl\textsubscript{4}-induced chronic heptatitis lead to disorganized sinusoidal regeneration and exacerbated fibrosis\textsuperscript{159}. Cytochrome P450 1a1 (Cyp1a1), which was down-regulated (-1.78-fold vs. control) is a prototypical target of the arylhydrocarbon receptor and is up-regulated in animal models of TCDD-induced nonalcoholic steatohepatitis\textsuperscript{160}. Interestingly, in this model, although it was up-regulated by prototypical ligands of LXR and CAR in addition to AhR, it was strongly down-regulated by PXR ligand exposure. Carboxyesterase 2 (Ces2b), which was down-regulated in our model (-1.41-fold vs. control), and in the livers of NASH patients. Experimental ablation of Ces2b in a mouse model causes ER stress in hepatocytes and stimulates lipogenesis in an SREBP-1-dependent manner\textsuperscript{161}. Aldo-keto reductase family 1, member B7 (Akr1b7), which was down-regulated in our model (-0.90-fold vs. control) is enriched in adipose stromal vascular fraction, but not in mature adipocytes. In a mouse model, Akr1b7 KO increased basal adiposity (adipocyte
hyperplasia and hypertrophy) with diet-independent development of liver steatosis and insulin resistance.\textsuperscript{162} Hemochromatosis, type 2 (Hfe2), which was down-regulated in our model (-0.83 vs. control), is expressed at significantly lower levels in NAFLD patients vs. those with no disease. Because Hfe2 is involved in iron-sensing pathways, it is hypothesized that lower levels of Hfe2 are related to the dysregulated iron-sensing pathways leading to iron overload in NAFLD.\textsuperscript{163} Thrombospondin-1 (Thbs1), was up-regulated in our model (+0.64 vs. control). Transcription of Thrombospondin-1 is increased in individuals with chronic liver disease and in mouse models of liver fibrosis.\textsuperscript{164} Interleukin 33 (Il33) was up-regulated in our model (+0.62 vs. control), and is elevated in the serum of NASH patients, increasing with increasing histologic severity.\textsuperscript{165}

Several of the genes differentially transcribed with PCB exposure in this model affect pathways of interest. Sprouty-related protein with EVH-domain 3 (Spred-3), which was up-regulated with PCB (+1.31-fold vs. control) potently inhibits ERK1/2 signaling\textsuperscript{166, 167}. Four And A Half LIM Domains 3 (FHL3) physically interacts with SMAD proteins (TGFβ) pathway.\textsuperscript{168} RAB31 is associated with modulation of EGFR trafficking. It physically interacts with EGFR and its overexpression increases early-late endosome trafficking and degradation of EGFR.\textsuperscript{169, 170} T lymphoma invasion and metastasis 1 (Tiam1), which is strongly down-regulated with PCB (-2.51-fold vs. control) is differentially regulated in hepatocellular carcinoma and pancreatic cancer tissues.\textsuperscript{171, 172} In pancreatic cancers, the Par3 interacts with Tiam1 to affect tight junctions by downregulating Claudin-1 and Occludin.\textsuperscript{172} Tiam1 is also a target suppressed by several miRNAs.\textsuperscript{173, 174} Sustained ectopic exposure to Sema3E (up-regulated by PCB exposure in this model) has been found to result in disorganized regeneration of liver sinusoids, contributing to fibrosis, in a mouse model of liver regeneration.\textsuperscript{159} SRY (sex determining region Y)-box 4 (Sox-4), was down-regulated with PCB exposure in our model (-1.17-fold vs. control). In HepG2 cells, inhibition of Sox-4 blocks caspase-1-dependent apoptosis.\textsuperscript{175} Glutathione S-transferase, mu 3 (Gstm3), which was down-regulated with PCB exposure in our model (-1.10-fold vs. control) is involved in glutathione-dependent clearance of xenobiotics (Phase II metabolism).\textsuperscript{176} Protein Tyrosine Phosphatase, Receptor Type E (Ptpre) was up-regulated with PCB exposure, and functions to modulate insulin signaling in hepatocytes and skeletal muscle by suppressing
phosphorylation of targets down-stream of insulin signaling such as Akt, ERK and GSK3.\textsuperscript{177}

Porcupine homologue (Porcn), which was down-regulated (-0.89-fold vs. control) is an ER protein essential for the processing of Wnt proteins, and its inhibition inhibits Wnt signaling.\textsuperscript{178}

Lastly, several of the genes differentially transcribed with PCB exposure in this model are affected by pathways of interest. Na\textsuperscript{+}-P\textsubscript{i} Cotransporter NaPi-IIb is regulated by glucocorticoid, estrogen, EGF, aging,\textsuperscript{179} dietary phosphate status, hormones like parathyroid hormone, 1,25-OH2 vitamin D3 or FGF2\textsuperscript{180}. Expression of Gstm is induced by wnt/β-catenin activation and inhibited with Ras activation.\textsuperscript{181} Aldo-keto reductase family 1, member B7 (Akr1b7) is induced in the liver by activation of FXR\textsuperscript{182} CAR, PXR, and LXR via direct interaction with DR4 elements in the promoter, and that the influence of PXR/LXR is additive.\textsuperscript{183}

The MetaCore\textsuperscript{TM} curated GO processes most significantly enriched in genes affected by Aroclor 1260 exposure included several recurring objects with roles in Wnt signaling, cell adhesion and/or EMT: pathways which are altered in the progression of fatty liver disease\textsuperscript{184}. Of these, up-regulation of Claudin-1 was unique to Aroclor 1260 exposure and although more than one prototypical ligand induced differential expression of E-cadherin (PCN and BA), it was up-regulated only with PCB exposure. Vimentin, in contrast, was up-regulated with PCN and TCPOBOP as well as PCB exposure. Importantly, EMT in hepatocytes is characterized by a decrease in E-cadherin and claudin-1, corresponding to increased inhibition by SNAIL/SLUG signaling down-stream of TGFβ. EMT in hepatocytes is characterized by decreases in E-cadherin and claudin-1, and increased Vimentin, however, with PCB exposure, we saw increases in expression of both epithelial (E-cadherin and Claudin-1) biomarkers, along with increased Vimentin (a mesenchymal biomarker). Although decreases in expression are associated with mesenchymal change, exogenously expressed Claudin-1 promotes the acquisition of mesenchymal characteristics in hepatocellular carcinoma\textsuperscript{185}. Decreased Claudin-1 and E-cadherin in Increases in Claudin-1 expression characterize HUVEC cells undergoing differentiation to endodermal and hepatic stages.\textsuperscript{186}

In the context of liver damage and regeneration, the designation of “epithelial” or “mesenchymal” refers not to the inflexible characteristic of lineage (origin) but rather, the plastic
cellular organization and metabolic commitments underlying tissue-level function\textsuperscript{167}. Epithelial cells are characterized by tight cell-cell contacts and apico-basal polarity. In epithelioid adult liver parenchymal cells, (hepatocytes and cholangiocytes), these characteristics are critical to their function as a selectively permeable, transformative metabolic layer receiving input from enterohepatic circulation (sinusoidal/basolateral) and contributing modified output to systemic circulation and the biliary system (cannalicular/apical). The levels, ratio, and distribution of claudins, members of the main transmembrane protein family forming hepatocyte intercellular tight junctions form the structural underpinning of this polarity/permeability, and so define specific identity and function of the cell.

In contrast, traits associated with mesenchymal cells include a lack or loss of polarity and loss or differential organization of the protein architecture required to maintain cell-cell and cell-ECM contacts. A transition from epithelial to mesenchymal or mesenchymal to epithelial qualities involves the gradual loss of characteristic markers of one state and gain of markers characteristic of the other, with transitioning cells often expressing some of each. In this case, high E-cadherin and claudin would be indicative of epithelioid character, while Vimentin is typically a mesenchymal marker\textsuperscript{140}.

In summary, in primary hepatocytes, differential transcription induced by PCB exposure cannot be completely explained by direct ligand-induced transcriptional activity of the AhR, PXR, or CAR by congeners within the Aroclor 1260 mixture. This is surprising, considering the vast amount of research that has focused on these three receptors as mediators of PCB effect. AhR and PXR had the largest areas of overlap, however, the direction of differential transcription was often opposite between Aroclor 1260 DTGs and the DTGs produced by treatment with these prototypical ligands, particularly PXR. LXR, which is unlikely to be bound by congeners within the mixture, is likely to crosstalk with PXR and CAR at the level of chromatin binding, as it recognizes the same DR-4 motif response element. LXR is often implicated as a key transcription factor involved in the development of steatosis leading to steatohepatitis, however, transcriptional changes due to direct ligand activation of LXR did not have a large overlap with the Aroclor 1260-dependent differential transcriptome either. We conclude from the information in this model that
other transcription factors are likely responsible for a large portion of the transcriptional changes observed with PCB exposure.

Transcription factors that appear to be involved in PCB-dependent transcription are often directly or indirectly influenced by EGFR-mediated cell signaling via phosphorylation, consistent with our recent report that PCBs inhibit EGFR signaling\textsuperscript{20}. MetaCore\textsuperscript{TM} pathway analysis of the PCB-DTG set indicated enrichment in biomarkers associated with liver disease, and components pathways known to be involved in the progression of fatty liver disease. Targets uniquely modified by PCB exposure in this model include markers of epithelioid character and hepatocyte polarity, as well as ECM modifiers. Together, these suggest that at least some of the diseases associated with PCB exposure are due to differential transcription mediated by one or more receptors. More work is needed to determine the relevance of engaged pathways suggested by this preliminary investigation.
CONCLUSIONS

The study of human disease related to environmental exposures requires a multidisciplinary approach unique in biomedical research. It requires a balance between overly reductionist approaches that ignore poorly understood pathways and massive, non-mechanistic association studies which muddy the waters and yield unapproachable data. The experimental approaches to PCB research suffer from both problems, resulting in a body of literature that is measured “by the pound, not by the page”\textsuperscript{39}: a massive body of exposure data with mechanistic assumptions based on changes to one or two transcriptional targets of one or two xenobiotic receptors. The overall result of this status is that even 80 years after publication of the first paper linking PCB exposure to human disease, the mechanisms of PCB-related diseases are poorly understood.

The Cave laboratory began with a study of the people exposed to PCBs – every adult in the US population, represented by the massive, cross-sectional National Health and Nutrition Evaluation Survey, or NHANES. That study demonstrated that PCBs are ubiquitous and associated with liver injury in the general population\textsuperscript{37}. A logical next step was then an epidemiological evaluation of liver disease in a population with a relatively high exposure to environmental PCBs – that of Anniston, Alabama, already under investigation to determine whether PCB exposure was associated with multiple metabolic diseases.

Both the positive and negative findings of our study were striking and novel – although nonalcoholic fatty liver disease in Anniston was clearly elevated compared to expected prevalence in the general US and worldwide population, the mechanistic biomarkers employed showed that the overall level of the PCB exposure represented by the sum of all congeners was
not correlated with the severity of liver injury or inclusion in a liver disease category in the overall population.

We considered two potential reasons for this observation which were not mutually exclusive. First, the Anniston population represents a complex, but not atypical, exposure situation, which was one of the acknowledged limitations of the study. Chemical exposures alone included not only PCBs, but also heavy metals and pesticides, many of which are associated with liver or metabolic disease\textsuperscript{37, 121, 188}, while nutritional coexposures inferred from the high prevalence of obesity/overweight in this population could contribute independently to fatty liver disease. A second possibility is that, like other endocrine/metabolism-disrupting chemical exposures\textsuperscript{189}, increasing PCB dose could result in a nonmonotonic dose-response (NMDR) with respect to damage biomarkers – not steadily increasing or decreasing with increasing exposure concentration. At the cellular level, differential engagement of crosstalking mechanisms may result in different output at different exposures. At the organismal level, PCB effects on multiple systems must be considered: suppressive effects on inflammatory pathways could lead to higher overall liver damage indicators at a lower exposure level, interference with circadian control could contribute to hyperphagy and decreased energy expenditure, while effects on hormonal signaling could communication between concerted systems. For this last consideration, nutritional coexposures play a role as well: direct effects of PCBs to reduce insulin output could limit the compensatory role of the pancreas in glucose allostasis, putting more stress on connected systems including the liver.

The animal study previously reported by Wahlang \textit{et al.}\textsuperscript{23} was an attempt to disambiguate the effects of PCB exposure level and nutritional coexposure in an animal model of chronic PCB/HFD coexposure. We integrated our epidemiological study with our animal model by comparing serology and phenotype in both studies. The condition represented by animals coexposed to HFD and moderate PCBs (20 mg/kg) was designed to most closely model the Anniston exposure, and, indeed, the phenotype of animals within this condition approximated the findings in Anniston with respect to physical characteristics of metabolic syndrome and
serological evidence of liver injury, inflammation, and metabolic dysfunction. The exposure to higher levels of PCBs in this animal model did not result in additional histological evidence of liver injury, suggesting that it was possible to observe nonmonotonic dose responses to PCBs with respect to serological biomarkers of liver injury.

One of the major findings of the Wahlang et al. study was that Aroclor 1260 exposure contributed to liver injury not by exacerbating steatosis, but by increasing inflammation, particularly in the HVvsH20 model. Our original hypothesis was that, at higher levels of Aroclor 1260 exposure, the concentration of trace dioxin-like PCBs within the mixture would reach a “tipping point” that would quell immune response in our inflammation-primed HFD-fed mice. Previous reports suggested that the ED50 for Aroclor 1260 immunotoxicity (in mice) was 360 mg/kg, still higher than our highest in vivo dose. We saw differences in the moderate vs. high dose with regards to transcriptional output of IL-6→JAK→STAT-3 signaling, which plays a role in chronic inflammation.

Inflammatory response is a process that is both context-modulated and dynamic, involving initiation and resolution processes that confound a simple understanding of “pro-inflammatory” and “anti-inflammatory” signaling molecules. IL-6, which is produced by many cell types, including hepatocytes and Kupffer cells (liver-resident macrophages), is often categorized as a “pro-inflammatory” cytokine, and was elevated in both the ACHS cohort and in the in vivo moderate dose + HFD. Certainly, IL-6 is elevated in inflammation and has down-stream effects that promote inflammation; on the other hand, IL-6 has distinctly “anti-inflammatory” effects in the liver as well, particularly to oppose exaggerated cytokine release from neighboring Kupffer cells.

Components of IL-6 signaling pathways were more enriched in the moderate PCB/HFD model (Figure 22). IL-6 signaling mediators down-stream of STAT-3 transcriptional regulation leading to cell differentiation pathways (cFos and cJun – 1.23-fold and 0.64-fold increased, respectively), were also affected with the high PCB exposures (cJun only: 0.80-fold, p=0.00005 and 1.15-fold, p=0.00005 in the high PCB exposure with HFD and CD, respectively). Another group of STAT-3 targets with PCB-dependent transcriptional changes were the suppressors of cytokine signaling (SOCS2 and SOCS3 – 1.10-fold and 0.71-fold increased, respectively in the
Figure 22. Exposure to PCB with or without HFD coexposure alters transcription of multiple components of IL-6 signaling. The red circles correspond to targets differentially regulated in a comparison between 0 and 20mg/kg Aroclor 1260 within the control diet group while the black circles correspond to targets differentially regulated in a comparison between control and HFD within the Aroclor 1260 20mg/kg group.
SOCS3 is an important player in the attenuation of IL-6-mediated STAT-3 signaling. Potently up-regulated by active STAT-3, SOCS3 binds to and inhibits JAK2/gp130 kinases, which couple IL-6 to STAT-3 signaling. SOCS3 also independently contributes to hepatic insulin resistance and metabolic dysfunction by binding to and inhibiting both insulin receptor and its down-stream mediator IRS-1 and well as leptin receptor.

SOCS3 was only up-regulated in the moderate PCB/HFD exposure, while in the high PCB/HFD exposure, SOCS2 was up-regulated as well (0.71-fold, p=0.00005).

In addition to transcriptional changes downstream of STAT-3 signaling, the HFD/moderate exposure animals had decreased transcription of IL-6 receptor alpha (IL-6Rα: -0.67-fold, p=0.0000). IL-6Rα plays an important role in mechanisms contributing to chronic STAT-3 activation and related metabolic dysfunction and chronic inflammation. Of interest is the relationship between IL-6Rα and EGFR. Independent of EGF activation, EGFR forms a complex with both IL6Rα and STAT-3 in a mechanism which potentiates STAT-3 phosphorylation even in the presence of SOCS-3. EGFR/IL-6Rα-mediated STAT-3 activation contributes to chronic IL-6 expression by hepatocytes. Expression of EGFR itself was down-regulated in HFD alone (-0.85-fold, p=0.0027), but was up-regulated in both the moderate and high PCB + HFD exposures (1.15-fold, p=0.00005 and 0.78-fold, p=0.0011, respectively). If protein levels were similarly affected, this might represent a mechanism by which PCBs and HFD contribute to chronic IL-6 release. Alternatively, liver-specific knockout of IL-6Rα has been shown to enhance the release of IL-6 and TNFα from Kupffer cells (liver-specific tissue-resident macrophages), preventing the IL-6-mediated down-regulation of these cytokines. Abrogation of this receptor in liver parenchymal cells also reduces insulin-stimulated glucose uptake in white adipose tissue and skeletal muscle, contributing to systemic insulin resistance. Therefore, by altering IL-6 signaling within hepatocytes, PCBs may affect not only the transduction of inflammatory signals in the liver, but also signals coordinating metabolic response between tissues. Future studies may be able to pinpoint whether PCB-mediated EGFR/IL-6Rα/STAT-3 perpetuation of STAT-3 signaling and/or IL-6Rα inhibition contribute to systemic IL-6 elevation, which has been associated with T2DM and many other metabolic diseases.
Another factor contributing to increased systemic IL-6 may be hyaluronic acid, an extracellular matrix protein which was significantly increased with PCB exposure in sera from the ACHS-II cohort. Hyaluronic acid binds and stabilizes extracellular IL-6, resulting in increased serum protein levels without affecting IL-6 mRNA transcription. Multiple factors contributing to high chronic systemic IL-6 may therefore represent a self-sustaining system by which PCBs exacerbate pre-existing metabolic dysfunction. Chronic IL-6 elevation may also represent a point of convergence for liver injury mechanisms, agreeing well with the “multiple-hits hypothesis”.

PCB exposure did not contribute to increased steatosis in our animal model beyond the effects of HFD, nevertheless, genes encoding elements of hepatic lipid processing were differentially transcribed in the exposure models relative to vehicle-treated controls on the same diet. Key events regulating the development of steatosis include increased fatty acid uptake, increased lipid synthesis, decreased fatty acid oxidation, and decreased lipid efflux.

Transcription of CD36, a FA uptake receptor, was up-regulated in high-exposure/control diet (0.74, p=0.0004) and with HFD alone (CVvsHV: 0.57-fold, p=0.00185), and was down-regulated in both moderate exposure models (CVvsC20: -0.75-fold, p=0.00045, and HVvsH20: -0.89-fold, p=0.00005). Transcription of long-chain acyl-CoA synthetase 4 (ACSL4), involved in lipid synthesis, was down-regulated in high-exposure/control diet (-0.47-fold, p=0.00315) as in HFD alone (-0.91-fold, p=0.00005), but was up-regulated in moderate exposure/HFD (1.05-fold, p=0.00005). These patterns do not suggest a consistent increase in pro-steatotic molecular changes, which would be consistent with the observation that Aroclor 1260 exposure (particularly at the moderate dose) did not worsen steatosis. They do, however, suggest that PCB exposure at both high and low levels affects cellular events which can alter hepatocellular lipid flux, and, moreover, PCB exposure affects the components of those events which are known to be influenced by nuclear receptor-driven transcriptional changes.

The classically understood function of xenobiotic receptors is to respond to the presence of chemical ligands by heterodimerizing with RXR (nuclear receptors) or ARNT (AhR), translocating to the nucleus, and binding response elements in the promoters of their respective cytochrome p450 oxidase targets. A more nuanced understanding includes the association of
unliganded receptors with specific binding partners in a corepressor complex and liganded receptors with coactivators. In addition to ligand-binding, post-translational modifications such as phosphorylation, acetylation, and sumoylation can change the receptor's protein-protein associations, adding tremendous range to both the direct and indirect transcriptional targets affected by xenobiotic sensing. This provides a compelling mechanism by which the changing chemical environment can shape the pattern of physiological metabolism.

Just as multiple systems create a dynamic balance by shifting chemical pressures, rhythmic metabolic processes affected by the central or peripheral circadian clock alter metabolic tides in response to temporal cues. An exploration of PCB effects on the suprachiasmatic nucleus (SCN) which regulates the central clock is beyond the scope of this work, however, the behavioral changes in our mouse model described in Chapter 2 (anachronistically increased movement during typical sleep cycles in transgenic mice chronically exposed to 20mg/kg Aroclor 1260) are most likely a manifestation of central clock alterations. In peripheral tissues including the liver, however, oscillations in the transcription of specific gene sets create feedback loops which reinforce the periodic cycling within those tissues. Importantly, the challenge of nutritional stress – HFD\textsuperscript{136} or time-restricted\textsuperscript{135} feeding – can uncouple the peripheral circadian clock from the central, leading to differential temporal expression of targets of timekeeping transcription factors (CLOCK and BMAL1) as well as new oscillations of previously non-cycling gene targets of transcription factors such as PPAR\textsubscript{γ}\textsuperscript{136}.

It is not now known whether the behavioral changes seen in our transgenic mouse model were a direct effect of PCBs on the SCN neurons or a product of peripheral PCB effect feeding back by some mechanism to reprogram the central clock. Studies investigating the effects of dietary stresses on circadian cycling have indicated that while peripheral tissues are reprogrammed by nutritional challenge, the SCN central pacemaker remains unaffected. However, these studies have also reported changes to the clock output genes (Per1/2 and Cry1/2 isoforms) without changes to expression of the core clock genes (Clock and Bmal1). In our in vivo experiment, we observed changes in both clock output and core clock genes under multiple conditions (Table 64). Differential transcription of Clock, however, was unique to the moderate
Table 64

Differentially transcribed circadian-rhythm related targets from *in vivo* and *in vitro* experiments

<table>
<thead>
<tr>
<th></th>
<th>In vivo</th>
<th>In vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HFD vs CD</td>
<td>FC vs. CD/V</td>
</tr>
<tr>
<td>Core Clock Genes</td>
<td></td>
<td>C20</td>
</tr>
<tr>
<td>Clock</td>
<td>0.77</td>
<td></td>
</tr>
<tr>
<td>Bmal1</td>
<td>2.19</td>
<td>1.04</td>
</tr>
<tr>
<td>Clock output Genes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cry1</td>
<td>-0.73</td>
<td>0.48</td>
</tr>
<tr>
<td>Per1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per2</td>
<td>-1.39</td>
<td>-0.74</td>
</tr>
<tr>
<td>Selected Clock-associated genes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melatonin receptor 1A</td>
<td>2.80</td>
<td>1.51</td>
</tr>
<tr>
<td>ROR-g</td>
<td>-0.74</td>
<td>0.88</td>
</tr>
<tr>
<td>TrkB</td>
<td>0.66</td>
<td>-1.28</td>
</tr>
</tbody>
</table>

Table 64 shows fold changes for the comparisons listed above. Targets are grouped by their relationship to circadian rhythm control machinery (core clock genes, clock output genes, or clock-associated genes). Numbers are fold change *vs.* the indicated control, *p*<.05. Blank fields were not significantly different in the listed comparison.
PCB/control diet condition, however, where it was up-regulated compared to vehicle/control diet (0.77-fold, p=0.00005). Our in vitro experiment did not indicate differential regulation of clock-related genes with Aroclor 1260 exposure, but did indicate down-regulation of one core clock gene (Bmal1) with PCN or BA, and down-regulation of one clock output gene (Cry2) with PCN exposure. The direction of fold change was again opposite from any of the in vivo conditions in which these genes were differentially transcribed.

The mechanism by which PCBs affect the transcription of peripheral circadian rhythm machinery is unclear from our in vivo or in vitro experiments, although there exists no shortage of potential interactions between elements of these processes and xenobiotic receptors. BMAL1, also known as the arylhydrocarbon receptor nuclear translocator-like (ARNTL), and CLO CK are PAS-domain proteins which readily associate with AhR, and their regulation of Per1 has been shown to be disrupted by AhR activity in response to TCDD\textsuperscript{196}. In addition, the hepatocyte-specific cyclic AMP responsive element-binding protein (CREBH) is a transcription factor with transcriptional activity controlling the rhythmic expression of hepatic triglyceride and fatty acid metabolic targets via its associations with PPAR\(\alpha\) and LXR\(\alpha\)\textsuperscript{131}, which crosstalk with xenobiotic nuclear receptors as previously described. The processes leading to circadian activation of CREBH are controlled by BMAL1 via GSK3\(\beta/\)AKT pathways\textsuperscript{131}. Other isoforms of CREB physically interact with and are inhibited by PXR (Figure 13).\textsuperscript{197}

A clear limitation of the experiment in this area is the lack of tissue harvest timepoints designed to capture oscillations in transcription at multiple timepoints. Harvest was carried out only during the light cycle and over a period of approximately 8 hours. Future studies to explore PCB effect in this area could be modeled on the methods of Eckel-Mahan et al.\textsuperscript{136}, to capture potential PCB exposure-related shifts in the temporal expression of normally cyclic or normally acyclic hepatic genes.

A final pattern observed in the enrichment analyses of both the in vivo and in vitro study was that of cell adhesion and related cell-cell communications apparatus. Components of ephrin signaling were highly differentially expressed between conditions. Ephrin receptors are part of a large class of receptor tyrosine kinases which form bi-directional communication complexes...
between cells. Ephrins and ephrin receptors are well-studied in the context of cytoskeletal remodeling during neuronal path-finding and development, and, importantly, play a role in adhesion and communication between cells of the same or different types, including monocytes and endothelial cells. The ephrin signaling system consists of two classes of receptor (A and B, based on sequence homology and corresponding to structural characteristics) which respond to ligands produced by neighboring cells. Both receptor and ligand are generally membrane-bound, facilitating communication between cells that are in physical contact, however, there is evidence that some ligands, specifically Ephrin A1, can be shed as soluble ligands to affect cells over longer distances. In the ephrin signaling system, signal transduction in the direction of the receptor is described as forward-signaling and signal transduction in the direction of the ligand is described as reverse signaling. Ephrin-A/EphA forward signaling affects many of the pathways activated by other RTKs, including IGF-1-activated Ras-Erk, and may inhibit or activate these cascades in a cell-type specific manner.

In our experimental models, both ephrin receptors and ephrin ligands were differentially regulated under some or all conditions (Figures 23-25). Interestingly, Ephrin A1 (Efna1) was significantly up-regulated in every in vivo comparison except moderate PCB/control diet exposure as well as in vitro PCB exposure, and was one of the targets which was uniquely regulated in PCB exposure (Figure 23). Ephrin A5 (Efna5), another ligand, was also up-regulated in all HFD-exposed groups and and upon exposure to 200 mg/kg PCB with CD (Figure 24). Ephrin A3 (Efna3) was strongly up-regulated only in the moderate PCB/HFD coexposure (3.85-fold, p=0.00095), and was otherwise not significantly different from vehicle/CD. Ephrin receptor B2 was differentially regulated under all conditions (Figure 25).

Differential expression of ephrin receptors and ligands is associated with pro-inflammatory states and changes in inflammatory cytokines in multiple tissue. Expression of EphA2 (receptor) and Ephrin A1 (ligand) have been shown to increase in lung tissue after LPS exposure, and posttreatment with mAb against EphA2 receptor reduces lung injury and permeability in LPS-exposed animals, as well as the production of pro-inflammatory cytokines (IL1β, MIP-2).
Fig. 23. Ephrin ligand A1 (Efna1) was differentially regulated in multiple comparisons. The vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads (FPKM) for each condition, with significant differences indicated by bridging lines. Panel A shows the respective aggregate FPKM for six in vivo conditions, while Panel B shows the same for the in vitro experiment, with exposure to Aroclor 1260 and PCN shown. Treatment with prototypical ligands for AhR, CAR, and LXR did not induce significant changes in Efna1 expression.
Figure 24. Ephrin ligand A5 (Efna5) was differentially regulated in multiple comparisons. The vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads (FPKM) for each condition, with significant differences indicated by bridging lines.
Figure 25. Ephrin receptor B2 (EphB2) was differentially regulated in multiple comparisons. The vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads (FPKM) for each condition, with significant differences indicated by bridging lines.
Differential expression of ephrin receptors and ligands is also associated with transitions between differentiated (epithelial) and undifferentiated (mesenchymal) cell characteristics. In the context of cancer, it has been observed that overexpression of ephrin receptors tends to favor metastatic characteristics (loss of adhesion), while overexpression of ligand tends to favor increased cell adhesion\textsuperscript{203}. To that effect, EphA2 was found to be overexpressed in neoplastic cells, and the distribution changed from clustered localization of EphA2 at sites of cell-cell contacts to either a diffuse pattern or concentration in the leading edge of migrating cells\textsuperscript{204}. This loss of localization at sites of stable cell-cell contacts led to decreased ligand-dependent phosphorylation of EphA2, because the membrane-bound Ephrin-A ligands also localize at these sites. E-cadherin forms homodimers with E-cadherin in adjacent cells to mediate highly stable calcium-dependent cell adhesion foci, and E-cadherin function in these cell-cell junctions is necessary to prevent decreased phosphorylation of EphA2. Given the role of ephrin receptors and ligands in cytoskeletal remodeling during growth and development as well as regeneration, development, especially with the sequential events necessary for cells to form properly oriented relationships with one another. In all PCB exposures, both in vivo and in vitro, the expression of adhesion proteins such as Claudin-1 and E-Cadherin was up-regulated vs. untreated control. Most literature describing changes to these proteins in the context of liver disease deals with their importance as biomarkers of cell identity during periods of physiological or pathological change: development, regeneration, and neoplasia. Up-regulation of these proteins is associated with a more terminally differentiated, epithelioid cell, but in the larger context, expression of these proteins is necessary for proper orientation of cells relative to one another within the larger tissue structure.

Ephrin signaling is important in other tissues which participate in metabolic allostasis. For instance, pancreatic beta cells employ ephrin signaling to synchronize release of insulin in response to glucose, using engagement of EphA forward signaling to inhibit insulin secretion and ephrin-A reverse signaling to stimulate insulin secretion\textsuperscript{205}. If expression of Ephrin-A1 is similarly up-regulated in the pancreas as it is in the liver, this may represent another mechanism by which
PCBs and PCB+HFD contribute to the phenotype of reduced serum insulin observed in both Anniston and our mouse model.

Xenobiotic receptors are known to crosstalk with signaling cascades down-stream of tyrosine kinase signaling. Ephrin receptor signaling may crosstalk with regulation of the constitutive androstane receptor in a similar way to EGFR. The receptor for activated c-kinase 1 (RACK-1) associates with ligand-bound, autophosphorylated and active EphB3, forming a complex with PP2A and AKT and promoting the dephosphorylation of AKT at S473\(^{203}\), an event which leads to reduced cell migration as well as apoptosis. Active (dephosphorylated) RACK-1 also facilitates the interaction of CAR with PP2A, an event which is necessary for the nuclear translocation of CAR, the indirect or ligand-independent pathway for CAR activation described by Mutoh \textit{et al.}\(^{21}\). This pathway is critical to PCB research, because it activates CAR via EGFR inhibition, a mechanism which is shared by phenobarbital and PCB congeners\(^{20}\). Input into CAR transcriptional activity via ephrin signaling represents a mechanism by which inflammatory status and cell-cell communication status can crosstalk with the output of xenobiotic receptors, providing more nuanced control over adaptive metabolic control. Our in vitro experiment, however, indicated that only one target related to ephrin signaling was differentially regulated by Aroclor 1260 exposure: the Ephrin A ligand Efna1 (Figure 26, Panel B). Interestingly, Efna1 was also differentially regulated in hepatocytes cells exposed to PCN, although in an opposite direction (-0.66-fold, \(p=0.00005\)), which may be another example of the trend of PCB-dependent up-regulation of targets \textit{in vivo} which are negatively regulated by PCN exposure, and presumably PXR activation, \textit{in vitro}. \(^{176}\)

Our combined approach of epidemiological assessment followed by in vivo and in vitro mechanistic exploration has uncovered many interesting relationships between environmental PCB exposure and human disease. While the question of the roles of xenobiotic receptors in PCB-associated fatty liver disease is far from resolved, we have at least pushed the understanding of those roles beyond direct, ligand-activated transcriptional activity of a few (or worse, one), xenobiotic-responsive transcription factor. It is likely that a great many of the effects of PCB-associated TASH are independent of direct effects of CAR, PXR, or AhR. It is equally
likely that input from these receptors is indirectly involved in the pathways and processes modulated by PCB effects. We have described three groups of effects which are related to effects seen in all three of our models: systemic inflammatory dysregulation via IL-6 signalling, disruption of circadian rhythm processes, and modulation of cell adhesion and cell-cell communication via differential expression of E-cadherin/claudin-1 and related ephrin signaling pathways. These effects appear to be directly related to PCB exposure, are strongly involved in and modulated by dietary coexposures, and are likely to affect multiple systems involved in metabolic disease. Simultaneous dysregulation of these systems during PCB exposure could explain the “2-hit” phenomenon, providing a mechanism by which PCB/HFD coexposures could accelerate allostatic overload – crippling the normal adaptive response to metabolic challenge.

Future studies will likely focus on individual components of these effects, and may involve analysis of tissues other than liver. It remains to be determined whether PCB-dependent changes to IL-6 signalling lead to failure of feedback inhibition from hepatocytes to Kupffer cells and subsequent uncontrolled inflammation, or whether the systemic IL-6 elevations seen in Anniston arise from a different tissue – adipose, for instance. Likewise, an assessment of the PCB-dependent changes to circadian signaling require evaluation of PCB-dependent changes to clock output and, more intriguingly, core clock gene transcription not only in peripheral tissues, but in the SCN as well. Exploring the mechanism and effects of the PCB-dependent transcriptional changes to ephrin signaling components and cell adhesion molecules may allow us to determine whether cell-cell communication between hepatocytes, endothelial cells, and/or Kupffer cells are dysregulated in PCB exposure, and whether changes to cell adhesion mediators is indicative of failed regenerative processes which could explain the apparent “chronic necrosis” observed in the Anniston population as well as the increased biomarkers of fibrosis.

As for the activities of the xenobiotic receptors themselves, our in vitro model was interesting from the standpoint that it showed that a substantial portion of the targets differentially transcribed with Aroclor 1260 exposure were not attributable to activation of AhR, PXR, CAR, or LXR. Targets within the set differentially transcribed with Aroclor 1260 exposure were associated with many liver and metabolic disease states, however, in a direct comparison between targets
differentially transcribed with Aroclor 1260 exposure *in vitro* and *in vivo*, there were very few shared between the *in vitro* (Figure 27) and moderate exposure, with far more shared between the *in vitro* and high exposure. Although the *in vitro* experiment used 5 µg/ml Aroclor 1260, a concentration lower than the concentration used to induce activity of human PXR, CAR, and AhR transfected into a HepG2 model luciferase reporter system\textsuperscript{19}, there were more DTGs shared between the *in vitro* and the two high-dose *in vivo* models than the *in vitro* and two moderate-dose *in vivo* models. It is possible, therefore, that 5 µg/ml is still too high to accurately model a relevant environmental exposure in primary hepatocytes. With that in mind, however, targets such as Claudin-1, E-Cadherin, Ephrin-A, and Tribbles-3 pseudokinase were conserved across more than one of the comparisons, suggesting that they may be part of common mechanisms for PCB effect. Because the raw data from the *in vitro* work will be available for further interrogation, it is likely that alternative bioinformatics tools may bring some clarity to the specific roles of these receptors in the observed transcriptional changes. If, instead of direct transactivation PXR, CAR, and/or AhR are involved via protein-protein interactions with other transcription factors, this may be due to a PCB-dependent intracellular milieu that favors specific post-translational modifications and corresponding specific protein associations.

This laboratory set out to investigate the relationship between exposure to PCBs a widespread class of persistent organic pollutant, and steatohepatitis, a widespread manifestation of metabolic disease. Because xenobiotic receptors drive the metabolic machinery responsible for recognizing and detoxifying foreign chemicals, and because of historic attention to the role of one part of this machinery, the cytochrome p450s, in generating carcinogenic metabolites from polycyclic aromatic hydrocarbons\textsuperscript{206} including PCBs, we and others expected to find a central role for these receptors which placed down-stream transcriptional targets as effectors in disease. Although some targets of these receptors are undoubtedly involved in steatohepatitis and other disease states, I find that the evidence from this study suggests a more peripheral role for these xenobiotic receptors in PCB-associated TASH: modulating metabolic responses with the additional information about the presence of toxicants. This makes sense from a standpoint of phenotype: moderate-dose PCBs alone did not induce steatohepatitis in our mouse model, and
**Figure 26.** *In vivo* comparison diagrams. Venn diagrams show the overlapping region between *in vitro* study (white), 20 mg/kg Aroclor 1260 in vivo (red) and 200 mg/kg in vivo (black) on *in vivo* datasets grouped by diet. **Panel A**, control diet, shows a larger proportion of DTGs overlapping between the *in vivo* and high Aroclor. Shared targets include Gstm3, Cldn1, Pim1, Orm3, Trib3, and Akr1b7. In **Panel B**, which shows the overlap with the HFD in vivo exposures, a larger proportion of the DTGs identified in the *in vitro* Aroclor 1260 exposure overlapped with the moderate *in vivo* exposure + high fat diet. Shared targets include Cdh1, Moxd1, Slc10a2, Efna1, Orm3, Rab30, Cyp1a2, Hist1h1c, Rarres1, Ces2b, Akr1b7, Ugt2b37, Orm2, and G6pc.
there is not a clear dose-response relationship between total PCB load or the concentration of a
defined PCB functional grouping and TASH in Anniston. The requirement for co-occurring
metabolic stress would also explain the convergence in phenotype seen in both human
NASH/TASH and in mouse models. PCB exposure appears to change elements of the response
to this metabolic pressure – hepatocyte death mechanism, and inflammatory response, for
instance, or elements of cell-cell signaling and adhesion important in regeneration. Lastly, the
extrahepatic effects of PCBs on the liver cannot be overemphasized. Our human population
showed inappropriate insulin production in response to hyperglycemia, strongly suggesting direct
PCB effects in the pancreas, and a transgenic mouse (CAR-/-) in our laboratory demonstrated
altered circadian patterns in response to PCB. One or both of these effects may involve the
activity of xenobiotic receptors – their role in mediation of PCB effect in extrahepatic tissues is
beyond the scope of this project – however, both effects have the potential to impact the
development of steatohepatitis through effects on other metabolic allostatic machinery. These
studies have strengthened the body of evidence connecting environmental PCB exposures to
toxicant-associated steatohepatitis, have shifted the focus of mechanism from strictly xenobiotic-
receptor-mediated effects, and have pointed to new areas of inquiry we can explore to address
the health effects of PCB exposure in the Anniston population and in all PCB-exposed humans.
REFERENCES


Val1483Ile in FASN gene is linked to central obesity and insulin sensitivity in adult white men, Obesity (Silver Spring) 17, 1755-1761.


progenitors increases with severity of fatty liver damage in mice, *Lab Invest* 87, 1227-1239.


<table>
<thead>
<tr>
<th>ENSEMBL ID</th>
<th>Gene ID</th>
<th>FC_B</th>
<th>FC_C</th>
<th>FC_D</th>
<th>FC_E</th>
<th>FC_F</th>
<th>FC_G</th>
<th>FC_P</th>
<th>FC_T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG0000000032315</td>
<td>CYP1α1</td>
<td>1.77</td>
<td>3.82</td>
<td>1.53</td>
<td>3.43</td>
<td>1.77</td>
<td>3.82</td>
<td>1.53</td>
<td>3.43</td>
<td>1.77</td>
</tr>
<tr>
<td>ENSMUSG000000006434</td>
<td>Wfdc3</td>
<td>2.13</td>
<td>1.60</td>
<td>2.45</td>
<td>1.60</td>
<td>2.45</td>
<td>1.60</td>
<td>2.45</td>
<td>1.60</td>
<td>2.45</td>
</tr>
<tr>
<td>ENSMUSG0000000024889</td>
<td>Tiam1</td>
<td>2.73</td>
<td>2.51</td>
<td>2.73</td>
<td>2.51</td>
<td>2.73</td>
<td>2.51</td>
<td>2.73</td>
<td>2.51</td>
<td>2.73</td>
</tr>
<tr>
<td>ENSMUSG0000000024442</td>
<td>Nasc</td>
<td>3.73</td>
<td>4.20</td>
<td>3.73</td>
<td>4.20</td>
<td>3.73</td>
<td>4.20</td>
<td>3.73</td>
<td>4.20</td>
<td>3.73</td>
</tr>
</tbody>
</table>

**References and Summary:**

- Neurofascin is an L1 family immunoglobulin cell adhesion molecule with multiple IgCAM and fibronectin domains.
- Tiam1 is a target of suppression for miRNA 141 and miRNA 377.
- Wfdc3 regulates calcium
- Tiam1 is a target of suppression for miRNA 141 and miRNA 377.
- Nasc is an L1 family immunoglobulin cell adhesion molecule with multiple IgCAM domains.

**Fold Change and Summary Information:**

Fold change with Aroclor 1260 exposure, compared to fold change with prototypical ligand exposure.
**References and Summary**

Carboxylesterase 2 is downregulated in the livers of NASH patients. Experimental ablation of Ces2b in a mouse model causes ER stress in hepatocytes and stimulates lipogenesis in an SREBP-1-dependent manner.

Pro-inflammatory cytokine signaling can affect expression of carboxylesterases: LPS treatment reduces the expression of human Ces2 and Ces1. Because Ces2 and Ces1 are involved in glutathione-dependent clearance of xenobiotics (Phase II metabolism), reductions in expression can also affect drug metabolism in the liver and in the intestine.

Gremlin 2, DAN Family BMP Antagonist, inhibits BMP2 and BMP4. Upregulated during mucosal regeneration, opposes cell migration in (primary airway) epithelial cells during mucosal regeneration; opposes cell migration in SφRP and BMP4. Upregulated.

**Predicted gene, known lincRNA**

---

The expression of human Ces2 (and Ces1) does not increase with Ras activation.

Exposure of mouse lung after asbestos exposure downregulated in a model of disrupted epithelial migration in (primary airway) epithelial cells during mucosal regeneration; opposes cell migration in SφRP and BMP4. Upregulated.

---

**Gene ID**

- ENSMUSG00000038156
  - Spon1
  - Carboxyesterase 2 is downregulated in the livers of NASH patients.
  - Experimental ablation of Ces2b in a mouse model causes ER stress in hepatocytes and stimulates lipogenesis in an SREBP-1-dependent manner.

- ENSMUSG00000050097
  - Ces2b
  - Carboxyesterase 2 is downregulated in the livers of NASH patients. Experimental ablation of Ces2b in a mouse model causes ER stress in hepatocytes and stimulates lipogenesis in an SREBP-1-dependent manner.

- ENSMUSG00000097461
  - Gm26735
  - Predicted gene, known lincRNA

- ENSMUSG00000076431
  - Sox4
  - SRY (sex determining region Y)-box 4.

- ENSMUSG00000004038
  - Gstm3
  - Glutathione S-transferase, mu 3 is involved in glutathione-dependent clearance of xenobiotics (Phase II metabolism). Expression of Gstm is inhibited with Ras activation.

- ENSMUSG00000050069
  - Grem2
  - Gremlin 2, DAN Family BMP Antagonist, inhibits BMP2 and BMP4. Upregulated during mucosal regeneration, opposes cell migration in (primary airway) epithelial cells during mucosal regeneration; opposes cell migration in SφRP and BMP4. Upregulated.

- ENSMUSG00000004038
  - Gstm3
  - Glutathione S-transferase, mu 3 is involved in glutathione-dependent clearance of xenobiotics (Phase II metabolism). Expression of Gstm is inhibited with Ras activation.

- ENSMUSG00000050069
  - Grem2
  - Gremlin 2, DAN Family BMP Antagonist, inhibits BMP2 and BMP4. Upregulated during mucosal regeneration, opposes cell migration in (primary airway) epithelial cells during mucosal regeneration; opposes cell migration in SφRP and BMP4. Upregulated.

---

**Gene ID**

- ENSMUSG00000038156
  - Spon1
  - Carboxyesterase 2 is downregulated in the livers of NASH patients. Experimental ablation of Ces2b in a mouse model causes ER stress in hepatocytes and stimulates lipogenesis in an SREBP-1-dependent manner.

- ENSMUSG00000050097
  - Ces2b
  - Carboxyesterase 2 is downregulated in the livers of NASH patients. Experimental ablation of Ces2b in a mouse model causes ER stress in hepatocytes and stimulates lipogenesis in an SREBP-1-dependent manner.

- ENSMUSG00000097461
  - Gm26735
  - Predicted gene, known lincRNA

- ENSMUSG00000076431
  - Sox4
  - SRY (sex determining region Y)-box 4.

- ENSMUSG00000004038
  - Gstm3
  - Glutathione S-transferase, mu 3 is involved in glutathione-dependent clearance of xenobiotics (Phase II metabolism). Expression of Gstm is inhibited with Ras activation.

- ENSMUSG00000050069
  - Grem2
  - Gremlin 2, DAN Family BMP Antagonist, inhibits BMP2 and BMP4. Upregulated during mucosal regeneration, opposes cell migration in (primary airway) epithelial cells during mucosal regeneration; opposes cell migration in SφRP and BMP4. Upregulated.
<table>
<thead>
<tr>
<th>ENSEMBL ID</th>
<th>Gene ID</th>
<th>FC_A</th>
<th>FC_B</th>
<th>FC_G</th>
<th>FC_P</th>
<th>FC_T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000041992</td>
<td>Rapgef5</td>
<td>-0.99</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Associated with decreased SMAD1/5/8 protein and increased SMAD2 phosphorylation. Antagonizes BMP4 to affect proximal-distal patterning of the lung during development.</td>
</tr>
<tr>
<td>ENSMUSG00000030909</td>
<td>Anks4b</td>
<td>-0.97</td>
<td>-0.51</td>
<td>0.55</td>
<td></td>
<td></td>
<td>Ankyrin Repeat And Sterile Alpha Motif Domain Containing 4B is a target of HNF4a in pancreatic beta cells, and is decreased in the β-cells of an HNF4a KO mouse model and during HNF4a KD in cell line. HNF4a KD also. It binds to glucose-related protein 78 (GRP78) – an ER chaperone – and enhances ER stress/ER stress-related apoptosis.</td>
</tr>
<tr>
<td>ENSMUSG00000053168</td>
<td>9030619P08Rik</td>
<td>-0.96</td>
<td>-1.02</td>
<td>-1.24</td>
<td></td>
<td></td>
<td>A known transcribed unprocessed pseudogene</td>
</tr>
<tr>
<td>ENSMUSG00000052305</td>
<td>Hbb-bs</td>
<td>-0.96</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hemoglobin Subunit Beta was elevated in the serum of patients with NASH, and increased with increasing severity of disease.</td>
</tr>
<tr>
<td>ENSMUSG00000101206</td>
<td>Gm5266</td>
<td>-0.95</td>
<td>-1.74</td>
<td>-1.14</td>
<td>-0.96</td>
<td></td>
<td>Centromere Protein J is a transcriptional coactivator of NFkB, via synergistic CREB1/p300/NFKB interaction. CENPJ associates with the p65 (RelA) subunit of NFKB. In HCC, CENPJ contributes to TNFa-induced NFKB activation by increasing phosphorylation of p65 and phosphorylation/degradation of IKBα (involved in recruitment of IKK to inactive cytoplasmic NFKB complexes).</td>
</tr>
<tr>
<td>ENSMUSG00000064128</td>
<td>Cenpi or CPAP</td>
<td>-0.92</td>
<td>-1.38</td>
<td>-1.42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000091572</td>
<td>Vmn2r3</td>
<td>-0.92</td>
<td>-0.72</td>
<td>-1.21</td>
<td></td>
<td></td>
<td>Vomeronasal 2, receptor 3</td>
</tr>
<tr>
<td>Ensembl ID</td>
<td>Gene ID</td>
<td>FC_A</td>
<td>FC_B</td>
<td>FC_G</td>
<td>FC_P</td>
<td>FC_T</td>
<td>References and Summary</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------------------------</td>
</tr>
<tr>
<td>ENSMUSG000000041132</td>
<td>N4bp2l1</td>
<td>-0.73</td>
<td>-0.84</td>
<td>-0.84</td>
<td>-0.84</td>
<td>-0.84</td>
<td>associated candidate gene, NED4 binding protein 2-like 2, highyrogen binding protein-like 2, Hhip1-like</td>
</tr>
<tr>
<td>ENSMUSG000000042160</td>
<td>Hhip1</td>
<td>0.48</td>
<td>-0.48</td>
<td>-0.48</td>
<td>-0.48</td>
<td>-0.48</td>
<td>associated candidate gene, Porcupine homologue is an ER protein catalyzes the palmitoylation of Wnt proteins, allowing secretion and activity. Inhibition of Porcn (by LGK974, IWP-1/2, ETC/A<em>STAR1/2, synthetic Porcn inhibitors) used as a chemotherapeutic strategy because it inhibits aberrant Wnt signalling, which is often dysregulated in cancer. ETC/A</em>STAR2, synthetic Porcn inhibitors.</td>
</tr>
<tr>
<td>ENSMUSG000000043116</td>
<td>Porcn</td>
<td>-0.86</td>
<td>-0.86</td>
<td>-0.86</td>
<td>-0.86</td>
<td>-0.86</td>
<td>expression is induced by FXR activation. Inhibition of Porcn by LGK974, IWP-1/2, ETC/A*STAR2, synthetic Porcn inhibitors.</td>
</tr>
<tr>
<td>ENSMUSG000000045234</td>
<td>AK41p7</td>
<td>0.90</td>
<td>1.46</td>
<td>0.74</td>
<td>0.74</td>
<td>0.74</td>
<td>development of liver lesions and insulin resistance. In the liver, Ak41p7 deletion results in a mouse model, Ak41p7 KO increases basal adiposity and hyperglycaemia, decreases insulin sensitivity, and increases body weight. In a diet-induced obese mouse model, Ak41p7 KO increases basal adiposity and hyperglycaemia, decreases insulin sensitivity, and increases body weight.</td>
</tr>
</tbody>
</table>

References and Summary:

- Aldo-keto reductase family 1, member B7 is expressed in oral squamous cell carcinoma.
- GWAS associated candidate gene, Fam47e expression is significantly positively correlated with CKD (is a CKD-risk gene).
- Hhip1, like Hhip1, is a secreted protein with an N-terminal signal peptide, and is expressed in hepatic intercalating protein-like 1, like Hhip1, a secreted protein with an N-terminal signal peptide, and is expressed in hepatic intercalating protein-like 1, like Hhip1, a secreted protein with an N-terminal signal peptide.
- Loss of macrophage-derived Wnt ligands in Porcn-null mice prevents recovery after radiation-induced damage to the intestine.
- A SNP in Hhip1 is linked to coronary artery disease by Mendelian randomization, and is expressed in hepatic intercalating protein-like 1, like Hhip1, a secreted protein with an N-terminal signal peptide, and is expressed in hepatic intercalating protein-like 1, like Hhip1, a secreted protein with an N-terminal signal peptide.
<table>
<thead>
<tr>
<th>ENSEMBL ID</th>
<th>Gene ID</th>
<th>FC_R</th>
<th>FC_G</th>
<th>FC_P</th>
<th>FC_T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000055312</td>
<td>Them7</td>
<td>-0.84</td>
<td>-0.61</td>
<td>-0.64</td>
<td></td>
<td>Thioesterase superfamily member 7 is a member of the Acyl-CoA thioesterase (ACOT) family – enzymes which catalyze the hydrolysis of fatty acyl-CoA molecules and other substrates. This family has roles in control of intracellular FFA (vs fatty acyl-CoA), as well as the production of inflammatory metabolites. Another member of this family, Them1/ACOT11 is differentially regulated in vivo, and contains a C-terminal START domain and binds to StarD14.</td>
</tr>
<tr>
<td>ENSMUSG00000038403</td>
<td>Hfe2</td>
<td>-0.83</td>
<td>-0.57</td>
<td>-0.54</td>
<td></td>
<td>Hemochromatosis type 2 is associated with hepcidin function, and is downregulated in NAFLD possibly as a consequence of impaired hepatic iron sensing, which may contribute to iron accumulation in NAFLD. Hfe expression is also negatively correlated with TNF α expression in patients with NAFLD.</td>
</tr>
<tr>
<td>ENSMUSG00000078612</td>
<td>1700024P16Rik</td>
<td>-0.81</td>
<td>-0.63</td>
<td>-0.66</td>
<td></td>
<td>RIKEN cDNA 1700024P16 gene is protein-coding and of unknown function.</td>
</tr>
<tr>
<td>ENSMUSG00000020000</td>
<td>Moxd1</td>
<td>-0.80</td>
<td>-0.65</td>
<td>-0.65</td>
<td></td>
<td>Monooxygenase, DBH-like 1, is a widely expressed ER protein with copper-binding capabilities. Its expression has been reported to be influenced by insulin and to be associated with NAFLD. The expression is also negatively regulated in NAFLD.</td>
</tr>
<tr>
<td>ENSMUSG00000030107</td>
<td>Usp18</td>
<td>-0.85</td>
<td>-0.57</td>
<td>-0.57</td>
<td></td>
<td>Ubiquitin specific peptidase 1B is an acrolein-phase protein.</td>
</tr>
<tr>
<td>ENSMUSG00000061540</td>
<td>Orm2</td>
<td>-0.83</td>
<td>-0.63</td>
<td>-0.66</td>
<td></td>
<td>Oromuscoid 2 is an acute-phase protein mainly synthesized and secreted by hepatocytes. Its expression is also negatively regulated in NAFLD. Its ectopic expression opposes HCC metastasis. ORM2 is highly expressed in cancerous tissues.</td>
</tr>
<tr>
<td>Gene ID</td>
<td>FC_A</td>
<td>FC_B</td>
<td>FC_G</td>
<td>FC_P</td>
<td>FC_T</td>
<td>References and summary</td>
</tr>
<tr>
<td>------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------------------------</td>
</tr>
<tr>
<td>ENSMUSG00000028359</td>
<td>0.74</td>
<td>0.64</td>
<td>0.75</td>
<td>1.90</td>
<td>-1.58</td>
<td>Solute Carrier Family 41 Member 3 plays a role in magnesium homeostasis in the kidney (distal convoluted tubule) and intestine by functioning as a cation transporter and regulating basolateral Mg(^{2+}) extrusion (into the blood). Expression is increased by low-Mg(^{2+}) diet. Mice with loss of function mutation in this transporter suffer from severe hypomagnesemia (cannot extrude recovered magnesium to blood). Interestingly, individuals on EGFR inhibitors often suffer from hypomagnesemia.</td>
</tr>
<tr>
<td>ENSMUSG00000030089</td>
<td>0.75</td>
<td>0.64</td>
<td>0.75</td>
<td>1.90</td>
<td>-1.58</td>
<td>UDP Glucuronosyltransferase Family 2 Member B37 was a target of SMAD3-dependent transcription inhibition. Ugt2b37 is involved in the metabolism of endogenous compounds (bilirubin, bile acids, fatty acids, cholesterol, fatty acid, sterol, and vitamin D).</td>
</tr>
<tr>
<td>ENSMUSG00000028359</td>
<td>0.74</td>
<td>0.64</td>
<td>0.75</td>
<td>1.90</td>
<td>-1.58</td>
<td>Oromusoid 3, like Oram2, is an acute-phase protein of the immunocalin subfamily: small-molecule-binding proteins that function to modify immune responses and in the clearance of damaged cells. Unlike Oram2, Orcmisid 3 interacts with Oram2, inhibiting its binding to its ligand, IL-10. Orcmisid 3 is expressed in a variety of tissues, including the liver, kidney, and spleen. Expression is increased by LPS challenge. Orcmisid 3 interacts with Oram2 to inhibit its binding to IL-10, leading to decreased IL-10 production. These results suggest that Orcmisid 3 has a role in regulating the inflammatory response.</td>
</tr>
<tr>
<td>Gene ID</td>
<td>ENSMUSG00000022032</td>
<td>Scara5</td>
<td>-0.72</td>
<td>-1.97</td>
<td>-1.34</td>
<td>-0.62</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>Description</td>
<td></td>
<td>Scavenger Receptor Class A Member 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>binds to extracellular ferritin and controls its endocytosis and the capture of its iron.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>References and Summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>ENSMUSG00000063659</th>
<th>Zbtb18</th>
<th>-0.71</th>
<th>-1.10</th>
<th>-0.90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td></td>
<td>Zinc Finger And BTB Domain Containing 18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>encodes a C2H2-type zinc finger protein, a transcriptional repressor of genes involved in neuronal development.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>References and Summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>ENSMUSG00000046027</th>
<th>Stard5</th>
<th>-0.71</th>
<th>-0.61</th>
<th>-0.50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td></td>
<td>Steroidogenic Acute Regulatory - Related Lipid Transfer Domain Containing 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>encodes a cytosolic cholesterol transport protein which is additionally able to bind and transport other sterol-derived lipids such as primary bile acids and 25-hydroxycholesterol.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>References and Summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>ENSMUSG00000032715</th>
<th>Trib3</th>
<th>-0.69</th>
<th>-0.77</th>
<th>-0.85</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td></td>
<td>The tribbles pseudokinase 3 gene (TRIB3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>which is associated with insulin resistance/T2DM, cardiovascular risk, and polycystic ovary syndrome in various human populations.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>References and Summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>ENSMUSG00000022244</th>
<th>Amacr</th>
<th>-0.67</th>
<th>-0.62</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td></td>
<td>Alpha-Methylacyl-CoA Racemase (p504s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>interconverts pristanoyl-CoA and C27-bile acylCoAs from (R)- to (S)-stereoisomers, a necessary step in the degradation of these substrates by peroxisomal beta-oxidation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>References and Summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSEMBL ID</td>
<td>Gene ID</td>
<td>FC_A</td>
<td>FC_B</td>
<td>FC_G</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>ENSMUSG00000020553</td>
<td>Pctp</td>
<td>0.67</td>
<td>1.33</td>
<td>-1.02</td>
</tr>
<tr>
<td>ENSMUSG00000046794</td>
<td>Ppp1r3b</td>
<td>-0.66</td>
<td>-1.59</td>
<td>0.60</td>
</tr>
<tr>
<td>ENSMUSG00000003762</td>
<td>Adck4/COQ8B</td>
<td>-0.65</td>
<td>-1.33</td>
<td>-1.02</td>
</tr>
<tr>
<td>ENSMUSG00000056148</td>
<td>Rdh9</td>
<td>-0.65</td>
<td>0.69</td>
<td>0.60</td>
</tr>
<tr>
<td>Gene ID</td>
<td>FC A</td>
<td>FC B</td>
<td>FC C</td>
<td>FC D</td>
</tr>
<tr>
<td>---------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>ENSMUSG000000031482</td>
<td>-0.65</td>
<td>-0.82</td>
<td>-0.52</td>
<td></td>
</tr>
<tr>
<td>Proline Rich 16 encodes the protein Largen, a factor affecting the translation of specific mRNA. Overexpression causes increased cell size and increased mitochondrial mass. Largen controls cell size independent of Hippo and mTOR pathways.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000030835</td>
<td>-0.64</td>
<td>-0.64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histone Cluster 1 H Family Member C encodes a protein which interacts with DNA to regulate the higher order structure of chromatin.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000036181</td>
<td>-0.64</td>
<td>-0.64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histone Cluster 1 H Family Member C encodes a protein which interacts with DNA to regulate the higher order structure of chromatin.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000033665</td>
<td>-0.65</td>
<td>-0.82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitochondrial transport of ornithine across the mitochondrial inner membrane is mediated by Solute Carrier Family 25 Member 15. Mutation can cause human hyperornithinemia-hyperammonemia-hyperuricemia syndrome.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000031482</td>
<td>-0.46</td>
<td>-0.63</td>
<td>0.90</td>
<td>2.77</td>
</tr>
<tr>
<td>Fibroblast growth factor 21 encodes a starvation-induced hepatokine which functions to increase hepatic insulin sensitivity and upregulate β-oxidation pathways. Serum levels of FGF21 can be used as a biomarker to distinguish preservation-induced hepatic ischemia from NASH. Mice lacking Fgf21 were more likely to develop simple steatosis from NASH-like liver disease.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Homocitrullinuria (HHH) syndrome, an urea cycle defect.

Dopey Family Member 2 encodes a protein involved in morphogenesis and embryonic patterning, which is overexpressed in Down Syndrome and may contribute to developmental defects in the brains of those affected.

Glutathione S-Transferase Mu 2 encodes a protein in the class of enzymes responsible for the detoxification of xenobiotic and endobiotic compounds by conjugation with glutathione. It is upregulated specifically in African-American NASH patients and also shows age- and sex-specific patterns of expression vs. Caucasian NASH patients. Expression of this GST subunit is overexpressed in (mouse) hepatoma cells with activating CTNNB (beta-catenin) mutations, and its perivenous expression preference is driven by beta-catenin. Glutathione S-Transferase Mu 2 is overexpressed in African-American NASH patients of the liver of African-American NASH syndrome. It is differentially expressed in relation to the detoxification of xenobiotic and endobiotic compounds by conjugation with glutathione. S-Transferases are enzymes involved in the detoxification of xenobiotic compounds.

Perilipin 5 encodes a protein involved in hepatic lipid accumulation. It is upregulated in Notch1 KO mice, contributing to metabolic dysfunction, and ablation of Plin5 is protective in MCD-diet-induced steatosis. Ablation of Plin5 is protective in MCD-diet-induced steatosis, contributing to metabolic dysfunction, and ablation of Plin5 is protective in MCD-diet-induced steatosis. Ablation of Plin5 is protective in MCD-diet-induced steatosis, contributing to metabolic dysfunction, and ablation of Plin5 is protective in MCD-diet-induced steatosis. Ablation of Plin5 is protective in MCD-diet-induced steatosis, contributing to metabolic dysfunction, and ablation of Plin5 is protective in MCD-diet-induced steatosis. Ablation of Plin5 is protective in MCD-diet-induced steatosis, contributing to metabolic dysfunction, and ablation of Plin5 is protective in MCD-diet-induced steatosis. Ablation of Plin5 is protective in MCD-diet-induced steatosis, contributing to metabolic dysfunction, and ablation of Plin5 is protective in MCD-diet-induced steatosis. Ablation of Plin5 is protective in MCD-diet-induced steatosis, contributing to metabolic dysfunction, and ablation of Plin5 is protective in MCD-diet-induced steatosis. Ablation of Plin5 is protective in MCD-diet-induced steatosis, contributing to metabolic dysfunction, and ablation of Plin5 is protective in MCD-diet-induced steatosis.
Induction of perilipin 5 is pronounced in hepatocytes of livers with chronic (vs acute) steatosis and the protein localizes to large (macrovesicular) lipid droplets. Hydroxycarboxylic Acid Receptor 2 is one of a family of G-protein-coupled receptors that sense endogenous intermediates of metabolism. It is a high-affinity receptor for nicotinic acid and β-hydroxybutarate. It is stimulated by LPS, and has anti-inflammatory effects. This is a good candidate for exploring the machinery coupling diet to immunomodulation.

Flavin Containing Monooxygenase 5 is a component of xenobiotic detoxification processes. It positively regulates cholesterol biosynthesis. Fmo3 KO mice maintain a lean phenotype during aging with carbohydrate oxidation during the active period. Transcription differed in KO mice - upregulated: HMG-CoA reductase, squalene synthase, and sterol regulatory element-binding protein-2 (SREBP-2) and downregulated: aldolase B, cytosolic malic enzyme, and ER stress-induced enzymes. Induction of perilipin 5 is pronounced in hepatocytes of livers with chronic (vs acute) steatosis and the protein localizes to large (macrovesicular) lipid droplets. Hydroxycarboxylic Acid Receptor 2 is one of a family of G-protein-coupled receptors that sense endogenous intermediates of metabolism. It is a high-affinity receptor for nicotinic acid and β-hydroxybutarate. It is stimulated by LPS, and has anti-inflammatory effects. This is a good candidate for exploring the machinery coupling diet to immunomodulation.
Mitochondrial Leucyl-TRNA Synthetase 2 is a target gene of c-Myc. Genetic variants of Lars2 are associated with Perrault syndrome, a severe multisystem metabolic disorder (hydrops, sideroblastic anemia, lactic acidosis) and (controversially) T2DM.

Cytochrome P450 Family 1 Subfamily A Member 2 encodes a p450 enzyme which catalyzes the oxidation of some polycyclic aromatic hydrocarbons as well as other xenobiotics such as caffeine, aflatoxin B1, and acetaminophen. Its expression is attenuated in NAFLD progression.

Rab30 may interact with LKB1 kinase in the regulation of Golgi apparatus morphology. It is necessary for maintaining Golgi apparatus morphology. Rab30 might transport cholesterol from peroxisomes to the Golgi apparatus, where it is incorporated into the Golgi membrane. Rab30 may interact with IKB kinase in the Golgi apparatus.

The Hop Homeobox protein, which lacks DNA binding capabilities, is a stem cell marker in intestinal epithelial cells, which lacks DNA binding capabilities. It is a downstream effector of FGF10 (during differentiation) and is downregulated by rapamycin. Along with Klf4, it encodes the HOP Homeobox protein.

Rab32 encodes a small GTPase involved in maintaining Golgi apparatus morphology. It is necessary for small GTPases with roles in intercellular RAS oncogene family. It is one of a family of RAS oncogene family. The protein encoded by Rab32, Member Ras Oncogene Family is one of a family of RAS oncogenes involved in cell growth, division, and death. The protein encoded by Rab32, Member Ras Oncogene Family is one of a family of RAS oncogenes involved in cell growth, division, and death.

The protein encoded by Rab30, Member Ras Oncogene Family is one of a family of RAS oncogenes involved in cell growth, division, and death.
vesicle trafficking and localized to the mitochondria and the mitochondrial associated membrane of the ER. Rab32 anchors the type II regulatory subunit of protein kinase A to the mitochondrion and aids in mitochondrial fission. In a mouse model, Rab32 KO resulted in decreased lipid accumulation within the liver.

Rab32 affects lipid accumulation via lipolysis by promoting the transcription of ATGL.

Primary mouse hepatocytes were differentiated into a hepatocyte-like cell line, which is blocked by RU-486 in dexamethasone-induced liver hypertrophy. The gene leads to cholesterinosis, dysfunction in endosomes, and defects in the transcription regulatory program leads to cholesterinosis. Dysfunction in endosomes, and defects in the transcription regulatory program leads to cholesterinosis.
<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC P</th>
<th>FC T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000035671</td>
<td>0.55</td>
<td>0.51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000021998</td>
<td></td>
<td>0.51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000024773</td>
<td></td>
<td>0.52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000016382</td>
<td>0.48</td>
<td>0.41</td>
<td>0.40</td>
<td>0.37</td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000037260</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

- **Gene ID:** ENSMUSG000000035671
- **FC:** 0.55, 0.51
- **References and Summary:**
  - Increase in TJ function.
  - ENGR signaling, resulting in an overall increase in TJ function. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.

---

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC P</th>
<th>FC T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000012428</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

- **Gene ID:** ENSMUSG000000012428
- **FC:** 0.45, 0.49
- **References and Summary:**
  - NF1 expression is regulated by AP-1 and in cholesterol homeostasis, it encodes a bile acid transporter with a role in intercellular tight junctions. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.

---

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC P</th>
<th>FC T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000023073</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

- **Gene ID:** ENSMUSG000000023073
- **FC:** 0.45
- **References and Summary:**
  - NF1 expression is regulated by AP-1 and in cholesterol homeostasis, it encodes a bile acid transporter with a role in intercellular tight junctions. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.
  - NF1 expression is regulated by AP-1 and in cholesterol homeostasis, it encodes a bile acid transporter with a role in intercellular tight junctions. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.

---

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC P</th>
<th>FC T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000021998</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

- **Gene ID:** ENSMUSG000000021998
- **FC:** 0.46, 0.49
- **References and Summary:**
  - NF1 expression is regulated by AP-1 and in cholesterol homeostasis, it encodes a bile acid transporter with a role in intercellular tight junctions. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.

---

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC P</th>
<th>FC T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000021998</td>
<td>0.46</td>
<td>0.49</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

- **Gene ID:** ENSMUSG000000021998
- **FC:** 0.46, 0.49
- **References and Summary:**
  - NF1 expression is regulated by AP-1 and in cholesterol homeostasis, it encodes a bile acid transporter with a role in intercellular tight junctions. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.

---

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC P</th>
<th>FC T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000021998</td>
<td>0.46</td>
<td>0.49</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

- **Gene ID:** ENSMUSG000000021998
- **FC:** 0.46, 0.49
- **References and Summary:**
  - NF1 expression is regulated by AP-1 and in cholesterol homeostasis, it encodes a bile acid transporter with a role in intercellular tight junctions. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.

---

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC P</th>
<th>FC T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000021998</td>
<td>0.46</td>
<td>0.49</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

- **Gene ID:** ENSMUSG000000021998
- **FC:** 0.46, 0.49
- **References and Summary:**
  - NF1 expression is regulated by AP-1 and in cholesterol homeostasis, it encodes a bile acid transporter with a role in intercellular tight junctions. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.

---

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC P</th>
<th>FC T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG000000021998</td>
<td>0.46</td>
<td>0.49</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

- **Gene ID:** ENSMUSG000000021998
- **FC:** 0.46, 0.49
- **References and Summary:**
  - NF1 expression is regulated by AP-1 and in cholesterol homeostasis, it encodes a bile acid transporter with a role in intercellular tight junctions. Claudin-1, a structural component of intercellular tight junctions, is downregulated by TNFα/IL17.
<table>
<thead>
<tr>
<th>Ensembl ID</th>
<th>Gene ID</th>
<th>FC_A</th>
<th>FC_B</th>
<th>FC_C</th>
<th>FC_D</th>
<th>FC_E</th>
<th>FC_F</th>
<th>FC_G</th>
<th>FC_H</th>
<th>FC_I</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000030790</td>
<td>Amo 0.51</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Salt-inducible kinase 1 (Ser/Thr kinase) is a member of the AMP-activated protein kinase family. It inhibits CREB1 function independently of CREB1 localization. Its expression is induced by hypoxia, where it upregulates the expression of hypoxia-inducible genes (such as CYP19 and VEGF), as well as phosphorylating and inhibiting the transcriptional activator MYC. It also negatively regulates the expression of Akt and Akt-dependent TORC2.</td>
</tr>
<tr>
<td>ENSMUSG00000047777</td>
<td>Phf13 0.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phf13 is a member of the PAK family of serine/threonine kinases. It negatively regulates theexpression of CREB1 and CREB2.</td>
</tr>
<tr>
<td>ENSMUSG00000024042</td>
<td>Sik1 0.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Salt-inducible kinase 1 (Ser/Thr kinase) is a member of the AMP-activated protein kinase family. It inhibits CREB1 function independently of CREB1 localization, probably by inhibiting nuclear translocation. Its expression is induced by hypoxia, where it upregulates the expression of hypoxia-inducible genes (such as CYP19 and VEGF), as well as phosphorylating and inhibiting the transcriptional activator MYC. It also negatively regulates the expression of Akt and Akt-dependent TORC2.</td>
</tr>
<tr>
<td>ENSMUSG00000068876</td>
<td>Cgd 0.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cingulin is a regulatory protein localizing to tight junctions (cytoplasmic side) and regulating RhoA signaling. At the apical cell membrane, microtubule ends are anchored to the tight junction via cingulin, an interaction which is controlled by AMPK phosphorylation.</td>
</tr>
<tr>
<td>ENSMUSG00000024014</td>
<td>Pim1 0.53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pim-1 Proto-Oncogene, Serine/Threonine Kinase phosphorylates a set of targets involved in cell survival and proliferation. Its targets partially overlap with those of Akt and Akt-dependent TORC2. Its expression is induced by hypoxia, where it upregulates the expression of hypoxia-inducible genes (such as CYP19 and VEGF), as well as phosphorylating and inhibiting the transcriptional activator MYC. It also negatively regulates the expression of Akt and Akt-dependent TORC2.</td>
</tr>
<tr>
<td>ENSMUSG00000068876</td>
<td>Cgd 0.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cingulin is a regulatory protein localizing to tight junctions (cytoplasmic side) and regulating RhoA signaling. At the apical cell membrane, microtubule ends are anchored to the tight junction via cingulin, an interaction which is controlled by AMPK phosphorylation.</td>
</tr>
<tr>
<td>ENSMUSG00000068876</td>
<td>Cgd 0.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cingulin is a regulatory protein localizing to tight junctions (cytoplasmic side) and regulating RhoA signaling. At the apical cell membrane, microtubule ends are anchored to the tight junction via cingulin, an interaction which is controlled by AMPK phosphorylation.</td>
</tr>
<tr>
<td>ENSMUSG00000024042</td>
<td>Sik1 0.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Salt-inducible kinase 1 (Ser/Thr kinase) is a member of the AMP-activated protein kinase family. It inhibits CREB1 function independently of CREB1 localization. Its expression is induced by hypoxia, where it upregulates the expression of hypoxia-inducible genes (such as CYP19 and VEGF), as well as phosphorylating and inhibiting the transcriptional activator MYC. It also negatively regulates the expression of Akt and Akt-dependent TORC2.</td>
</tr>
<tr>
<td>Gene ID</td>
<td>FC_A</td>
<td>FC_B</td>
<td>FC_P</td>
<td>FC_T</td>
<td>References and Summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000032350 Gclc</td>
<td>0.56</td>
<td>1.06</td>
<td>0.35</td>
<td>0.76</td>
<td>Glutamate-Cysteine Ligase Catalytic Subunit forms part of the protein complex Glutamate-cysteine ligase, the rate-limiting enzyme of GSH synthesis. In a mouse model, loss of GSH secondary to Gclc KO causes rapid-onset steatosis and mitochondrial dysfunction progressing to liver failure.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000019854 Reps1</td>
<td>0.54</td>
<td>-0.63</td>
<td>0.99</td>
<td>0.76</td>
<td>RALBP1 Associated Eps Domain Containing 1 forms an endocytic complex with Numb, which has been shown to regulate the endocytosis and trafficking of Notch, E-Cadherin, and integrins. The association of Reps1 with Rab11-FIP2 and alpha-adaptin to regulate the endocytosis and trafficking of EGFR.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020034 Tcp11l2</td>
<td>0.55</td>
<td>0.79</td>
<td>0.85</td>
<td>0.56</td>
<td>T-Complex 11 Like 2 encodes a basic leucine zipper protein.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025351 Cd63</td>
<td>0.56</td>
<td>0.76</td>
<td>0.85</td>
<td>0.56</td>
<td>CD63 is a cell surface protein which acts as a receptor for TIMP (metallopeptidase). Expression of CD63 is altered in the liver under high glucose conditions. CD63 can be found on the surface of microsomes released by preadipocytes.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000078866 Gm14420</td>
<td>0.56</td>
<td>0.53</td>
<td>0.82</td>
<td>0.56</td>
<td>Encodes Zinc Finger Protein 970</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000957 Mmp14</td>
<td>0.57</td>
<td></td>
<td></td>
<td></td>
<td>Matrix metalloproteinase 14 is a cell surface MMP with activity against ECM components. It is overexpressed in HCC, MMP with activity against ECM and is associated with worse prognosis.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000032350 Cd63</td>
<td>0.56</td>
<td>0.76</td>
<td>0.85</td>
<td>0.56</td>
<td>CD63 is a cell surface protein which acts as a receptor for TIMP (metallopeptidase). Expression of CD63 is altered in the liver under high glucose conditions.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000019854 Reps1</td>
<td>0.54</td>
<td>-0.63</td>
<td>0.99</td>
<td>0.76</td>
<td>RALBP1 Associated Eps Domain Containing 1 forms an endocytic complex with Numb, which has been shown to regulate the endocytosis and trafficking of EGFR.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000020034 Tcp11l2</td>
<td>0.55</td>
<td>0.79</td>
<td>0.85</td>
<td>0.56</td>
<td>T-Complex 11 Like 2 encodes a basic leucine zipper protein.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000025351 Cd63</td>
<td>0.56</td>
<td>0.76</td>
<td>0.85</td>
<td>0.56</td>
<td>CD63 is a cell surface protein which acts as a receptor for TIMP (metallopeptidase). Expression of CD63 is altered in the liver under high glucose conditions.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000078866 Gm14420</td>
<td>0.56</td>
<td>0.53</td>
<td>0.82</td>
<td>0.56</td>
<td>Encodes Zinc Finger Protein 970</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG00000000957 Mmp14</td>
<td>0.57</td>
<td></td>
<td></td>
<td></td>
<td>Matrix metalloproteinase 14 is a cell surface MMP with activity against ECM components. It is overexpressed in HCC, MMP with activity against ECM and is associated with worse prognosis.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensembl ID</td>
<td>Gene ID</td>
<td>FC A</td>
<td>FC B</td>
<td>FC C</td>
<td>FC P</td>
<td>FC T</td>
<td>References and summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>----------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENSMUSG000000019960</td>
<td>Dusp6</td>
<td>0.59</td>
<td>1.30</td>
<td>0.95</td>
<td>0.58</td>
<td>0.59</td>
<td>During liver regeneration in a 1/3 hepatectomy model, which does not induce upregulation of HB-EGF, low levels of exogenous HB-EGF expression are required for quiescent hepatocytes to enter the cell cycle (priming). HB-EGF expression precedes EGF and TNFα, which are key regulators of liver regeneration. DUSP6 expression is increased during liver regeneration. DUSP6 interacts with and dephosphorylates FOXO1, preventing its nuclear export and promoting induction of gluconeogenic gene targets (Pepck and G6pase). DUSP6 is upregulated in cancers with aberrant RTK/Ras/RAF signaling, acting as a negative feedback inhibitor of MAPK signaling in a negative feedback mechanism. DUSP6 is downregulated in pancreatic cancer because of promoter hypermethylation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene ID</td>
<td>Ensembl ID</td>
<td>FC</td>
<td>References and summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>-----</td>
<td>------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocyte antigen 96 (MD2)</td>
<td>ENSMUSG00000025779</td>
<td>0.61</td>
<td>Lymphocyte antigen 96 (MD2) expresses functional domains that facilitate the assembly of TLR2/4 and regulate TLRs activation. Blocking Ly96 reduced TLR4-mediated lung injury after orthotopic liver transplantation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ENSEMBL ID

Gene ID

FC_A

0.62

0.61

Il33

0.64

Fst

ENSMUSG00000024810

Thbs1

ENSMUSG00000021765

ENSMUSG00000040152

FC_B

0.70

1.62

FC_G

FC_P

0.64

1.97

FC_T

0.79

References and summary

driven cell protrusions in developing kidney
epithelia through a Raf/MAPK-independent
but RhoA/Raf1-dependent mechanism,
involving inhibition of ROCK (Raf1
competitor).345
Follistatin is a natural antagonist of
members of the TGFβ superfamily, primarily
Activin. In primary human hepatocytes, Fst
transcription is inhibited by adiponectin, but
this effect is impaired with free fatty acid
loading.347
Interleukin 33 is an IL-1 family member
which drives production of Th2 cytokines
(↑IL4, IL5, IL13) and M2 polarization of
macrophages. It is upregulated in both
MCD and HFD mouse models of
steatohepatitis. In these models, exogenous
IL33 ameliorated IR and glucose
intolerance but exacerbated hepatic
fibrosis, and increased transcription of
TGFB and Col1A1. Serum IL33 is
increased in NASH patients and levels are
positively associated with NASH severity.165
Thrombospondin 1 inhibits MMPs,
preventing the release of VEGF. It can also
bind directly to VEGF and mediate its
uptake and clearance. THBS1 is therefore
anti-angiogenic.348 THBS1 binds to
adiponectin in serum.349 Transcription of
Thrombospondin-1 is increased in
individuals with chronic liver disease and in
mouse models of liver fibrosis (CCl4 and
DDC).164

224


<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Gene Symbol</th>
<th>FC_A</th>
<th>FC_B</th>
<th>FC_G</th>
<th>FC_P</th>
<th>FC_T</th>
<th>References and Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000079427</td>
<td>Mthfsl</td>
<td>0.65</td>
<td>0.82</td>
<td>0.72</td>
<td>1.42</td>
<td>1.02</td>
<td>The gene encodes a protein which catalyzes the transformation of 5-formyltetrahydrofolate to 5,10-methenyltetrahydrofolate.</td>
</tr>
<tr>
<td>ENSMUSG00000078952</td>
<td>Lincenc1</td>
<td>0.65</td>
<td>-0.59</td>
<td>0.54</td>
<td>-0.50</td>
<td>0.67</td>
<td>Long non-coding RNA, embryonic stem cell expressed 1, is a known lincRNA.</td>
</tr>
<tr>
<td>ENSMUSG00000044134</td>
<td>Fam109a</td>
<td>0.65</td>
<td>1.01</td>
<td></td>
<td></td>
<td></td>
<td>Family with sequence similarity 109, member A (IIPPA, Ses1) encodes a protein which binds the 5-phosphatase Inpp5b to affect receptor recycling from endosomes. This protein is implicated in the pathology of Lowe syndrome and Dent disease.</td>
</tr>
<tr>
<td>ENSMUSG00000024912</td>
<td>Fosl1 or Fra1</td>
<td>0.66</td>
<td>0.95</td>
<td>0.55</td>
<td></td>
<td></td>
<td>Fos-like antigen 1 is a modular constituent of the Activator Protein-1 (AP1) complex. The inclusion of Fra1 as part of the AP1 (hetero)dimer confers resistance to acetaminophen toxicity and inhibits PPARγ expression and lipid synthesis in hepatocytes.</td>
</tr>
<tr>
<td>ENSMUSG00000000141</td>
<td>Nat8f4</td>
<td>0.67</td>
<td>1.42</td>
<td>0.82</td>
<td>0.72</td>
<td></td>
<td>N-acetyltransferase 8 (GCN5-related family member 4) encodes an ER protein expressed in liver and kidney. NAG is a known member of the NAG family.</td>
</tr>
<tr>
<td>ENSMUSG00000024912</td>
<td>Fosl1 or Fra1</td>
<td>0.68</td>
<td>0.56</td>
<td>0.34</td>
<td>1.02</td>
<td></td>
<td>Glucose-6-phosphatase catalytic subunit localizes to the ER and functions to catalyze the hydrolysis of D-glucose 6-phosphate.</td>
</tr>
<tr>
<td>ENSMUSG00000000141</td>
<td>Nat8f4</td>
<td>0.69</td>
<td>0.56</td>
<td>0.34</td>
<td>1.02</td>
<td></td>
<td>N-acetyltransferase 8 (GCN5-related family member 4) encodes an ER protein expressed in liver and kidney. NAG is a known member of the NAG family.</td>
</tr>
<tr>
<td>ENSMUSG00000000141</td>
<td>Nat8f4</td>
<td>0.68</td>
<td>0.56</td>
<td>0.34</td>
<td>1.02</td>
<td></td>
<td>N-acetyltransferase 8 (GCN5-related family member 4) encodes an ER protein expressed in liver and kidney. NAG is a known member of the NAG family.</td>
</tr>
<tr>
<td>ENSMUSG00000000141</td>
<td>Nat8f4</td>
<td>0.68</td>
<td>0.56</td>
<td>0.34</td>
<td>1.02</td>
<td></td>
<td>N-acetyltransferase 8 (GCN5-related family member 4) encodes an ER protein expressed in liver and kidney. NAG is a known member of the NAG family.</td>
</tr>
<tr>
<td>ENSMUSG00000000141</td>
<td>Nat8f4</td>
<td>0.68</td>
<td>0.56</td>
<td>0.34</td>
<td>1.02</td>
<td></td>
<td>N-acetyltransferase 8 (GCN5-related family member 4) encodes an ER protein expressed in liver and kidney. NAG is a known member of the NAG family.</td>
</tr>
<tr>
<td>ENSMUSG00000000141</td>
<td>Nat8f4</td>
<td>0.68</td>
<td>0.56</td>
<td>0.34</td>
<td>1.02</td>
<td></td>
<td>N-acetyltransferase 8 (GCN5-related family member 4) encodes an ER protein expressed in liver and kidney. NAG is a known member of the NAG family.</td>
</tr>
</tbody>
</table>

**References and Summary**

- **5, 10-methenyltetrahydrofolate synthetase-like**: Encodes a protein which catalyzes the transformation of 5-formyltetrahydrofolate to 5,10-methenyltetrahydrofolate. This enzyme is involved in the metabolism of folates.
- **Long non-coding RNA, embryonic stem cell expressed 1 (Lincenc1)**: Known lncRNA involved in embryonic stem cell differentiation.
- **Fam109a**: Encodes a protein involved in receptor recycling and implicated in the pathology of Lowe syndrome and Dent disease.
- **Fosl1 or Fra1**: Modular constituent of the AP1 complex involved in resistance to acetaminophen toxicity and regulation of lipid synthesis.
- **N-acetyltransferase 8 (Nat8f4)**: ER protein involved in the metabolism of xenobiotics and responsible for catalyzing the hydrolysis of D-glucose 6-phosphate.
- **Glucose-6-phosphatase catalytic subunit (G6pc)**: Localizes to the ER and functions to catalyze the hydrolysis of D-glucose 6-phosphate.
<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC A</th>
<th>FC B</th>
<th>FC C</th>
<th>FC D</th>
<th>FC E</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000000478</td>
<td>3.34</td>
<td>0.7</td>
<td>0.78</td>
<td>0.69</td>
<td>0.76</td>
<td>Liver lumen, expressed in phagocytic-macrophage, member of AaBbC family with sequence similarity 8</td>
</tr>
<tr>
<td>ENSMUSG00000000479</td>
<td>0.57</td>
<td>0.75</td>
<td>0.65</td>
<td>0.74</td>
<td>0.72</td>
<td>Other cell types, expressed in macrophage, member of AaBbC family with sequence similarity 1</td>
</tr>
<tr>
<td>ENSMUSG00000000480</td>
<td>0.71</td>
<td>1.07</td>
<td>0.65</td>
<td>0.71</td>
<td>0.71</td>
<td>Chloracne</td>
</tr>
<tr>
<td>ENSMUSG00000000481</td>
<td>0.67</td>
<td>0.67</td>
<td>0.67</td>
<td>0.67</td>
<td>0.67</td>
<td>Higher risk for NASH</td>
</tr>
</tbody>
</table>

**References and summary:**

- **Liver lumen,** expressed in phagocytic-macrophage, member of AaBbC family with sequence similarity 8
- **Other cell types,** expressed in macrophage, member of AaBbC family with sequence similarity 1
- **Chloracne:** In cultured skin keratinocytes, CD44 expression is induced by TCDD treatment. Transglutaminase 1 is proteolytic cross-linking enzyme.
- **Higher risk for NASH:** Increased expression of CD44 in the promoter region of the 5'-flanking region of the CD44 gene in animal models of alcoholic steatohepatitis, measured in the liver.
- **Chloracne:** CD44 is a receptor for TCDD and plays a role in the pathogenesis of chloracne.
<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC_A</th>
<th>FC_B</th>
<th>FC_G</th>
<th>FC_P</th>
<th>FC_T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000009565</td>
<td>0.42</td>
<td>0.51</td>
<td>0.84</td>
<td>0.56</td>
<td>Rab31</td>
<td>Protein Tyrosine Phosphatase, Receptor Type E suppressed phosphorylation of Akt, ERK and GSK3 and suppressed. It modulates insulin signaling, suppressing insulin-induced glycogen synthesis and inhibiting insulin-induced suppression of ERK and GSK3 and suppressing the type I and II insulin-induced phosphatase receptor.</td>
</tr>
<tr>
<td>ENSMUSG00000006333</td>
<td>0.76</td>
<td>0.87</td>
<td>0.77</td>
<td></td>
<td></td>
<td>Semaphorin 3E is expressed by damaged hepatocytes and sequestered, inducing Semaphorin 3E expression in metabolically unhealthy obese individuals.</td>
</tr>
<tr>
<td>ENSMUSG00000002672</td>
<td>1.29</td>
<td>0.77</td>
<td></td>
<td></td>
<td>Vim</td>
<td>Vimentin is an intermediate filament protein associated with epithelial cells. Loss of Vimentin is associated with EMT. Vimentin was upregulated by LPS treatment but not by lipid filling.</td>
</tr>
<tr>
<td>ENSMUSG00000004183</td>
<td>0.77</td>
<td></td>
<td></td>
<td></td>
<td>Pire</td>
<td>Semaphorin 3E expression is associated with metabolically unhealthy obese individuals vs. metabolically healthy obese individuals.</td>
</tr>
</tbody>
</table>

**References and summary:**

1. LeP, suggesting that PTPRE may act as a link between tissues in obesity-related diseases. An elevated differential correlation exists between leptin and PTPRE expression with genes that are coming upregulated by LPS treatment but not by lipid filling. Semaphorin 3E expression in metabolically unhealthy obese individuals is associated with metabolically healthy obese individuals vs. metabolically healthy obese individuals. PTPRE shows altered co-expression with genes that are coming upregulated by LPS treatment but not by lipid filling.
<table>
<thead>
<tr>
<th>Gene ID</th>
<th>FC_A</th>
<th>FC_B</th>
<th>FC_C</th>
<th>FC_P</th>
<th>FC_T</th>
<th>References and summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSMUSG00000097073</td>
<td>0.85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rab31 physically interacts with EGFR and overexpression increases EGFR endocytosis and trafficking to late endosomes.</td>
</tr>
<tr>
<td>ENSMUSG00000097879</td>
<td>0.85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fhl3, a nuclear protein gene which is induced by the hedgehog signaling pathway, is implicated in HGCC.</td>
</tr>
<tr>
<td>ENSMUSG00000046733</td>
<td>0.88</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dio3, an iodothyronine 5-deiodinase, catalyzes the inactivation of thyroid hormone to inactive metabolites.</td>
</tr>
<tr>
<td>ENSMUSG00000032643</td>
<td>0.88</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Spp1, osteopontin, which is induced by the hedgehog signaling pathway, is implicated in fibrogenesis during liver repair.</td>
</tr>
<tr>
<td>ENSMUSG00000075707</td>
<td>0.92</td>
<td>0.87</td>
<td>0.87</td>
<td>0.92</td>
<td>0.99</td>
<td>Ankrd1, a nuclear protein gene which is induced by pro-inflammatory cytokines in endothelial cells.</td>
</tr>
<tr>
<td>ENSMUSG00000024803</td>
<td>1.09</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Spred3, a nuclear protein gene which is induced by pro-inflammatory cytokines in endothelial cells.</td>
</tr>
<tr>
<td>ENSMUSG00000037239</td>
<td>1.31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Spry4, a nuclear protein gene which is induced by pro-inflammatory cytokines in endothelial cells.</td>
</tr>
</tbody>
</table>

Phosphorylation residues of tyrosine kinases, regulated by the EGFR. Overexpression increases EGFR endocytosis and trafficking to late endosomes, while loss of Rab31 inhibits endocytosis and trafficking to the endosomal-association domain. EVF-1 is the isoform expressed in Spred4, a nuclear protein gene which is induced by pro-inflammatory cytokines in endothelial cells.
Spred proteins are associated with liver disease. Decreased Spred-1 and -2 are associated with increased invasiveness/malignant phenotypes associated with liver disease. inhibitors Ras/MAPK signaling.
NAME: Heather Brooke Clair

DATE OF BIRTH: Clearwater, FL – April 12, 1977

EDUCATION AND TRAINING:

Master of Science
University of Louisville Department of Biochemistry and Molecular Genetics
May, 2015

Master of Science in Agriculture
University of Georgia College of Agricultural and Environmental Science
August, 2001

Bachelor of Science – Animal Science
University of Georgia College of Agricultural and Environmental Science
May, 1999

Bachelor of Science – Dairy Science
University of Georgia College of Agricultural and Environmental Science
May, 1999

AWARDS:

Travel award – NIEHS 25 Years of Endocrine Disruption Meeting
2016

Ruth L. Kirschstein National Research Service Award Individual Fellowship (F30ES025099)
2015-present

IPIBS Fellowship
2013-2014

Summer Research Scholar Program Fellowship (UofL School of Medicine)
2011-2012

Cum laude, BS in Animal Science, BS in Dairy Science (University of Georgia)
May, 1999

University of Georgia Honors Program
1995-1999

HOPE Scholarship (Awarded by State of Georgia)
1995-1999

Georgia Governor’s Scholarship (Awarded by State of Georgia)
1995-1999

Governor’s Honors Program (State of Georgia)
1994
PROFESSIONAL SOCIETIES:

- American Physician Scientist Association
  2013-present
- Society of Toxicology
  2013-present
- American Association for the Study of Liver Disease
  2016

PUBLICATIONS:


**ABSTRACTS AND CONFERENCES:**


Wahlang, B; Falkner, KC; **Clair, HB**; Al-Eryani, L; Guardiola, JJ; Prough, RA; Cave, MC. Hepatic Receptor Activation By Polychlorinated Biphenyls - Implications For Xenobiotic/Energy Metabolism And Nonalcoholic Fatty Liver Disease. (Poster: 64th Annual Meeting of the American Association For The Study Of Liver Disease. Washington, DC 2013.)

Al-Eryani, L; Wahlang, B; **Clair, HB**; Guardiola, JJ; Falkner, KC; Prough, RA; Cave, MC. Identification And Validation Of Environmental Chemical Nuclear Receptor Agonists Which Could Contribute To Nonalcoholic Fatty Liver Disease. (Poster: 64th Annual Meeting of the American Association For The Study Of Liver Disease. Washington, DC 2013.)

Wahlang, B; Song, M; Beier, Ji; Al-Eryani, L; **Clair, HB**; Guardiola, JJ; Falkner, KC; Prough, RA; Cave, MC. Aroclor 1260 Exposure Worsens Hepatic And Systemic Inflammation In An Animal Model Of Diet-Induced Obesity And Nonalcoholic Fatty Liver Disease. (Poster: 64th Annual Meeting of the American Association For The Study Of Liver Disease. Washington, DC 2013.)
Al-Eryani, L.; Wahlang, B; Clair, HB; Guardiola, JJ; Falkner, KC; Prough, RA; Cave, MC. Identification Of Pesticides And Other Environmental Chemicals Associated With The Development Of Nonalcoholic Fatty Liver Disease In Rodents. (Poster: 64th Annual Meeting of the American Association For The Study Of Liver Disease. Washington, DC 2013.)

Cave, MC; Beier, JI; Wheeler, B; Falkner, KC; Bellis-Jones, HJ; Clair, HB; McClain, CJ; Occupational vinyl chloride exposures are associated with significant changes to the plasma metabolome: implications for toxicant associated steatohepatitis. (Poster: 63rd Annual Meeting of the American Association For The Study Of Liver Disease. Boston, MA 2012.)

Falkner, KC; Wahlang, B; Bellis-Jones, HJ; Clair, HB; Prough, RA; Cave, MC. LXR and PXR crosstalk on DR4 response elements is sequence dependent. (Poster: 18th North American Regional International Society For The Study Of Xenobiotics. Dallas, TX 2012.)

Clair, HB; Wahlang, B; Falkner, KC; Cave, M. An optimized DR 4 nuclear response element is bound and activated by PXR and LXR in the presence of known ligands, but not polychlorinated biphenyls. (Poster: Research Louisville. Louisville, KY 2012)


Clair, HB; Herbert, D; Sag, D; Hansen, R; Suttles, J. C68-driven expression of a dominant-negative AMPKα1 protein results in spontaneous obesity and hepatosteatosis. Research Louisville. Louisville, KY 2011.

Zhou, GH; Keskey, AL; Goel, M; Hamid, T; Guo, SZ; Clair, HB; Brittian, KR; Sansbury, BE; Hill, BG; Prabhu, SD. Endoplasmic reticulum (ER) stress is critical for the development of diabetic cardiomyopathy. Circulation supplement, published Nov. 23, 2010.


Nair, D.; Li, R.; Clair, H.; Cheng, Y; Gozal, D. Neuroglobin overexpression attenuates cognitive deficits in mice exposed to chronic intermittent hypoxia during sleep. Sleep supplement, published 2010.
